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ABSTRACT 
This study aimed to characterise aspects of the aetiopathogenesis of feline chronic gingivostornatitis 
(FCGS) and to assess the comparable effectiveness of four different treatments in the management of 
this disease. Serum and salivary immunoglobulin (1g) levels were measured by ELISA. Oral biopsies 
were analysed using immunohistochemical methods to characterise the nature of the inflammatory 
infiltrate, and a serniquantitative reverse transcription polymerase chain reaction (RT-PCR) assay was 
used to determine the expression of cytokine mRNA by these cells. Feline calicivirus was isolated 
from all cats with FCGS (n = 30), with an average isolation rate of 90% from duplicate samples taken 
six months apart. Four cases were seropositive for feline immunodeficiency virus. Compared to 
controls, cats with FCGS had elevated concentrations of serum IgG, IgM and IgA, and salivary IgG 
and IgM, but lower concentrations of salivary IgA. The cells infiltrating the mucosal lesions in FCGS 
were mainly CD79+ IgG-secreting plasma cells, and Ll' monocytes/granulocytes, with fewer CD3+ T- 
cells, amongst which CD8+ cells predominated over those expressing CD4+. Healthy oral mucosa 
generally expressed mRNA coding for interleukin(IL)-2, IL-10, IL-12 and interferon(IFN)-y, and 
occasionally IL-6, but not IL-4 or IL-5. By comparison, oral mucosal lesions from cats with FCGS had 
increased expression of IL-2, IL-4, IL-6, IL-10, IL-12, and IFN-y, but not IL-5. The results indicate 
that FCGS is associated with a switch from the type I-biased immunity found within healthy oral 
mucosa, towards a mixed type I and type 2 response, and that the local and systemic B-cell response is 
dominated by IgG production. A controlled clinical trial was conducted to analyse the effects of 
treatment with oral hygiene products, methylprednisolone, sodium aurothiomalate, or metronidazole 
and spiramycin over a six month period. After six weeks, methylprednisolone was shown to be the 
treatment of choice, however none of the treatments demonstrated superiority in their clinical response 
after three or six months of therapy, 
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CHAPTER 1: Introduction and Literature Review 
1.1 FELINE CHRONIC GINGIVOSTOMATITIS: CLINICAL FEATURES, AETIOPATHOGENESIS AND 
TREATMENT 
Oral diseases are common in cats (Lund et al., 1999). One of the most important of these conditions is 
feline chronic gingivostomatitis (FCGS), which is a syndrome largely seen in adult cats that is 
characterised by persistent chronic inflammation involving the gingiva and oral mucosa (Harvey, 1991 
& 1995; Pedersen, 1992). The aetiopathogcnesis of this disease is poorly understood and many cases 
are refractory to treatment. Furthermore, the effectiveness of treatments for this condition have rarely 
been evaluated using controlled studies. Consequently, FCGS has been identified as a major problem 
within the field of feline medicine requiring further investigation (Gruffydd-Jones, 1991). 
Epidemiology ofFCGS 
The prevalence of FCGS within the domestic feline population is unknown, but the disease has been 
estimated to occur in around 1.5 to 3% of all cases admitted to veterinary practices for the treatment of 
orodental disease (Crossley, 1991; Harvey, 1995). The disease is seen in all breeds of domestic cats, 
however some studies have suggested that pure-bred cats are predisposed, especially those of the 
Abyssinian, Siamese and Persian/Himalayan breeds (Von Schlup, 1982; Frost & Williams, 1986; 
Tenorio 1991). 
Diagnostic criteria of FCGS 
FCGS is a poorly-defined syndrome for which there is no definitive diagnostic test. Moreover, as 
FCGS is likely to have a multifactorial actiology (Gruffydd-Jones, 1991), the underlying causes may 
differ between cases. Consequently, a presumptive diagnosis is made based primarily upon the clinical 
presentation, distribution, and histological appearance of the lesions. This has led to a range of 
descriptive terms for the condition, based upon the morphological features and location of the oral 
lesions, such as gingivostomatitis; feline gingivitis-stomatitis-pharyngitis; plasmacytic stomatitis- 
pharyngitis; and feline plasma cell gingivitis-pharyngitis (Johnessee & Hurvitz, 1983; Reindel et al., 
1987; White et al., 1992; Williams & Aller, 1992; Diehl & Rosychuk, 1993). Williams & Aller (1992) 
have proposed that four discrete syndromes involving chronic gingivitis and stornatitis can be 
identified in the cat. They described two syndromes in young cats associated with eruption of the 
permanent dentition, termed feline juvenile hyperplastic gingivitis, and feline juvenile-onset 
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periodontal disease (Gaskell & Gruffydd-Jones, 1977; Joshua, 1979); while adult cats were separated 
into those suffering from adult-onset periodontal disease (Page & Schroeder, 1976; Reichart et al., 
1984; Hennet & Harvey, 1992), and those with extensive mucogingival lesions (adult 
gingivostomatitis). Within this latter group, Harvey (1991 & 1995), has categorised affected cats into 
three groups based upon whether the lesions affect the mucogingival tissues or the fauces, or both. 
However, it is not known if such topographically-based subdivisions are associated with different 
aetiopathoIogical features. 
Clinical signs and lesion morpholqy 
The initial presenting signs seen in cats suffering from FCGS frequently include dysphagia, halitosis, 
weight loss, inappetence and ptyalism (Lyon, 1990; Gruffydd-Jones, 1991; Williams & Aller, 1992, 
White et al., 1992). Many cases have a polyclonal hypergammaglobulinaernia (Johnessee & Hurvitz, 
1983; Zetner et al., 1989; White et al., 1992), but routine serum biochemical analysis is often 
otherwise unremarkable. Haernatological changes are inconsistent between cases, but may include 
neutrophilia, lymphopenia and eosinophilia (Johnessee & Hurvitz, 1983; White et al., 1992). The oral 
lesions typically include areas of focal or diffuse inflammation involving the gingiva and adjacent 
buccal and, less commonly, the palatine and lingual mucosa. The glossopalatine arches, or fauces, are 
also frequently affected (Harvey, 1991; Reubel et at., 1992). With increasing severity of disease, the 
mucogingival lesions may become proliferative and ulcerated. 
There are few detailed descriptions of the histological analysis of oral tissue biopsies from cases with 
FCGS. In 1983, Johnessee & Hurvitz briefly summarised the histological changes in biopsies from a 
series of 9 cats with chronic mucogingival disease, which they termed "feline plasma cell gingivitis- 
pharyngitis". They reported mucosal hyperplasia with frequent ulceration, and a subinucosal infiltrate 
consisting predominantly of plasma cells interspersed with neutrophils, lymphocytes and macrophages. 
Similar h istopatho logical features have since been briefly described by other workers (Reindel et al., 
1987; Lyon, 1990; Gruffydd-Jones 1991; Williams & Aller, 1992; White et al., 1992; Hennet, 1995; 
Harvey, 1995). A single report (Dillon, 1986) makes passing reference to a significant eosinophilic 
infiltrate in cases of "glossopharyngitis" involving ulceration of the posterior oral cavity. In a summary 
of a more detailed but unpublished study of cats with gingivitis, Harvey (1991) reported that a 
neutrophil infiltrate predominated in approximately half of the cases examined, whereas a principally 
lymphocytic or plasmacytic response was found in the remaining cases. No correlation was found 
between the clinical severity of the gingival disease and the type of inflammatory cell predominating, 
however the extent of the infiltrate correlated significantly with the disease severity. 
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A etiological studies 
The aetiology of FCGS remains obscure. The presence of a polyclonal hypergammaglobulinaemia, 
and the histopatho logical features of a pronounced lymphocytic/plasmacytic infiltrate within the 
lesions, have prompted a hypothesis that there is an underlying immune-mediated basis for the 
condition (Johnessee & Hurvitz, 1983; Lyon, 1990). Investigations into potential aetiological factors 
have concentrated upon viral and bacterial agents, and possible underlying immunological defects. 
Viral agents 
A number of reports have studied the prevalence and involvement of viral agents in chronic oral 
inflammatory disease in cats (Table 1.1). These investigations have concentrated upon the detection of 
feline calicivirus (FCV) (Wardley, 1976; Harbour et al., 1991), feline leukaemia virus (FeLV), and 
feline immunodeficiency virus (FIV) (Pedersen et al., 1987; Barr et al., 1991; Cotter, 1998). 
FCV is a common pathogen in the cat (Fastier, 1957; Kahn & Gillespie, 1970 & 1971; Gaskell & 
Dawson, 1998), however its potential role in the aetiopathogenesis of FCGS is controversial. Acute 
FCV infection is associated with signs of upper respiratory tract infection and oral ulceration, which 
typically resolves within a few weeks of initial infection (Povey, 1986; Knowles et al., 1991; Addie & 
Jarrett, 1998), although in many cases a long-term carrier state develops with continued shedding of 
virus into the oral cavity from the tonsillar region (Wardley et al., 1974; Wardley, 1976; Dick et al., 
1989; Pedersen & Floyd Hawkins, 1995). The prevalence of cats shedding FCV within a population is 
related to a number of factors, including age, genotype, and the degree of contact with other cats 
(Pedersen, 1992; Fromont et aL, 1996; Reade et al., 1998), and has been reported to range from 0.4 to 
51%, depending upon the population sampled (Wardley et al., 1974; Ellis, 1981; Hirano et al., 1986; 
Tenorio et al., 1991, Reubel et al., 1992; Coutts et al., 1994; Yamaguchi et al., 1996). 
The circumstantial evidence linking FCV with the presence of chronic oral disease is convincing. 
Harbour et al., (1991) reported a4 fold increase in the recovery rate of FCV from cats with chronic 
gingivitis or stomatitis in comparison with asymptomatic cats in a retrospective study over a 10 year 
period. In a survey of cats with chronic gingivitis and stomatitis from first and second opinion 
practices within the UK, Knowles et al. (199 1) found 79 to 92% to be carriers of FCV by comparison 
to 19% of controls. These results are supported by similar surveys performed in the UK, Austria, and 
Australia (Table 1.1). However, slightly lower prevalence rates (50 to 60%) were found in two smaller 
studies performed in the USA (Table 1.1). The range of oral lesions present within the cases analysed 
in the above studies was not documented. However, in a study by Reubel et al. (1992), the 
inflammatory oral lesions were recorded and categorised by the site of involvement. As before, a high 
prevalence of FCV was found in cases with oral disease (61%, 14/23), but most striking was the 
observation that FCV was isolated from all cats with ulceroproliferative faucitis (8/8). This supports 
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the hypothesis first suggested by Povey (1976) that calicivirus can induce chronic lesions of the 
fauces. 
Despite the apparent strong association between FCV and FCGS, the evidence relating to the 
hypothesis that FCV infection, or specific FCV strains, can specifically cause chronic oral 
inflammatory disease is conflicting. Reubel et al. (1992) described the development of acute and self- 
limiting faucitis in cats infected both experimentally and naturally with field strains of FCV. However, 
studies of serum neutralisation patterns, and phylogenetic analysis, of FCV isolates have identified a 
range of strains from cats with chronic gingivostornatitis (Knowles et al., 1990 & 1991; Reubel et al., 
1992; Dawson et al., 1993b; McArdle et al., 1996; Geisser et al., 1997; Glen et al., 1999). Dawson et 
al. (I 993b) reported that isolates from cats with chronic stomatitis had a different neutralisation pattern 
by comparison to isolates from cats with acute respiratory signs and from cats with limping syndrome 
(Dawson et al., 1994), but this finding has not been corroborated by other studies (Knowles et al., 
1990 & 1991; Reubel et al., 1992; McArdle et al., 1996; Geisser et al., 1997; Glen et al., 1999). No 
significant increase in either the prevalence or severity of chronic oral lesions was demonstrated in cats 
infected solely with FCV (Tenorio et al., 1991). Moreover, experimental cats inoculated with FCV 
strains isolated from FCGS cases developed typical acute disease, but failed to show any signs of 
chronic oral disease during a7 to 10 month follow-up period (Knowles et al., 1991; Reubel et al., 
1992). Thus the current balance of evidence would suggest that FCGS is not associated with specific 
strains of FCV. 
An increase in the severity of oral lesions was found in cats co-infected with FCV and FIV by 
comparison to cats infected with one or other agent (Knowles et al., 1989; Tenorio et al., 1991; 
Dawson et al., 199 1). These findings were further supported by Waters et al. (1993), who reported the 
development of chronic gingivitis following the inadvertent introduction of FCV into an experimental 
cat colony containing FIV. However, a short-term experiment involving dual infection with FCV and 
FIV failed to produce any signs of oral disease (Dawson et al., 1991). It has been suggested that this 
may be due to the viral strain types used, or that insufficient time was given for oral disease to occur 
(Waters et al., 1993). The mechanism underlying the synergistic effect of FCV and FIV is unclear, and 
no evidence of a similar effect has been documented in cats co-infected with FCV and FeLV (Tenorio 
et al., 199 1). 
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Table 1.1 Prevalence of feline calicivirus (FCV), feline leukaemia virus (FeLV) and feline 
immunodeficiency virus (FIV) recorded in cats with chronic gingivostomatitis (FCGS) 
Reference 
Geographical source ofcases Cases FCV FeLV FIV 
Johnessee & Hurvitz, 1983 
Animal Medical Centre, N. Y, USA FCGS NT 0%(0/9) nd 
Thompson et al., 1984 
Murdoch University, W. Australia FCGS 80%(8/10) 0%(0/9) nd 
[Controls] [0% (0/ 10)] [0% (0/10)] nd 
Knowles et al., 1989 
Liverpool University, UK FCGS 92%(33/36) 4%(1/27) 81%(22/27) 
[Controls] [19% (7/36)] [11% (2/19)] [16% (3/19)] 
General practices, UK FCGS 79%(33/42) 16%(3/19) 75%(12/16) 
[Controls] [19% (37/191)] nd nd 
University of Pennsylvania, USA FCGS 50%(9/18) 15%(2/13) 54%(7/13) 
[Controls] [0% (0/12)] [0% (0/ 10)] [50% (5110)] 
Zetner et al., 1989 
Vienna University, Austria FCGS nd 10%(3/30) 10%(3/30) 
University of Pennsylvania, USA FCGS 60%(9/15) 13%(2/15) 80%(12/15) 
Gruffydd-Jones, 1991 
Bristol University, UK FCGS 70%(37/53) 7%(3/41) 48%(29/60) 
White et al., 1992 
Colorado State University, USA FCGS nd 17%(6/36) 28%(5/18) 
Hennet, 1995 
Referralpractice, France FCGS nd 0%(0/23) 13%(3/23) 
nd = not detennined 
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Gingivitis or stornatitis has been reported as a common clinical sign in FeLV infection and is estimated 
to occur in approximately a quarter of viraemic cases (Hardy, 1982 & 1988; Hoover & Mullins, 199 1, 
Anon, 1992). However, this level of oral disease is similar to that found in the normal feline 
population (Lund et al., 1999). Moreover, various studies have failed to demonstrated any association 
between the severity of oral lesions and concurrent FeLV infection (Hosie et al., 1989; Friend et al., 
1990; Tenorio et al., 1991). The prevalence of FeLV infection in cases of FCGS has consistently been 
found to be low (Table 1.1). Nevertheless, a recent study by Uthman et al. (1996) using the 
polymerase chain reaction (PCR) demonstrated the presence of FeLV long terminal repeat (LTR) 
sequence in gingival tissue in 2 of 15 cats with chronic oral inflammation which were non-viraemic. 
Furthermore, as with FCV, coinfection with FeLV and FIV is associated with oral lesions of greater 
severity (Tenorio et at., 199 1). 
There has been considerable interest in the possible involvement of FIV in FCGS. FIV causes an 
acquired immunodeficiency-like syndrome in cats characterised by a progressive decline in CD4+ T 
lymphocytes and an inversion of the normal CD4"/CD8+ T-cell ratio, which compromises both 
humoral and cell-mediated immune responses (Callanan, 1995; Willet et al., 1997). Oral lesions, such 
as periodontitis, gingivitis, and stornatitis are reported to be the most common clinical signs seen in 
FIV-infected cats, and have been reported to occur in over 50% of cases (Pedersen et al., 1987; 
Shelton et al., 1989; Ishida et al., 1989; Hopper et al., 1989; Friend et al., 1990; Shaw et al., 1990; 
O'Connor et al., 199 1; O'Neill et al., 199 1; Peri et al., 1994). Furthermore, the oral lesions recorded in 
FIV-seropositive cats have been reported to be more severe than those in seronegative cats (Tenorio et 
al., 1991). These findings parallel the situation in humans infected with human immunodeficiency 
virus (HIV) which produces similar immunological aberrations to FIV (Willet et al., 1997; Cohen et 
al., 1999), and in which oral diseases are common (Robinson, 1992; Gillespie & Marino, 1993; 
Martinez-Canut et al., 1996). 
The current available evidence implicates FIV as a potential contributory factor in a significant 
proportion of FCGS cases (Table 1.1). In a review by Callanan (1995), the prevalence of FIV infection 
within various populations has been reported to range from I to 12% in healthy cats to 13 to 44% in 
sick cats. Additional surveys of cats with FCGS have demonstrated a wide range in the prevalence of 
FIV, ranging from 10 to 80% (Table 1.1). Further evidence that implicates FIV in FCGS are the 
documented reports of the remission of chronic oral inflammatory lesions in FIV-seropositive cats 
treated with antiviral agents such as 3'azido-3'thymidine (AZT) and 9-(2-phophono- 
methoxyethyl)adenine (PMEA) (Egberink et al., 1990; Tizard, 1991; Hartmann et al., 1995a & b). 
Nevertheless, a number of authors have speculated that FIV induces oral lesions by predisposing the 
host to secondary infection rather than by any direct action (Yamamoto et al., 1989; Knowles et al., 
1989; Egberink & Horzinek, 199 1; Harvey, 199 1; Williams & Aller, 1992; Waters et al., 1993). 
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Feline herpesvirus, Type I (FHV-1) is a common cause of severe upper respiratory disease in cats 
(Povey, 1976; Gaskell & Dawson, 1998). During the acute stages of FHV-induced disease small 
ulcerations involving the tongue or pharynx are occasionally seen, however these heal completely 
during the recovery period (Gaskell & Dawson, 1998). Nevertheless, most cats that have recovered 
from FHV infection develop a latent carrier state and may intermittently shed virus with or without the 
recrudescence of clinical signs, especially during periods of stress (Plummer et al., 1970; Gaskell & 
Povey, 1973,1977,1979; Reubel et al., 1993; Gaskell & Dawson, 1994; Stiles et al., 1997). No 
association with FHV has been noted in surveys of FCGS (Table 1.1). FHV carriers are, however, 
difficult to detect because of their pattern of intennittent viral shedding. 
FeSFV is another retrovirus, but has not been associated with any major disease syndrome and appears 
to be largely non-pathogenic (Greene, 1998). FeSFV infection is widespread and is typically present in 
4 to 50% of the feline population (Greene, 1998). The virus is actively shed into the saliva and the 
main route of transmission is considered to occur through close social contact and bites. The 
prevalence of FeSFV within cases of FCGS has not been reported. In a recent but poorly described 
study (Zetner et al., 1996) FeSFV titres were determined in 60 cases with FCGS however the results 
were not presented. 
Thus, the role of viral agents within the aetiopathogenesis of FCGS is unclear. 
Bacterial agents 
The role of bacteria within FCGS is uncertain. Many cases show some clinical improvement when 
treated with antibiotics; although this is rarely maintained once the therapy is withdrawn. Some authors 
have suggested that bacteria may play a secondary role in the pathogenesis of FCGS (Gruffydd-Jones, 
199 1; Harvey, 199 1). However, other workers hypothesise that bacteria play a more dominant role and 
that the disease results from the manifestations of an immunosuppressed or hyperimmune response to 
the presence of bacterial plaque (Williams & Aller, 1992; Diehl & Rosychuk, 1993). 
Relatively few studies characterising the oral flora of the cat have been performed. Nevertheless, as is 
the case in other species such as man (Newman et al., 1976; Wade et al., 1992; Marsh & Martin 1992; 
Petsios et al., 1995) and the dog (Hennet & Harvey, 1992; Sarkiala et al., 1993) a wide variety of both 
aerobic and anaerobic bacteria have been isolated from healthy and diseased feline gingival sites 
(Chastain et al., 1977; Brazier et al., 1987; Mallonee et al., 1988; Tannock et al., 1988; Love et al., 
1989 & 1990; Gruffydd-Jones, 1991; Griego et al., 1995; Harvey et al., 1995; Norris & Love, 1995, 
1999, & 2000). A few studies have sought to compare the isolation rates of various microbial groups 
with the prevalence and severity of gingival and periodontal disease in cats (Mallonee et al., 1988; 
Tannock et al., 1988; Love et al., 1989; Gruffydd-Jones, 1991). The results, however, have failed to 
illustrate any striking differences between the predominant bacterial species present in healthy and 
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diseased sites. Nevertheless, due predominantly to a rise in the number of Gram-negative anaerobic 
rods, especially Prevotella and Porphyromonas spp, the composition of the flora was noted to be 
significantly more anaerobic as the severity of gingivitis increased (Mallonee et al., 1988). Such 
changes have also been documented in association with gingivitis and periodontal disease in other 
species including the dog (Hennet & Harvey, 1992; Sarkiala et al. 1993) and man (Newman et al. 
1976; Marsh & Martin, 1992). 
Many studies have focused specifically upon the isolation or host response to the presence of certain 
anaerobic bacteria - especially Gram-negative rods such as Prevotella and Porphyromonas spp. These 
bacteria are considered to be associated with gingivitis and periodontal disease in man and other 
species (Newman et al., 1976; Marsh & Martin, 1992; Sarkiala et al., 1993). Prevotella and 
Porphyromonas spp. can be isolated from most feline gingival sites irrespective of the state of health 
of the cat (Mallonee et al., 1988; Tannock et al., 1988; Love et al., 1989; Gruffydd-Jones, 1991; 
Norris & Love, 1999). Consequently their significance is difficult to assess based purely upon their 
positive isolation. However, Sims et al. (1990) demonstrated the presence of IgG and IgM serum 
antibodies reactive to various Gram-negative oral bacterial antigens derived from both feline and 
human oral isolates. This study also suggested that, in contrast to humans, cats with FCGS recognise 
bacterial protein antigens more vigorously than LPS antigenic sites. This observation led the authors to 
suggest that cats with FCGS may not be able to produce an appropriate response to bacterial 
carbohydrate to enable the infection to be controlled. Norris & Love (1995) also noted an increased 
serum response of cats with periodontal and gingival disease to various polypeptides from 
Porphyromonas spp. of feline origin using western blot analysis. 
Spirochaetes are commonly found in the oral cavity and have also been implicated in the development 
of gingivitis in many species (Burrows et al., 1985; Amend & Tinkelman, 1985; Bennet & Harvey, 
1991). Furthermore, the host response to infection with such organisms is often characterised by a 
plasmacytic infiltrate (Fox et al., 1996). These organisms are not cultivable using routine 
bacteriological techniques, and their presence has not been assessed in most oral bacteriological 
studies performed in the cat. White et al. (1992) found evidence of spirochaetes in histological 
sections in only 2 of 29 cats with chronic mucogingival diseases, 
Immunological abnormalities 
There are two primary ways in which immunological abnormalities may be manifest. The first is a 
deficiency in the host response to immunological challenge resulting from an absence, or failure, of 
normal function of one or more components of the immune system, This may involve non-specific 
immunodeficiencies affecting elements of the innate immune system, such as defects in complement or 
neutrophil function, or specific immunodeficiencies caused by defects in the adaptive immune system 
affecting normal B- and T-lymphocyte function (Day, 1999). Primary immunodeficiencies are intrinsic 
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and mainly caused by heritable genetic defects (WHO Scientific Group, 1997). Secondary 
immunodeficiencies result from extrinsic or environinental causes, including infectious agents such as 
FIV (Bishop, 1995), immunosuppressive therapeutic drugs such as corticosteroids (Wilckens, 1995), 
and immunosuppressive xenobiotics such as dioxins (Amos, 1993). The second way in which 
immunological abnormalities may present involves pathways of immune-mediated host tissue 
destruction. This may occur through hypersensitivity reactions (type 1,11,111 or IV), or by the 
production of self-reactive antibodies or T-cells resulting in auto-immune disease (Day, 1999). 
A small number of studies have searched for evidence of immunological abnormalities in cats with 
FCGS. Harvey (1991) has drawn attentionto the similarities between the lesions of FCGS and those of 
mink with Ch6diak-Higashi syndrome. This autosomal recessive disorder affects neutrophil function 
and is associated with systemic neutropenia, and has been described in Persian cats (Prieur & Collier, 
1987). However, while cats with Chddiak-Higashi syndrome show signs of early-onset periodontal 
disease and tooth loss, FCGS has not been reported in such cases (Williams & Aller, 199 1). Moreover, 
studies analysing neutrophil function in cats with FCGS have not demonstrated any significant 
abnormalities (Harvey & Campbell, 1989; Sato et al., 1996). Anderson & Pedersen (1996a & b) have 
reported preliminary results of the analysis of peripheral blood CD4+ and CD8+ lymphocytes counts in 
cats with FCGS. Counts were normal or elevated for both CD4+ and CD8+ T-cells, and CD4: CD8 
ratios were normal (2: 1) or slightly less than normal (Anderson & Pedersen, 1996a & b). Many cats 
with FCGS have elevated serum globulin levels (Johnessee & Hurvitz, 1983, Zetner et al., 1989, 
White et al., 1992), and a small study involving clinical cases from Austria and the USA demonstrated 
elevated mean serum IgG, IgM and IgA levels in affected cats by comparison to a control population 
(Zetner et al., 1989). Furthermore, a recent but poorly reported study using a putative anti-feline IgE 
antibody has suggested that serum IgE levels are increased in approximately one third of cats with 
FCGS (Zetner et al., 1996), however, no correlation could be found between individual dietary 
components and levels of antigen-specific IgE (Zetner et al., 1996). This finding supports the 
observation that hypoallergenic diets are rarely beneficial in the management of FCGS (Johnessee & 
Hurvitz, 1983; Harvey, 1995). 
Comparative aspects ofFCGS with oral disease in other species 
Chronic gingivitis related to bacterial ly-induced periodontal disease (PD) has been recognised and 
described in many species including man (Page et al., 1976), dog (Hennet & Harvey, 1992), cat 
(Reichart ct al., 1984; Frost & Williams, 1986), horse (Baker, 1985), ruminants (Andrews, 1985) and 
rodents (Wiggs & Lobprise, 1995). The histological features and pathogenesis of PD are well defined. 
The initial lesion is dominated by an acute inflammatory response in which polymorphonuclear 
neutrophils prevail. However, as the lesion progresses the phenotypic characteristics of the infiltrate 
changes, first to a predominantly T-cell response, then to a mainly B-cell/plasma cell dominated lesion 
Chapter 1 
(Page & Schroeder 1976; Lehner, 1992). Notably, unlike FCGS, the lesions seen in PD are generally 
confined to the periodontal tissues, and the lesions do not extend significantly beyond the 
mucogingival junction. Furthermore, some cats with FCGS are reported to have no or minimal 
evidence of advanced PD (Gruffydd-Jones, 199 1). 
A condition described as plasma-cell gingivitis has been recorded in man. This uncommon disease is 
characterised by erythematous, oedematous, non-ulcerated gingival tissue with occasional involvement 
of other mucosal sites including the tongue, lips, pharynx and larynx (Palmer & Eveson, 198 1; Timms 
& Sloan, 1991; Sollecito & Greenberg, 1992). Histopathological examination of affected sites 
typically reveals epithelial hyperplasia and infiltration of the lamina propria with dense sheets of 
mature plasma cells (Palmer & Eveson, 1981; Timms & Sloan, 1991; Sollecito & Greenberg, 1992). 
This disease has been linked to exposure to an allergen, notably chewing gum, toothpaste, and 
flavoured mints in some cases (Sollecito & Greenberg, 1992). However, in others the aetiology is 
unknown. Management of these latter cases has relied upon the use of long-term systemic and topical 
corticosteroids to control the severity of the lesions (Palmer & Eveson, 198 1; Timms & Sloan, 199 1; 
Sollecito & Greenberg, 1992). 
Thus, the histological features of plasma-cell gingivitis in man bear some resemblance to those 
described in FCGS. Nevertheless a number of clinical and aetiological differences exist. Studies have 
failed to find any evidence to implicate an underlying allergic aetiology in FCGS (Johnessee & 
Hurvitz, 1984; White et al., 1992; Zetner et al, 1996), although the role of allergens as causal agents 
in FCGS has not been widely investigated. FCGS has not been reported to extend to involve the 
laryngeal tissues as has been reported in plasma-cell gingivitis in man. Furthermore, the clinical 
severity of the disease appears to be less pronounced in man than in cats. 
Treatment of FCGS 
A large number of different therapeutic regimes have been utilised in cats with FCGS, however none 
are universally successful. The poor understanding of the aetiopatho genesis of this disease has resulted 
in the use of empirical treatments rather than elimination of specific underlying causal factors. 
Moreover, few clinical studies have been conducted to assess the comparative effectiveness of these 
treatment regimes. 
The maintenance of dental health and oral hygiene is considered by many to be the cornerstone of 
treatment of FCGS (Harvey, 1991; William & Aller, 1992; Pedersen, 1992; Diehl & Rosychuk, 1993). 
Professional scaling alone is thought to be of only short-term value (White et al. 1992; Harvey, 1995). 
Consequently, many authors have advocated the use of antibacterial oral rinses and gels (Gaskell & 
Gruffydd-Jones, 1977; Dillon, 1986; Frost & Williams, 1986; Gaskell et al., 1988; Lyon, 1990; 
Harvey, 1991; Williams & Aller, 1992; Diehl & Rosychuk, 1993; Rosenkranz, 1993). However, little 
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work has been published reporting the efficacy or practicalities of such treatment using commercially 
available products (Miller & Harvey, 1994). Toothbrushing once or twice weekly in cats can reduce 
the amount of calculus accumulation (Richardson, 1965; Harvey 1991). The use of propriety dental 
chews was also shown to reduce plaque accumulation in cats over a short term period (Gorrel et al., 
1998). Furthermore, the use of hard diet (dry diet or biscuit) has been demonstrated to reduce plaque 
and/or calculus accumulation in comparison to soft diets (canned foods) in cats and dogs (Burwasser 
& Hill, 1939; Ruben et al., 1962; Studer & Stapley, 1973; Watson, 1994). However, Harvey (1991) 
reported no significant clinical change in the appearance of lesions in FCGS cases following 
professional pre-scaling and long-terin toothbrushing with 0.2% chlorhexidine several times a week. 
By contrast, Hermet (1995) reported clinical recovery after I to 2 years in 60% of cases (n = 30) 
treated with a combination of antibiotics and chlorhexidine gluconate gel with aggressive dental 
therapy, which included extraction of any retained roots, teeth with feline odontoclastic resorptive 
lesions (Harvey, 1991; Okuda & Harvey, 1992; Ohba et al., 1993a & b; Okuda et al., 1995; Berger et 
al., 1996; Hoffman-Lehmann et al., 1998) and teeth with moderate or severe periodontal disease (Frost 
& Williams, 1986). Other workers have recently claimed similar or higher levels of success using 
radical dental extraction techniques involving removal of all premolars and molars or all of the teeth, 
although these studies are poorly reported (Williams & Aller, 1992; Pedersen, 1992; Harvey, 1995). 
As an adjunct to radical dental extractions and antibacterial therapy a pilot study by Goldstein et al. 
(199 1) suggested that radiation therapy 3 times weekly for 2 weeks post operatively may provide long- 
term benefits in reducing inflammation. Their study, however, contained only one control case. A 
number of authors have also suggested that cryotherapy may produce additional benefits when used 
either alone or in conjunction with dental extractions (Turner, 1986; Harvey, 1991), whereas others 
have suggested that this may eventually lead to increased inflammatory tissue proliferation (Gaskell & 
Gruffydd-Jones, 1977; Gruffydd-Jones, 1991). 
Several reports and reviews have cited the use of antibiotic agents either alone or in conjunction with 
other therapeutic agents. Antibiotics are considered to provide only short-term clinical benefits, with 
signs returning once therapy ceases (Gruffydd-Jones, 199 1; Harvey, 199 1). However, these reports are 
based upon the clinical experiences and impressions gained by the authors rather than controlled 
clinical trials. A number of authors recommend the use of antibiotics with activity against Gram- 
negative and anaerobic organisms, including amoxycillin-clavulanic acid, enrofloxacin, lincomycin, 
clindamycin, spiramycin, metronidazole, and tetracyclines, to be prescribed for a period ranging from 
5-21 days (Gaskell et al., 1988; Pfeifer et al., 1988; Lyon, 1990; Zetner & Van Gool, 1991; Harvey 
199 1; Rosenkrantz 1993; Beck & Osthold, 1996). White et al. (1992) reported that systemic antibiotic 
therapy produced clinical benefits in around one third of cases in a limited study. However the 
duration of therapy and concurrent treatment was not stated. In a short comparative study by Beck & 
Osthold (1996), spiramycin and cephalexin were reported to produce a greater clinical response than 
did clindamycin. 
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Numerous studies and reviews within the literature advocate the use of corticosteroids for the 
treatment of FCV both at anti-inflammatory and immunosuppressive doses (Gaskell & Gruffydd- 
Jones, 1977; Dillon, 1986; Gaskell et al., 1988; Pfeifer et al., 1988; Lyon, 1990; Gruflydd-Jones, 
1991; Diehl & Rosychuk, 1993; Rosenkrantz, 1993). Nevertheless, there are few reports in which the 
response to corticosteroid therapy has been critically evaluated. Pfeifer et al. (1988) reported an 
excellent response in 90% of cats treated with subgingival injection of up to 10mg of triamcinolone in 
conjunction with dental scaling, polishing and extractions, in addition to metronidazole-spiramycin 
therapy. The multiple therapies given make it impossible to evaluate the individual effect of 
triamcinolone and the criteria for assessing the severity of the lesions were not stated. Another study 
reported an improvement in 50% (n = 6), 73% (n = 15) and 86% (n = 11) of cases given long-term 
prednisolone, methylprednisolone and triamcinolone respectively at anti-inflammatory levels (White et 
al., 1992). Some of the cats also received other drugs, and the authors did not state which animals 
received combinations of treatment. The same authors reported that the effectiveness of corticosteroid 
therapy may decrease over a period of time (White et al., 1992). 
Other anti-inflammatory agents that have been utilised in FCGS cases include megoestrol acetate and 
non-steroidal anti-inflammatory drugs (NSAID). Cases of FCGS have been reported to respond 
favourably following the administration of megoestrol acetate, with or without concurrent antibiotic 
therapy (Johnessee & Hurvitz, 1983; White et al., 1992), however the side-effects associated with this 
drug can result in its withdrawal in a large percentage of cases (White et al., 1992). The oral 
application of sodium salicylate was reported to alleviate the discomfort displayed by cats with FCGS 
following scaling and polishing of the teeth in comparison to unmedicated controls (Harvey, 1991). 
Both immunosuppressive and immunostimulatory agents have been utilised with mixed success. Gold 
salts (chrysotherapy) have been utilised successfully in animals and man for the treatment of chronic 
immune-mediated disorders such as rheumatoid arthritis, autoimmune conditions and feline plasma 
cell pododermatitis (Manning et al., 1982; Medleau et al., 1982; McGirr et al., 1984; Griffin, 1991; 
Serra & White, 1989; Kristensen & Mehl, 1992). The precise mode of action of gold salts is unknown. 
Documented effects include anti-immunogenic, anti-inflammatory, anti-microbial, and anti-enzymatic 
activity (Rosenberg & Lipsky, 1979; Long, 1986; Riestra et al., 1988; Griem et al., 1995; Hirohata 
1996; Ishii et al., 1998). A single published study using gold aurothioglucose in cats with FCGS 
reported that 82% (n = 17) of cases showed improvement within 16 weeks of commencing treatment 
(White et al., 1992). As before, some of these cats were given additional treatment, and the criteria for 
the assessment of the severity of disease were not documented. 
Alternative immunosuppressive therapies that have been used or suggested for the treatment of FCGS 
include azathioprine, cyclophosphamide, or chlorambucil (White et al., 1992; Diehl & Rosychuk, 
1993; Rosenkrantz, 1993). However, there is no information about their efficacy. 
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The use of immunostimulatory regimes has produced mixed results in the treatment of FCGS. The use 
of levamisol has been advocated, however anecdotal reports have suggested that it is ineffective 
(Gruffydd-Jones, 1991; Johnessee & Hurvitz, 1983; White et al., 1992). In contrast, Mayr et al. (199 1) 
reported the results of a study which compared the oral administration PIND-ORF (an attenuated strain 
of Parapoxvirus ovis produced in cell culture) for 4 to 14 days with the results from treatment using 
"existing therapeutic measures against chronic stomatitis". They claimed 42% (n = 33) of cases treated 
with PIND-ORF responded favourably without recrudescence over a6 to 19 month period compared 
to 13% (n = 39) of control cats. The authors considered that unspecified viruses play an important role 
in the aetiopathogenesis of FCGS and argued that oral administration of PIND-ORF results in local 
paramunization with stimulation of the local mucosal immune system in an unspecified manner. 
However no immunological studies were performed to support this conclusion. Furthermore, following 
initial claims that PIND-ORF could be used successfully for the treatment of FeLV (Hbrber & Mayr, 
199 1; H6rber et al., 1992), a subsequent double-blind study did not show any significant benefit in the 
treatment of cats infected with FeLV (Hartmann et al., 1998). 
Recently, the effect of oral administration of bovine lactoferrin in FCGS has been assessed (Sato et al. 
1996). Lactoferrin is produced endogenously in saliva and is reported to have antibacterial and 
immunomodulatory functions, especially in relation to neutrophil function (Hoek et al., 1997; Peen & 
Erga, 1998). In a small study involving 3 FIV-seropositive cats and 4 FIV-seronegative cats treated for 
a2 week period with 40mg/kg bovine lactoferrin, the authors reported an overall clinical improvement 
in all of the cats. A modest increase in neutrophil phagocytosis in both diseased and healthy cats was 
demonstrated. Furthermore, the data presented suggested that cats with FCGS had normal or slightly 
increased phagocytic activity both before and after treatment. However, a negative control population 
was not included. The authors suggested that the clinical improvement may, in part, be related to 
increased neutrophil phagocytic function. However, they also suggest that lactoferrin may act by other 
means, such as alteration of expression of neutrophil adherence molecules. 
Other therapies that have been reported include the use of anti-viral agents in FIV infected cases. 
Treatment with AZT and PMEA in a small number of cases has shown promising results, with some 
individuals showing long-term remission of oral inflammation (Egberink et al., 1990; Tizard, 1991; 
Hartmann et al., 1995a & b). The use of soft-tissue lasers has been reported with limited success in a 
small sample of 8 cases (Harvey, 1991). Other postulated but undocumented treatments include 
multivitamin supplementation (Gaskell & Gruffydd-Jones, 1977; Lyon, 1990; Gruffydd-Jones, 1991) 
and chemical cautery (Gaskell & Gruffydd-Jones, 1977; Joshua, 1979; Dillon, 1986). 
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1.2 INIMUNOGLOBULINS 
Adaptive immune responses are generated through the clonal selection of antigen-specific lymphocytes 
and can be divided into cell-mediated and humoral responses. Cell-mediated responses involve the 
concerted action of a variety of cells, whilst humoral immunity is mediated by immunoglobulins. 
Immunoglobulins (1g), or antibodies, comprise a heterogenous group of glycoproteins involved in 
immune recognition and the generation of effector responses to antigens (Davies & Metzger, 1983). 
They are produced exclusively by plasma cells of the B-lymphocyte lineage, and can exist either as 
membrane-bound cell surface molecules or as soluble products within extracellular fluids (Frazer and 
Capra, 1999). 
Immunoglobulin structure 
Detailed reviews of immunoglobulin structure and function are provided by Davies & Metzger (1983), 
and Frazer and Capra (1999). Feline immunoglobulins have been reviewed by Barlough et al., (1981) 
and Pedersen. (1987). Based upon the type of heavy chain present within individual immunoglobulin 
molecules, up to five classes (isotypes) of antibody are recognised in mammals - IgG (y), IgM (ýt), IgA 
(cc), IgE (e) and IgD (5). In addition, up to five IgG subclasses and 2 IgA subclasses have been 
described for some species (Mazza et al., 1994; Baldwin & Denham, 1994; Grant, 1995; Tizard, 1996; 
Leduc et al., 1997; Frazer and Capra, 1999). 
Membrane bound immunoglobulin 
Membrane-bound immunoglobulin (mlg) is anchored to the cell membrane by a short 3 to 28 amino 
acid C-terminus hydrophobic transmembrane domain (Davies & Metzger, 1983; Max, 1999). In 
conjunction with two accessory transmembrane polypeptides, Ig-ct (CD79a) and Ig-P (CD79b), mlg 
forms part of the B-cell antigen receptor (BCR) (Pleiman et al., 1994). All isotypes of mlg can form 
BCRs with Ig-a and Ig-P (Venkitaraman et al., 1991). Binding of antigen to mlg initiates cross linking 
of BCRs, which stimulates internalisation of the BCR-antigen complex, and causes activation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) present within the cytoplasmic domains of 
Ig-cc and Ig-P, which mediate signal transduction via a phosphorylation cascade (Cambier et al., 1994; 
Reth & Weinanads, 1997; MacLennan, 1999; Kurosaki, 1999). Thus, by binding to the BCR, antigen 
promotes expansion and differentiation of B-cell clones which are committed to producing specific 
immunoglobulin capable of recognising the same antigen. 
Cross reactive reagents against Ig-cc (CD79a) are often used for the detection of B-cells in various 
species (Callanan et al., 1996, Day, 1998; Day et al., 1999). Human and murine studies have indicated 
that Ig-(x is expressed during all stages of B-cell development, although in plasma cells Ig-cc is retained 
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within the cytoplasm and is not expressed on the cell membrane (Mason et al., 1992; Meffre et al., 
1996; Lassoued et al., 1996; Ghia et al., 1998). Extensive analysis of CD79a expression during the 
development of B-cells has not been documented in the cat. Nonetheless, studies using murine 
monoclonal antibodies raised against peptides from the intracytoplasmic domain of Ig-cc have 
demonstrated specific membrane-staining of B-cell-dependent areas of lymphoid tissues, and 
cytoplasmic staining of plasma cells (Callanan et al., 1996; Day, 1998; Day et al., 1999). These 
findings suggests that a molecule analogous to murine Ig-cc is present in mature feline B-cells. 
Soluhle immunoglohulins 
Immunoglobulins produced by plasma cells lack the C-terminus hydrophobic transmembrane domain 
present in mIg, consequently, these are secreted into the extracellular fluid as soluble immunoglobulins 
(Arpin et al., 1995; Slifka & Ahmed, 1998; McHeyzer-Williams & Ahmed, 1999; Max, 1999). Soluble 
immunoglobulins are bifunctional. Antigen binding is mediated by the variable regions, where the 
affinity and specificity of each inummogIobulin is determined by the structural confirmation of the 
antigen-binding sites (Amit et al., 1986; Alazari et al., 1988; Frazer and Capra, 1999). In addition, 
various class- and subclass-dependant effector functions are mediated by the Fc portion of the heavy 
chain (Burton & Woof, 1992; Frazer and Capra, 1999). 
Feline IgG 
In the cat, immunoelectrophoretic studies documented by Okoshi et al. (1968) and Schultz et al. 
(1974) suggested the presence of multiple IgG subclasses (BarIough et al., 1981). Subsequent studies 
using ion-exchange and affinity chromatography methods have isolated three distinct subclasses of 
IgG (termed IgG 1, IgG2, IgG3) (Baldwin & Denham, 1994; Grant, 1995a) - although it is not clear if 
the nomenclature applied to each of these subclasses is consistent between studies. In addition, Grant 
(1995a) has presented preliminary evidence for the existence of a fourth IgG subclass, however these 
findings have yet to be substantiated. Furthen-nore, Kanai et al. (2000) recently reported the discovery 
of two alleles within one of the subclasses of the feline y-chain (referred to as IgGl). Analysis of the 
molecular weight of the y-chain present in each of the three confirmed subclasses of feline IgG found 
them all to be approximately 50 kDa (Grant, 1995a). The molecular weight of the whole IgG monomer 
is approximately 150 K Da (Pedersen, 1987). These values are comparable to IgG from other species. 
Partial sequences of IgG paraproteins by Kehoe et a]. (1972) demonstrated a high level of homology 
with human IgG (Barlough et al., 1981). However, functional studies detailing specific biological 
differences between the IgG subclasses have not been reported, although it is known that cats produce 
both complement-fixing and non-complement-fixing IgG (Olsen et al., 1974). 
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Feline IgM 
The presence of IgM was first suggested in the cat by Okoshi et at. (1968). Subsequent studies 
confirmed the existence of IgM in serum and a range of mucosal secretions from cats (see below) 
(Schultz et al. 1974). Nonetheless, few studies have characterised the physical characteristics or 
effector functions of feline IgM. The molecular weight of feline IgM in serum has been reported to be 
approximately 900 kDa (Pedersen, 1987), and the ýi-chain to be 74kDa (Grant 1995a). These findings 
are consistent with IgM from other species (Tizard, 1996). 
Feline IgA 
The existence of IgA in cats was first suggested by Okoshi et al. (1968), and was confirmed by 
Vaerman et al. (1969). Subsequent studies indicated that IgA was present predominantly as a dimer 
within serum, and that IgA could be detected within a range of mucosal secretions, including saliva 
and bile (Orlans & Feinstein, 1971; Vaerman, 1973, Schultz et al., 1974; Yamada et al., 1984 & 1992; 
Grant, 1995a). Similar to other species, feline dimeric IgA has a molecular weight of around 350 kDa 
(Pedersen, 1987) and the cc-chain is reported to be 54 kDa (Grant, 1995a). Currently, only one type of 
IgA is recognised in the cat, however studies by Grant (1995a) have suggested that 2 subclasses may 
exist, as is the case in humans (Russell et al., 1999). Studies analysing the functional properties of 
feline IgA have not been documented. 
Feline IgE 
A number of studies have provided compelling evidence for the existence of IgE in the cat, and its 
involvement in allergic diseases (Pedersen, 1987; DeBoer et al., 1993; Foster et al., 1995; Gilbert & 
Halliwell, 1998a & b; Halliwell et al., 1998). In addition, the full nucleotide sequence of putative 
feline e-heavy chain has been determined (A. P. Foster & C. R. Helps, personal communication). 
Nevertheless, this immunoglobulin has yet to be isolated and purified from feline tissues. 
IgD 
IgD is primarily a cell surface receptor expressed during B-cell differentiation (Ghia et al., 1998; 
Melchers & Rolink, 1999), however it has yet to be identified in a number of species, including the cat 
(Tizard 1996). IgD is found in serum at very low levels, but it is not secreted during immune responses 
or in response to mitogenic stimulation. Consequently secreted IgD is not considered to play an 
important role in humoral immunity (Frazer & Capra, 1999). 
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Immunoglobulins infeline bodyfluids 
A number of investigators have measured serum immunoglobulins in cats (Schultz et al., 1974; Hiraga 
et al., 1981; Yamada et al., 1984; Pedersen, 1987; Zetner et al., 1989; Ackley 1990; Poli et al., 1992; 
Baldwin & Denham, 1994; Grant, 1995b). As expected, IgG was shown to be the predominant 
immunoglobulin present within serum, and IgG I, IgG2 and IgG3 (as defined by Baldwin & Denham, 
1994) were reported to account for approximately 45,40 and 15% respectively of the total IgG 
concentration in normal cats (Hiraga et al., 198 1; Yamada et al., 1984; Pedersen, 1987; Ackley et al., 
1990; Baldwin & Denham, 1994; Grant, 1995b). Nonetheless, the levels of serum immunoglobulin 
reported in healthy cats varies considerably between studies, which most likely reflects differences in 
the methodologies and the environments in which the cats were raised. In a study of various cat 
populations, Pedersen (19 87) reported that conventionally reared adult cats housed in a cattery had the 
highest serum IgG levels, whereas a population of young adult household cats and adult specific- 
pathogen free cats (SPF) had similar serum TgG concentrations. By contrast Grant (1995b) found that 
SPF cats had lower IgG levels than healthy pet cats. Serum immunoglobulin concentrations also vary 
with age. Hiraga et al. (1981) intermittently monitored the postnatal development of serum 
immunoglobulin and protein levels during the first year of life of germ-free cats which were 
transferred to a SPF environment at 60 days of age. A progressive increase in serum immunoglobulin 
concentrations occurred during this time-period. Furthermore, a prominent increase in serum 
immunoglobulin concentrations was seen following the environmental change, which probably reflects 
the resultant increased exposure to bacteria. Nevertheless, the serum inummoglobulin concentrations 
reported in this latter study were exceptionally low, and it is not clear how well these findings relate to 
the situation in conventionally reared cats. Studies by Yamada et al. (1992) in experimental cats from 
I to 12 months of age demonstrated that the serum IgG, IgM and IgA levels increased progressively up 
to 5 to 7 months of age, and then remained unchanged. These findings agree with those of Groulade et 
al. (1965) who analysed serum protein levels in healthy, free-ranging cats aged from I month to 18 
years. These authors concluded that adult globulin levels were attained by 6 months of age, although 
there was a gradual and progressive increase in the gammaglobulin fraction with increasing age. By 
comparison, studies in humans have shown that adult serum immunoglobulin levels are reached by 
around 16 years of age, and tend to decrease in the elderly (Arranz et al., 1990; Challacombe et al., 
1995). 
Few studies have examined immunoglobulins within mucosal secretions from cats (Orlans & Feinstein, 
1971; Vaerman, 1973; Schultz et al., 1974; Yamada et al., 1984 & 1992; Pedersen 1987; Poli et al., 
1992). IgA was found to be the predominant immunoglobulin in saliva, tears, nasal secretions, tracheal 
secretions, bile, and intestinal fluid, however IgG was predominant in milk and colostrurn (Yamada et 
al., 1984; Pedersen, 1987). The effects of the rearing environment upon immunoglobulin levels in 
mucosal secretions has not been examined. However, Yamada et al. (1992) demonstrated that the 
concentration of immunoglobulins in bile from cats increased progressively until about 8 to 9 months 
old, although biliary IgA reached adult levels by 4 to 5 months of age. Similar studies have not been 
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performed on other mucosal secretions in this species. In humans, however, adult salivary IgA levels 
are not attained until after 2 years of age (Tappuni & Challacombe. 1994). Furthcrinore, a significant 
increase in the immunoglobulin concentrations of whole saliva are seen in elderly patients (Ganguly et 
al., 1986; Challacombe et al. 1995), although this was mainly attributed to a decrease in the salivary 
flow rate (Challacombe et al. 1995). 
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1.3 CYTOKINES 
Cytokines are potent regulatory polypeptides that possess pleotropic activity and play a central role in 
modulating inflammatory and immune responses, and in the growth and differentiation of embryonic 
cells. Reviews of cytokine biology are provided by Meyers & Murtaugh, (1995); Schijns & Horzinek 
(1997); Thomson, (1998); Leonard, (1999); and Dunham (1999). Cytokines are produced by a large 
array of cell-types and may act in an autocrine, paracrine, or endocrine manner. They are produced 
constitutively by some cells, but more often cytokines are induced through altered gene transcription 
or translation. Individual cells often secrete multiple cytokines. Furthermore, most cytokines can have 
a multitude of effects, and different cytokines can have similar biological effects, consequently there is 
a level of redundancy within the cytokine network. The biological effects of cytokines are mediated by 
specific cytokine-receptors present on the surface of target cells. These receptors are under regulatory 
control, and some receptors can exist in a soluble form, and therefore act as regulatory antagonists. On 
binding to cell-surface receptors, cytokines initiate an intercellular signal cascade which mediates 
regulatory changes in cellular gene transcription, protein expression, and biological function. 
Cytokine regulation ofthe immune response: The type 1: type 2 paradigm 
In the 1980s it was shown that many murine CD4+ T-helper (Th) cell clones could be separated into 
distinct functional subsets based upon the pattern of cytokines they produced (reviewed by Mosmann 
& Coffinan, 1989). Thl type cells produced interferon (IFN)-y, interleukin (IL)-2, and turnour necrosis 
factor (TNF)-o and were shown to mediate delayed-type hypersensitivity (DTH) responses (Mosmann 
et al., 1986; Cherwinski et al., 1987; Cher & Mosmann 1987), while Th2 type cells produced IL4, IL- 
5, IL-6, IL- 10 and IL- 13 and were found to support B-cell IgG I and IgE humoral responses (Mosmann 
et al., 1986; Cherwinski et al., 1987; van Snick et al., 1989; Fiorentino et al., 1989). Moreover, the two 
subsets tend to cross-regulate one another by acting in an autocrine fashion to promote the 
development of cells of the same subset, and by suppressing the activity of the opposing subset (Abbas 
et al., 1996). Nevertheless, it was also found that some clones produced a mixture of Thl and Th. 2 
cytokines, such as IFN-y, IL-2, IL4, and IL-5 (Firestein et al., 1989; Mosmarm & Coffman, 1989; 
Seder & Paul, 1994). These clones were designated ThO, and it is thought that they may represent 
intermediary cells in the differentiation of Thl or Th2 cells, or end-stage cells that do not conform to 
the Th I /Th2 model (Seder & Mosmann, 1999). 
Following these in vitro studies, it was demonstrated that murine Thl and Th2 T-cell subsets exist in 
vivo (Seder & Mosmann, 1999). Furthermore, the appearance of these subsets correlated with cell- 
mediated and humoral responses respectively (Reiner & Locksley, 1995). Hence, these findings led to 
the notion that immune responses could be classified as Thl or Th2 responses based upon the pattern 
of cytokines produced by the effector Th cells. 
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Subsequently, it has been established that Thl/Th2 cells also exist in humans and some other species 
(Romagnani, 1994 & 1996; Brown & Estes, 1997) - although it is clear that some species differences 
exist in the cytokines produced by Thl and Th2 cells by comparison to mice (Seder & Mosmann, 
1999). Furthermore, it has become increasingly recognised that immune responses are often 
hetcrogenous rather than polarised, such that Thl and Th2 cytokine patterns are likely to represent 
opposing ends of a spectrum of profiles (Kelso, 1995; Abbas et a]., 1996; London et al., 1998). In 
addition, there is growing evidence that CD8+ cytotoxic T-cells (Tc) can be differentiated into Thl- 
like (Tc Q and Th2-like (Tc2) subsets based upon their pattern of cytokinc production (Salgame et al., 
1991; Croft et al., 1994; Caruso et al., 1998; Seder & Mosmann, 1999). Moreover, cytokines released 
by non-T-cells within the tissues will contribute to the local cytokine milieu and will therefore 
influence the immune response. Consequently, this has led to the argument that immune responses 
should be referred to as 'type I' or 'type 2' responses (Bloom et al., 1992; Abbas et al., 1995; 
Constant & Bottomly, 1997), In general, type I responses are dominated by cell-mediated immune 
responses (and the production of antibody classes/subclasses that promote cell-mediated responses) 
and are associated with preponderance of Thl -like cytokines (e. g. IFN-y, IL-2) and others, such as IL- 
12 (see below) which promote Thl development. By contrast, type 2 responses involve humoral 
responses and allergic reactions, and are associated with Th2-like cytokines (e. g. IL-4, IL-5) (see 
below), 
Recently, specialised populations of regulatory CD4+ T-cells have been identified. T-helper 3 (Th3) 
cells have been described in mice and are found in the intestine. These cells secrete high levels of 
transforming growth factor (TGF)-P (Weiner, 1997) and are thought to play an important role in the 
generation of oral tolerance (reviewed by Mowat & Weiner, 1999). A unique subset of CD4' cells 
which produce high levels of IL- 10 has also been identified in mice and humans, and have been termed 
T-regulatory cells (Trl) (Groux et at., 1997; Cavani et al., 2000). TrI cells inhibit T-cell proliferative 
responses in an IL-10-dependent manner, and are considered to play an important role in the 
generation of peripheral tolerance, and the regulation of Thl-mediated responses (Groux et al., 1997; 
Asseman & Powrie, 1998; Cavani et al., 2000). Other regulatory populations may also exist (Lepault 
Gagnerault, 2000). 
Do cats generate type I and type 2 responses? 
A range of cytokines have been identified and cloned in the cat (Table 1.2). It has not yet been 
demonstrated that feline T-cells can be divided in to Thl- and ThNike subsets, however a number of 
studies have examined the expression of type I and type 2 cytokines in response to experimental 
infection with various micro-organisms. Pedersen et at. (1998) analysed the cytokine responses in cats 
inoculated with Listeria monocylogenes (intracellular) or Serratia marcesens (extracellular). 
Comparison of the changes in TNF-cc, IFN-y, IL-12, IL-10, and IL-4 mRNA expression induced within 
the draining lymph node showed that L. monocytogenes infection was associated with a significantly 
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greater increase in IFN-y gene expression, and that S marcesens induced a significantly greater 
increase in TNF-a expression (Pedersen et al., 1998). Both bacteria evoked an increase in the 
expression IL- 10 and IL- 12, whereas IL-4 expression was variable and no significant differences in the 
level of expression were found between the two responses (Pedersen et al., 1998). A further study 
found that inoculation with another intracellular bacterium, Yersina pseudotuberculosis, induced 
upregulation of TNF-a, IFN-y, IL-12, and IL-10, but downregulation of 114 (Sukura et al., 1998). 
Additional experiments analysing the responses in cats challenged with Toxoplasma gondii have also 
demonstrated that protective immune responses are associated with increased expression of IFN-y, IL- 
2, and IL-12 mRNA, whereas susceptibility to toxoplasma infection in FIV-infected cats is associated 
with a failure to upregulate IL-2 and IL-12, and increased expression of IL-10 (Levy et al., 1998; 
Koyama et al., 1999). Together these results indicate that the pattern of cytokine expression induced 
during the generation of cell-mediated responses in the cat is consistent with a type I profile. 
However, insufficient studies have been reported analysing cytokine expression during hurnoral 
responses to determine whether cats can generate classical type 2 cytokine profiles under such 
circumstances. 
Table 1.2 Cloned feline cytokines 
Cytokine Reference 
IL-la Straubinger et al., 1999 
IL-lp Daniel et al., 1992 
IL-2 Cozzi et al., 1993 
IL-4 Schijns et al., 1995 
IL-5 Padrid et al., 1998 
IL-6 Ohashi et al., 1993; Bradley et al., 1993 
IL-8 Genbank (Accession no. A17158588) 
IL-10 Genbank (Accession no. AF060502) 
IL-12 (p35 & p40) Schijns et al., 1997; Fehr et al., 1997 
IL-15 Genbank (Accession no. AF108148) 
IL- 16 Leutenegger et al., 1998 
IL-18 Hanlon et al., 1998 
IFN-(x Nakamura et al., 1991 
IFN-y Argyle et al., 1995; Schijns et al., 1995 
TNF-cc McGraw et al., 1990; Daniel et al., 1992; Rimstad et al., 1995 
G-CSF Genbank (Accession no. Y08558) 
GM-CSF Genbank (Accession no. AF053007) 
Stem cell factor Dunham & Onions, 1996 
Erythropoietin Genbank (Accession no. U00685) 
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The cytokines 
There follows a summary of the major properties of the cytokines analysed in the work presented in 
Part IV, References to texts providing comprehensive reviews of cytokines are provided above. 
IFN-r 
IFN-y is the principle Th type I cytokine. IFN-y is secreted as a biologically active homodimer by Th I 
T-cells, CD8' T-cells, and natural killer (NK) cells (Farrar & Schreiber, 1993) and it plays a central 
role in the generation of cell-mediated immune responses. 
IFN-y production is induced by IL-12 released by APCs during activation of naive Th-cells (Gately et 
al., 1998; Trinchieri 1997). In addition IL-12 induces expression of receptors for IL-18 on activated T- 
cells (Okamura et al., 1998). IL-18 is also released by APCs and acts synergistically with IL-12 to 
induce IFN-y from activated T-cells (Murphy, 1998; Okamura et al., 1998). In turn, IFN-y primes 
phagocytes for greater IL-12 production, thereby creating a positive feedback loop (Trinchieri, 1997). 
During the differentiation of Th cells, IFN-y promotes the production of Thl cells by facilitating the 
ability of naive cells to respond to IL-12 (Seder & Paul, 1994; Seder & Mosmann, 1999), and recent 
studies have shown that IFN-y induces expression of the IL-12RP2 chain during activation of naive 
Th-cells (Szabo et al., 1997; Murphy; 1998). 
IFN-y also contributes to cell-mediated responses through a number of other mechanisms. In 
macrophages IFN-y promotes MHC class 11 expression, and stimulates killing of intracellular 
pathogens by enhancing mechanisms such as the production of reactive oxygen intermediates (Gordon, 
1999). Furthermore, in conjunction with other factors, IFN-y promotes macrophage turnoricidal 
activity (De Maeyer & De Maeyer-Guignard, 1998). IFN-y induces increased expression of MHC 
class I and class 11 molecules in a range of cells (reviewed by Farrar & Schreiber, 1993). IFN-y also 
possesses some antiviral activity (De Maeyer & De Maeyer-Guignard, 1998; Ahmed & Biron, 1999). 
In addition, IFN-y has effects upon the hurnoral immune response. However, its effect is variable and 
may be inductive or inhibitory depending upon the activation status of the B-cell and the presence of 
other factors (reviewed by Snapper, 1996). In the mouse, IFN-y promotes class switching to IgG2a, 
and may promote or inhibit class switching to IgG3, depending on how the cell is activated (Snapper, 
1996; Snapper & Finkelman, 1999). Furthermore, IFN-y can inhibit many of the effects of IL-4 upon 
B-cells, and can therefore inhibit class switching to IgE, and IgGI (murine) or IgG4 (human) (Snapper 
& Finkelman, 1999). Thus, IFN-y tends to promote the production of immunoglobulin isotypes (IgG3 
and lgG2a) that are able to assist in cell-mediated responses through their capacity to fix complement, 
to act as opsinins, and to assist in ADCC. 
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IL-2 
IL-2 is a Th type I cytokine produced almost exclusively by activated T-cells (especially CD4'), 
although activated B-cells may be able to produce limited amounts of IL-2 (Justement et al., 1989). IL- 
2 acts as a growth and differentiation factor for T-cells, and acts upon activated B-cells expressing the 
high affinity IL-receptor (IL-2R) to enhance proliferation and antibody production (Mcllraith & 
Lipsky, 1996). IL-2 can also stimulate the growth and differentiation of NK cells, macrophage- 
monocytes, and oligodendrocytes (Smith, 1984 & 1988; Gaffen et al., 1998). The IL-2 receptor (IL- 
2R) comprises 3 polypeptide chains, IL-2R a, P, and y. IL-2cc and the IL-2py heterodimer can each 
bind IL-2 with low affinity, however high affinity binding is only achieved with the IL-2Rccpy 
heterotrimer (Weiss, 1999). The y-chain (y-common) is also part of the IL-4, IL-7 IL-9, and IL-15 
receptors (Sugamura et al., 1996). 
IL-4 
IL-4 is the principle Th type 2 cytokine and is produced by T-cells (CD4' Th2 cells and CD8'cells) 
(Mosmarm & Coffman, 1989; Padmini et al., 1991) and some atypical T-cells (NKI. I'CD4"') 
(Yoshimoto et al., 1995), mast cells and eosinophils (Bradding et al., 1992; Dubucquoi et al., 1994). 
IL-4 plays a fundamental role in promoting the differentiation of Th2 cells (Abehsira-Amar et al., 
1992; Maggi et al., 1992; Seder & Paul, 1994) and suppressing the development of Th I cells (Seder & 
Paul, 1994; Abbas et al., 1996). This latter effect may, in part, be mediated through the ability of IL4 
to downregulate expression of the IL-12R P2-subunit (Szabo et al., 1997; Murphy 1998). In B cells, 
IL-4 promotes B-cell proliferation and differentiation, and enhances expression of MHC class 11, 
CD40, and other receptors and co-receptors, such as CD23 (the low-affinity IgE receptor -FccRII), and 
CD80 (117-1) and CD86 (137-2) (De Vries & Punnonen, 1996; Chomarat et al., 1998). These factors 
increase the ability of B-cells to present antigen to T-cells. IL4 promotes class switching to IgE and 
IgG I in the mouse and to IgE and IgG4 in humans (Snapper & Finkelman, 1999). 
IL4 acts with TNF to induce expression of VCAM-I and downregulate E-selectin on vascular 
endothelial cells (Thornhill et al., 1991; Nelms et al., 1999), which is thought to promote the 
extravasation of eosinophils and T-cells in to inflamed sites. 
IL-5 
IL-5 is a Th type 2 cytokine and is produced by T-cells, mast cells and eosinophils and occurs as a 
homodimer (Takatsu et al., 1994; Takatsu, 1996). IL-5 supports the proliferation and secretion of 
immunoglobulin in activated B-cells and can enhance the secretion of IgA (Coffinan et al., 1987). IL-5 
also promotes class switching to IgGI and IgE (Snapper & Finkelman, 1999) In addition, IL-5 
promotes the differentiation of eosinophils (Takatsu et al., 1994). 
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IL-6 
IL-6 is a proinflammatory Th type 2 cytokine. It is synthesised by a range of cells including T-cells, B- 
cells, macrophage-monocytes, granulocytes, mast cells, fibroblasts, keratinocytes, endothelial cells 
smooth muscle cells, and osteoblasts (Tanaka et al., 1996). IL-6 enhances differentiation of B-cells 
into plasma cells and promotes antibody production of all isotypes (Tanaka et al., 1996; Kishimoto & 
Hirano 1988). IL-6 is necessary for antigen-specific antibody production in primary responses, but not 
secondary responses (Hilbert et al., 1989). T-cell activation and growth is also enhanced by IL-6 
(Hirano 1998). IL-6 stimulates and promotes differentiation of haernatopoietic cells (Hirano 1998). In 
conjunction with other factors such as IL-I and TNF, IL-6 is involved in the induction of the acute 
phase response following tissue injury (Baumann & Gauldie 1994). Overproduction of IL-6 is 
associated with polyclonal hypergammaglobulinaernia (Jourdan et al., 1990; Hagiwara & Klinman, 
1996; Hirano, 1998). 
IL-10 
IL-10 was first identified in murine Th2 cells as a factor that inhibited cytokine synthesis in Thl cells 
(Fiorentino et al., 1989). Subsequently however, IL-10 has been shown to be produced by both Thl 
and Th2 cells in humans (Del Prete et al., 1993). Nevertheless, IL-10 is still generally regarded as a 
type 2 cytokine. IL-10 can be produced by range of cells, including by T-cells, macrophages, 
keratinocytes, activated mast-cell lines, B-lymphomas, and BI-cells (reviewed by Moore et al., 1993; 
and Briere et al., 1996). 
IL-10 has potent inhibitory effects on antigen presenting cells (APCs), such as macrophages- 
monocytes and dendritic cells, and on granulocytes. These effects include inhibition of the production 
of a wide range of cytokines, including IL-Icc, IL-1P, IL-6, IL-8, IL-10 itself, IL-12, and TNF-oc, and 
the expression of various co-receptors and MHC class 11 in monocytes-macrophages (for further 
discussion see Moore et al., 1993; and Waal Malefyt & Moore, 1998). The effects of IL-10 on APCs 
profoundly reduces their ability to activate T-cells. Thus, through inhibition of IL-12 production by 
APCs, IL- 10 inhibits IFN-y production from Th I -type cells (Koch et al., 1996; Trinchieri, 1997). 
By contrast, IL-10 enhances many B-cell and mast cell functions (Moore et al., 1993). IL-10 enhances 
B-cell growth and antibody secretion, and can increase MHC class 11 expression (Moore et al., 1993; 
Briere et al., 1996). The effects of IL-10 upon isotype switching in B-cells are controversial and vary 
depending upon the presence of additional factors. In general, IL-10 appears to promote class- 
switching to particular IgG subclasses and IgA (Briere et al., 1996; Waal Malefyt & Moore, 1998; 
McIntyre & Strober, 1999). 
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IL-12 
IL-12 is a proinflammatory cytokine of which the biologically active form is a heterodimer (p70) 
composed of a heavy (p40) and light chain (p35) which are differentially regulated (Podlaski et al., 
1992; Trinchieri 1995). Many cell types can express the p35 gene, however expression of p40 is 
primarily restricted to antigen presenting cells such as dendritic cells, and to macrophages and 
neutrophils (D'Andrea et al., 1992; Cassatella et al., 1995; Trinchieri, 1995 & 1997; Storkus et al., 
1998; Gately et al., 1998). Although IL-12 can be produced by Epstein-Barr virus (EBV)-transformed 
B-cells, studies by Gu6ry et al. (1997) suggest that normal B-cells do not secrete IL-12. In accordance 
with this, Dean & Pedersen (1998) did not detect IL-12 p40 expression in feline B-cells, nor CD4+ or 
CD8' T-cells. The p35 chain is only secreted as part of the p70 homodimer, whereas the p40 chain is 
secreted in excess to the heterodimer and can form p40 homodimers, (p40)2 (D'Andrea et al., 1992). 
While the p40 homodimers are biologically inactive, they can bind to the IL-12 receptor and may act 
as a physiological regulator of the biologically active heterodimer (Yashimoto et al., 1988; Gately et 
al., 1998). 
In phagocytic cells, IL- 12 production by is induced by various viruses, bacteria, and bacterial products 
(D'Andrea 1992; Biron & Gazzinelli 1995; Klinman et al., 1996; Trinchieri 1997). In addition, 
activated T-cells expressing CD40 ligand (CD40L) can stimulate IL-12 production by dendritic cells 
and macrophages expressing CD40 (Shu et al., 1995; Koch et al., 1996; Grewal & Flavell, 1998; Van 
Kooten & Banchereau, 1997). 
IL-12 is considered to be a primary factor in promoting and regulating the extent and magnitude of the 
Th I response (Seder & Mosmann, 1999). IL-12 is a potent inducer of IFN-y production by T-cells and 
NK cells (Seder et al., 1993; Manetti et al., 1993; Hseih et al., 1993). IL-12 induces expression of IL- 
18 receptor on T-cells, and acts synergistically with IL-18 to induce IFN-y production (Ahn et al., 
1997; Okamura et al., 1998). In mice IL-12 promotes the differentiation of Thl cells and inhibits the 
generation of Th2 (IL-4 producing) cells (Hseih et al., 1993), however this effect is less pronounced in 
human T-cells (Manetti et al., 1994). IL-12 also primes T-cells for IL-10 production (Meyaard et al., 
1996), which acts to inhibit IL-12 production (Koch et al., 1996). This is thought to prevent 
overproduction of IL-12, which can cause toxic or lethal effects (Gazzinelli et al., 1996). 
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1.4 DEFENCE MECHANISMS IN THE ORAL CAVITY 
The oral mucosa plays an important role in the maintenance of oral health by acting as a physical 
barrier to prevent the penetration of micro-organisms and antigenic macromolecules. However, the 
oral cavity has a number of anatomical (the anatomy of the feline mouth and teeth has been reviewed 
by Orsini & Hennet, 1992; and Miles & Grigson, 1990) and functional features that make it different 
from other mucosal surfaces. The oral mucosal membranes have evolved to be sufficiently durable to 
protect the underlying tissues from mechanical trauma, infectious agents, toxins, and other antigenic 
substances, while retaining sufficient compliance and flexibility to facilitate the ingestion of food. In 
addition, the oral mucosa has to accommodate being breached by the dentition. Moreover, the teeth 
provide hard, non-shedding surfaces upon which bacteria can attach and grow (Marsh & Martin, 
1992). Consequently, a number of non-specific and specific defence mechanisms exist to help preserve 
and protect the oral mucosal surfaces. 
Mucous membrane 
The mucous membrane of the oral cavity varies with anatomical location (Johnson et al., 1987; 
Berkovitz et al., 1992). Three types of mucosa are recognised. Masticatory mucosa protects against 
compression and friction and is found in areas such as the hard palate and the attached gingiva. It is 
characterised by keratinised epithelium and a thick lamina propria tightly bound to the underlying 
mucoperiosteurn (Johnson et al., 1987; Orsini & Hennet, 1992). Lining mucosa is mobile and elastic 
and is found in areas of the mouth not subject to high friction, such as the lips, buccal mucosa, soft 
palate, and the floor of the mouth. The epithelium in these mucosal sites is generally thin and non- 
keratinised or parakeratinised, and has loose lamina propria and, commonly, a submucosa, which may 
contain minor salivary glands (Richardson, 1965; Crawford et al., 1975; Okuda et al., 1996). By 
contrast to primates, the lip and buccal mucosal epithelium in the cat are amongst the thinnest of the 
oral regions, and the buccal epithelium shows a tendency towards parakeratinisation (Johnson et al., 
1987). The third type of mucosa is specialised mucosa, such as the gustatory mucosa of the dorsurn of 
the tongue. 
Oral lymphoid tissues 
Extra-oral and intraoral lymphoid tissue is associated with the oral cavity. While these tissues have 
been relatively well-characterised in humans, they have been poorly defined in the cat. 
Extra-oral lymphoid tissue 
In the cat, the submandibular, parotid and retropharyngeal lymph nodes all receive afferent lymph 
draining from the mouth (Sisson, 1976). Microbes or antigenic components gaining entry through the 
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oral epithelium can drain directly to the lymph node via the lymphatics, or be transported by 
phagocytic cells such as Langerhans cells, whereupon an immune response can be generated. Effector 
cells can then home back to the oral mucosa (Butcher & Picker, 1996). Although similar studies have 
not been performed in cats, it is notable that the mucosal addressin cell adhesion molecule 
(MAdCAM)-I, which acts as a key homing molecule at intestinal sites, is not expressed by the oral 
mucosa (Butcher, 1999; Brandtzaeg et al., 1999). However, various other adhesion molecules, 
including intracellular adhesion molecule (ICAM)-I, endothclial leucocyte adhesion molecule 
(ELAM)-I, and E-selectin, have been identified in healthy and diseased human oral mucosal tissues 
(Moughal et al., 1992; Verdickt et al., 1992; Crawford, 1992; Nylander et al., 1993; Takeuchi et al., 
1995; Haapasalmi et al., 1995; Pietrzak et al., 1996; Tonetti et al., 1998). 
Intraoral lymphoid tissue 
The intraoral lymphoid tissues in the cat have been poorly documented. In humans, four types of 
intraoral lymphoid aggregations are recognised: tonsillar, salivary, submucosal, and gingival (Lehner 
1992; Perry & Whyte, 1998 ). The tonsils in the cat are reported to comprise the palatine, lingual and 
para-epiglottic tonsils (Pedersen, 1987). Structurally, the tonsils comprise a lymphoepitheliurn which 
is folded to form tonsillar crypts that overlies lymphoid follicles and interfollicuar regions (Perry & 
Whyte, 1998; Day, 1999). Functional and phenotypic studies of the feline tonsil have not been 
documented, however the immunology of the human tonsils has been subject to extensive investigation 
and is reviewed by Perry & Whyte (1998) and Bernstein et at. (1999). 
By contrast to the well-ordered structure of the tonsils, diffuse aggregations of lymphoid cells are 
present within the salivary glands, submucosal tissues, and gingiva. Lymphocytes and plasma cells are 
found associated with the major and minor salivary glands, and studies in humans and dogs have 
demonstrated that the majority of these plasma cells secrete IgA (Lehner 1992; Sozmen et a]., 1996). 
In addition, aggregates of lymphoid tissues can be found associated with some salivary ducts (Nair & 
Schroeder, 1996 & 1987). A diffusely scattered collection of lymphoid cells is found within the 
submucosa. These cells have been poorly characterised, however inununoglobulin from the IgG- and 
IgA-secreting plasma cells found within this population may diffuse into the oral cavity (Challacombe 
& Shirlaw, 1999). Aggregations of plasma cells, lymphocytes, macrophages and neutrophils are found 
within the gingiva. It is considered that these cells are responding to dental plaque within the gingival 
sulcus (Lehner, 1992; Challacombe & Shirlaw, 1999). Phenotypic analysis of these cells have not been 
reported in the cat. However, studies in humans and dogs have shown that initially this infiltrate 
consists predominantly of lymphocytes, but with development of gingivitis there is a dramatic increase 
in plasma cells, of which IgG-secreting cells predominate (Attstrom & Egelberg 197 1; Attstrbm et al., 
1975; Payne et al., 1975; Page & Schroeder 1976; Seymour et al., 1983; Lehner, 1992). 
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Intraepithelial T-lymphocyles 
An additional lymphoid population that is present within the oral mucosa consists of the intraepithelial 
T lymphocytes (IEL). Reviews of IEL are provided by Kiyono & McGhee (1994); Lefronqois & 
Puddington (1999); and Aranda et al. (1999). IEL are found within the epithelium at all mucosal sites 
and are considered to constitute a first line of defence against invading micro-organisms. IELs can 
express either an ap-TCR or y5-TCR, but in contrast to circulating T-cells, a high proportion of IELs 
express y5-TCRs (Boismenu & Havran, 1998); although the proportion of ap: y8 T-cells varies at 
different sites and between species. Studies of the human mucogingival mucosa have found that y5 T- 
cells account for <1 to 35% of the IEL population (Colasante et al., 1992; Lundqvist & Hammarstroin 
1993; Pepin et al., 1993; Kawahara et al., 1995; Walton et al., 1996 & 1998). Four main subsets of 
1ELs are recognised based upon their pattern of expression of CD4 and CD8. These are CD4+CD8' or 
CD4-CDS+ single positive cells, CD4+CDS+ double positive cells, and CD4'CD8' double negative 
cells. In addition CD8+ cells may be subdivided in those expressing heterodirneric (ap) and 
homodimeric ((xcc) CD8 chains. Studies by Lundqvist & Harnmarstr6m (1993) of human oral mucosal 
epithelium found that in healthy tissue most ccp T-cells were CD8+. By contrast most y5 T-cells were 
double-negative in healthy tissue, but in inflamed tissues the majority of Y8 T-cells were CD8+ 
(Lundqvist & Hammarstr6m, 1993). 
IEL possess a number of functional properties. Mouse and human CD8+ IEL have been demonstrated 
to be constutively cytolytic and are considered to contribute to cell-mediated immune responses 
against viral and intracellular bacterial pathogens (reviewed by McGhee & Kiyono 1999; and Aranda 
et al., 1999). In addition, IEL produce various Thl and Th2 cytokines (see above) and it is thought 
that they may regulate humoral responses through cytokine production, particularly IgA production in 
the intestine (Fujihashi et al., 1994; McGhee et al., 1994; Aranda et al., 1999). IEL are also thought to 
play an important role in controlling epithelial cell growth and functions through the provision of 
essential cytokines (Croitoru & Ernst, 1994; McGhee & Kiyono 1999). However it would appear that 
this is a reciprocal arrangement, as recent studies have shown that epithelial cells can influence y5 T- 
cell function - particularly through the production of IL-7, which appears to be essential for y8 T-cell 
development and activation (Fujihasi ct al., 1997; Malek et al., 1999; McGhee & Kiyono 1999). 
In the cat, intraepithelial lymphocytes have been reported within the intestine (Sturgess, 1997; 
Roccabianca et al., 1997) and hepatic bile ducts (Day, 1998), however they have not been documented 
within the oral cavity. In addition, y8 T-cells have not been documented in the cat, due to the lack of 
appropriate reagents. 
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Secretory IgA 
Dimeric IgA is actively and selectively secreted in association with an accessory molecule, secretory 
component, which is derived from the polymeric Ig receptor (plgR) (Brandtzaeg 198 1; Vaerman et al., 
1998; Mestecky et al., 1999; Mostov & Kaetzel, 1999). The pIgR is a transmembrane receptor 
expressed on the basolateral aspect of epithelial cells at mucosal sites, such as the gastrointestinal tract 
and salivary ducts, which facilitates the transcytosis of bound immunoglobulin to the apical surface of 
the cell. Here, the extracellular portion of the receptor bound to IgA is cleaved from its transmembrane 
tail to release secretory IgA (sIgA). Hence slgA consists of dimeric IgA and non-covalently bound 
secretory component (Mestecky et al., 1999). The presence of secretory component in sIgA affords a 
degree of protection against enzymatic degradation (Kilian & Russell, 1999). As binding of Ig is not 
necessary for the pIgR to undergo transcytosis and cleavage of secretory component, excess free 
(unbound) secretory component is also found in most mucosal secretions (Brandtzaeg, 19 8 1). 
Detailed reviews of the functional properties of sIgA have been provided by Childers et al. (1989) and 
Russell et al. (1999). In summary, the primary function of sIgA is considered to be the protection of 
mucosal sites by binding and cross-linking pathogens, thereby preventing them from attaching to 
mucosal surfaces. In addition, sIgA can also bind to and neutralise toxins and viruses. Furthermore, 
during transcytosis through infected epithelial cells, IgA can act to neutralise viruses intracellularly 
(Mazanec et al., 1996; Lamm, 1997). Secretory IgA can also interact with and enhance the action of 
innate antimicrobial factors, such as lactoferrin, peroxidases, and lysozyme present in saliva 
(Challacombe & Shirlaw, 1999). The ability of IgA to activate complement is controversial. Overall, 
the body of evidence suggests that IgA has, at best, minimal capacity to activate complement (for 
further discussion, see Russell et al., 1999). 
Saliva 
Whole saliva comprises a complex mixture of secretions from the major salivary glands (parotid, 
submandibular, and sublingual salivary glands) (Orsini & Hennet, 1992), the minor salivary glands, 
and the gingival crevicuIar fluid (GCF) (see below). While the constant flow of saliva in the oral 
cavity helps to control the accumulation and adherence of many micro-organisms to the mucosal 
surfaces, saliva contains a number of specific and non-specific defence factors which protect the oral 
mucosa (reviewed by Lehner, 1992; and Challacombe and Shirlaw, 1999). 
Immunoglobulins are present within saliva (see 1.2), and these are derived from a number of sources 
(Challacombe & Shirlaw, 1992). The most important source is the saliva secreted by the major and the 
minor salivary glands, which contains predominantly sIgA. However, immunoglobulins within the 
GCF will also contribute to the salivary immunoglobulin pool (Challacombe et at., 1978; Ebersole et 
aL, 1996). As discussed below, GCF contains serum-derived immunoglobulins and some locally- 
produced immunoglobulins secreted by plasma cells within the oral mucosa (Ebersole et al., 1996). 
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Consequently GCF is the main source of salivary IgG, IgM and non-secretory IgA within the saliva. 
Inflammation and disruption of the epithelium will lead to increased transudation of immunoglobulins 
through the oral mucosa and into the saliva (Poli et al., 1992). Non-specific antibacterial agents have 
been found in saliva ftorn various species, including lysozyme, lactoferrin, lactoperoxidase, 
peroxidase, salivary agglutinins, and complement (Lehner, 1992; Hoek et al., 1997; Peen & Erga, 
1998, Challacombe & Shirlaw, 1999). While it is likely that these factors are present in feline saliva, 
studies documenting their presence have not been reported. 
Gingival crevicularfluid 
GCF is serum-like fluid that flows through the junctional epithelium of the gingiva into the gingival 
crevice (Gavin, 1968). The formation and composition of this fluid is reviewed by Lehner (1992). In 
summary, there is a continuous flow of transudated serum containing both cellular and humoral 
components from the gingival capillaries through the junctional epithelium into the gingival crevice 
(Challacombe et at., 1978). Increased GCF flow is stimulated by inflammation, and normally this is 
induced by dental plaque. In contrast to saliva, IgG is the predominant immunoglobulin, and IgA, IgM 
and complement are also present. The majority of these immunoglobulins are derived from serum, 
however these are augmented by locally secreted immunoglobulin (Ebersole et al., 1996). Most of the 
cells within GCF are neutrophils, although some lymphocytes and macrophages may also be present 
(Gavin, 1968). Various enzymes, such a collagenase, trypsin, and elastase can be detected in GCF 
(Marsh & Martin, 1992). GCF passes from the gingival crevice into the oral cavity whereupon it mixes 
with the saliva from the major and minor salivary glands. 
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1.5 STUDY AIMS AND THESIS OUTLINE 
The successful treatment and management of FCGS is hindered by the lack of understanding of the 
aetiopathogenesis and the paucity of clinical trials evaluating the effectiveness of the various 
therapeutic agents advocated for use in this condition. This study intended to address these 
deficiencies. 
The aims of the study were as follows: 
1. To characterise the immunopatho logical changes occurring in cats with chronic gingivostornatitis 
11. To identify possible aetiological factors or co-factors in FCGS 
111. To compare the effectiveness of four different therapeutic regimes for the treatment of FCGS using 
a controlled clinical trial 
IV. To the analyse effects of these treatments upon the underlying immunopathological features of the 
disease. 
Part I (Chapters 2,3, & 4) provides an analysis of selected clinical findings in cats seen at a specialist 
clinic established to investigate and treat cases with FCGS. The results of a controlled clinical trial 
comparing the relative effectiveness of four different treatment regimes over a six month time course 
are presented. 
In Part 11 (Chapters 5,6,7, & 8) the development of class-specific ELISAs for the determination of 
serum and salivary immunoglobulins in the cat is described. These assays were then utilised to 
examine the immunoglobulin concentrations in serum and saliva from cats with FCGS, and to assess 
the comparative effects of four treatments upon these parameters. 
Histological and immunohistochernical methods are used in Part III (Chapters 9,10,11, & 12) to 
examine the morphological and phenotypic characteristics of oral mucosal lesions seen in cats with 
FCGS. In addition, the comparative effects of treatment upon the cellular infiltrate present within these 
tissues are appraised. 
Part IV (Chapters 13,14,15 16) describes a semi-quantitative reverse-transcription polymerase chain 
reaction (RT-PCR) assay which was used to detect the expression of a range of cytokine genes within 
oral mucosal biopsies from healthy cats, and cats with FCGS. The effect of treatment upon the relative 
levels of cytokine gene expression is also assessed. 
Finally, a general discussion of the study findings is presented in Chapter 17. 
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PART 1: Clinical Findings and Clinical Response to Treatment in 
Cats with Chronic Gingivostomatitis 
Part 1 32 
CHAPTER 2: Materials and Methods for Part 1 
2.1 CATS 
2.1.1 Clinical cases and criteria for inclusion 
Clinical studies were performed between September 1996 and January 1998 on 30 cats with chronic 
gingivostomatitis referred to a specific clinic established for this purpose at the University of Bristol. 
The primary criterion for inclusion into the study was the presence of clinical signs of oral disease 
characterised by substantial oral inflammatory lesions affecting the gingiva and/or the alveolar mucosa 
and/or the fauces (glossopalatine arches). In addition, lesions were to have been present and 
unresolved for a period at least 2 months immediately preceding the initial point of referral. In order to 
exclude cats suffering purely from signs of classical plaque-induced periodontal disease, the 
inflammatory lesions had to be considered to be disproportionately severe in relation to any visible 
accumulation of plaque and calculus. Cats with a history and clinical signs of profuse gingival 
hyperplasia consistent with the condition described by Williams & Aller (1992) as juvenile 
hyperplastic gingivitis were not eligible to enter the study. Cats with focal or linear, raised or 
proliferative oral lesions suggestive of either feline eosinophilic granulomas or neoplastic lesions, such 
as squamous cell carcinoma or fibrosarcoma, were not permitted to enter the study. The cats also had 
to have no clinical signs of any concurrent systemic illness or be suffering from any additional 
condition which would predictably require medication in the subsequent 6 month period. Finally, any 
prescribed medication was asked be withdrawn prior to the initial date of refer-rat, wherever possible, 
for a minimum period of 2 weeks, or 4 to 6 weeks in the case of corticosteroid therapy. 
2.1.2 Comparative samples 
During the period from November 1998 to June 1999 oropharyngeal swabs and serum samples were 
collected for the detection of various viruses from 10 cats with diseases other than chronic 
gingivostornatitis referred to the Feline Centre, University of Bristol, and which matched the breed, 
sex and age (± I year) of clinical case cats (2.1.1). 
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2.2 VIROLOGY 
Virological assays were performed by the Feline Virology Diagnostic Service, University of Bristol. 
2.2.1 FeLV and FIV 
Serum samples were analysed for evidence of FeLV antigen (Petcheck FeLV, IDEXX Labs Ltd., 
Buckinghamshire, UK) and FIV antibody (Petcheck Anti-FIV, IDEXX) as per the manufacturer's 
instructions. 
2.2.2 FCV and FHV virus isolation procedure 
Virus isolation for feline calicivirus and feline herpesvirus was performed from oropharyngeal swabs 
as previously described (Harbour et al., 199 1), except that Feline Kidney Colorado University (FKCU) 
cells were used. Samples were processed within 24 hours of collection. Growth of FCV and FHV was 
detected by the appearance of characteristic cytopathic effects (Fastier, 1957). 
2.3 ORAL EXAMINATION AND CLINICAL INDICES 
Detailed oral examinations were performed under general anaesthesia. Cats were premedicated with a 
combination of pethidine (3 mg/kg; Pethidine Injection; Amolds, Shrewsbury, UK), and acepromazine 
malate (0.03 mg/kg; ACP; C-Vet, Lancashire, UK) with or without atropine sulphate (20 to 30 gg/kg; 
Atropine Sulphate Injection BP (Vet); C-Vet); anaesthesia was induced with sodium thiopentone (6 to 
16 mg/kg; Intraval; Merial, Harlow, UK) or propofol (4-6 mg/kg; Rapinovet; Schering-Plough, 
Uxbridge, UK) and maintained using halothane (Halothane-RM; Merial) or isoflurane (Isoflo; 
Schering-Plough) with oxygen and nitrous oxide. In some cases intravenous fluid therapy was 
administered during anaesthesia using Hartmann's solution or glucose saline at I to 2 times 
maintenance requirement. 
During the assessment time-points when the animals were not anaesthetised some cats were lightly 
sedated to facilitate oral inspection using ketamine (2.5 mg/kg; Ketaset; Fort Dodge, Southampton, 
UK) and midazolarn (0.125 mg/kg; Hypnovel, Roche Products Limited, Welwyn Garden City, UK), or 
ketamine (3.5 to 5.0 mg/kg) and diazeparn (0.175 to 0.25 mglkg; Diazemuls; Dumex Ltd, Tring, UK), 
or medetomidine (20 to 50 gg/kg; Domitor; Pfizer, Sandwich, UK) with or without ketamine (0.7 to 
1.4 mg/kg). 
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2.3.1 Stomatitis index 
The degree of oral inflammation was measured using a modified gingival index scoring system (Loe 
and Sillness, 1963, Robinson and Gorrel, 1995) which was termed the stornatitis index (SI). The 
gingival and mucosal inflammation was scored on a four point scale based primarily upon visual 
criteria, however the gingival bleeding response to gentle probing with a periodontal probe was also 
assessed when the animals were anaesthetised. The four categories were as follows: 
0: Absence of inflammation - tissue pink or pale with no evidence of oedema, no bleeding after 
probing 
1: Mild inflammation - some redness, slight oedema may be seen, delayed bleeding on probing 
2: Moderate inflammation - obvious redness and oedema, bleeds on probing 
3: Severe inflammation - marked redness and cedema, tissue hypertrophy and ulceration may be 
present, may bleed spontaneously, bleeds readily on probing 
The oral cavity was partitioned into 7 areas as shown in Figure 2.1 based upon anatomical features. 
Each area was assessed at 2 aspects or sites, In areas I to 6 the buccal and the palatal/lingual aspects of 
the mucogingival tissue were scored separately, while in area 7 the left and right fauces were scored 
individually. All scores were based upon the worst affected tissue present at the aspect/site. 
Subsequently, each area score was calculated from the sum of the 2 aspect/site scores (range 0 to 6), 
and the patient stornatitis index was computed from the sum of the 7 area scores (range 0 to 42). 
2.3.2 Calculus index 
The calculus index was a modiflcation of the method described by DeBowes et al., (1996) in the dog. 
Each tooth was independently scored on the buccal and palatal/lingual aspect as follows: 
0: No calculus 
1: Calculus covers less than one third of the crown 
2: Calculus covers between one third and two thirds of the crown 
3: Calculus covers more than two thirds of the crown 
The dentition was partitioned into areas I to 6 as shown in Figure 2.1. Each area score was calculated 
by adding the single highest buccal and the single highest palatal/lingual calculus score of all of the 
teeth present within an area (range 0 to 6). The patient calculus index was then derived from the sum 
of the 6 area scores (range 0 to 36). 
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Figure 2.1 Diagrammatic representation of the 7 areas of the oral cavity used in the calculation 








2.3.3 Probing depth index 
1. Upper canines and incisors 
2. Upper right premolars and molars 
3. Upper left premolars and molars 
4. Lower right premolars and molars 
5. Lower left premolars and molars 
6. Lower canines and incisors 
7. Left and right fauces 
The sulcus around each tooth was examined using a periodontal probe (Henry Schein Rexodent) and 
scored on the buccal and palatal/lingual aspect based upon the depth of the sulcus as follows: 
0: Up to I mm deep 
1: Greater then I mm up to 3 mm deep 
2: Greater than 3 mm up to 5 mm deep 
3: Greater than 5 mm deep 
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The dentition was partitioned into areas I to 6 as shown in Figure 1.2. Each area score was calculated 
by adding the single highest buccal and the single highest palatal/lingual probing depth score of all of 
the teeth present within an area (range 0 to 6). The patient probing depth index was then derived from 
the sum of the 6 area scores (range 0 to 36). 
2.4 DENTAL WORK 
2.4.1 Extractions 
Teeth which were deemed to be severely compromised by periodontal disease or defects of the tooth 
substance were extracted using closed or open techniques (Gorrel & Robinson, 1995). In some cases 
where root fragments remained in situ, the roots were atomised using a high-speed drill (Vet-Base V, 
Henry Schein) with water cooling to a level below the height of the surrounding alveolar bone. 
Whenever possible the gingiva was sutured to close the socket using Metric 3.0 chromic catgut 
(Ethicon Ltd, Edinburgh, UK) or Metric 2.0 Polyglactin 9 10 (Vicryl, Ethicon). 
2.4.2 Dental hygiene procedure 
Supragingival scaling was performed using a combination of hand- and ultrasonic-scaling. Subgingival 
scaling and root planing was performed using a gingival curette (Gracey No. 11/12, Henry Schein) 
The teeth were polished using a prophylaxis angle mounted onto a slowly rotating low-speed 
handpiece (Vet-Base V, Henry Schein) with a rubber prophylaxis cup and surplus prophylaxis paste 
(Henry Schein). Finally, the oral cavity and gingival sulcus were lavaged with a 0.12% chlorhexidine 
gluconate solution (CHX Oral Cleansing Solution, St Jon Veterinary Prescription, Egham, UK) 
2.5 CLINICAL TRIAL 
2.5.1 Consultation I 
At the point of initial referral, all cases underwent a standard initial examination and treatment 
protocol over a2 day period. In each case a full history was taken and physical examination 
performed. Wherever possible the age, breed, sex, diet, and the origin of the animal was recorded. In 
addition, the duration of the oral disease, the number of cats in the household and the availability of 
access to indoor and outdoor environments were also noted. The vaccination status of each cat was 
recorded. Blood samples were collected for haematological and biochemical analysis, and for viral 
serology for FeLV and FIV (2.2). Additional blood was collected for quantification of serum 
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immunoglobulins (see Part 11). Finally, oral swabs were obtained for upper respiratory tract virus 
isolation (2.2) and for quantification of salivary immunoglobulins (see Part 11). 
During the second day, a detailed examination of the oral cavity was performed under anaesthesia 
(2.3). The stomatitis index, calculus index and probing depth index were recorded (2.3) and dental 
radiographs taken. Excisional biopsies were collected for histopathological examination and analysis 
by PCR (see Parts III & IV), and any necessary extractions were performed (2.4). Finally a standard 
oral hygiene procedure was performed (2.4). During the immediate post-operative period most cats 
received carprofen (2 to 4 mg per kg; Rimadyl; Pfizer) or pethidine (2 mg per kg; Amolds) to provide 
short term analgesia. In addition, all cases were prescribed a 7-10 day course of 12 mg per kg of 
metronidazole and 23 mg per kg of spiramycin (Stomorgy]; Merial). Each cat was then randomly 
allocated (2.6) to receive one of four long-term treatments (2.7). 
2.5.2 Consultation 2 
Owners were asked to return with the cats six weeks after the first consultation. The cats were not 
anaesthetised at this stage, however in a few cases sedation (2.3) was required to enable an 
examination to be performed. The stomatitis index was recorded (2.3), and in selected cases blood 
samples were collected. 
2.5.3 Consultation 3 
Approximately three months after the initial consultation the cats were re-examined. Blood samples 
were collected for haematological and biochemical analysis and for quantification of serum 
immunoglobulins (see Part 11). In addition, oral swabs were obtained for quantification of salivary 
immunoglobulins (see Part II). Wherever possible, a detailed oral examination was performed under 
general anaesthesia (2.3) and the stomatitis index, calculus index, and periodontal index were recorded 
(2.3), and repeat biopsies were taken (see Part III & IV). A few cases undergoing a repeat biopsy 
procedure were prescribed a7 day course of metronidazole and spiramycin (as below), however the 
owners were asked to only administer the medication if the animal appeared to be in undue discomfort 
during the post-operative period. 
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2.5.4 Consultation 4 
Cases were re-examined approximately 6 months after the initial consultation. Sedation was used to 
permit examination of a few cases (2.3), otherwise all procedures were conducted with the animal fully 
conscious. The stornatitis index was recorded (2.3). Blood samples and oropharyngeal swabs were 
collected for haernatological and biochemical analysis, and viral isolation procedures respectively 
(2.2). Additional serum samples and oral swabs were taken for quantification of immunoglobulins (see 
Part II). 
2.5.5 Criteria for withdrawal from the clinical trial 
Participation within the clinical trial was voluntary, however owners were encouraged to complete the 
trial, wherever possible. Cats could be withdrawn from the clinical trial upon ethical grounds if either 
the owner, or the veterinary surgeons involved in managing the case, were of the opinion that the 
allocated treatment was not able to sufficiently control the disease, and consequently, that the cat was 
suffering unduly. Additional reasons for withdrawal from the trial could include a deterioration in 
general health, or the occurrence of drug side-effects, for examPle. 
2.6 RANDOMISATION PROCESS 
Cases were allocated to one of four treatment groups using a block randomisation procedure. A short 
computer program was written to generate a table of 50 blocks with each block containing the numbers 
I to 4 in a randomised order. Each of the four treatment groups was then randomly allocated a 
different number ranging from I to 4. The starting point and the direction in which the table was read 
were chosen arbitrarily. The table was concealed in a manner such that when each new number was 
revealed, the previous and future numbers were not visible. 
2.7 TREATMENT GROUPS 
2.7.1 Oral hygiene products 
Oral hygiene products containing chlorhexidine and glucose-oxidase/lactoperoxidase active 
ingredients (CHX Oral Cleansing Solution, CHX-Guard LA Oral Gel, CET Dentifrice Paste; all St Jon 
Veterinary Prescription) were used to attempt to reduce the oral bacterial and plaque burden. During 
the first week owners were requested to administer I unit of CHX Guard LA Gel to each side of cat's 
mouth each morning and evening. After 4-5 days they were asked to gently brush the cat's teeth with 
warm water using a cat toothbrush (St Jon Veterinary Prescription) shortly before the oral gel was 
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applied. During the second and third week, the owners were to administer I unit of CHX guard LA gel 
or apply I to 2 ml of CHX oral rinse to the mouth each morning, while in the evening they were asked 
to gently brush the teeth with CET toothpaste. From the fourth week onwards until the end of the trial 
the owners were instructed to brush the teeth twice daily with CET paste. However, if this could not be 
achieved, they were to advised to apply I to 2 ml of oral rinse, or I unit of oral gel in place of 
brushing. In addition, owners were asked, wherever possible, to encourage dietary chewing by 
including a dry cat food as a significant part of the diet, and by regularly offering strips of cooked, 
tough meat. Feeding of bones was not advised. 
2.7.2 Chrysotherapy 
Cats allocated to the second group received sodium aurothiornalate (Myocrisin; Rh6ne-Poulenc Rorer, 
Eastbourne, UK). As Myocrisin is not licensed for use in the cat, the owner's written consent was 
obtained. Sodium aurothiomalate was administered once weekly by deep intramuscular injection by 
the referring veterinary surgeon. A test dose of I mg per cat was given, and provided no side-effects 
were noted, 2 mg per cat was given in the second week, and thereafter the weekly dose was I mg/kg 
body weight. Veterinary surgeons administering the drug were advised to be aware of potential side- 
effects including protein losing nephropathy, blood dyscrasias and bleeding disorders, skin reactions, 
mouth ulcers, and cholestasis, and were told to cease treatment immediately if any untoward clinical 
signs were noted. During treatment, blood and urinary parameters were monitored for signs of blood 
dyscrasia or glomerular damage. Blood samples, and, wherever possible, urine samples were collected 
after 2,4,6,8,12,16 and 20 weeks of treatment for haernatological and biochemical analysis. 
Treatment was ceased if any unexplained abnormalities were noted or side-effects were suspected. 
However in some cases, upon resolution of these signs, and at the consent and discretion of all parties 
involved, the drug was re-administered. Wherever possible treatment was maintained for a6 month 
period. 
2.7.3 Corticosteroids 
Cats in the third treatment group received oral methylprednisolone (Medrone-V; Upjohn, Crawley, 
UK). Initially they were prescribed I mg/kg each day to be administered as a single or divided dose for 
6 weeks (or until the cat was represented for the first scheduled check up). The dose was then reduced 
to 0.5 mg/kg daily for a further 6 weeks (or until the next scheduled examination). Thereafter the dose 
was tapered to approximately 0.5 mg/kg every other day or every third day over the following 3 
months, dependent on the clinical response, until the end of the trial. 
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2.7.4 Antibiotics 
The fourth treatment group received 12 mg per kg metronidazole and 23 mg per kg spiramycin once 
daily for one week every alternate week throughout the clinical trial. 
2.8 STATISTICS 
Statistical analyses were performed using Minitab version 12.1 (Minitab Inc, Pasadena, USA) or 
GraphPad Prism for Windows version 3.00 (GraphPad Software Inc., San Diego, California, USA) or 
Systat for Windows version 5.02 (Systat Inc., Evanstown, Illinois, USA). Where appropriate data sets 
were tested for Normality using the Anderson-Darling or Ryan-Joiner test; data sets with a resulting 
P<0.05 or those with obvious skewing of the Normality plot were considered not to follow a Normal 
distribution. Comparisons between two populations were performed using the Mest or Mann-Whitney 
test, as appropriate. Paired comparisons were performed using the paired Mest. Analysis between 3 or 
more groups were performed using ANOVA for data which was Normally distributed and had P>0.05 
for Barlett's homogeneity of variance test, otherwise the Kruskal-Wallis test was used. Multiple 
comparisons following ANOVA were performed with Tukey's all pairwise comparisons or Hsu's 
multiple comparisons of the best (Hsu, 1996). Multiple comparisons following Kruskal-Wallis tests 
was performed using Dunn's pairwise comparisons. Tukey's all pairwise comparisons and Dunn's 
pairwise comparisons were only performed when the one way analysis of variance test P value was < 
0.1. In other situations where multiple testing was performed, a correction factor was applied to 
produce an adjusted P value (P') using the layered Bonferroni method (Darlington, 1990). Correlations 
were performed using Pearson's or Spearman's method, as appropriate. Residuals were assessed for 
Normality following multiple linear regression analysis and logistic regression analysis. Unless 
otherwise stated, the results of statistical analyses were considered to be significant when P<0.05. 
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CHAPTER 3: Clinical Observations in Cats with Chronic Gingivostomatitis 
3.1 INTRODUCTION 
Chronic gingivostornatitis is a widely recognised, sporadic disease syndrome affecting adult domestic 
cats, however, the aetiopathogenesis remains poorly understood (see Chapter 1). This chapter collates 
selected clinical findings from adult cats referred for the investigation of feline chronic 
gingivostornatitis. In addition to further characterising the clinical features of feline chronic 
gingivostomatitis, such studies can help to uncover aspects of the disease aetiopathogenesis. 
3.2 MATERIALS AND METHODS 
The relevant materials and methods are described Chapter 2. 
3.3 RESULTS 
30 cats meeting the diagnostic criteria for feline chronic gingivostomatitis (FCGS) were recruited on to 
the trial. Treatment was successfully withdrawn by the referring veterinary surgeon, as requested, prior 
to the first consultation in the majority of cases. In a minority of cases it was necessary under ethical 
grounds to permit metaclopromic acid (Metacam; Bhoeringer Ingelheim Ltd, Bracknell, UK), a non- 
steroidal anti-inflammatory, to be used to provide short-term pain relief during this period, however it 
was requested that this treatment be withdrawn at least one to two days prior to the first consultation. 
3.3.1 Case-specific information 
A summary of the main information obtained from the case histories is given in Table 3.1. No 
significant difference (P = 0.36) was found in the proportion of male and female cats assuming a 
predicted proportion of 0.5. Multiple linear regression analysis was performed to investigate potential 
relationships between the age at onset of disease and other case-specific variables. As the current age 
and booster status were not relevant to the time of onset, these factors were excluded from the analysis 
procedure. Feeding of canned food and envirom-nental variables were also not included, as almost all 
cases regularly received canned food and had access to both an indoor and outdoor environment. 
Similarly, vaccination status was also excluded, as only one case (Cat 3: Table 3.1 ) was unvaccinated. 
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Thus, the variables selected for analysis were breed, sex, number of cats in the household at the time of 
onset of disease, feeding dry diet, and feeding freshly prepared food. Cat 16 was a Persian Angora 
crossbred and although this cat could not be classified as pure-bred it was included in the pedigree 
group. The number of cats in the household at the time of onset of disease was categorised as 1,2,3, 
4, or >4 and binary variables were used for breed (0 = pedigree [including pedigree cross]; I= 
DSH/DLH), sex (0 = female or neutered female; I= neutered male), source (0 = breeder, non- 
professional breeder or pet shop; I= stray or rescue), feeding dry diet (0 = not fed; I= fed) and 
feeding freshly prepared food (0 = not fed; I= fed). 
During preliminary analyses, inspection of the Normal plot of residuals indicated that a square-root 
transformation of the onset of disease data was appropriate to maintain the assumptions of the 
regression model. A forward stepwise regression strategy was adopted with a 10% significance level as 
the criterion for inclusion. The results (Table 3.2) indicated that breed and the number of cats present 
in the household at the time of disease onset were significant factors, and that within the model these 
factors account for 34% of the variation in the age of onset of disease between cats. Figure 3.1 
illustrates these findings and demonstrates that pedigree breeds have a tendency to develop disease at a 
younger age than non-pedigree cats, as do cats from higher household population densities. 
3.3.2 Virology 
3.3.2.1 FeLV & FIV 
At the time of the first consultation, none of the cases tested positive for FeLV, whereas 13.3% (4 out 
of 30) of cases were positive for FIV (Table 3.3). Serum samples collected from the 10 age, sex and 
breed-matched cats within the comparative group all tested negative for FeLV and FIV (Table 3.4). 
The difference in FIV prevalence between the matched cats was not statistically significant (Table 
3.5). 
3.3.2.2 FCV & FHV 
Oropharyngeal swabs were collected from the 30 cases at the beginning and the end of the treatment 
trial, and from the ten age, sex and breed-matched cats within the comparative group at a single time- 
point. Table 3.3 shows that FCV was isolated from 87% (26/30) and 93% (28/30) of the cats with 
chronic gingivostomatitis at consultations I and 4 respectively. By contrast, FCV was not isolated 
from any of the cats within the comparative group (Table 3.4). FHV was not detected in any of the 
samples from either group (Tables 3.3 & 3.4). 
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Table 3.2 Regression of age of square root of onset of disease on breed and number of cats in 






Constant 2.365 0.326 7.26 0.000 
Breed 0.766 0.265 2.89 0.008 
No. cats in household -0.213 0.076 -2.80 0.009 
S=0.6134 R-Sq = 38.4% R-Sq (adj) = 33.8% 
Analysis of Variance 
Source of Degrees of Sum of Mean squares Fp 
variation freedom squares 
Regression 2 6.323 3.162 8.40 0.001 
Residual 27 10.158 0.376 
Figure 3.1 The relationship between the number of cats in the household and age at the onset of 


















Number of cats in household at onset of disease 
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Table 3.3 Results for viral tests on cats with chronic gingivostomatitis 
FeLV FIV FCV FHV 
Consultation I 1 14 14 
Cat 
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3.3.3 Oral indices 
The stomatitis index, probing depth index and calculus index were recorded in the 30 cases at 
consultation I (Table 3.6; Figures 3.2-3.4). The stomatitis index was also recorded in the ten age-, 
breed-, and sex-matched control cats (Table 3.4). A paired comparison demonstrated that the control 
cat stomatitis indices were significantly lower than the clinical cases (Table 3.7). 
Significant positive correlations were found between the stomatitis index and the probing depth index 
(Figure 3.5), and the calculus index and the periodontal index (Figure 3.6). A positive, but not 
statistically significant correlation, existed between the stomatitis index and calculus index (Figure 
3.7). Linear regression analysis was performed to investigate the predictive potential of the probing 
depth index on the stomatitis index. Figure 3.5 shows that the 95% predictive interval was wide and 
that there was a large degree uncertainty attached to the estimated stomatitis index. 
Multiple linear regression analysis was also performed to investigate the relationships of age, duration 
of disease (square root of number of months), breed, sex, FIV status, and booster vaccination status on 
the stomatitis index using a forward stepwise model with a 10% inclusion level. During the initial 
analysis cats with the longest duration of disease were found to have disproportionate influence on the 
model, consequently the square root of the duration was used to abrogate this effect. The final model 
shown in Table 3.8 retained the breed and the duration of disease. These findings indicate that the 
stornatitis index increases as the duration of disease increases, and that non-pedigree cats tend to have 
higher stornatitis indices compared to pedigree cats. 
Additional multiple linear regressions were performed using age, breed, duration of disease, FIV 
status, feeding of dry diet, feeding of freshly prepared food on the periodontal index and on the 
calculus index using a forward stepwise model with a 10% inclusion level, however none of the factors 
were retained within the model (analyses not shown). 
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Figure 3.2 Mucogingival lesions at consultation 1 (Cat 24) 
(a) Florid ulcerative and proliferative inflammatory lesions affecting left and right fauccs and (b) the 
buccal aspect of the gingiva and alveolar mucosa in the upper right oral quadrant. 
Figure 3.3 Mucogingival lesions at consultýjfion I (Cat 27) 
(a) Severe inflammation affecting the buccal aspect of the gingiva and extending into the alveolar 
mucosa of oral upper right quadrant - (b) note the well circumscribed margin of the mucogingival 
inflammatory lesion (contrast with Figure 3.2 b). 
(a) Proliferative gingival inflammatory lesions affecting the buccal aspect of the upper and lower left 
oral quadrants. (b) Proliferative gingival inflammatory lesion extending around upper left prcmolar 3 
(PM3). A mild inflammatory focus is present in the right fauces (F). 
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Figure 3.4 Mucogingii a] lesions at consultation I (Cat 30) 
Table 3.6 Clinical indices, number of extractions and the allocated treatment group for 30 cats 
with chronic gingivostomatitis at consultation I 
Cat Stomatitis Probing Depth Calculus Index Number of Treatment 
Index Index Extractions Group 
1 26 4 10 1 OH 
2 30 12 is 2 OH 
3 32 6 5 0 GS 
4 29 3 6 1 cs 
5 19 8 






..................................... ................................... 6 ............................... 30 .............. . ... ......... 11 .... 20 0 cs 
7 FIV 37 24 26 3 GS 
8 35 9 13 2 AB 
9 32 11 23 4 OH 





..................................... ................................... 11 ............................... 23 ..................................... 3 ... ....................... 15 0 OH 
12 24 0 11 0 AB 
13 33 3 11 1 GS 
14 38 23 26 14 cs 







..................................... ...................... . ............ 16 ................................ 30 ......... . .......................... 12 ..... 15 2 GS 
17 39 23 25 2 OH 
18 29 7 6 1 OH 
i 9F1V 30 20 21 4 GS 





..................................... ................................... 21 ............................... 31 . ................................... . 12 ..... 14 0 AB 
22 32 8 14 2 GS 
23 37 11 6 2 cs 
24 31 13 18 4 AB 





.................................... ................................... 26 ............................... 24 . ................................... . 9 ..... 14 0 AB 
27 FIV 22 5 20 1 OH 
28 24 9 14 3 cs 
29 24 11 13 1 GS 
30 23 7 7 0 GS 
Mean 29.6 10.0 14.3 1.9 
SD 5.14 6.30 6.25 2.62 
Median 30.0 9.0 14.0 1.0 
Min 19 0 5 0 
Max 39 24 26 14 
OH oral hygiene, CS = corticosteroids, GS = gold salts, AB = antibiotics, SD = standard deviation, 
Min minimum value, Max = maximum value, FIV = cat tested FIV positive by ELISA 
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Table 3.7 Paired I test for the comparison of the mean stomatitis index in cats with chronic 
gingivostomatitis and matched comparative cases 
Group No. of cats Mean SI SD Minimum Maximum 
Comparative cases 10 10.7 4.32 2 17 
(CC) 
Gingivostomatitis 10 31.4 6.13 22 39 
cases (Gc) 
Mean difference (Cc - Gc) = -20.7 (95% Confidence interval = -25.7, -15.7) 
Paired Student's t-test: P<0.001 
SI = Stornatitis index, SD = Standard deviation 
Figure 3.5 Correlation and linear regression plot for the stomatitis index and the probing depth 
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Figure 3.6 Correlation between the calculus index and probing depth index from 30 cats with 
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Spearman's correlation coefficient (r, ) = 0.673 (P < 0.001) 
Figure 3.7 Correlation between the stomatitis index and calculus index from 30 cats with 


















Pearson's correlation coefficient (r) = 0.285 (P = 0.126) 
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Table 3.8 Regression of breed and square root of duration of disease (months) index on the 
stomatitis index 
Variable Regression Standard tp 
coefficient deviation 
Constant 20.872 2.941 7.10 0.000 
Breed 5.323 1.981 2.69 0.012 
Duration 1.256 0.586 2.14 0.041 
S=4,533 R-Sq = 27.5% R-Sq (adj) = 22.2% 
Analysis of Variance 
Source of Degrees of Sum of Mean squares Fp 
variation freedom squares 
Regression 2 210.64 105.32 5.13 0.013 
Residual 27 554.73 20.55 
3.4 DISCUSSION 
When studying any disease it is essential to set criteria by which individual cases can be defined. 
Ideally these criteria should establish a definitive diagnosis; however this objective cannot always be 
met, and in such circumstances the defining criteria must, therefore, be sufficiently broad to maximise 
the inclusion of true cases of the disease, while maintaining sufficient specificity to exclude cases with 
unrelated conditions. A definitive diagnostic test for feline chronic gingivostomatitis is lacking. 
Accordingly, within the present study a diagnosis was made presumptively, based upon the clinical 
history and the appearance, distribution, and duration of the oral inflammatory lesions. Cats with a 
clinical history and signs consistent with other causes of chronic inflammatory oral lesions were 
excluded from the study. 
To enable comparison of the degree of mucosal inflammation between cats and the subsequent 
response to treatment to be monitored it was necessary to have a method for quantifying the severity of 
the lesions. The most frequently used method for scoring gingival inflammation in human studies is the 
gingival index (GI) (Loe & Sillness, 1963). Studies have shown that the GI correlates relatively well 
with microscopic evidence of gingivitis (Oliver et al., 1969; Payne et al. 1975; Seymour et al., 1983). 
A number of authors have successfully used or adapted the GI scoring criteria for use in animals, 
including the cat (Robinson & Gorrel, 1995; Anderson, 1996; Gorrel & Rawlings, 1996; Allaker et al., 
1997). Hence, an adapted version of the GI was utilised in the present study and termed the stomatitis 
index (SI). As recommended by Addy et al. (1993), scores were recorded from both buccal and 
lingual/palatal aspects at a number of different sites representing the entire dentition. At each dental 
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site, the area assessed comprised the gingiva and the directly adjacent mucosa. An additional site was 
included in order to incorporate information relating to the degree of faucal inflammation. Thus, in 
contrast to the GI, which only quantifies the level of gingivitis, these adaptations enabled the SI to 
incorporate information relating to the severity of gingival and mucosal inflammation. 
In addition to measuring the level of mucogingival inflammation, it was desirable to assess the clinical 
severity and extent of periodontal disease in cats within the study. Many surveys assess the extent of 
periodontal disease by measuring the loss of periodontal attachment or the absolute depth of 
periodontal pockets, or both (Smith et al., 1985; Hermet & Harvey, 1992; Robinson & Gorrel, 1995; 
DeBowes et al., 1996). As the absolute pocket depth may be influenced by gingival hyperplasia or 
gingival recession, the loss of attachment of the attached gingiva from the cementoenamel junction is 
regarded as a true measurement of the pocket depth. However, during preliminary work it was found 
that a number of factors, such as the small size of many teeth and odontoclastic resorptive lesion 
(FORL)-related loss of the tooth substance, made measurement of the loss of attachment in cats with 
chronic gingivostomatitis difficult and potentially unreliable. Furthermore, supereruption is seen quite 
commonly in cats, especially involving the canine teeth, and in such cases the loss of attachment will 
no longer represent the true depth of the periodontal pocket (Lyon, 1992; Mulligan et al., 1998). 
Consequently, only the absolute pocket depth was used as a physical measure of periodontal disease in 
this study. Depth measurements were recorded on the buccal and lingual/palatal sites in each of the six 
segments of the jaw to ensure that the mouth score comprised elements from all aspects of the 
dentition. 
Plaque and calculus indices are commonly recorded in studies evaluating the efficiency of oral hygiene 
products in preventing the accumulation of plaque and calculus (Logan & Boyce, 1994). In the present 
study, however, the primary aim was to assess the effect of treatment upon the level of mucosal 
inflammation. In view of this fact, and the desire to avoid prolonged periods of anaesthesia, only the 
level of calculus was quantified. A simple and rapid scoring system was selected based upon a 
previous study in dogs (DeBowes et al., 1996). As with the other indices, the calculus index was 
scored on both buccal and palatal/lingual aspects of the teeth at multiple sites in order to gain a 
representative score for the whole mouth. 
During the course of the study, the stornatitis index was seen to reflect the clinical severity of oral 
disease the cats examined. In addition, the baseline stornatitis indices recorded in the affected cats 
were all higher than those recorded the control cats. These findings illustrate that the stomatitis index 
was capable of differentiating between cats with different degrees of oral inflammation. This 
conclusion is further supported fact that that the SI correlated with histological characteristics of the 
inflammatory response (Chapter 11). 
As the stomatitis index and the probing depth index are both evaluating different aspects of 
periodontal disease, it was not surprising that a significant correlation was found between these two 
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parameters. Despite this, however, a direct causal relationship cannot be inferred. Linear regression 
analysis showed that the probing depth index alone failed to account for a substantial proportion of the 
mucosal inflammation seen in these cats, and was a relatively poor predictor of the stornatitis index. 
During the development of periodontal disease gingivitis usually, but not always, precedes the 
development of periodontitis (Page & Schroeder, 1976; Page, 1986; Marsh & Martin, 1992; Lehner, 
1992). Nevertheless, the factors that control the progression of the disease are not fully understood, 
and the presence of gingivitis in itself does not always result in the development of periodontitis (Page 
& Schroeder 1976; Page, 1986; Lehner, 1992). Once periodontitis arises, however, the destructive 
changes that occur in the periodontal tissues tend to encourage the retention of plaque, which 
subsequently promotes gingivitis. Consequently, the finding of a significant, but poorly predictive, 
relationship between the stomatitis index and the probing depth index is consistent with the 
pathogenesis of periodontal disease. Hence, it may be concluded that in cats with chronic 
gingivostomatitis there is an increasing trend for cases to have more severe periodontal pocketing as 
the severity of the mucogingival lesions increases, and vice-versa. Nevertheless, the finding that cats 
with very little or no pocketing have a relatively high level of mucosal inflarnmation suggests that 
additional factors other than destructive periodontal disease are involved in the generation of mucosal 
inflammation. These results, therefore, provide the foundation for a simplified model of the mucosal 
inflammation seen in cats with chronic gingivostornatitis consisting of a periodontal disease-associated 
component and a periodontal disease-independent component. 
Human and animal studies have reported a variable, but usually positive, association between calculus 
and signs of periodontal disease (Studer & Stapely, 1973; Smith et al., 1985; Gengler et al., 1995; 
Norderyd & Hugoson, 1998; Albander et al., 1998; Pattanaporn & Navia, 1998). The present study 
found that the extent of calculus deposition correlated significantly with the severity of periodontal 
pocketing. This finding is consistent with the general theory that calculus predisposes to the 
development of periodontal disease by promoting the retention of dental plaque (Frost & Williams 
1986, Marsh & Martin 1992). By contrast, the level of calculus deposition was not significantly related 
to the severity of mucosal inflammation, although a positive trend was present. This suggests that the 
severity of the mucogingival lesions in cats with chronic gingivostomatitis is not directly influenced by 
dental calculus. However, an indirect relationship can be proposed via the significant positive 
association between calculus and periodontal disease. 
Multiple linear regressions were used to determine if the age, breed (pedigree versus non-pedigree 
DSH/DLH), FIV status, duration of disease and diet had a significant predictive relationship with any 
of the oral indices. The duration of disease and the breed were found to have a significant positive 
relationship with the stomatitis index, implying that the severity of mucogingival lesions increases over 
time, and that DSH and DLH cats tend to have a higher stomatitis index than pedigree breeds. By 
contrast, none of the variables were found to relate significantly to the probing depth index. Thus, the 
duration of disease and the breed may be considered as significant factors within the periodontal 
disease-independent component of the above model. None of the variables were found to relate 
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significantly to the calculus index. This is perhaps surprising as calculus generally accumulates with 
age (Gengler et al., 1995), and it has been suggested that pure-bred cats are predisposed to calculus 
formation (Von Schlup, 1982). Furthermore, calculus accumulation may be influenced by diet (Studer 
& Stapely, 1973). However, the majority of the cats within this study had undergone a dental scale and 
polish at one or more occasions prior to being referred, which may have compromised the ability to 
detect potential relationships between the calculus index and various factors. Investigation of calculus- 
related disease would be best performed prospectively under controlled conditions (Boyce, 1992; 
Gorrel et al., 1998). 
Case-specific and retrospective epidemiological details from the cats with chronic gingivostornatitis 
were analysed. No significant sex bias was seen in affected cats, which is in agreement with previous 
reports (Johnessee & Hurvitz, 1983; White et al., 1992). The majority of the affected cats were non- 
pedigree domestic short-haired, however three Siamese, two Burmese, a British Colour Point short- 
haired, and a Persian Angora crossbred were also present within this population. This breed 
distribution is similar to that seen in previous studies of cats with chronic gingivostomatitis (Johnessee 
& Hurvitz, 1983; Hennet, 1997 White et al., 1992). Previous reports have suggested that pure-bred 
cats, particularly Siamese, Persian/Himalayan, Burmese and Abyssinian breeds, are predisposed to the 
development of oral disease (Frost & Williams, 1986; Tenorio et al. 1991; Harvey 1991); although 
Williams & Aller (1992) reported no such breed predilections. An insufficient number of cats were 
present in this study to enable conclusions regarding specific breed dispositions to be drawn, and, 
furthermore, a comparative population was lacking. In order to resolve this issue it would be necessary 
to conduct a suitably large, controlled, epidemiological survey. 
Much of the analyses of the case-specific information was based upon the age at which signs of disease 
were first noted. The age at onset ranged from 6 months to 13 years, but signs most commonly arose 
during middle-age with the average age of onset being 6 years. Multiple linear regression analysis 
provided no evidence to indicate that the sex, diet, vaccination status or environmental access had any 
significant bearing upon age of onset. By contrast, as the number of cats in the household increased, 
there was a significant tendency for cats to develop disease at a younger age. Nevertheless, the 
regression coefficient for population density was relatively low, which implies that the effect of this 
factor alone was not particularly pronounced. The relevance of this relationship is not clear. 
Population density has been recognised as an important risk factor in determining the prevalence and 
severity of many of feline infectious diseases (Pedersen, 1991). High population densities generally 
provide a greater reservoir of potential carriers and, where relevant, an increased level of 
environmental contamination. These factors promote the risk of infection in susceptible cats by 
increasing both the exposure rate and the dose of infectious agent. Consequently, these results may 
provide evidence to support the hypothesis that infectious agents are involved in the aetiopathogenesis 
of feline chronic gingivostomatitis. However, cats from households with larger populations generally 
experience greater social stress, which is often thought to predispose affected individuals to the 
development of disease (Pedersen, 1991). Thus, this may provide an alternative mechanism by which 
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cats from households with larger populations become predisposed to the development of chronic 
gingivostornatitis at a younger age. 
The results also indicate that pedigree cats are inclined to develop disease at a younger age by 
comparison to non-pedigree cats. This finding would support the hypothesis that genetic factors play a 
role within the aetiopathogenesis of chronic gingivostomatitis. Together, the breed and household 
population density explained approximately one third of the variance seen in the age of onset of 
disease. However this also implies that the majority of the variance must be determined by other 
factors. 
Serum antibodies against FIV were detected by ELISA in 13% of the cats with chronic 
gingivostomatitis. By contrast, all of the cats within the comparative group were seronegative for FIV, 
although this difference was not statistically significant. The ELISA has been estimated to have a 
sensitivity of 95% and a specificity of 98% for the detection of FIV-specific serum antibodies by 
comparison to results derived by western blotting (Barr et al., 1991). Thus, it is recognised that the 
ELISA may yield occasional false-negative or false-positive results. In addition, the assay will fail to 
identify infected cats that have not undergone seroconversion (Yamamoto et al., 1989; Hopper et al., 
1989). However, as seroconversion generally occurs within 2 months of infection it was expected that 
most, if not all, of the cases infected with FIV would have undergone seroconversion by the time of 
referral. 
Serological surveys have indicated that the prevalence of FIV within the domestic feline population 
varies between countries (reviewed by Hopper et al. 1994), but most surveys report a higher 
prevalence of FIV in sick cats compared with healthy cats. Within the UK it has been estimated that up 
to 19% of sick cats and 6% of healthy cats are scropositive for FIV (Hosie et al. 1989, Hopper et al. 
1994). Thus, by comparison to this historical data, the results of the present study suggest that the 
prevalence of FIV in cats with chronic gingivostomatitis is akin to that found within the general sick 
feline population. 
Since the discovery of FIV (Pedersen ct A, 1987) many authors have implicated this virus in the 
pathogenesis of chronic oral disease (Hosie et at., 1989; Knowles et al., 1989; Zetner et al., 1989; 
Friend et al., 1990; Gruffydd-Jones, 199 1; Tenorio et al., 199 1; White et al., 1992; Waters et al., 1993; 
Hennet, 1995). Nonetheless, its potential role in chronic gingivostornatitis remains largely unresolved. 
The results of present study are in accordance with previous investigations which have estimated the 
prevalence of FIV in cats with chronic gingivostornatitis to range from 10 to 81% (see Table 1.1). 
Local and international environmental and genetic differences between feline populations, in addition 
to potential methodological differences, explain much of the variation in the results between these 
studies (Barr et al.. 1991; Jarrett et al., 1991; Egberink et al., 1991; Reid et al., 1992; Macy, 1994; 
Hopper et al., 1994). However, the absence of the virus from a considerable proportion of cats with 
chronic gingivostomatitis, as reported herein, suggests that FIV is not a primary aetiological agent in 
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the disease pathogenesis. Nevertheless, it seems likely that the presence of FIV infection can act as a 
significant factor or co-factor in the disease pathogenesis in some cases. This opinion is supported by 
documented reports of remission of oral lesions in FIV-positive cases cats with chronic 
gingivostomatitis following treatment with some antiviral agents (Egberink et al., 1990; Tizard, 199 1; 
Hartmann et al., 1995a & b). The cumulative evidence suggests that the inimuno-suppressive effects of 
FIV somehow facilitate the expression of disease in susceptible cats, possibly by altering the host 
response to infection with primary aetiological agents, or by perturbing the response to external agents 
or self-tissue in such a manner that disease is precipitated. (Yamamoto et al., 1989; Williams & Aller, 
1992; Bishop, 1995; English & Thompkins, 1995). Further studies are required to investigate these 
possible mechanisms and their potential role in the induction of chronic oral disease in the cat. 
Signs of oral disease have commonly been reported in cats with FeLV infection (Hardy, 1982; Hardy, 
1988; Hoover & Mullins, 1991; Anon, 1992). However, large-scale controlled surveys detailing the 
prevalence of various clinical signs in cats with FeLV are generally lacking. Moreover, FeLV infection 
alone was not found to be associated with an increase in the prevalence or severity of oral lesions in 
various mixed feline populations (Hosie et al., 1989; Friend et al., 1990; Tenorio et al., 1991). Thus, 
there is little convincing evidence to support the hypothesis that FeLV infection predisposes to the 
development of oral disease. 
In the present study none of the cats suffering from chronic gingivostomatitis, nor any of the cats 
within the comparative group, tested positive for FeLV. These findings are in accordance with 
previous reports, in which FeLV was detected in 0 to 17% of cats with chronic gingivostomatitis cats 
compared to 0 to 11% of control cats (Thompson et al., 1984; Knowles et al., 1989; Zetner et al., 
1989; Gruffydd-Jones, 1991; White et al., 1992; Hennet, 1995). One potential problem associated with 
the use of ELISA, and other techniques which rely upon the presence of viraemia for the detection of 
FeLV, is the inability to detect non-viraemic latent infections (Cotter, 1998). Uthman et al. (1996) 
recently demonstrated the presence of exogenous long terminal repeat (LTR) FeLV sequence by PCR 
in gingival tissue in 2 of 15 cats which tested non-viraemic by ELISA. The significance of latent virus 
at this site is not known, although the authors speculated that it may be able induce impairment of local 
defences. While this latter study does indeed highlight methodological problems in the detection of 
FeLV infection, it also indicates that the majority of non-viraemic cats do not have evidence of latent 
FeLV within their oral tissue. Thus, the cumulative evidence suggests that FeLV is not a primary 
aetiological agent in the pathogenesis of feline chronic gingivostornatitis. 
The persistent nature of FHV (Gaskell & Povey, 1979) and its potential to cause oral cavity disease 
(Gaskell & Dawson, 1998) affords this virus a potential role in the pathogenesis of chronic 
gingivostomatitis. However, in the present study FHV was not isolated from any of the oropharyngeal 
swabs taken from cats with chronic gingivostornatitis or the comparative group. This finding is in 
accordance with Harbour et al. (1991) who did not isolate FHV from oropharyngeal swabs collected 
from 412 cats diagnosed as suffering from gingivitis or stomatitis alone. Furthermore, FHV isolation 
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was not reported in studies where oropharyngeal swabs were collected for the identification of upper 
respiratory tract viruses in clinical cases of chronic gingivostomatitis (Knowles et al. 1989, Zetner et 
al. 1989). However, owing to the intermittent nature of viral shedding, the detection of FHV-carrier 
cats can be problematic and unpredictable using single oropharyngeal swabs. Thus it is possible, and 
indeed highly likely, that latent FHV-carriers have gone undetected in the present or previous studies 
(Ellis, 1981; Gaskell & Dawson, 1998). In future, it would be advantageous to collect multiple 
samples for analysis over a prolonged time-period in order to increase the likelihood of collecting 
samples during a period of viral shedding, and to use more sensitive detection methods, such as PCR- 
based assays for the amplification of specific FHV DNA sequences (Reubel et al., 1993; Stiles et al., 
1997; Weigler et al., 1997). 
The ability of FCV to persist for prolonged periods within the oral cavity and the strong association 
between FCV and FCGS (Table 1.1) have led a number of authors to hypothesise that this virus could 
play a role in the pathogenesis of chronic gingivostornatitis (Povey, 1976; Knowles et al., 1989; 
Gruffydd-Jones, 1991; Reubel et al., 1992). In the present study, samples collected six months apart 
revealed that on average 90% of the cats were shedding detectable levels of FCV at each time-point, 
and collectively that FCV infection was detected in all 30 cases with chronic gingivostomatitis. By 
contrast, FCV was not isolated from any of the ten control cats which were swabbed at a single time- 
point. These results are in accordance with previous reports where 48 to 92% of cats with chronic 
gingivostornatitis have been reported to be shedding FCV, compared to 0 to 19% of cats within control 
populations (Thompson et al., 1984; Knowles et al., 1989; Zetner et al., 1989; Gruffydd-Jones, 1991). 
Moreover, it is the first report to document the isolation of FCV from all of the cats within a large 
series of cases suffering from chronic gingivostomatitis. 
The use of oropharyngeal swabs for the detection of FCV is a standard technique. However, the 
successful detection of positive cases depends upon the amount of virus being shed into the saliva, and 
while most carriers can be detected following a single sample, occasionally it is necessary to take 
repeated samples (Wardley, 1976). Within the present study it was not possible to swab the control 
cats on more than one occasion. Thus, it is conceivable that some of these latter cats could have been 
shedding low levels of virus which went undetected. Equally, this factor could account for the 
discordance seen between some of the swabs taken at different time-points from cats with chronic 
gingivostomatitis. Moreover, it could account for the differences in the prevalence rates of FCV 
recorded between the present and previous studies. 
Following the administration of live FCV vaccines, oropharyngeal shedding of the attenuated virus can 
occur for at least 5 days in the case of subcutaneous vaccines, and a number of months with intra-nasal 
vaccines (Orr et al., 1980; Bennet et al., 1989; Pedersen & Floyd Hawkins, 1995). In the present study 
there was no history of any of the cats with chronic gingivostomatitis ever having received an 
intranasal vaccine. Furthermore, none of the cats had recently been vaccinated prior to the collection 
of samples for FCV isolation. 
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In the absence of a recent vaccination or signs of acute infection, the positive isolation of FCV usually 
implies that cat is a persistent carrier (Gaskell & Dawson, 1998). Under experimental conditions 
Wardley & Povey (1977b) found that the number of detectable carriers within a population declines 
exponentially with a half life of 75 days; although a small proportion of cats continued to shed FCV 
for a prolonged time. While subsequent studies have not always conformed to this model, they have 
shown that most cats cease to shed detectable levels of virus within 2 to 5 months of the establishment 
of infection (Knowles et al., 1991; Rebel et al., 1992; Pedersen & Floyd Hawkins, 1995). Thus, within 
this study the finding of FCV in 80% of cats with chronic gingivostomatitis at time-points six months 
apart is exceptional. Hence, the results reported herein support the hypothesis that cats with chronic 
gingivostornatitis remain persistently infected with FCV. Nevertheless, it is also possible that some 
cases may have been undergoing an acute infection with a non-pathogenic strain, or a transitory re- 
infection at one or more of the sample time-points. In order to prove that these cats are truly 
persistently infected it would be necessary to isolate each individual from all external sources of FCV 
and collect regular samples over a prolonged time course. Such a study would be difficult, but not 
impossible, to perform. 
Although the results of the present study add further weight to the body of evidence supporting an 
association between FCV and signs of chronic oral disease (Thompson et al., 1984; Knowles et al., 
1989; Zetner et al., 1989; Gruffydd-Jones, 1991; Reubel et al., 1992), the link remains circumstantial. 
The issue is complicated by the fact that whereas FCGS is a relatively uncommon disease, chronic 
carriage of FCV is relatively common within cats and may affect up to 25% of the feline population 
within the UK (Wardley et al., 1974; Coutts et al., 1994). In this respect it was surprising that FCV 
was not detected in any of the 10 control cats - although this most likely reflects the small number of 
cats within this group. Infection with FCV alone has not been associated with any increase in the 
severity or prevalence of oral lesions within a mixed population (Tenorio et al., 1991). Moreover, 
deliberate attempts to experimentally induce signs of chronic gingivostornatitis in SPF cats using FCV 
isolates from clinical cases were not successful (Knowles et al., 1991; Reubel et al., 1992). However, 
these findings are confounded by the fact that chronic gingival lesions were reported in a number of 
cats within an experimental colony infected with FIV into which FCV was inadvertently introduced 
(Waters et al., 1993). Despite this latter report, the cumulative evidence suggests that FCV infection in 
itself is not generally associated with the development of signs of chronic gingivostomatitis. This, 
therefore, implies that either FCV is not a primary aetiological agent in the pathogenesis of chronic 
gingivostomatitis, or that additional exogenous and/or endogenous co-factors are necessary for the 
induction of clinical signs of chronic gingivostomatitis in individual cases. 
An understanding of the mechanisms and factors affecting the persistence of FCV in the host could 
provide an important insight into aspects of the pathogenesis of chronic gingivostomatitis (Povey at 
al., 1973; Wardley, 1976; Wardley & Povey, 1977a; Dick & Johnson, 1989; Dick et al., 1989). Recent 
studies have suggested that the persistence of FCV infection is driven and regulated primarily by the 
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host immune response rather than specific characteristics of the viral strain (Johnson, 1992; Radford et 
al., 1998; Kreutz et al., 1998). Thus, the continuance of FCV infection in cats with chronic 
gingivostornatitis may indicate that there is an underlying defect or dysregulation of the host immune 
response. 
Additional factors that may interplay with FCV to induce disease could include other infectious agents, 
especially those which have the potential to cause significant immune dysfunction. One obvious 
candidate is FIV. Co-infection with FIV and FCV has been associated with both a higher prevalence of 
oral disease and oral lesions of greater severity when compared to cats infected with one or neither of 
these viruses (Tenorio et al., 1991; Waters et al., 1993). Furthermore, experimental evidence suggests 
that co-infection with FIV can enhance acute signs of FCV infection and cause increased and 
prolonged shedding of FCV (Dawson et al., 1991; Reubel at al., 1994). The precise mechanism(s) 
responsible for these effects has not been determined. However, there is some evidence to suggest that 
a lower evolutionary rate of FCV exists in cats co-infected with FIV, which may result from reduced 
immune selection pressure caused by the immunosuppressive effects of FIV (Radford et al., 1998). 
Alternatively, it is conceivable that a direct interaction between the viral genes could result in 
enhanced viral pathogenicity (Laurence, 1990; Golden et al., 1992). While a similar role could be 
envisaged for FeLV, and possibly other viruses, there is no supporting evidence. Other infectious 
agents that could potentially interact with FCV include bacteria. A huge array of bacterial species can 
reside within the oral cavity, many of which possess immunomodulatory and other pathological 
properties (Marsh & Martin, 1992; Lehner, 1992; Wilson et al., 1998). Thus, it is possible that these, 
or other organisms, may interact with FCV in a synergistic manner to promote disease. 
Some authors have raised concerns over the potential for live-attenuated FCV strains used in 
vaccinations to induce acute disease and prolonged viral shedding (Dawson et al. 1993a, Pedersen & 
Floyd Hawkins 1995). Analysis of any potential effect of vaccinations per se in the induction of 
chronic gingivostomatitis was not possible within this study as almost all of the cats had been 
vaccinated. However, no difference was found in the severity of the oral disease present in cats which 
had or had not received a booster vaccine against FCV, FHV and feline enteritis within the previous 
18 months. Hence, this study provides no evidence to support the hypothesis that booster vaccinations 
may influence the pathogenesis of FCGS. 
If FCV is a primary factor in the pathogenesis of chronic gingivostomatitis, it is interesting to 
speculate as to its possible mode of action. Reubel et a]. (1992) suggested that a minority of cases 
infected with FCV may mount an atypical immune response which results in excessive damage to self- 
tissue and the production of chronic faucitis. The authors also proposed that concurrent FIV infection 
could enhance this process by promoting the FCV carrier state and perturbing the immune response to 
FCV. Thus the disease may represent a frustrated attempt by the host to clear persistent FCV infection. 
An alternative immune-based mode of action may be that the presence of FCV directly, or indirectly, 
disturbs the local host response to other antigenic sources present in the oral cavity, such as bacteria. A 
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third possible mechanism may be that FCV initiates the oral lesions by causing physical damage to 
epithelial structures, thereby disrupting the integrity of the mucosal barrier and permitting access of 
other pathological factors into deeper tissue. 
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CHAPTER 4: Clinical Responses to Treatment 
4.1 INTRODUCTION 
A wide range of therapeutic agents and procedures have been advocated for the treatment of chronic 
gingivostomatitis in cats (see Chapter 1). Nonetheless, the relative effectiveness of the majority of 
these treatments has not been adequately explored. This chapter presents the results of a clinical trial 
which sought to compare the effectiveness of four different therapeutic agents in their ability to 
alleviate the clinical signs of oral inflammation in cats with chronic gingivostornatitis over a treatment 
period lasting for up to six months. 
4.2 MATERIALS& METHODS 
These are presented in Chapter 2. 
4.3 RESULTS 
4.3.1 Treatment allocation 
Thirty cats were entered onto the treatment trial and each cat was randomly allocated to one of four 
treatment groups as shown in Table 3.6. 
4.3.2 Treatment trial withdrawals 
During the course of the trial 6 cats were withdrawn from the study. Two cases, both in the gold salt 
treated group, were withdrawn prior to the second consultation because of suspected adverse reactions 
to the drug. Cat 13 suffered an episode of diarrhoea and lethargy shortly following the first injection of 
gold salts. Cat 29, cat developed ulcerative lesions at the commisures of the lips and nasal philtrum, 
accompanied by pyrexia, inappetence and a neutrophilic leucocytosis approximately one month after 
gold salt therapy commenced. 
Following the second consultation, a further two cats were withdrawn from the study. In the case of 
Cat 2 (oral hygiene group) the owners were having difficulty in administering the treatment, and they 
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were unwilling to continue applying oral hygiene products. The owners of Cat 26 (antibiotic group) 
felt that the cat was not responding to treatment and was in considerable discomfort, consequently this 
case was withdrawn on ethical grounds. 
Two additional cats were withdrawn from the trial following the third consultation. Cat I (oral hygiene 
treatment) was not eating well due to the oral discomfort and had lost approximately 20% of its body 
weight since the start of the trial. Consequently, this case was also withdrawn on ethical grounds. In 
the case of Cat 7 (gold salts group), there was slight worsening of his condition during the previous 3 
months, the cat was in discomfort, and there was a persistent mucopurulent film in the proliferative 
tissue in the glossopharyngeal areas. Although this cat remained on gold salts, a concurrent long term 
course of metronidazole and spiramycin was prescribed. Consequently, this cat was withdrawn from 
the study because of the fact that an additional long term treatment was being administered. 
Cat 30, which was being treated with gold salts, developed a mild neutropenia during the final month 
of treatment. As a result of this, the last two gold salt injections were not administered prior to the final 
consultation - at which point the neutrophil count had reverted to normal, Since this cat had received 
the vast majority of the prescribed treatment the results from this case were included in the analysis. 
4.3.3 Dental extractions 
All of the clinical cases underwent a dental hygiene procedure and in the majority of cases one or more 
dental extractions were performed (Table 3.6). Table 4.1 shows that there was no significant difference 
between treatment groups in the number of extractions performed. 
Table 4.1 One way analysis of variance results for the number of extractions performed in each 
treatment group 
Kruskal-Wallis Test on number of extractions: 
Group OH GS cs AB 
Median rank 12.5 16.3 20.0 4.5 
Ave Rank 15.3 15.9 17.8 13.0 
z -0.07 0.14 0.78 -0.86 
H =1.1 I DF 3P=0.77 (adjusted for tied ranks) 
OH = Oral hygiene, GS Gold salts, CS = corticosteroids, AB = Antibiotics 
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4.3.4 Clinical indices 
4.3.4.1 Stomatitis index 
4.3.4.1.1 Comparison between group stomatitis index scores at consultation I 
No significant differences were found to exist between treatment groups in the stornatitis index at 
consultation I (Figure 4.1 and Table 4.2). Consequently, at subsequent consultations the change in 
stornatitis index was calculated for each cat relative to the baseline value scored at consultation 1. 













OH GS cs AB 
Group 
Group OH GS cs AB 
Mean SI 28.5 30.1 32.1 27.6 
SD 5.43 4.64 4.88 5.47 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics. Horizontal bars are group means. P value 
calculated by ANOVA (Table 4.2) 
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Table 4.2 One way analysis of variance test results on the stomatitis index at consultation 1 
One-way Analysis of Variance (ANOVA) on stomatitis index 







28.6 1.10 0.39 
26.1 
4.3.4.1.2 Stornatitis index at consultation 2 
After approximately six weeks of treatment the stomatitis index was measured in all of the 28 cats 
remaining within the clinical trial (Figure 4.2). The data were analysed by ANOVA followed by Hsu's 
method for multiple comparisons with the best (MCB) (Hsu, 1996) (Figure 4.3). Hsu's MCB method 
provides confidence intervals for the difference between each treatment and the best (in this case the 
most negative) of the other treatment means, whilst maintaining an overall cc level of 0.05. The 
confidence intervals are constrained to contain 0, therefore, if the upper confidence limit of a treatment 
group is 0 then this implies that it is the best treatment, whereas if the lower confidence limit of a 
treatment group is 0 then this implies that it is not the best treatment. The results (Figure 4.3) show that 
the mean reduction in the stomatitis index was significantly greater in the corticosteroid group by 
comparison to that seen in any of the other treatment groups. Therefore, after six weeks of therapy 
methyl prednisolone was shown to be the best treatment. 
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OH GS cs AB 
Group 
OH = Oral hygiene, GS - Gold salts, CS = Corticosteroids, AB - Antibiotics, 
Wd = Withdrawn. Horizontal bars are group medians. 
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Figure 4.3 One way analysis of variation and Hsu's MCB (multiple comparisons with the best) 
on the change in stomatitis index at consultation 2 
Summary statistics 
Group OH GS CS AB 
Number of cases 8 6 7 7 
Mean ASI -1.13 -1.38 -8.86 -0.86 
SD ASI 5.44 3.42 6.74 5.15 
Mean ASI (% baseline) -4.3 -6.8 -28.7 -5.7 
ASI = change in stornatitis index 
One-way Analysis of Variance (ANOVA) on change in stomatitis index 







107.1 3.87 0.021 
27.7 
Confidence intervals for Hsu's MCB 
Family error rate = 0.05 
Critical value = 2.17 








Interval OH GS CS AB 
Lower 0.00 0.00 -13.39 0.00 
Centre 7.73 7.48 -7.48 8.00 
Upper 13.64 13.39 0.00 14.10 
OH - Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB = Antibiotics 
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An additional analysis was performed in order to be able to incorporate information from all of the 
cats that had entered the study. The two withdrawn cases, from the gold salt-treated group, were 
assigned the highest overall score for the change in stomatitis index (ASI = 43) to ensure that they 
would receive the maximum ranking score within non-parametric tests. In keeping with the principles 
of Hsu's MCB method it was only necessary to compare the results for the gold salt-treated group 
against the best of the remaining treatment groups (i. e. the group with the lowest ASI median). 
Consequently a single Mann-Whitney test was performed between the gold salts group and the 
corticosteroid group. The results (Table 4.3) show that the reduction in stomatitis index shown in the 
corticosteroid group was significantly greater than that shown by the gold salts group. 
Table 4.3 Mann-Whitney test (adjusted for tied ranks) comparing the change stomatitis index 
between the corticosteroid treated group and the gold salts treated group at consultation 2 
Group n Median wp 
cs 7 -12.0 36.0 0.024 
GS 8 1.0 
CS = Corticosteroid, GS = Gold salts 
4.3.4.1.3 Stornatitis index at consultation 3 
Twenty six cats were re-examined approximately three months after treatment commenced (Figures 
4.6 - 4.8). The change in stomatitis index was calculated for each individual (Figure 4.4). Subsequent 
analysis by ANOVA and Hsu's MCB method showed that none of the treatments could be identified 
as being the best (Figure 4.5). However the lower confidence interval for the mean change in 
stomatitis index within the oral hygiene group was 0, which implies that this treatment was not the best 
(Figure 4.5). 
A second analysis was performed to incorporate information from the withdrawn cases. As before, the 
withdrawn cases were equally assigned a maximum ranking score (ASI = 43). A Kruskal-Wallis test 
was performed followed by selected multiple comparisons using Dunn's method, whereby each 
treatment group was compared against the best (i. e. the group with the lowest ASI median) of the 
remaining groups. The results in Table 4.4 show that the corticosteroid group had a significantly 
greater reduction in the median change in stomatitis index than the oral hygiene group after 3 months 
of treatment. 
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OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics 
Wd = Withdrawn. Horizontal bars are group medians. 
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Figure 4.5 One way analysis of variation and Hsu's MCB (multiple comparisons with the best) 
on the change in stomatitis index at consultation 3 (withdrawn cases excluded) 
Summary statistics 
Group OH GS CS AB 
Number of cases 7 6 7 6 
Mean ASI -1.71 -3.17 -9.14 -6.17 
SD ASI 6.58 5.66 4.85 5.95 
Mean ASI (% baseline) -3.8 -11.5 -28.6 -24.0 
ASI = change in stornatitis index 
One-way Analysis of Variance (ANOVA) on change in stornatitis index 
Source DF Ss ms FP 
Group 3 223.9 74.6 2.24 0.11 
Error 22 732.0 33.3 
Confidence intervals for Hsu's MCB 
Family error rate = 0.05 
Critical value = 2.19 








Interval OH GS CS AB 
Lower 0.00 -1.04 -9.99 4.04 
Centre 7.43 5.98 -2.98 2.98 
Upper 14.17 12.99 4.04 9.99 
OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB - Antibiotics 
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Table 4.4 Kruskal-Wallis test and selected multiple comparisons tests for the change stomatitis 
index between treatment groups at consultation 3 
Kruskal-Wallis Test (adjusted for tied ranks) on change in stomatitis index 
Group OH GS CS AB 
Median 1.5 -0.5 -12.0 -3.0 
Ave Rank 19.4 18.7 8.3 14.5 
z 1.48 1.22 -2.48 -0.34 
H=7.52 DF =3P=0.052 
Dunn's Multiple Comparison Tests 
Group Comparison Difference in rank sum P value 
OHvCS 11.15 < 0.05 
GSvCS 10.46 > 0.05 
ABvCS 6.21 > 0.05 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics 
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Figure 4.6 Mucogingival lesions at consultation 3 (Cat 24 - antibiotic treatment group) 
This cat showed a poor response to treatment. Widespread severe proliferative gingivitis and 
stomatitis still affect the (a) fauces and (a & b) most aspects of the gingiva. Change in stomatitis 
index = -3 
Figure 4.7 Mucogingival lesions at consultation 3 (Cat 25 - oral hygiene treatment group) 
This cat showed no clinical response to treatment. (a) Severe mucogingival lesions are present and 
gingival recession is evident. (b) Bilateral inflammatory lesions extend along the length of the 
glossopalatine arches. Change in stornatitis index = +5 
Figure 4.8: Mucogingival lesions at consultation 3 (Cat 28 - corticosteroid treatment group) 
This cat demonstrated a moderate clinical improvement. (a & b) Mild inflammation still affects the 
gingiva around the upper and lower canines and extends along the mucosa overlying the alveolar 
bone crest. (b) Moderate to severe gingivitis is present around the right upper third and fourth 
premolars but is less severe around the lower molar and fourth premolar. Change in stomatitis index 
= -12 
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4.3.4.1.4 Stornatitis index at consultation 4 
The stomatitis index was recorded in the 24 cats remaining within the study at consultation 4 and the 
relative change from consultation I was calculated (Figures 4.9 & 4.11-4.13). As before, analyses 
were performed with and without the inclusion of maximum ranking values for cats which bad 
withdrawn from the trial. Figure 4.10 and Table 4.5 show that no significant difference was 
demonstrable between the treatment groups in the change in stomatitis index at this time. 
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Table 4.5 Kruskal-Wallis test for the change stornatitis index between treatment groups at 
consultation 4 
Kruskal-Wallis Test (adjusted for tied ranks) on change in stomatitis index 
Group OH GS cs AB 
Median -3.0 -2.5 -8.0 -6.0 
Ave Rank 17.3 18.7 11.8 13.4 
z 0.68 1.22 -1.27 -0.71 
H =3.10 DF=3 P=0.377 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics 
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Figure 4.10 One way analysis of variation and Hsu's MCB (multiple comparisons with the best) 
on the change in stomatitis index at consultation 4 
Summary statistics 
Group OH GS CS AB 
Number of cases 6 5 7 6 
Mean ASI -5.83 -7.60 -7.71 -9.83 
SD ASI 6.62 7.93 6.80 9.26 
Mean, &Sl (% baseline) -20.0 -24.8 -23.7 -38.3 
ASI = change in stornatitis index 
One-way Analysis of Variance (ANOVA) on change in stornatitis index 
Source DF SS ms FP 
Group 3 48.2 16.1 0.27 0.84 
Error 20 1176.3 58.8 
Confidence intervals for Hsu's MCB 
Family error rate = 0.05 
Critical value = 2.21 








Interval OH GS CS AB 
Lower -5.77 -8.01 -7.30 -11.53 
Centre 4.00 2.23 2.12 -2.12 
Upper 13.77 12.50 11.53 8.01 
OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB = Antibiotics 
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Figure 4.11 Mucogingival lesions at consultation 4 (Cat 10 - corticosteroid treatment group) 
This cat showed a good response to treatment. (a) Moderate inflammatory lesions still affect the left 
(L) fauces and the gingiva surrounding the right upper premolars. (a & b) The mucogingival 
inflammation affecting the left buccal aspect has reduced and some areas appear normal. Change in 
stornatitis index = -16 
Figure 4.12 Mucogingival lesions at consultation 4 Cat 12 - antibiotic treatment group) 
This cat showed an excellent clinical improvement (a) Slight gingivitis remains around the upper 
and lower canines. (a & b) The alveolar mucosa and faucal mucosa appear normal. Change in 
stornatitis index = -21 
Figure 4.13 Mucogingival lesions at consultation 4( Cat 17 - oral hýgiene treatment group) 
This cat demonstrated a moderate clinical improvement. (a & b) Focal areas of moderate or severe 
inflammation still affect the gingiva and fauces. Change in stomatitis index = -14 
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4.3.4.2 Probing depth index 
4.3.4.2.1 Probing depth index at consultation 1 
No significant difference was demonstrable in the probing depth index between treatment groups at 
consultation I (Figure 4.14 and Table 4.6). 











OH GS cs AB 
Group 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics. Horizontal bars are 
group medians. P value calculated using the Kruskal-Wallis test (Table 4.6) 
Table 4.6 Kruskal-Wallis Test on probing depth index results at consultation 1 
Group OH GS cs AB 
Median 6.0 9.5 11.0 9.0 
Ave Rank 13.3 16.9 18.3 13.3 
z -0.84 0.52 0.96 -0.61 
H =1.72 DF =3P=0.63 (adjusted for tied ranks) 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics 
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4.3.4.2.2 Probing depth index at consultation 3 
The probing depth index was scored in 23 cats at consultation 3. In Cats 7,22, and 23 the probing 
depth index was not recorded because they could not be anaesthetised at the time of the consultation. 
Figure 4.15 shows the change in probing depth index from the baseline levels measured at consultation 
I (section 3.2.4.2.1). Table 4.7 demonstrate that there was no significant difference between any of the 
treatment groups in the change in probing depth index at this time. 











OH Gs cs AB 
Group 
Summary Statistics 
Group OH GS CS AB 
Mean A PDI -1.0 -7.5 -7.2 -1.3 
SD 8.58 7.23 4.96 3.01 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics, APDI = Change in 
probing depth index, SD = standard deviation. Horizontal bars are means. P value calculated using 
ANOVA (Table 4.7) 
Table 4.7 One way analysis of variance test results on the change in probing depth index at 
Consultation 3 
One-way Analysis of Variance (ANOVA) on change in probing depth index 
Source DF SS ms FP 
Group 3 214.1 71.4 1.76 0.19 
Error 19 769.2 40.5 
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4.3.4.3 Calculus index 
4.3.4.3.1 Comparison between groups at consultation 1 
Analysis of the results obtained at consultation I revealed no difference in the calculus index between 
treatment groups (Figure 4.16 and Table 4.8). 











OH cs cs AB 
Group 
Summary Statistics 
Group OH GS CS AB 
Mean CI 15.4 14.0 14.1 13.6 
SD 7.41 6.91 7.63 2.99 
OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics, CI = calculus index, SD 
= standard deviation. Horizontal bars are group means. P value calculated using ANOVA (Table 4.8) 
Table 4.8 One way analysis of variance test results on the calculus index at consultation 1 
One-way Analysis of Variance (ANOVA) on calculus index 
Source DF SS MS FP 
Group 3 13.9 4.6 0.11 0.96 
Error 26 1120.4 43.1 
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4.3.4.3.2 Calculus index at consultation 3 
The calculus index was scored in 23 cats at consultation 3 (Figure 4.17) Owing to factors which 
prevented the cat being anaesthetised on the day of the consultation the calculus index was not 
recorded in Cats 7,22, and 23. Table 4.9 demonstrate that there was no significant difference between 
the treatment groups in the calculus index following three months of treatment. 
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OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB = Antibiotics, CI = calculus index, SD 
= standard deviation. Horizontal bars are group Means. P value calculated using ANOVA (Table 4.9) 
Table 4.9 One way analysis of variance test results on the calculus index at consultation 3 
One-way Analysis of Variance (ANOVA) on calculus index 







15.0 1.49 0.25 
10.0 
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4.3.4.4 Correlations between clinical indices at consultation 3 
Figures 4.18 - 4.20 show the correlations between the stomatitis index, probing depth index and 
calculus index scores measured at consultation 3. A significant relationship was only found to exist 
between the stomatitis index and the probing depth index (Figure 4.18). 
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Probing depth index 
Pearson's correlation coefficient (r) = 0.530 (P = 0.009) 
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Calculus index 
Pearson's correlation coefficient (r) = -0.079 (P = 0.72) 
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Probing depth index 
Pearson's correlation coefficient (r) = 0.344 (P = 0.11) 
0.344 
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4.3.4.5 The relationship between the change in stomatitis index and the change in probing depth 
index at consultation 3 
The correlation between the change in stomatitis index and the change in probing depth index was 
examined (Figure 4.21) and showed that a highly significant relationship existed between these two 
variables. These findings raised the question as to what extent the changes that were seen in the 
stornatitis index were associated with the treatment prescribed and/or changes in periodontal disease. 
Consequently, a multiple linear regression analysis was performed using a forward stepwise model 
with a 10% inclusion level with the change in stomatitis index regressed on probing depth index and 
treatment. The treatment groups were represented by dummy variables (0 = not in treatment group, I= 
in treatment group). Table 4.10 shows that only the change in periodontal index remained within the 
model and this parameter predicted 41.8% of the variation in the change in stomatitis index. 
Figure 4.21 Correlation between the change in stomatitis index and the change in probing depth 
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Change in stomathis index 
Pearson's correlation coefficient (r) = 0.677 (P = 0.001) 
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Table 4.10 Regression of change in stomatitis index on change in probing depth index 
Variable Regression Standard tp 
coefficient deviation 
Constant -2.87 1.112 -2.58 0.017 
A PDI 0.602 0.147 4.10 0.001 
S=4.61 R-Sq = 44.4% R-Sq (adj) = 41.8% 
Analysis of Variance 
Source of Degrees of Sum of Mean squares Fp 
variation freedom squares 
Regression 1 356.05 356.05 16.79 0.001 
Residual 21 445.26 445.26 
A PDI = change in probing depth index at consultation 3 
4.4 DISCUSSION 
A clinical trial is an experiment designed to evaluate the effectiveness of one or more treatments. 
Under ideal conditions this is accomplished using a randomized, double blind, controlled trial to 
compare the response of groups of patients who differ only in respect to the treatment they receive. 
However, in practice, these criteria cannot always be met. In such circumstances the design of the 
clinical trial should aim to minimise, as far as is reasonably possible, potential sources of bias. 
Bias commonly arises from a lack of uniformity between cases. Within the present study a number of 
methods were used minimise this potential effect. Strict criteria were set to assure the selection of 
affected cats and to exclude cats with other diseases. Moreover, to minimise the influence of any 
therapy given prior to cases entering the clinical trial, all medication was withdrawn, wherever 
possible, at least two weeks prior to the first consultation. During this period the severity of the disease 
in a limited number of cases was such that it was necessary to provide pain relief with a non-steroidal 
anti-inflammatory agent. As this was a relatively short acting agent, and was withdrawn at least one to 
two days prior to the first consultation, it is unlikely that this treatment had any significant effect upon 
the results. Each case also underwent a standard dental hygiene procedure to remove plaque, calculus 
and other debris, followed by a short course of metronidazole and spiramycin, which provided a 
common 'clean-mouth' baseline. However, additional factors such as the residual dentition and the 
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degree of periodontal disease could not be standardised across cases. Dental extractions were 
performed in most, but not all, cases. While this intervention was undesirable within the context of the 
clinical trial (as it adds an additional unstandardised factor), it was necessary to attend to any severe 
and concurrent dental disease present in these cases. 
The random allocation of cases into treatment groups serves two main purposes. First, it eliminates any 
potential source of bias in deciding which treatment each individual will receive. Second, any pre- 
existing inter-case variability will also be distributed between the treatment groups in a random 
manner. Consequently, it was hoped that this action would result in the construction of treatment 
groups between which there was no significant difference in variance, and this was shown to be the 
case for the parameters examined at the first consultation. This enabled the change from the pre- 
treatment, or baseline, measurement to be utilised as an outcome measure for each parameter at 
subsequent time-points, which reduced the level of natural variation within the results. 
Investigator and owner/patient blindness is an aspect of clinical trials which aims to eliminate bias 
during the measurement of outcome variables. However a number of factors prevented this clinical 
trial from being performed under double-blind conditions. The study was conducted by a single 
investigator and additional man-power was not available. Therefore, following the first consultation it 
was not possible for the investigator to remain blind to the treatment being received by each cat. 
Furthermore, the nature of some of the treatments were such that it would have been impossible to 
blind the owners to the identity of the treatment. Sodium aurothiornalate is not licensed for use in the 
cat, and therefore the owner's written consent was required before it could be administered. Moreover, 
because of the potential risk of side-effects with sodium aurothiomalate it was necessary that the owner 
and the investigator were aware of the fact that the cat was receiving this treatment. Consequently, it is 
possible that the partially-subjective oral health measurements recorded in this study could have be 
influenced by operator bias; although the use of indices with defined scoring criteria will have 
moderated any such effect. 
A further important aspect of clinical trials is the need for a comparative group against which the 
response to treatment can be compared. In many clinical studies this is achieved through the use of a 
control group in which no treatment is given or a placebo is administered. In view of the severity of 
the disease in some cats with chronic gingivostomatitis it was considered ethically unacceptable to 
have an untreated or placebo control group in the present study. Nonetheless, the study was controlled 
through the use of more than one treatment group, which permits the comparative effectiveness of 
treatments to be assessed. 
The selection of the four treatments analysed within this study was based upon a number of factors. 
First, the treatments had to be considered as being potentially beneficial for the treatment of feline 
chronic gingivostornatitis based upon established clinical practices, previous clinical experience, or 
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published studies. Furthermore, the therapeutic agents had to be readily available within the UK. And 
finally, it was desirable that wherever possible the product should be licensed for use in the cat. 
Corticosteroids have been recommended by a number of authors for the treatment of FCGS and are 
commonly used for this purpose within general practice (Gaskell & Gruffydd-Jones, 1977; White et 
al., 1992; Williams & Aller, 1992; Diehl & Rosychuk, 1993). However their clinical effectiveness for 
the treatment of this condition has not been critically evaluated. MethyIprednisolone was selected for 
use as it has potent anti-inflammatory activity with minimal mineralocorticoid activity, and is licensed 
for use in cats within the UK. An oral preparation was used in preference to a depot preparation to 
facilitate greater control over the dose level. An initial daily dose level of lmg/kg body weight was 
selected based upon published anti-inflammatory dose levels (Tennant, 1997). 
Although it is not licensed for use in cats, previous studies conducted within the USA have 
recommended the use of an injectable gold salt, sodium aurothioglucose, for the treatment of feline 
chronic gingivostornatitis (White et a]., 1992). This drug is not available within the UK, but an 
alternative injectable gold salt, sodium aurothiornalate, can be readily obtained. Despite the fact that it 
is also unlicensed for use in animals, sodium aurothiomalate has been used successfully for the 
treatment of autoimmune conditions in the cat (Kristensen & Mehl, 1989). However, prior to the 
present study its use for the treatment of FCGS had not been investigated. Consequently, based upon 
these factors, sodium aurothiornalate was selected as one of the treatment groups. A maintenance dose 
of lmg/kg body weight administered once weekly was chosen based upon previously published 
protocols (Kristensen & Mehl, 1989). As the clinical effects of gold salts may take many months to 
become apparent (Long, 1986), in order to be able to fully assess the effectiveness of sodium 
aurothiomalate it was necessary to continue treatment for a period of up to 6 months. 
Antibiotics are commonly prescribed in cases of FCGS and a number of authors have advocated their 
short-term use, however their effectiveness has been poorly evaluated (Gruffydd-Jones, 1991; Harvey, 
1991; Williams & Aller, 1992). A product containing metronidazole and spiramycin (Stomorgyl, 
Merial) was selected for its broad spectrum of activity against both aerobic and anaerobic bacteria. 
Furthermore, it is the only antibiotic licensed within the UK specifically for the treatment of 
periodontal and oral conditions in the cat, and has the added convenience of once daily dosing. The 
manufacturer's recommended dose rate was given for a duration of I week, every second week. An 
alternate week regimen was used to minimise any risk of toxic effects arising from the accumulation of 
active components or metabolites during the 6 month treatment period. 
Finally, over the past decade there has been an increase in the availability of oral hygiene products 
aimed specifically for use in domestic pets. Many of these products have been advocated for use in the 
treatment of FCGS and the maintenance of oral health (Harvey, 1991). Nonetheless, their clinical 
effectiveness has been poorly assessed. Consequently, a range of oral healthcare products designed 
and marketed for use in the cat were chosen for use in one treatment group on a twice daily basis. 
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The response to treatment was monitored at three time-points over a six month period. Although more 
frequent examinations would have been desirable, the study was dependent upon the co-operation of 
the referred clients - most of which lived some considerable distance from the referral centre - and it 
was felt that owner-compliance may be lost if additional examinations were requested. The second 
consultation was scheduled to occur six weeks after treatment commenced. This time-point provided 
an opportunity for the short-term effect of treatment to be assessed, and provided the owners with an 
opportunity to discuss any possible problems they may be experiencing with the trial. The oral 
examination undertaken at this time was performed with the cat conscious or, in fractious cases, under 
mild sedation. The third consultation was conducted three months after treatment commenced. There 
was concern at the commencement of the trial that a large number of the cases might withdraw from 
the study at, or before, this time-point if their condition was not being suitably controlled by their 
allocated treatment. Consequently, the oral examination was scheduled to be conducted under general 
anaesthesia to enable a detailed examination to be performed. As it transpired, however, most cases 
remained within the study for the full duration. Six months after treatment commenced a final 
examination was performed with the cat conscious or, where necessary, under light sedation. This was 
considered to be sufficient time to observe the long-term clinical response to all of the selected 
treatments. 
A problem that often arises in clinical trials is the loss of data resulting from the withdrawal of cases 
during the assessment period. There is no universally accepted method for dealing with this anomaly. 
A frequent approach is to simply omit the withdrawn cases from the analysis. This, however, may 
introduce bias into the findings, especially if cases withdrew because of treatment-related reasons. To 
counter this an alternative approach is to assign a suitable value to the withdrawn cases and then to 
compare the results of analyses performed with and without the inclusion of these cases (Altman, 
1991). If the results are similar, then this will increase the confidence in the findings. This latter 
methodology was utilised within the present study during the analysis of the changes in the stomatitis 
index. To reflect the fact that the withdrawn cases were caused by treatment failure - either because of 
the development of side-effects or because of an insufficient response to treatment - these cases were 
assigned an equivalent maximum ranking score for their change in stomatitis index at all time-points 
following their withdrawal from the study. 
The results from the treatment trial demonstrated that significant short-term but not long-term 
differences could be demonstrated between the effectiveness of the four regimes. Methylprednisolone 
was shown to be the best treatment after six weeks of therapy. However, after three months of therapy 
no single treatment was identified as being significantly better than the others. At this time, the group 
receiving methylprednisolone showed the greatest reduction in mean stornatitis index, and this 
response was significantly greater than that seen following oral hygiene, but not antibiotic or gold salt 
treatment. Nonetheless, inspection of Hsu's MCB analysis results shows that the vast majority of the 
95% confidence interval for the difference in the mean change in the stomatitis index between the gold 
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salt and corticosteroid-treated groups is greater than zero. This suggests that the response to 
methylprednisolone is likely to be better than to gold salt therapy over a three month treatment period. 
Thus, it can be concluded that treatment with either methyl prednisolone or metronidazole and 
spiramycin is likely to produce the greatest reduction in the stomatitis index after three months of 
treatment. Following six months of therapy, the individual responses within all of the treatment groups 
were highly variable and no significant difference was found in the mean change in the stomatitis 
index. Inspection of Hsu's MCB confidence intervals showed that none of the treatments can be 
considered, with any high degree of confidence, as being either the best, or not the best, for the long- 
term treatment of FCGS. 
The finding that methylprednisolone was the best short-term treatment validates a number of previous 
reports which have advocated the use of corticosteroids for the treatment of FCGS (Gaskell & 
Gruffydd-Jones, 1977; Dillon, 1986; Gaskell et al., 1988; Lyon, 1990; Gruffydd-Jones, 1991; Diehl & 
Rosychuk, 1993; Rosenkrantz, 1993). However, the mean change in the stomatitis index induced by 
methyl prednisolone represented only a 28% reduction from the mean baseline stomatitis index. Thus 
even the best treatment was only moderately effective in its ability to abrogate the mucogingival 
inflammation seen FCGS. The results also show that the response to methylprednisolone tended to 
plateau by the first six weeks of treatment. This effect may have been caused by the gradual reduction 
in the dose level during the course of the trial. Nevertheless, it indicates that the long-term 
administration of methylprednisolone does not induce any additional clinical response over and above 
that seen during the initial period of treatment (White et al., 1992). 
The response to gold salts was generally disappointing with only one case demonstrating a substantial 
clinical improvement by the end of the trial. Moreover, possible adverse signs were seen in three of the 
eight cases prescribed sodium aurothiomalate. The potential toxicity of gold salts is well recognised, 
although adverse reactions to sodium aurothiomalate have not been previously documented in the cat. 
However, similar signs to those observed in the present study - diarrhoea, mucocutaneous ulceration 
and ncutropenia - have been reported in suspected adverse reactions to gold salts in humans and, to a 
lesser extent, in dogs (McGirr et al., 1984; Long, 1986; Serra & White, 1989; Kristensen & Mehl, 
1992). When considering the use of any treatment, the risk of adverse reactions has to be balanced 
against the likelihood of a favourable clinical response. Thus, the risk of side-effects resulting from the 
use of sodium aurothiornalate would appear to outweigh the likelihood of significant clinical benefits. 
Consequently, sodium aurothiomalate cannot be recommended as a primary treatment for FCGS, 
although it might be considered for use in cases which are unresponsive to other treatments. 
This conclusion contrasts with that of White et al., (1992) who recommended the use of sodium 
aurothioglucose in FCGS. This discrepancy may reflect differences in the formulation of the two gold 
salt products or potential differences in their pharmacological activity (Lawrence, 1976). Alternatively, 
and more likely, as this latter study was perfonned retrospectively and relied upon subjective clinical 
impressions of the response to treatment and gave no indication of the magnitude of the response, the 
Chaptcr 4 88 
differing conclusions may be a consequence of dissimilarities in the study methodologies. A 
comparative study of the two gold salts is needed to resolve this issue. 
The effect of the antibiotic combination of metronidazole and spiramycin upon the level of 
mucogingival inflarnmation was variable over time. During the initial six weeks of therapy the 
response to metronidazole and spiramycin was significantly less than that induced by methyl 
prednisolone. Thus, this study suggests that metronidazole and spiramycin cannot be recommended as 
the treatment of choice over a short term period. Previous short term studies conducted over ten day, 
and three week treatment periods, have concluded that spiramycin and metronidazole are effective in 
reducing the signs of oral inflammation in cats with gingivitis or gingivostornatitis (Zetner & Van 
Gool, 1991; Beck and Osthold, 1996). However, in the current study only one of the seven cats treated 
with metronidazole and spiramycin showed any significant reduction in the level of oral inflammation 
over a six week treatment period. The reason for these conflicting findings is not clear, but may be due 
to differences in the study protocols and case selection criteria. 
It is notable that in the present study two cases receiving metronidazole and spiramycin demonstrated a 
progressive and clinically significant reduction in their stomatitis index by the end of the 6 month 
treatment period. The long-term treatment of FCGS with antibiotic agents has not been previously 
investigated, and while it is well documented that the clinical response to agents such as gold salts may 
take many months to become apparent (Long, 1986; White et al., 1992), the notion that a significant 
clinical response to antibiotics may also take several months to occur has not previously been 
considered. It is interesting to note that a similar, but less pronounced, response was seen in some of 
the cats receiving oral hygiene treatment. Alternatively, however, the changes observed in these cases 
simply represent natural variation of this disease within individuals over time. Further studies 
examining the natural history of the disease and the long-term response to treatment are required to 
differentiate between these two possibilities. If it is the case that some cats can show a slowly 
progressive, or delayed response to certain types of treatment then this would have important 
implications for treatment recommendations, and the future design of clinical trials assessing the 
effectiveness of treatments. In short, therefore, the results suggest that the prolonged use of 
metronidazole and spiramycin might be of significant clinical benefit in a minority of cats with chronic 
gingivostomatitis, however ftirther studies are required to corroborate this theory. 
Oral hygiene products were the least effective of the treatments throughout the trial. The mean 
reduction in the mucogingival inflammation observed in this treatment group was shown to be 
significantly less than that seen in the best treatment group (methylprednisolone) following six weeks 
and three months of therapy. Thus, it can be concluded that oral hygiene products alone cannot be 
considered as the treatment of choice for the short-term management of FCGS. The lack of 
comparative effectiveness of these products may be related, in part, to difficulties encountered by a 
number of owners in administering the treatment or complying with the treatment protocol (Miller & 
Harvey, 1994). Hence, it is important to differentiate between the apparent efficacy and effectiveness 
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of a treatment. Over a six month treatment period a minority of the cats treated with oral hygiene 
products demonstrated a moderate reduction in their level of mucogingival inflammation, although, as 
discussed above, further studies would be required to determine whether this response was treatment- 
related or due to natural variation in the severity of the clinical signs. Nonetheless, because no 
significant difference between treatment groups was found in their effectiveness over the long-term, 
oral hygiene products can, therefore, be considered as an acceptable treatment for long-term use in 
FCGS. 
Analysis of additional clinical indices showed that after three months of treatment the probing depth 
index remained significantly correlated with the stomatitis index and that the change in the probing 
depth index and was able to predict a significant proportion of the variation within the change in the 
stomatitis index, Moreover, the change in the probing depth index and the change in the stomatitis 
index were both found to be significantly correlated with the number of extractions performed. These 
findings imply that alterations in the depth of the gingival sulci or periodontal pockets, or both, are 
strongly associated with changes in the degree of inflammation present within the mucogingival tissue 
in cats with chronic gingivostomatitis. In addition, they suggest that a considerable proportion of the 
changes in oral inflammation seen within this study may have been related to the extraction of teeth 
(Hennet, 1995). 
These latter conclusions raise the question as to whether the dental extractions performed at the start of 
the trial may have biased the changes in the stomatitis index measured in the treatment groups. 
However, as the dental extractions were performed prior to each cat being allocated under randomized 
conditions to their treatment group, it would be expected that any effects attributable to the extractions 
would also be distributed randomly amongst the treatment groups. This assumption is supported by 
fact that there was no significant difference between treatment groups in the number of extractions 
performed. Moreover, no significant difference was demonstrable between treatment groups in the 
change in probing depth index following three months of treatment. Together, therefore, these findings 
would imply that any significant differences found between treatment groups in the change in the 
stomatitis index can be attributed to treatment related factors. 
After three months of treatment the calculus index was not significantly correlated with the stomatitis 
index. This fiiiding supports the observation from the first consultation that the level of calculus is not 
significantly related to the level of mucogingival inflammation. The relationship between the calculus 
index and the probing depth index was also not found to be significant at this time. This contrasts with 
the results from the first consultation, however such a result was not altogether unexpected, as the 
dental descaling procedure and the extraction of teeth is likely to have disrupted any prior relationship 
that may have existed between these two indices. 
Tooth brushing has been shown to be an effective method for preventing the formation of dental 
calculus (Richardson, 1965; Tromp et al., 1986), and a previous study in cats by Richardson (1965) 
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indicated that some antibiotic agents may have the ability to reduce the development of dental plaque 
over an 18 week timc-course. However, in the present study no significant difference was found 
between the treatment groups in the calculus index after three months of treatment. Many cats will not 
tolerate tooth brushing - especially if they have concurrent oral pain - and a number of the owners 
reported difficulties in brushing their cat's teeth during the study period. Thus, poor owner compliance 
may have diminished the potential effectiveness of tooth brushing in preventing the formation of 
dental calculus (Miller & Harvey, 1994). Most of the owners of cats receiving oral hygiene treatment 
claimed that they were able to administer the oral gel or oral rinse on a daily basis. Studies using these 
products have not been previously reported in the cat, however the primary active ingredient, 
chlorhexidine, has been shown to cause increased calculus deposition in some long-term studies in 
man (Yates et al., 1993; Hase et al., 1998). This fact may have contributed to the finding that the 
majority of the cats within the oral hygiene group had relatively high calculus indices following three 
months of treatment. The effect of metronidazole and spiramycin upon calculus development has not 
been previously reported. It is perhaps surprising that the group receiving these agents did not 
demonstrate a comparatively lower level of calculus formation. A study in dogs suggested that over a 
ten day treatment period metronidazole and spiramycin were very effective in reducing dental plaque 
levels, although a control population was lacking (Zetner & Van Gool, 199 1). Such an effect might be 
expected to retard the development of calculus. In the present study the extent of plaque formation was 
not assessed, however additional studies (data not presented) demonstrated that there was a dramatic 
decrease in the cultivable anaerobic population within dental plaque from the cats receiving 
metronidazole and spiramycin. Nevertheless, it would appear that this compositional alteration did not 
influence the development of dental calculus. 
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PART 11: Serum and Salivary Immunoglobulin Concentrations in 
Cats with Chronic Gingivostomatitis 
Part 11 92 
CHAPTER 5: Materials and Methods for Part 11 
5.1 ANIMALS 
5.1.1 Clinical Cases 
Paired serum and unstimulated saliva samples were collected from 30 cats with chronic 
gingivostornatitis (see Chapter 2). Samples were collected immediately prior to cats entering a 
treatment trial (see Chapter 2), and again after 3 and 6 months of treatment. 
5.1.2 Controls 
Paired serum and unstimulated saliva samples were collected at a single time-point from 32 clinically 
healthy domestic short haired (DSH) cats housed within indoor facilities at the University of Bristol 
(Table 5.1; CC-1 to CC-32). The stornatitis index (SI) (Chapter 2) was recorded whenever possible 
(Table 5.1). Stimulated saliva samples were collected from 6 of these cats after collection of the 
unstimulated sample (CC-1, CC-10, CC-12, CC-13 & CC-14). Cats CC-1 to CC-14 were undergoing 
pre-screening salivary and serum sample analysis prior to subsequent studies. Cats CC-15 to CC-30 
were involved in a ongoing vaccination trial to determine the serological responses to a combined 
rabies-flu-feline enteritis vaccine. Cats CC-31 to CC-33 were negative control cats involved in FIV 
vaccination studies. Additional unstimulated saliva samples were collected as required from 10 
clinically healthy, adult DSH pet cats. Unstimulated saliva samples harvested from 4 adult DSH pet 
cats at 12 hourly intervals (8am and 8pm) over 4 consecutive days were collected prior to feeding in 
the morning and 3 hours after feeding in the evening. Excess serum was harvested from blood samples 
collected from two cats undergoing clinical investigation at the University of Bristol. 
5.2 SALIVA AND SERUM SAMPLES 
UnstimuIated saliva was collected by gently rolling a plain sterile cotton swab (Medical and Wire 
Equipment Co. (Bath) Ltd., Wiltshire, UK) along the oral mucosa until suitably moistened. The head 
of the swab was sealed in a 0.5 ml microcentrifuge tube (Sarstedt, NUmbrecht, Germany) and placed 
on ice. Two swabs were collected in quick succession from each animal. Saliva was extracted and 
clarified by centrifugation. A small hole was pierced in the base of the 0.5 ml microcentrifage tube and 
this was then placed into a Iml microcentrifuge tube. Both tubes were then centrifuged together at 
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13,000g for 5 minutes. The saliva was extracted and clarified by centrifugation. Stimulated saliva was 
collected from six cats following sedation with 10mg/kg ketamine (Parke, Davis & Co. Ltd, 
Pontypool, UK) and stimulation of salivary flow with 0.2ml lemon juice placed onto the tongue. 
Excess drool was collected into plain glass containers (VacutainerlD, Becton Dickenson, Meylan 
Cedex, France) and held on ice. Saliva was clarified by centrifugation at 13,000g for 5 minutes. Serum 
was harvested from blood samples obtained by jugular venepuncture and collected into plain glass 
containers (VacutainerO, Becton Dickenson). Saliva and serum samples were aliquoted and stored at 
-20"C or below until required. 
5.3 STANDARD SERUM POOL 
A standard serum was produced by pooling excess cat serum obtained from 10 blood samples sent to 
the Feline Diagnostic Service at the University of Bristol. 
5.4 METHODS 
5.4.1 Double immunodiffusion 
5ml of I% agarose gel was prepared and wells were cut using 5mm diameter punch. I OPI purified cat 
IgG (1.6 mg/ml) (Sigma Chemical Co. Ltd, Poole, UK), IgM (0.84 mg/ml) (Custom Monoclonals, 
Sacramento, California, USA) or IgA (0.45 mg/ml) (Custom Monoclonals) was pipetted into the 
central well. 10pl each of rabbit anti-cat IgG(Fc), goat anti-cat IgM(Fc) antiserum, and goat anti-cat 
19A(Fc) antiserum (all Nordic Immunological Labs, Tilberg, The Netherlands) were pipetted in to 
adjacent separate outer wells. The plate was then placed inside a humidified box and inspected after 24 
and 48 hours for precipitin bands. 
5.4.2 Single radial immunodiffusion (SRID) 
SRID assays were modified from the method previously described by Day & Penhale (1988). Briefly, 
a I% agarose gel solution (Sigma) containing 2.5% rabbit anti-cat IgG(Fc), or 10% goat anti-cat IgM 
(Fc), or 10% goat anti-cat IgA(Fc) (all Nordic) was poured onto a clean glass plate. 3MM diameter 
wells were cut in the gel and loaded with 5gl (IgG & IgM assays) or lOgI (IgA assay) of undiluted 
saliva, 1: 50 (IgG assay) or 1: 4 to 1: 10 QgM and IgA assays) diluted serum, or serially diluted standard 
solution comprising purified cat IgG (1.6 mg/ml) (Sigma), IgM (0.84 mg/ml) (Custom Monoclonals), 
IgA (0.45mg/ml) (Custom Monoclonals), or standard serum (see 5.3). The plate was then placed in a 
humidified box, and after 24 or 48 hours the mean diameter of each precipitin ring was calculated from 
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two perpendicular measurements made with a calibrated image analysis system (VIDS 111, Analytical 
Measuring Systems). Unknown sample concentrations (mg/ml) were derived relative to the standard. 
Table 5.1 Details of control cat population 
Control Cat Age Sex Mouth Sl 
CC-1 18m F NR 
CC-2 18M F NR 
CC-3 Ism F NR 
CC-4 Ilm F NR 
CC-5 18m F NR 
CC-6 18M F NR 
CC-7 18m F NR 
CC-8 18m F NR 
CC-9 12m F NR 
CC-10 12m F NR 
cc-li 6 yr F NR 
CC-12 14m F NR 
CC-13 Ilm F NR 
CC-14 4 yr F NR 
CC-15 16 m F 3 
CC-16 16 m F I 
CC-17 16 m MN 3 
CC-18 16 m F 3 
CC-19 16 m MN 4 
CC-20 16 m MN 4 
CC-21 16 m MN 7 
CC-22 16 m MN I 
CC-23 16 m MN 5 
CC-24 16 m MN I 
CC-25 16 m F 8 
CC-26 16 m F 4 
CC-27 16 m MN 4 
CC-28 16 m F 2 
CC-29 16 m MN 2 
CC-30 16 m MN I 
CC-31 8 yr F 9 
CC-32 Adult MN 5 
CC-33 8 yr F 2 
SI = Stomatitis Index, m= months, yr = years, MN = Male neutered, F= Female, NR = not recorded 
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5.4.3 Immunoglobulin class-specific capture ELISAs 
The reagents, volumes, dilutions and incubation times used in each class-specific ELISA are shown in 
Tables 5.2 & 5.3. All incubations were performed within a sealed humidified container at room 
temperature unless otherwise stated. Plates were washed 3 times with 0.05% Tween 20 (Sigma) in 
phosphate buffered saline (pH7.4) (PBSTw) between each incubation. Coating was performed using 
carbonate-bicarbonate buffer (15mM Na2CO3,35mM NaHC03, pH 9.6). Blocking buffer I comprised 
5% (w/v) milk powder (Marvel, Premier Beverages, Stafford, UK) in 0.1% Tween PBS. Blocking 
buffer 2 comprised 25% (w/v) milk powder in 0.5%Tween in PBS. Plates (Greiner, Labortechnik Ltd, 
Gloucester, UK) were coated overnight at VC with the primary (capture) antibody. Residual binding 
sites were blocked with blocking buffer I (IgG and IgM assay) or blocking buffer 2 (IgA assay) for I 
hour. Serum and saliva samples were double-diluted and duplicate standard solutions were triple- 
diluted with the inclusion of appropriate control wells (see below). Following the secondary and 
tertiary antisera, 75gl/well (IgG and IgM assay) or 100gl/well (IgA assay) 0.1% (w/v) p-nitrophenyl 
phosphate disodium. hexahydrate solution (Sigma) was added and the plates were read at 405run 
(Multiskan Biochromatic plate reader, Labsystems, Finland) when the maximum standard 
concentration reached an optical density (OD) reading of approximately 1.2, or after I hour. Serum 
and saliva titration curves were checked for parallelism and quantified relative to the standard using an 
ELISA analysis program (Elisanalysis, software release 5.53; J. H. Peterman, Birmingham, Alabama, 
USA). The results were expressed in terms of ELISA units (EU) where the concentration of the 
standard was defined as 100 EU. Control wells included in each plate comprised duplicate wells in 
which the primary antibody was absent and the highest concentration of the standard was included, and 
duplicate wells where goat serum (Sigma) was substituted in place of cat serum or cat saliva at the 
lowest equivalent standard dilution. 
5.4.4 Competitive feline albumin enzyme-linked immunosorbent assay 
Salivary albumin concentrations were determined using an indirect competitive ELISA (Van Kamp, et 
aL, 1989). All incubations were performed in a sealed humidified chamber at room temperature unless 
otherwise stated. Plates were washed three times with PBSTw (0.05%) between each incubation. 
Briefly, plates were incubated overnight at 4*C with 100pl/well of purified cat albumin (Sigma) at 
20lig/ml in carbonate-bicarbonate buffer. Residual binding sites were blocked with 200pl/well of 2.5% 
polyvinylpyrrolidone (Sigma) in PBS for 30 minutes. Duplicate saliva samples were triple-diluted in 
PBS (50pl/well) commencing at a dilution of 1: 4 to 1: 10. Standards were produced from 100pg/ml 
stock solution of cat albumin (Sigma) serially diluted 1: 4 or 1: 5 (50ýtl/well). 50PI of alkaline 
phosphatase-conjugated goat anti-cat albumin (1: 100 in PBS) was added to each well and the plate 
incubated at 371C for 3 hours. The plates were developed and analysed as described above (see 5.4.3). 
Duplicate control wells coated overnight with carbonate-bicarbonate buffer were included in all plates. 
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Primary Affinity purified goat anti- Goat anti-cat IgM(FC)b Goat anti-cat IgA(FC)b 
antibody cat IgG(Fc)4 
Secondary Affinity purified goat anti- Mouse anti-cat IgM(Fc) Rabbit anti-cat IgA(FC)b, e 
antibody cat IgG(H+L) AP (Clone CM6E)' 
conjugated 
Tertiary Goat anti-mouse IgG Goat anti-rabbit IgG 
antibody (whole molecule) AP (whole molecule) AP 
conjugated d conjugated d 
Standard Purified cat IgG d Cat serum pool Cat serum pool 
(2.5mg/ml) 
'Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA, bNordic, 'Custom 
MonoclonalS, d Sigma, ePre-incubated with 2.5% goat serum for I hour to reduce cross-reaction, AP 
Alkaline phosphatase. 
Table 5.3 Reagent volumes, dilutions, and incubation times used in immunoglobulin class- 
specific ELISAs 
Assay specificity 
IgG Igm IgA 
Reagent volume per well (pl) 50 so 75 
Primary antibody 
Dilution factor 2,000 1,000 400 
Sample/Standard 
Commencing dilution factor 
Serum 10,000 to 100,000 1,000 to 10,000 200 to 500 
Saliva 400 to 5,000 100 to 1,000 200 to 500 
Standard 5,000 1,000 400 
Incubation period (hrs) 1.5 2 1.5, 
Secondary antibody 
Dilution factor 15,000 1,000 200 
Incubation period (hrs) 1.5 2 1.5, 
Tertiary antibody 
Dilution factor n/a 1,000 1,000 
Incubation period (hrs) n/a 2 2' 
' Incubation performed on a rocking platform. n/a = not applicable 
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5.5 SERUM ALBUMIN CONCENTRATIONS 
Serum albumin concentrations were derived biochemically as described in Chapter 2. 
5.6 FREEZE-THAW CVCLING 
Repeated thawing-freezing of samples was performed by thawing at 371C in a heated water bath, then 
freezing by immersing the base of the sealed microcentrifuge tube containing the sample into liquid 
nitrogen. 
5.7 STATISTICAL ANALYSIS 
The statistical methods used during the analysis of the data are described in Chapter 2. 
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CHAPTER 6: Development and Validation of Methods for the Determination of 
Salivary and Serum Immunoglobulin Concentrations 
6.1 INTRODUCTION 
Abnormalities of immunoglobulin production and secretion can occur in a range of diseases, including 
infectious, autoinimune, immunodeficiency and lymphoproliferative disorders. The ability to quantify 
immumoglobulin levels in body fluids, such as serum and saliva, may be helpful in the detection, 
diagnosis and investigation of such disorders. Furthermore, monitoring the changes in immunoglobulin 
concentration may be useful for assessing the response to treatment in some conditions. 
The most common method employed for feline immunoglobulin quantification has been the single 
radial immuno-diflusion assay (SRID) (Mancini, 1965; Schultz, et al., 1974; Yamada et al., 1984). 
However, the limited sensitivity of SRID can preclude the detection or accurate quantification of 
immunoglobulins in body fluids in which the immunoglobulin concentration may be relatively low, 
such as saliva or tears (Schultz, et al., 1974; Yamada et al., 1984). By contrast, techniques such as the 
enzyme-linked immunosorbent assay (ELISA) offer greater sensitivity and are now commonly used for 
routine testing of human sera, but few reports have documented the use of ELISA for the measurement 
of feline immunoglobulins (Ackley et al., 1990; Grant 1995b). 
This chapter summarises the work undertaken to investigate and develop methods for the 
determination of IgG, IgM and IgA immunoglobulin concentrations in whole saliva and serum samples 
collected from cats. 
6.2 MATERIAL AND METHODS 
These are provided in Chapter 5. 
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6.3 RESULTS 
6.3.1 Development and optimisation of single radial immunodiffusion (SRID) assays 
6.3.1.1 Antiscrum concentrations 
The optimal concentration of each antiserum (5.4) within the agarose solution for the detection of 
precipitin rings was determined by titration against unstimulated saliva samples and dilutions of the 
standard pool serum (5.3) (data not shown). 
6.3.1.2 Standard dilution ranges 
Suitable dilution ranges of the standards were determined empirically. These studies indicated that the 
practical limit of quantification of the assays was 0.05 mg/ml for IgG, 0.1 mg/ml for IgM, and 0.05 
mg/mI for IgA (data not shown). 
6.3.1.3 Determination of immunoglobulin concentrations in the standard pool serum 
Using purified immunoglobulin classes as standards the IgG, IgM and IgA concentrations of the 
standard serum pool was derived on 3 consecutive occasions. The mean (standard deviation) 
immunoglobulin concentrations of the standard pool serum were 25.25 (3.25) mg/ml IgG, 3.45 (0.30) 
mg/ml IgM, and 1.56 (0.18) mg/nil IgA. The corresponding inter-slide coefficient of variation of each 
assay was 13.9%, 8.7% and 10.7% respectively. Owing to the limited availability of purified cat IgM 
and IgA the serum pool was subsequently used as the standard within the IgM and IgA SRID assays. 
6.3.2 Determination of salivary and serum concentrations from clinically healthy cats by single 
radial immunodiffusion (SRID) 
Table 6.1 details the immunoglobulin concentrations (mg/ml) measured in paired serum and 
unstimulated saliva samples from 14 control cats (CC- I to CC-14; Table 5.1), in addition to stimulated 
saliva samples from 4 of these cats. In 6 of the 14 unstimulated saliva samples, IgM could not be 
quantified (< 0.1 mg/ml), although small precipitin rings were visible. In the stimulated saliva samples, 
the concentrations of IgG and IgM were always below the absolute detection limits of the assays, and 
the IgA concentration was below the practical limit of quantification (< 0.05mg/ml) in one sample. 
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Table 6.1 Immunoglobulin concentrations (mg/ml) of serum and saliva from healthy cats 
derived by SRID 
Mean concentration [SD. ] and range (mg/ml) 
Sample No. tested IgG Igm IgA 
Serum 14 19.08 [5.381 2.04 [0.83] 2.60 [2.161 
9.99-30.30 0.98-4.30 0.22-5.31 
Unstimulated saliva 14 0.10 [0.02] 0.13 [0.01]" 0.54 [0.32] 
0.07-0.12 <0.10 - 0.15 0.18-1.31 
Stimulated saliva 4 nd nd 0.06 [0.01]b 
<0.05 - 0.08 
"Six IgM samples excluded with concentrations below quantification limit (<O. I 0mg/mI IgM) 
b One IgA sample excluded with concentration below quantification limit (<0.05mg/ml IgA). 
nd = not detectable. 
6.3.3 Development of immunoglobulin class-specific capture ELISAs 
6.3.3.1 IgG class-specific assay 
Preliminary investigations using rabbit anti-cat IgG(Fc) antiserum (Nordic Immunochemicals Ltd., 
Tilberg, The Netherlands) as the primary capture antibody, mouse anti-cat IgG(Fc) (Serotec Ltd, 
Kidlington, UK) as the secondary antibody then a tertiary layer of alkaline pbosphatase conjugated 
goat anti-mouse IgG(whole molecule) (Sigma Chemical Co. Ltd, Poole, UK), revealed a cross-reaction 
between the primary and secondary antibodies causing unacceptably high background levels. The use 
of various species serum in the blocking buffer (bovine, canine, goat or sheep serum) did not inhibit 
this cross-reaction. Subsequently, goat anti-cat IgG(Fc) (Jackson ImmunoResearch Labs, West Grove, 
Pennsylvania, USA) was substituted as the primary antibody, however, a cross reaction between the 
goat primary and mouse secondary antibodies occurred. Similarly, when goat anti-cat IgG(Fc) 
(Jackson), rabbit anti-cat lg(Fc) (Nordic) and alkaline phosphatase conjugated goat anti-Rabbit IgG 
(Sigma) were used as the primary, secondary and tertiary reagents respectively, high levels of cross- 
reaction occurred between the primary and secondary antibodies, In order to counteract any inter- 
species cross-reaction, the assay was redesigned using reagents derived from the same species. Goat 
anti-cat IgG(Fc) and alkaline phosphatase conjugated goat affinity purified anti-cat IgG(H+L) (both 
Jackson) were used as primary and secondary antibodies respectively, in a sandwich ELISA. These 
reagents produced minimal background signal in control wells. Optimisation of the reagent 
concentrations was performed by chequer-board titration (not shown). 
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6.3.3.2 IgM class-speciric ELISA 
Initial investigations using goat anti-cat IgM(Fc) antiserum (Nordic) as the primary capture antibody, 
mouse anti-cat IgM(Fc) (Serotec) as the secondary antibody and finally a tertiary layer of alkaline 
phosphatase-conjugated goat anti-mouse IgG(whole molecule) (Sigma) were unsuccessful due to the 
apparent deterioration of the secondary antibody during storage. This reagent was successfully 
substituted with an alternative mouse anti-cat IgM (Clone CM613; Custom Monoclonals, Sacramento, 
California, USA). Minimal evidence of cross-reaction was detected between the reagents. Chequer- 
board titration was used to optimise the reagent concentrations (not shown). 
6.3.3.3 IgA Capture ELISA 
Development of the IgA assay proved difficult due mainly to cross-reactions between the reagents. 
Initially goat anti-cat IgA(Fc) (Nordic), mouse anti-cat IgA (Serotec) and goat anti-mouse IgG-alkaline 
phosphatase-conjugated (Sigma) were used as primary, secondary and tertiary antibodies respectively. 
However, the Serotec reagent was found to have deteriorated during storage and was ineffective. This 
was replaced with mouse anti-cat IgA (clone A5313; Custom Monoclonals), however a cross-reaction 
occurred between the primary and secondary reagents. A similar problem was encountered when rabbit 
anti-cat IgA(Fc) (Nordic) was used as the primary reagent. Finally, a system using goat anti-cat 
IgA(Fc) (Nordic), rabbit anti-cat IgA(Fc) (Nordic) and goat anti-rabbit IgG-alkaline phosphatase 
conjugate (Sigma) as primary, secondary and tertiary antibodies respectively, produced the lowest but 
still significant cross-reaction between the primary and secondary antibodies. However, it was found 
that this cross-reaction could be almost eliminated by pre-incubating the diluted secondary reagent 
with 2.5% goat serum (Sigma) at room temperature for 2 hours in a rotating flask. 
A further problem encountered was an apparent tendency for IgA to stick to the plate at high 
concentrations (at serum dilutions of I in 200 or less). Tests using a number of substances as blocking 
agents (including 1% PVP, 1% glycine, 20% goat serum, 20% dog serum, 20% milk powder, cat 
albumin (Sigma) in either, or both, phosphate buffered saline (PBS) and carbonate- bicarbonate buffer 
were unable to completely prevent this phenomenon. The best blocking agents were found to be 20% 
milk powder (Marvel, Premier Beverages, Stafford, UK) in PBS and 20% goat serum (Sigma) in PBS. 
Chequer-board titrations were used to establish the optimum reagent concentrations. A rocking 
platform was utilised during the later incubation stages as this was found to give more consistent 
results (data not shown). 
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6.3.3.4 Specificity and precision of immunoglobulin class-specific ELISAs 
The specificity of each Ig-capture assay was demonstrated using purified feline IgG, IgM and IgA over 
an appropriate range of inimunoglobulin concentrations. The IgG and IgM assays were shown to be 
highly class-specific (Figure 6.1). Within the IgA assay a low positive signal was seen when the 
purified IgM sample was used at relatively high concentrations (Figure 6.1). In order to investigate the 
possibility that IgM present within a sample may influence the IgA assay titration curve the specificity 
assay was repeated with the additional inclusion of a serum sample (which was subsequently 
determined by ELISA to have 2.84 mg/nil of IgA and 3.03 mg/ml of IgM). The results in Figure 6.1 
show that the purified cat IgA and the serum sample gave matching titration curves. 
The intra-plate and inter-plate coefficient of variation of the class specific ELISAs were estimated 
from 6 saliva and serum samples each assayed on 3 occasions with 5 or 20 replicates per plate. The 
intra-plate coefficients of variation for the IgG, IgM, IgA ELISA assays were 11.9%, 15.0%, 16.6% 
and the inter-plate coefficients of variation were 8.4%, 11.5%, 17.5% respectively. 
6.3.4 Determination of saliva and serum immunoglobulins concentrations by ELISA 
Table 6.2 surnmarises the immunoglobulin concentrations of the salivary and serum samples from 14 
control cats (CC-1 to CC-14; Table 5.1) derived by ELISA (EU/ml). Only 10 of the 14 unstimulatcd 
saliva samples could be analysed owing to insufficient remaining volume in 4 samples (Control cats 
CC-4, CC- 10, CC- 13 & CC- 14). Quantification of each of the immunoglobulin classes was possible in 
all of the samples analysed. 
Table 6.2 Immunoglobulin concentrations (EU/mI) of serum and saliva from healthy cats 
derived by ELISA 
Sample n 
Mean concentration [standard deviation]and range (EU/ml) 
IgG Igm IgA 
Serum 14 647.2 [105.3] 85.1 [34.8] 123.0 [86.8] 
521.2 - 835.5 42.6-181.5 19.0-310.2 
Unstimulated saliva 10 1.90 [1.26] 1.64 [0.90] 69.2 [52.2] 
0.71-4.70 0.30-2.90 22.2-208.5 
Stimulated saliva 6 0.06 [0.011 0.10 [0.05] 10.8 [6.9] 
0.04-0.07 0.07-0.19 2.4-22.7 
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6.3.5 Correlation of single radial immunodiffusion and ELISA results 
Pearson's correlation coefficient (r) was calculated to provide a measure of the strength of the 
relationship between SRID and ELISA for the determination of serum and salivary immunoglobulins 
(Figure 6.2). There was a significant correlation between the two assays for the concentration of IgG, 
IgM and IgA in serum, and the concentration of IgG and IgA in unstimulated saliva. A high positive 
correlation was found between the two tests for salivary IgM, however the result was not statistically 
significant. Insufficient data points were available to determine correlation coefficients between the 
results for stimulated saliva. 
6.3.6 Determination of salivary albumin concentrations 
Preliminary investigations indicated that the albumin concentration of feline saliva was below the 
detection limits of the biochemical assay used to determine the serum albumin concentration. 
Consequently, an ELISA was used to measure the salivary albumin concentration. 
6.3.6.1 Development and optimisation of feline albumin ELISA 
Attempts were made to develop a capture ELISA for feline albumin. An ELISA using goat anti-cat 
albumin (Nordic), sheep anti-cat albumin (The Binding Site, Birmingham, UK) and donkey anti sheep- 
alkaline phosphatase (The Binding Site) as primary, secondary and tertiary antibodies was 
unsuccessful owing to a cross reaction between the goat and donkey reagents. A sandwich ELISA was 
then investigated using goat anti-cat albumin (Nordic) and goat anti-cat albumin-alkaline phosphatase 
(Bethyl Laboratories, Montgomery, Texas, USA), however, rather surprisingly, a cross-reaction was 
repeatably and consistently found to occur between the two reagents. Replacing the primary reagent 
with an alternative affinity purified goat anti-cat albumin from the same company as the goat conjugate 
(Bethyl Laboratories) did not resolve the problem. Furthermore, attempts to prevent this cross-reaction 
by using 20% goat serum in the blocking and dilution buffers was unsuccessful. The goat conjugate 
was also found to cross-react with sheep anti-cat albumin. 
An indirect competitive assay for the measurement of albumin based upon the method described by 
Van Kamp, et al. (19 89) was explored. The assay was optimised using a chequer board technique (data 
not shown). 
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Figure 6.2 (a-f) Paired IgG, IgM and IgA values determined by SRID (mg/ml) and ELISA 
(EU/ml) for serum and unstimulated salivary samples 
(a) P=0.0 11 (P'= 0.033) (b) P=0.014 (P = 0.028) 
1200 -- 
SerumIgG 6.0 -- 
SalivarylgG 
1000 -- 5.0 0 
800 00 4.0 
10 00 
600 0 0 0 
10 3.0 
0 0 0 
400 2.0 00 
200 -- r=0.66 1.0 -- 08 0 r=0.74 
0-iii1 0.0 -i i 
0 10 20 30 40 0 0.05 0.1 0.15 0.2 
MgIMI MgIMI 
(e) P<0.001 (PI < 0.003) (d) P=0.35 
200 - 
SerumIgM 4.0 -- 
Salivary IgM 
0 
150 - 3.0 0 0 




1.0 0 00 
r 0.94 r 0.65 
0-iii 0.0 
012345 0 0.05 0.1 0.15 0.2 
Mg/Ml Meml 
(e) P<0.001 (P'< 0.003) (f) P=0.002 (P' = 0.008) 
400 -- 











100 -- 0 0 
50 -- 09 
000 0 
000 r=0.83 0 r=0.85 
0-0ii 
01 iI 
0246 0.0 0.3 0.6 0.9 1.2 
Mg/Ml ing/ml 
EU = ELISA units where the standard has a value of 100. r= Pearson's correlation coefficient. P' 
adjusted P value for multiple testing using the lay ered Bonferroni method. 
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6.3.6.2 Reliability of the feline albumin competitive ELISA 
A serum and pooled salivary sample were each assayed on 3 independent occasions with 5 replicate 
determinations per plate. The mean inter-plate coefficient of variation was 9.6% and the mean intra- 
plate coefficient of variation was 15.8%. 
6.3.7 Determination of salivary albumin concentrations by ELISA 
The mean albumin concentration (and standard deviation) of unstimulated saliva samples from ten 
control cats (6.3.4) was 0.116 (0.080) mg/ml (range 0.030 - 0.272 mg/ml). In three cats, paired 
stimulated saliva samples were available for analysis, however in one of these samples the albumin 
concentration was below the quantification limits of the assay (-0.003 mg/ml). The two remaining 
samples were determined to contain 0.004 and 0.007 mg/ml albumin, which represented a 15 and 36 
fold reduction respectively, in the salivary albumin concentration following stimulation. 
6.3.8 Investigations into the salivary sample collection method and sample immunoglobulin and 
albumin stability 
The recovery of fluid from the cotton swabs used for the collection of saliva was investigated. Aliquots; 
of water (5 to 100ld) were pipetted directly onto swabs, and the volume of water subsequently 
extracted from each swab determined from the mass of the eluant (I mg =I gl). Figure 6.3 shows that 
the maximum recoverable volume was approximately 70-75% of the original volume. 
























Values are mean and standard deviation (upper & lower bars) of 3 replicates 
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Vol. added (gl) 
Experiments were performed to investigate the repeatability of the unstimulated saliva collection 
technique. Two swabs were collected from six cats (cats A to F) as described in Chapter 5, except that 
the saliva harvested from each swab was analysed separately for immunoglobulin and albumin content 
The paired swabs demonstrated a reasonable degree of agreement (Figure 6.4). 
The stability of the saliva sample over time and the effects of repeated freezing and thawing were 
investigated. Saliva collected from four adult pet cats (cats A, B, G, & H) was pooled, thoroughly 
mixed, then divided in to 12 aliquots. Seven aliquots were immediately placed into storage at -20'C of 
which five were subsequently subjected to 1,3,7,15, or 31 cycles of rapid thawing and freezing. The 
remaining five aliquots; were left at 4'C for 2,4,8,24 or 48 hours then stored at -200C. The 
immunoglobulin and albumin concentrations of each aliquot were then analysed (Figure 6.5a & b). 
Additional unstimulated samples were collected from four cats (cats A, B, C, & G) and one aliquot 
from each sample was immediately frozen to -20'C, a second was subjected to 31 freeze-thaw cycles, 
a third stored at 40C for 48 hours before being ftozen, and a fourth stored at room temperature for 48 
hours before being frozen (Figure 6.5d-f). The albumin concentration in one sample set could not be 
determined (Figure 6.5e). Surplus saliva was pooled and left at room temperature for 2,4,8,24,48 
and 72 hours prior to being stored at -20'C (Figure 6.5c). 
The results (Figure 6.5a-g) generally indicated that immunoglobulin and albumin concentrations in the 
saliva samples were relatively stable following repeated freeze thawing, or short-term storage at 4'C or 
room temperature. Table 6.3 shows that no significant difference was found between the results from 
saliva samples collected from individual cats (Figure 6.5d-g) following multiple freeze-thawing or 
after storage for 48 hours at either 4"C or room temperature. 
6.3.9 Stability of serum immunoglobulin and albumin concentrations 
The stability of serum immunoglobulin concentrations was also investigated using aliquots of excess 
serum collected from two adult cats. Immediately after collection the serum was aliquoted. Two 
aliquots were immediately placed at -20'C, one of which was subsequently subjected to 31 thaw- 
freeze cycles. Further aliquots were stored at 4'C or room temperature for 8 or 48 hours before being 
frozen. In order to investigate any possible effect the swabs used for the collection of saliva might 
have upon the subsequent immunoglobulin and albumin concentrations, 100ý11 serum was pipetted 
onto duplicate swabs, then eluted and stored at -20'C. Inspection of the results shown in Figure 6.6 (a 
& b) shows that the serum immunoglobulin and albumin concentrations were stable under each of the 
storage conditions tested. In addition, the swabs had no discernible effect upon the immunoglobulin 
concentration, although a marginal increase was seen in the serum albumin concentration in all of the 
samples eluted from the swabs by comparison with the Ix freeze-thaw aliquot (6.7 - 8.0%). 
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Mean diff. (Swab 2- Swab 1) = -0.60 Mean diff. (Swab 2- Swab 1) = 0.44 
Stand. dev. (Swab 2- Swab 1) = 2.45 Stand. dev. (Swab 2- Swab 1) = 1.35 
Mean coefficient of variation = 21.3% Mean coefficient of variation = 28.9%- 
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Mean diff. (Swab 2- Swab 1) -7.9 Mean diff. (Swab 2- Swab 1) -0. IS 
Stand. dcv. (Swab 2- Swab 1) 79.3 Stand. dev. (Swab 2- Swab 1) 0.60 
Mean coefficient of variation = 37.8% Mean coefficient of variation = 39.2% 
Saliva was harvested from paired swabs collected in quick succession from 6 pet cats. EU = ELISA 
units where the standard = 100 EU. 
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Table 6.3 Paired I-test results comparing the effects of various storage conditions upon the 
immunoglobulin (EU/ml) and albumin (pg/ml) concentrations derived from saliva samples 
versus FTx I 
IgG (EU/ml) IgM (EU/ml) IgA (EU/ml) Albumin (pg/ml) 
N 4 4 4 3 
FT x 32 p 0.51 0.21 0.33 0.20 
Mean diff -0.46 0.34 51.5 4.8 
95% cl (-2.47,1.54) (-0.34,1.01) (-88.4,191.5) (-6.1,15.7) 
4'C 48hrs p 0.14 0.12 0.43 0.42 
Mean diff -0.24 0.72 34.4 2.5 
95% cl (-0.24,1.06) (-0.35,1.78) (-95.6,172.4) (-8.1,13.0) 
Rt 48 hrs p 0.43 0.52 0.59 0.93 
Mean diff -1.8 0.23 10.2 -0.4 
95% CI (-1.80,1.00) (-0.76,1.22) (43.6,64.1) (-16.01,15.2) 
FT = Freeze thaw. Rt = Room temperature. 4'C = sample stored at 40C. EU = ELISA units where the 
standard = 100 EU. N= Number of paired samples analysed. Mean diff = mean difference in 
immunoglobutin or albumin concentration of paired samples. Cl = confidence interval for the mean 
difference (FT xI- 2nd sample). 
Figure 6.6 (a & b) Immunoglobulin (EU/mI) and albumin concentrations in aliquots of serum 
samples determined following storage under various conditions and after elution from swabs 
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6.3.10 Analysis of day-to-day salivary immunoglobulin and albumin levels 
The individual variability of unstimulated salivary immunoglobulin content over time was analysed in 
four adult pet cats (designated cats A, B, D& E) by determining the salivary IgG, IgM, IgA and 
albumin concentrations by ELISA from samples collected each morning and evening over four 
consecutive days (Figure 6.7). In cat E, the salivary albumin concentrations were indeterminable. 
Multiple linear regression analysis using loglo values to Normalise the residuals showed that neither 
the day, nor the time of sample collection had a significant effect on the sample immunoglobulin 
variance. However, significant differences in IgG and albumin, but not IgM or IgA were determinable 
between cats (Table 6.4 a-d). Pearson's correlation coefficient (r) indicated a significant correlation 
existed between the concentrations of IgM and IgA in cat B, IgM and IgG in cat A, and IgG and 
albumin in cat F (Table 6.5 a-d). 
Variability in salivary flow rates between individuals can increase the variance of results within a 
population. To counter this effect, the saliva immunoglobulin concentration is sometimes expressed in 
relation to a flow-independent component, such as albumin. Inspection of Figure 6.8 (a-c) shows that 
there was considerable daily variation in the immunoglobutin/albumin ratio for each class of 
immunoglobulin examined. Multiple linear regression analysis indicated that the inimunoglobulin/ 
albumin ratio was not affected by the day or the time of sample collection, however a significant 
difference could be detected between cats in all 3 of the immunoglobulin classes examined (Figure 
6.8a-c). 
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Table 6.4 (a-d) Multiple linear regression of cat, day, and time on salivary IgG, IgM, IgA 
(EU/ml), or albumin (gg/ml) 
(a) Loglo IgG 
Predictor Coefficient St. Dev. T p 
Constant -0.708 0.0118 -6.03 <0.001 
Cat 0.303 0.030 10.00 <0.001 
Day 0.041 0.030 1.34 0.191 
Time -0.018 0.068 -0.26 0.797 
S=0.192 RSq = 78.4% Rsq (adj) = 76.1 % 
(b) Logio IgM 
Predictor Coefficient St. Dev. T P 
Constant -0.019 0.175 -0.11 0.914 
Cat 0.035 0.046 0.77 0.446 
Day 0.081 0.046 1.77 0.088 
Time 0.019 0.103 0.18 0.856 
S=0.290 RSq = 11.8% Rsq (adj) 2.4% 
(c) Logio IgA 
Predictor Coefficient St. Dev. T P 
Constant 1.857 0.179 10.35 < 0.001 
Cat -0.011 0.046 -0.24 0.814 
Day 0.041 0.046 0.89 0.379 
Time 0.061 0.104 0.59 0.562 
S=0.0293 RSq = 4.1% Rsq (adj) 0.0% 
(d) Loglo albumin 
Predictor Coefficient St. Dev. T P 
Constant 1.193 0.172 6.93 <0.001 
Cat 0.192 0.043 4.51 <0.001 
Day -0.017 0.047 -0.35 0.728 
Time 0.041 0.106 0.39 0.704 
S=0.260 RSq = 50.8% Rsq (adj) = 43.4% 
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Table 6.5 (a-d) Correlation coefficients between IgG, IgM, IgA and albumin from 8 consecutive 
unstimulated salivary samples collected at 12 bour intervals 
(a) Cat A 
versus IgG Igm IgA 
Igm 0.949 
P<0.001 (PI < 0.01) 
IgA 0.534 0.716 
P=0.173 P=0.046 (P' = 0.98) 
Albumin 0.486 0.536 0.265 
P=0.223 P=0.171 P=0.526 
(b) Cat B 
versus IgG Igm IgA 
Igm 0.427 
P=0.291 
IgA 0.464 0.947 
P=0.247 P<0.001 (P' < 0.01) 
Albumin -0.030 0.266 0.447 
P=0.944 P=0.524 P=0.266 
(c) Cat E 
versus IgG Igm 
Igm 0.056 
p=0.90 
IgA 0.144 0.184 
P=0.73 P=0.66 
(d) Cat F 
versus IgG Igm IgA 
Igm -1.99 
P=0.637 
IgA -0.343 0.544 
P=0.406 P=0.16 
Albumin 0.934 -0.227 -0.301 
P=0.001 (P' = 0.019) P=0.59 P=0.47 
Cell contents are; Upper= Pearson's correlation coefficient (r), Lower= corresponding P value. P' = 
adjusted P value for multiple comparisons (n=21) using the layered Bonferroni method. r was derived 
using the log,,, values. 
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6.4 DISCUSSION 
SRID is commonly used for the quantification of serum immunoglobulins, however, as was 
demonstrated in the present study, the limited sensitivity of SRID can preclude the detection or 
quantification of immunoglobulins in body fluids, such as saliva, in which the immunoglobulin 
concentration may be relatively low (Schultz et al., 1974; Yamada et al., 1984). This was particularly 
the case when salivary flow was stimulated and there was dilution of the salivary proteins. 
Consequently, SRID was shown to be unsuitable for the determination of immunoglobulin 
concentrations in a significant proportion of salivary samples from healthy cats. Despite these 
shortcomings, the salivary and serum immunoglobulin concentrations measured in this study by SRID 
are consistent with those cited previously (Hiraga et al., 198 1; Yamada et al., 1984 & 1992; Pedersen, 
1987; Ackley et al., 1990; Poli et al., 1992). 
ELISA offers a methodology which has potentially greater sensitivity than SRID for the detection and 
quantification of immunoglobulins. Accordingly, class-specific capture ELISAs were developed for 
the determination of feline IgG, IgM and IgA concentrations. These assays were shown to be reliable 
and highly class-specific; although within the IgA assay a slight degree of cross-reactivity with the 
purified IgM sample was noted. This latter phenomenon may be due to cross-reactivity between the 
two classes of immunoglobulin, or to contamination of the purified IgM sample with IgA, or both. If a 
cross-reaction was occurring, then this factor would only have a significant bearing upon IgA 
quantification results in samples in which the IgM concentration is substantially greater than the IgA 
concentration, as a 50-fold greater concentration of IgM than IgA was required to generate equivalent 
ODs. The use of ELISA enabled determination of IgG, IgM and IgA concentrations in all of the 
stimulated saliva, unstimulated saliva, and serum samples analysed. Moreover, good correlation was 
demonstrated between results obtained by both SRID and ELISA. Consequently, the superior 
sensitivity of ELISA made this the method of choice for the subsequent determination of salivary 
immunoglobulin concentrations. 
An additional advantage of the ELISA method over SRID is that the method is less influenced by 
heterogeneity in the size of the antigen. This is a particular problem encountered when trying to 
determine IgA concentrations by SRID. The size of the precipitin ring produced during SRID is 
dependant upon both the concentration and the molecular weight of the antigen. Feline serum contains 
dimeric IgA and a lesser amount of monomeric IgA (Vaerman, 1973); whereas saliva predominantly 
contains secretory IgA (slgA) (Orlans & Feinstein, 1971). Consequently, the use of serum as a 
standard in SRID will inevitably result in a considerable underestimation of the slgA concentration 
present in saliva, owing to the greater molecular weight of sIgA than either dimeric or monomeric IgA 
(Bratthall & Ellen, 1982; Delacroix et al., 1982). By contrast, this diffusion-related anomaly is not an 
issue within ELISA-based methods. 
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The presence of immunoglobulin subclasses can pose potential problems during the quantification of 
total immunoglobulin concentrations depending upon the specificity of the reagents. Currently 3 
subclasses of IgG are recognised in the cat (Baldwin & Denham, 1994; Grant, 1995a), although it is 
hypothesised that a fourth IgG subclass may exist (Grant, 1995a). The use of a polyclonal anti-IgG 
reagents raised against total IgG in the ELISA and SRID assays should ensure that the reagents are 
capable of detecting all subclasses of feline IgG. Subsequent studies, described in Chapter 10, 
confirmed that both the primary and secondary reagents used in the IgG ELISA were capable of 
detecting all 3 feline IgG subclasses. Currently only one class of IgA is recognised in the cat, however 
Grant (1995a) has presented preliminary evidence which suggests that two subclasses may exist, as is 
recognised in other species. The use of polyclonal reagents raised against total IgA should ensure that 
both of these putative subclasses are detected within the assays. By contrast, only one class of IgM is 
recognised in the cat and other species (Grant 1995a). Consequently, either polyclonal and monoclonal 
anti-IgM reagents may be used for the quantification of IgM. 
Whole saliva is a complex fluid derived from a number of different sources. The major and minor 
salivary gland secretions, which are under autonomic regulation, account for the majority of the fluid 
and macromolecules (Baum, 1987; Proctor et al., 1989; Ekstrom et al., 1994). However, the 
immunoglobulins present within salivary gland secretions are produced by plasma cells resident within 
the salivary gland and ductal interstitium (Lehner, 1992; Sozmen et al., 1996), and the rate of secretion 
of inimunoglobulin from these cells is presumed to be independent of salivary flow rate and autonomic 
activity. The other major source of salivary immunoglobulin is the gingival crevicular fluid, which 
consists of a modified transudate produced from the gingival capillaries and immunologically active 
cells situated within the mucosa (Challacombe, et al., 1978; Lehner, 1992). Oral stimulation with 
substances such as citric acid increases flow rate from the major salivary glands (Mandel & Khurana, 
1969), but does not affect the flow rate of the crevicular fluid (Izumi et al., 1990). The results of the 
present study show that the predominant class of immunoglobulin secreted by the major feline salivary 
glands is IgA, which is in agreement with immunohistochemical studies showing a preponderance of 
IgA-bearing plasma cells in the feline salivary gland (Yamada et M., 1985). 
It was demonstrated that the immunoglobulin and albumin concentrations were both lower in 
stimulated saliva than in unstimulated saliva samples. So much so, that the immunoglobulin and 
albumin concentrations in stimulated saliva were near or below the lower quantification limits of some 
of the assays. In view of this finding, and the comparative ease of collection, unstimulated saliva 
samples were selected as the sample of choice. Moreover, unstimulated saliva samples are more likely 
to reflect the basal levels of salivary immunoglobulin bathing the oral mucosa than are artificially 
stimulated salivary samples. 
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The collection of saliva using absorbent cotton swabs is a commonly performed procedure in man and 
animals (Aufricht et al., 1992; Poli et al., 1992; German et al., 1998). It was demonstrated that the 
recovery of fluid from swabs was consistent, and that the proportion of absorbed fluid subsequently 
recovered was relatively stable once at least 30VI of fluid had been absorbed. Consequently, it was 
important to ensure that the swabs were visibly moistened following the collection of saliva. When 
serum was applied to the swab there was no discernible change in the concentration of 
immunoglobulins within the cluted serum, although very minor increases in the albumin concentration 
were noted. This most likely indicates that the methodology results in a slight concentration of the 
eluted sample. 
Examination of the effects of repeated freeze-thawing and short-term storage under various conditions 
indicated that salivary and serum immunoglobulin and albumin concentrations remained relatively 
constant. Consequently, the results are unlikely to be affected by minor variations in the sampling and 
storage conditions between samples. 
A number of physiological, psychological and environmental factors have been shown to affect 
salivary immunoglobulin concentration in man and animals (Graham et al., 1988; Skandakumar, et al. 
1995; Guhad & Hau, 1996). In order to investigate the variability of saliva on a day to day basis, serial 
unstimulated saliva samples were taken at the same time each morning and evening over a four day 
period from four cats. No consistent correlation was found between any of the immunoglobulin classes 
or albumin in the saliva. Furthermore, no evidence was provided to indicate that cats exhibit a diurnal 
variation in their salivary inimunoglobulin concentration. However, the saliva immunoglobulin and 
albumin levels were sufficiently constant that significant differences between cats could be identified. 
This finding provides evidence to support the validity of using swabs collected at a single time-point to 
provide an estimate of the salivary immunoglobulin concentrations in individual cats; although under 
ideal circumstances it would be preferable to collect repeated samples over a number of days. 
One of the main factors influencing the variability of salivary immunoglobulin concentration is the 
salivary flow rate (Mandel & Khurana, 1969; Aufricht et al., 1992). Recent studies in man have 
suggested that the collection of saliva by spitting over a given time is the most effective, non-invasive 
method for assessing salivary flow (Aufficht et al., 1992), but such collection techniques are not 
feasible in animal studies. To overcome this problem a flow-dependent salivary component such as 
albumin is commonly used to determine the salivary Ig/albumin ratio. This ratio is theoretically 
independent of salivary flow, but also assumes that the relative proportion of each class of 
immunoglobulin remains constant, irrespective of flow rate. In the present study, increased salivary 
flow caused a reduction in both immunoglobulin and albumin concentrations, but also altered the 
relative proportions of each immunoglobulin class. This implies that the Ig/albumin ratio does not 
permit comparison between individual results obtained using more than one of the collection 
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techniques described. Nonetheless, application of this ratio to serial unstimulated saliva samples from 
individual cats permitted significant differences in the Ig/albumin ratio to be identified between cats 
for IgG, IgM and IgA; whereas using the immunoglobulin concentrations alone significant differences 
were only noted in the IgG concentrations. This latter finding suggests that application of this ratio 
may reduce day-to-day variations in the estimated immunoglobulin concentrations within salivary 
samples collected from individual cats. 
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CHAPTER 7: Serum and Salivary Immunoglobulin Concentrations in Cats with 
Chronic Gingivostomatitis 
7.1 INTRODUCTION 
One of the cornerstones of the adaptive immune system is the humoral immune response. This 
response is mediated through processes which, depending upon the antigen, can be T-cell-dependant 
or T-cell-independent, and culminate in the production of antibodies (soluble immunoglobulins) 
against specific antigens by B-tymphocytes (Kishimoto & Hirano et at., 1988; Laman & Claassen, 
1995). Subsequent binding of antibodies to antigen can result either in the direct neutralisation or 
exclusion of antigen, or in the recruitment of additional effector mechanisms, such as complement or 
phagocytic cells (Frazer & Capra, 1999). Altogether, these antibody-mediated mechanisms provide 
immunological protection against various intracellular and extracellular micro-organisms, as well as 
toxins and other antigenic sources. 
Abnormalities of immunoglobulin production can occur in a wide range of diseases, including 
infectious, autoinunune, immunodeficiency and lymphoproliferative disorders, Increased 
immunoglobulin production normally occurs as a result of increased antigenic stimulation, and is 
therefore seen to occur in broad range of acute and chronic disorders. Less commonly, increased 
immunoglobulin production may result from over-production of various B-cell stimulating factors 
(Hirano et al., 1988; Jourdan et al., 1990; Hagiwara & Klinman, 1995). In some diseases, 
characteristic or selective increases in one or more immunoglobulin classes occur (Zola et al., 1995). 
These features can aid in the identification and diagnosis of such conditions, and may also provide an 
insight into the pathogenesis of the condition. Deficiencies in the production of one or more classes of 
immunoglobulin are also seen. A number of primary (or genetically determined) disorders are 
recognised, the most common of which is selective IgA deficiency (Buckley, 1999). Affected patients 
have low serum IgA concentrations accompanied by low IgA concentrations in mucosal secretions, 
and consequently they are predisposed to the development of diseases at mucosal sites, such as the oral 
cavity (Lehner, 1972; Childers et al., 1989; Buckley, 1999). This condition is recognised in man and 
other species (Felsburg et al., 1985; Buckley, 1999), but has not been described in the cat. Secondary 
(or acquired) humoral deficiency may be observed in disorders such as lymphoproliferative diseases, 
or following the administration of immunosuppressant drugs (Settipane et al., 1978; Lorber et al., 
1979; Hassan et al., 1986). 
Cats with chronic gingivostomatitis are commonly reported to have elevated serum globulin 
concentrations and a polyclonal hypergammaglobulinaernia (Johnessee & Hurvitz, 1983; White et al., 
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1992). Furthermore, Zetner et al. (1989) found that cats with oral lesions which were consistent with 
chronic gingivostornatitis had increased serum IgG, IgM and IgA concentrations. These latter findings 
have yet to be confirmed, although results in a study by Poli et al. (1992) suggested that both FIV 
seropositive and FIV seronegative cats with oral lesions, ranging from periodontitis to 
ulceroproliferative stomatitis, had elevated serum and salivary IgG concentrations. The local mucosal 
immanoglobulin response in cats with chronic gingivostomatitis has, however, not been specifically 
investigated. In order to further characterise the disease pathogenesis, and investigate potential 
predisposing factors such as deficiencies in local IgA secretion, studies analysing serum and salivary 
immunoglobulin levels in cats with chronic gingivostomatitis are required. 
This chapter reports the findings from investigations which analysed the salivary and serum IgG, IgM 
and IgA concentrations in cats with and without clinical signs of chronic gingivostornatitis. 
7.2 MATERIALS AND METHODS 
These are provided in Chapter 5 and Chapter 2. 
7.3 RESULTS 
7.3.1 Serum immunoglobulin and albumin concentrations 
Serum IgG, IgM and IgA concentrations (EU/nil) were determined by ELISA, and the serum albumin 
concentrations were measured biochemically, in 30 cats with chronic gingivostomatitis and 32 control 
cats (Figure 7.1 a-d). Cats with chronic gingivostomatitis were found to have significantly higher 
serum IgG, IgM and IgA concentrations, but significantly lower serum albumin concentrations than the 
control population. 
7.3.2 Salivary immunoglobulin and albumin concentrations 
Figure 7.2 (a-d) shows the salivary IgG, IgM and IgA concentrations (EU/ml) and salivary albumin 
concentrations (mg/ml) measured by ELISA in 30 cats with chronic gingivostornatitis and 28 control 
cats. Saliva samples were not available in 4 control cases (see 6.3.4). Cats with chronic 
gingivostornatitis were found to have significantly higher salivary IgG, IgM and albumin 
concentrations, but significantly lower salivary IgA concentrations than the control population. 
The relationship between the salivary albumin concentration and the concentration of each 
immunoglobulin class was investigated using Pearson's correlation coefficient (r). Table 7.1 shows 
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that a significant positive relationship was found between the concentrations of salivary IgG and 
albumin, and IgM and albumin, in cats with chronic gingivostomatitis. 
7.3.3 Estimation of serum-derived and locally produced immunoglobulins concentrations in 
saliva samples 
The amount of serum-derived immunoglobulin and locally produced immunoglobulin present in each 
salivary sample was calculated using the following formulas: 
Serum derived [1g] = Salivary [Alb] x 
Serum [1g] 
Serum [Alb] 




(Where Ig = Immunoglobulin and Alb = albumin) 
Cats with chronic gingivostomatitis were found to have a significantly higher concentrations of serum- 
derived IgG, IgM and IgA in their saliva compared to the control population (Figure 7.3). In addition 
cats with chronic gingivostomatitis had significantly higher concentrations of locally produced IgG, 
and significantly lower concentration of locally produced IgA, than the control cats (Figure 7.4). No 
significant difference between the two populations was found in the level of locally produced IgM 
(Figure 7.4). 
7.3.4 Correlation of serum immunoglobulin and salivary immunoglobulin and albumin 
concentrations with the stomatitis index in cats with chronic gingivostomatitis 
The relationships between the stomatitis index (SI) recorded in each cat (Chapter 3& Table 3.16) and 
the serum and salivary immunoglobulin and albumin concentrations were explored. Table 7.2 shows 
that the serum IgG and albumin concentrations demonstrated a relatively strong correlation with the 
SI, however following adjustment for multiple comparisons these relationships were not statistically 
significant. 
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Table 7.1 Correlation coefficients of albumin (mg/ml) with IgG, IgM or IgA (EU/mI) in saliva 
samples from cats with chronic gingivostomatitis (cases) and healthy control cats (controls) 
Albumin versus IgG Igm IgA 
Cases (r) 0.843 0.579 0.221 
(n = 30) p<0.001 p=0.001 P=0.24 
PI < 0.003 P, = 0.005 
Controls (r) 0.147 -0.001 -0.318 
(n = 28) P=0.46 p=1.0 p=0.10 
Pearson's correlation coefficient (r) calculated using loglo transformed values. T=P value adjusted 
for multiple testing using the layered Bonferroni method. n= number of cats 
Table 7.2 Correlation coefficients of stomatitis index (SI) with IgG, IgM or IgA (EU/ml) in 
serum samples and saliva samples from cats with chronic gingivostomatitis (cases) 
SI versus IgG Igm IgA Albumin 
Serum (r) 0.420 -0.055 0.060 -0.401 
(n =30) P 0.021 P=0.77 P=0.75 0.028 
P' 0.17 P' = 0.20 
Saliva (r) 0.278 -0.079 0.036 0.122 
(n = 30) P=0.14 P=0.68 P=0.85 P=0.52 
Pearson's correlation coefficient (r) calculated using logio transformed values. T=P value adjusted 
for multiple testing using the layered Bonferroni method. n= number of cats 
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7.4 DISCUSSION 
Cats with chronic gingivostornatitis were found to have significantly elevated serum IgG, IgM, and 
IgA concentrations by comparison to the control population, which is in accordance with the findings 
of previous studies in cats with oral lesions (Zetner et al., 1989; Poli et al., 1992). Differences between 
the case and control populations in the serum immunoglobulin concentrations was most pronounced 
for IgG, whereas for IgM, and especially IgA, the range of serum concentration within the two groups 
were relatively similar. These results are consistent with the serum electrophoresis results from the cats 
with chronic gingivostornatitis (data not shown), which were characterised by a broad-based 
polyclonal hypergammaglobulinaemia (Johnessee & Hurvitz, 1983; Zetner et al., 1989; White et al., 
1992). Hence, these findings indicate that cats with chronic gingivostomatitis do not have a systemic 
humoral deficiency in any of the three main immunoglobulin classes, although the presence of 
selective subclass deficiencies cannot be ruled out. Instead, the elevations seen in the systemic 
immunoglobulin concentrations are indicative of recent or ongoing B-cell activation occurring within 
secondary lymphoid tissues or the bone marrow, or both. This most commonly results from increased 
antigenic stimulation, but may also occur in circumstances in which there is over-production of B-cell- 
activating cytokines, such as interleukin (IL)-6 (Hirano et al., 1988; Jourdan et al., 1990), or in 
diseases in which dysregulation of B-cell activation and proliferation occur, for example during 
infection with FIV or HIV (Ackley et al., 1990; Grant, 1995b; Cohen et al., 1999). It cannot be 
detennined from the present study results which of these mechanisms may underlie the increases in 
serum immunoglobulin concentrations seen in cats with chronic gingivostomatitis. 
Under a hypothesis whereby the increase in B-cell activation in cats with chronic gingivostomatitis 
results from increased antigenic stimulation, perhaps as a result of altered integrity of the oral mucosa, 
it would be predicted that the specificity of the serum antibodies would be principally against a range 
of antigens to which the cat had been recently exposed. Indeed, an increase in antibody titres against 
various oral Gram negative anacrobcs commonly found in gingival and periodontal diseases has been 
demonstrated in cats with chronic gingivostornatitis (Sims et al., 1990; Norris & Love, 1995). By 
contrast, in circumstances in which increased serum immunoglobulin production results from over- 
production of B-cell-activating cytokines, or dysregulation of B-cell activation, non-specific 
polyclonal increases in immunoglobulin against a wide range antigens, including recent and historical 
antigens, are likely to occur (Grant, 1995b). Studies examining antibody titres against recall antigens, 
such as vaccine components, have not been reported in cats with chronic gingivostomatitis. Such 
investigations may be of considerable value in providing evidence to implicate the mechanism by 
which polyclonal activation of B-cells is occurring in cats with chronic gingivostomatitis. 
Only a few studies have examined serum immunoglobulin concentrations in diseased cats, and these 
have focused upon cats infected with feline leukaemia virus (FeLV) or feline immunodeficiency virus 
(FIV) (Ackley ct al., 1990; Poli et al., 1992; Grant, 1995b). Cats with FeLV demonstrated minimal 
changes in their serum immunoglobulin concentrations (Grant, 1995b), whereas cats with FIV had 
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elevated serum IgG, and normal or slightly elevated serum IgM and/or IgA concentrations (Ackley et 
al., 1990; Poli et al., 1992; Grant, 1995b). The mechanisms by which FIV induces B-cell activation are 
complex and not yet fully understood, and appear to vary through the course of the infection. Some of 
the factors implicated include increased antigenic stimulation resulting from infection with the virus 
during the early-stages of disease, and increased IL-6 production (Flynn et al., 1994; Willet et al., 
1997). Within the present study, four of the 30 cats with chronic gingivostomatitis were FIV 
seropositive. While there was no discernible difference in the serum IgM and IgA concentrations 
between cats with chronic gingivostornatitis which were FIV-seropositive or FIV-seronegative, it is 
interesting to note that the two highest serum IgG concentrations (by some considerable margin) were 
both from FIV-seropositive cases. It is tempting to suggest that this finding might represent an 
additive, or synergistic, effect of FIV-infection and chronic gingivostomatitis upon B-cell activation. 
In humans, non-specific elevation of all three major immunoglobulin classes, as was seen in cats with 
chronic gingivostomatitis, is a commonly recognised pattern encountered in a wide range of diseases. 
These include many bacterial and parasitic infections, chronic liver diseases, and some systemic 
autoimmune diseases (Zola et al., 1995). Thus, the changes seen in the serum immunoglobulin 
concentration in cats with chronic gingivostornatitis would appear not to display any outstanding 
characteristics. 
Examination of unstimulated salivary samples demonstrated that cats with chronic gingivostornatitis 
had significantly elevated salivary IgG, IgM and albumin concentrations, but significantly lower 
salivary IgA concentrations compared to the control population. The most pronounced differences 
between the two populations lay in the salivary IgG and albumin concentrations (Poli et al., 1992); 
whereas the case and the control populations showed considerable overlap in their range of salivary 
IgA concentrations, and to a lesser extent, their salivary IgM concentrations. The increase in salivary 
albumin concentration in cats with chronic gingivostomatitis is indicative of increased transudation of 
serum components into the saliva, presumably as a result of mucogingival inflammation. This factor 
would be expected to cause an elevation in the salivary concentration of all immunoglobulin classes, 
however, because of the greater difference in the serum and salivary concentrations of these classes of 
immunoglobulin compared to IgA, the relative effect would be most pronounced upon the IgG and 
IgM concentrations. This is supported by the finding that the salivary IgG and IgM concentrations 
were strongly correlated with the salivary albumin concentration in cats with chronic 
gingivostomatitis, whereas the salivary IgA and albumin concentrations showed only a weak positive 
relationship. 
Calculations were performed to estimate the amount of transudated and locally produced 
immunoglobulin present within the saliva samples. This was achieved by using the salivary albumin 
concentration to predict the amount of serum-derived inununoglobulin present within the saliva sample 
(Matthews et al., 1981). Such a methodology provides a relatively crude estimate of the amount of 
transudated and locally produced immunoglobulin. Factors such as differences in the molecular 
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weights of albumin and each of the immunoglobulin classes, and the extent of oral inflammation in 
each individual, will influence the true transudation rates of each of these molecules, Notwithstanding 
these shortcomings, the results support the conclusions discussed above that there is a significant 
increase in the transudation of IgG, IgM and IgA into the saliva of cats with chronic gingivostomatitis. 
Of more interest, however, is the finding that cats with chronic gingivostornatitis have significantly 
greater amounts of locally produced IgG, but not IgM in their saliva. Moreover, the amount of locally 
produced salivary IgA was found to be significantly lower in cats with chronic gingivostomatitis 
compared to the control population, although concentration ranges were similar in both populations. 
These results indicate that cats with chronic gingivostomatitis are able to secrete IgA into their saliva. 
However in most cases their total and locally produced salivary IgA concentrations were in the lower 
end of the normal range demonstrated by the control population. It is not clear if this factor may be 
sufficient to predispose these cats to the development of oral disease. IgA provides immunological 
protection for the oral cavity by neutralising pathogens and toxins, by inhibiting the adherence or 
growth of micro-organisms on the oral mucosa or teeth, and by enhancing the effectiveness of non- 
specific defence factors, such as mucin and lactoperoxidase (Challacombe & Shirlaw, 1999). In 
Chapter 3 evidence was presented for the chronic persistence of feline calicivirus (FCV) infection 
within the oropharynx of the cats with chronic gingivostomatitis. Low salivary IgA production may be 
a factor that prevents these cats from eliminating FCV. 
It is not clear from this study whether the relatively low salivary IgA concentrations detected in most 
of the cats with chronic gingivostornatitis is an inherent attribute, or a consequence of the disease. It is 
possible that the differences in the salivary IgA concentrations between the two populations are 
essentially artefactual, and result from differences in the flow rate of saliva. As discussed in Chapter 6, 
expression of the salivary immunoglobulin: albumin ratio is often used to try to adjust for differences in 
salivary flow rate between individuals. However, this method relies upon the assumption that the 
leakage of albumin into the saliva within each individual occurs at a similar and constant rate. In the 
present study the existence of variable amounts of oral inflammation between individuals will violate 
this assumption and therefore render the method invalid. Hence, further studies are required to 
investigate the ability of cats with chronic gingivostornatitis to secrete IgA. In particular, examination 
of their ability to transcytose IgA and produce secretory component would be of considerable interest. 
The most striking change within saliva from cats with chronic gingivostornatitis was the dramatic 
increase in the concentration of IgG. In addition to increased transudation of serum-derived IgG into 
the saliva, the results indicate that there is a significant increase in the amount of locally produced IgG. 
As IgG is not capable of being actively secreted by epithelial cells into saliva, the most likely source of 
this immunoglobulin is the large plasma cell population that typically infiltrates the mucogingival 
tissues during the development of the oral inflammatory lesions seen in this condition (Johnessee & 
Hurvitz, 1983; Reindel et al., 1987; Lyon, 1990; Gruffydd-Jones, 1991; Williams & Alter, 1992; 
White et al., 1992; Hennet, 1995), Subsequent immunohistochernistry studies (Chapter 11) confirmed 
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that the vast majority these plasma cells are IgG+. The IgG produced by these cells may access the oral 
cavity via the gingival crevicular fluid, or by transudation across the inflamed or damaged mucosal 
epithelium (Challacombe et al., 1978; Ebersole et al., 1996). The increase in IgG within the saliva may 
be of potential benefit to the host by assisting in the neutralisation of pathogens. However, unlike IgA, 
IgG does not enhance the antimicrobial effects of some non-specific defences, such as lactoferrin or 
lactoperoxidase (Challacombe & Shirlaw, 1999). Furthermore, as IgG is readily susceptible to 
proteolysis by enzymes produced by many oral bacteria, its effectiveness may be limited (Gregory et 
al., 1992). It is also possible that the increase in salivary IgG, and also IgM, could have a detrimental 
effect on the oral tissues by provoking increased inflammation through the activation of transudated 
complement components. 
In contrast to IgG, the increase in salivary IgM concentration seen in cats with chronic 
gingivostomatitis was shown to result only from increased transudation of IgM from serum. This 
finding would suggest that the local lesions in cats with chronic gingivostornatitis harbour relatively 
few, if any, IgM' plasma cells. Subsequent immunohistochemistry studies (Chapter 11) confirmed this 
to be the case. 
Although the number cases is too small to be able to draw widespread conclusions, it is interesting to 
note that the total IgA and estimated locally produced (secreted) IgA concentrations in three of the 
four FIV-seropositive cases are amongst the lowest of all of the cats examined. Decreased salivary IgA 
concentration has been reported to occur during infection with HIV, and is thought to result from a 
combination of decreased IgA secretion and a reduction in salivary flow from the major salivary 
glands (Sweet et al., 1995). Furthermore, the reduction in salivary IgA seen in these patients is 
associated with frequent opportunistic mucosal infections (Sweet et al., 1995). This possible parallel 
between HIV- and FIV-infection raises further questions as to the potential role of FIV in the 
aetiopathogenesis of chronic gingivostomatitis (see Chapter 3). 
The serum albumin concentration was found to be significantly lower in the cats with chronic 
gingivostomatitis than the control population. In diseases in which there is increased globulin 
synthesis, as is seen in feline chronic gingivostomatitis, the altered demands upon hepatocyte protein 
synthesis commonly results in down-regulation of albumin production (Wemer et al., 1994). 
Nevertheless, it is conceivable that the increased transudation of albumin into the saliva in cats with 
chronic gingivostomatitis, as was demonstrated in this study, could be sufficient to cause, or contribute 
to, a minor reduction in systemic albumin concentration. 
The relationships between the stomatitis index and the serum and salivary immunoglobulin 
concentrations were examined. No significant correlations were found, however there was a tendency 
for the serum IgG concentration to increase and the serum albumin concentration to decrease as the 
severity of the oral inflammation increased. Nonetheless, these findings imply that the severity of the 
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oral inflammation does not strongly influence class-specific local and systemic inununoglobutin 
production in cats with chronic gingivostomatitis. 
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CHAPTER 8: Changes in Serum and Salivary Immunoglobulin Concentrations 
in Cats with Chronic Gingivostomatitis During Treatment 
8.1 INTRODUCTION 
Few studies have analysed the effects of therapeutic agents upon aspects of the feline immune system 
(Scott et al., 1982; Weiss & Oostrom-Ram, 1990; Sato et al., 1996). More specifically, the effect of 
therapeutic agents upon local or systemic immunoglobulin concentrations in cats has not been 
reported. In Chapter 7 it was shown that cats with chronic gingivostornatitis have altered serum and 
salivary immunoglobulin concentrations by comparison to clinically healthy controls. Consequently, it 
was hypothesised that monitoring the changes in the salivary and serum immunoglobulin 
concentrations may provide a useful method for assessing the response to treatment. Furthermore, 
correlation of changes in immunoglobulin concentrations with changes in the clinical severity of the 
diseases during treatment may provide an insight into the disease pathogenesis. 
This chapter surnmarises and discusses the results of studies analysing the changes in serum and 
salivary irnmunoglobulin. concentrations during the administration of four different treatment regimes 
in cats with chronic gingivostomatitis. 
8.2 MATERIALS& METHODS 
These are provided in Chapters 5&2 
8.3 RESULTS 
8.3.1 Analysis of treatment groups at consultation I 
Cats with chronic gingivostomatitis were randomly allocated to one of four different long-term 
treatment groups following their first consultation (see Part 1). The IgG, IgM, IgA and albumin 
concentrations in serum and salivary samples collected at this time were analysed and are reported in 
Chapter 7. 
No significant differences in the serum inununoglobulin and salivary immunoglobulin and albumin 
concentrations were found between treatment groups prior to treatment commencing (Figure 8.1, 
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Tables 8.1 & 8.2). Similarly, no significant differences were found in the transudated or locally 
produced IgG, IgM or IgA concentrations between treatment groups calculated as described in Chapter 
7 (Table 8.3). 
Table 8.1 Tukey's pairwise comparison confidence intervals for mean group serum IgG 
concentrations (EU/mI) at consultation 1 
Group OH GS CS 
GS -912,196 
CS -511,636 -153,994 
AB -370,770 -12,1135 -451,733, 
Family error rate = 0.050 Individual error rate = 0.0 11 
Critical value = 3.88 
ANOVA P=0.068 (Figure 8.1). Values are lower and upper 95% confidence intervals for column 
group mean - row group mean. OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB 
Antibiotics 
Table 8.2 Tukey's pairwise comparison confidence intervals for mean group loglo serum IgA 
concentrations (EU/ml) at consultation 1 
Group OH GS CS 
GS -0.059,0.666 
CS -0.355,0.396 -0.659,0.095 
AB -0.362,0.389 -0.665,0.086 -0.395,0.381 
Family error rate = 0.050 Individual error rate = 0.0 11 
Critical value = 3.89 
ANOVA P=0,090 (Figure 8.1). Values are lower and upper 95% confidence intervals for column 
group mean - row group mean. OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB 
Antibiotics. EU = ELISA units where the standard = 100 EU 
Table 8.3 Analysis of transudated and locally produced salivary immunoglobulin concentrations 
(EU/ml) between treatment groups at consultation 1 
Locally produced ANOVA (P) Transudated ANOVA (P) 
IgG (EU/ml) 0.10 IgG (EU/ml) 0.65 
19M (EU/ml) 0.12 IgM (EU/ml) 0.33 
19A (EU/ml) 0.97 IgA (EU/ml) 0.37 
ANOVA performed using loglo values. EU = ELISA units where the standard = 100 EU 
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Figure 8.1 (a-h) Distribution and analysis of serum immunoglobulin and salivary immuno- 
globulin and albumin concentrations between treatment groups at consultation 1 
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8.3.2 Changes in serum and salivary immunoglobulin concentrations after three months of 
treatment 
Paired serum and saliva samples were collected at consultation 3 from 25 of the cats with chronic 
gingivostomatitis. Samples were not collected from Cats 2,7,13,26 & 29 as these individuals had 
withdrawn from the study (see Chapter 3). Serum and salivary IgG, IgM and IgA concentrations 
(EU/ml) and salivary albumin concentration (mg/ml) were determined by ELISA (Figure 8.2). The 
transudated and locally produced salivary IgG, IgM and IgA concentrations were calculated as 
described in Chapter 7. 
8.3.2.1 Serum IgG, IgM, IgA and concentrations 
Significant differences were found to exist between the treatment groups in the changes in serum 
albumin and IgG, but not IgM or IgA (Figure 8.2). Table 8.4 shows that the cats receiving 
corticosteroids; demonstrated a significantly greater reduction in their serum IgG concentrations than 
cats treated with gold salts or antibiotics, but not cats treated with oral hygiene products. Table 8.5 
demonstrates that cats treated with corticosteroids had a significantly greater increase in their change 
in serum albumin concentrations than cats treated with oral hygiene products, but not cats treated with 
gold salts or antibiotics 
8.3.2.2 Salivary IgG, IgM, IgA and albumin concentrations 
No significant differences were found to exist between treatment groups in the change in any of the 
salivary parameters measured (Figure 8.2 and Table 8.6) 
8.3.2.3 Correlation with the change in stomatitis index 
Correlations were performed between the change in the stomatitis index and the change in the salivary 
immunoglobulin and albumin concentrations. Tables 8.7 & 8.8 shows that the change in the stomatitis 
index was significantly correlated with the change in the total salivary IgM concentration and the 
change in the concentration of locally produced IgM. In addition, the change in the stomatitis index 
was found to have a strong positive relationships with the change in the salivary IgG concentration and 
the change in the concentration of locally produced IgG, however after adjustments were made for 
multiple comparisons neither of these relationships were statistically significant. 
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Figure 8.2 (a-h) Distribution and analysis of the change between consultations I&3 in serum 
immunoglobulin and salivary immunoglobulin and albumin concentrations between treatment 
groups 
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Table 8.4 Tukey's pairwise comparison conridence intervals for mean change in serum IgG 
(EU/ml) between consultations I and 3 
Group OH GS CS 
GS -544,240 
CS -37,678 80,864 
AB 438,307 -319,492 -758, -14 
Family error rate = 0.050 Individual error rate = 0.0 11 
Critical value = 3.94 
ANOVA P=0.012 (Figure 8.2). Values are lower and upper 95% confidence intervals for column 
group mean - row group mean. OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB 
Antibiotics. EU = ELISA units where the standard = 100 EU 
Table 8.5 Dunn's multiple comparisons tests for the change in serum albumin (g/L) between 
consultations I and 3 
Group comparison Difference in rank sum P value 
OH v GS -2.53 > 0.05 
OH v CS -10.71 < 0.05 
OHvAB -1.76 > 0.05 
GSvCS -8.19 > 0.05 
GS v AB 0.77 > 0.05 
CS v AB 8.95 > 0.05 
Kruskal-Wallis test P=0.034 (Figure 8.2). Off = Oral hygiene, GS = Gold salts, CS = Corticosteroids, 
AB = Antibiotics 
Table 8.6 Analysis between treatment groups of the change in transudated or locally produced 
concentrations of IgG, IgM and IgA (EU/ml) between consultations I and 3 
A Transudated pA Locally produced p 
IgG (EU/ml) 0.35" IgG (EU/ml) 0.30" 
IgM (EU/ml) 0.41' IgM (EU/ml) 0.80b 
IgA (EU/ml) 0.154 IgA (EU/ml) 0.56 b 
P value calculated using the "Kruskal-Wallis test or b ANOVA. A change in parameter from 
(consultation 3- consultation 1). EU = ELISA units where the standard 100 EU 
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Table 8.7 Correlation coefficients for change in stomatitis index (SI) and the change in IgG, 
IgM or IgA (EU/ml) in serum samples or saliva samples between consultations I and 3 
ASI versus AlgG (EU/ml) AlgM (EU/ml) AlgA (EU/ml) AAIbumin (mg/ml) 
Serum 0.126 a -0.1558 -0.264" -0.270 
(n =25) P=0.55 P=0.46 P=0.20 p=0.19 
Saliva 0.424 b 0.728 b 0.299" 0.214 b 
(n = 25) P=0.035 p<0.001 P=0.15 P=0.304 
P'= 0.25 PI < 0.004 
'Pearson's correlation coefficient (r). b Spearman's correlation coefficient (r, ). ND = Not determined. A 
= change in parameter (consultation 3- consultation 1). Sl = stomatitis index. EU = ELISA units 
where the standard = 100 EU. P' =P value adjusted for multiple testing using the layered Bonferroni 
method. n= number of cats 
Table 8.8 Correlation coefficients for change in stomatitis index (SI) and the change in the 
concentration of transudated or locally produced IgG, IgM and IgA between consultations 1 
and 3 
versus A locally produced IgG A locally produced IgM A locally produced IgA 
(EU/ml) (EU/ml) (EU/ml) 
Sl (r. ) 0.493 0.557 0.213 
(n = 25) P=0.012 P=0.004 P=0.307 
P' = 0.060 P' = 0.024 
A transudated IgG A transudated IgM A transudated IgA 
(EU/ml) (EU/ml) (EU/ml) 
S, (r. ) 0.138 0.132 0.056 
(n = 25) P=0.51 P =0.53 P =0.79 
r, = Spearman's correlation coefficient. A= change in parameter (consultation 3- consultation 1). EU 
= ELISA units, where the standard = 100 EU. F=P value adjusted using the layered Bonferroni 
method. 
8.3.3 Changes in serum and salivary immunoglobulin concentrations after six months of 
treatment 
Paired serum and salivary samples were collected from 24 cats at consultation 4, six months after 
treatment commenced. Samples were not collected from cats which had withdrawn from the trial by 
this stage (Cats 1,2,7,13,26 & 29). The salivary albumin could not be quantified in Cat 18 owing to 
insufficient volume of the remaining sample. The salivary sample from Cat 15 was lost during storage. 
The serum and salivary IgG, IgM and IgA concentrations (EU/ml), and the salivary albumin 
concentrations (mg/ml) were derived by ELISA. The transudated and locally produced salivary IgG, 
IgM and IgA concentrations were calculated as described in Chapter 7. 
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8.3.3.1 Serum IgG, IgM, IgA and albumin concentrations 
Figure 8.3 shows that after six months of treatment no significant differences were detectable between 
treatment groups in the change in the serum concentration of any of the immunoglobulin classes 
measured or albumin. 
8.3.3.2 Salivary IgG, IgM, IgA and albumin concentrations 
No significant differences were found between treatment groups in the change in the salivary IgG, 
IgM, IgA or albumin concentrations at consultation 4 (Figure 8.3). Similarly no significant difference 
was found between treatment groups in the change in the concentration of transudated or locally 
produced salivary IgG, IgM or IgA immunoglobulin. (Table 8.9). 
Table 8.9 Analysis between treatment groups of the change in transudated or locally produced 
IgG, IgM and IgA (EUIml) between consultations I and 4 
A Transudated A Locally produced P 
IgG (EU/ml) 0.94' IgG (EU/ml) 0.79' 
IgM (EU/ml) 1.00a IgM (EU/ml) 0.92" 
IgA (EU/ml) 0.41' IgA (EU/ml) 0.34 b 
P value calculated using the "Kruskal-Wallis test or b ANOVA. A change in parameter from 
(consultation 4- consultation 1). EU = ELISA units where the standard 100 EU 
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Figure 8.3 (a-h) Distribution and analysis of the change between consultations I&4 in serum 
immunoglobulin and salivary immunoglobulin and albumin concentrations between treatment 
groups 
(a) Serum IgG (b) Serum IgM 
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8.3.3.3 Correlation with the change in stomatitis index 
The change in the stomatitis index between consultations I and 4 was found to be significantly 
correlated with the change in the salivary IgM and IgA concentrations (Table 8.10). Further analyses 
indicated that the change in the stomatitis index correlated moderately well with changes in both the 
local production and transudation of IgM and IgA, however these relationships were not found to be 
statistically significant (Table 8.11). 
Table 8.10 Correlation coefficients for change in stomatitis index (SI) and the change in IgG, 
IgM or IgA (EU/mI) in serum samples saliva samples between consultations I and 4 
ASI versus AIgG (EU/ml) AlgM (EU/ml) AIgA (EU/mI) AAIbumin (mg/ml) 
Serum -0.292 b -0.073 b 0.221" -0.045' 
(n =24) P=0.17 P=0.73 P=0.30 P=0.84 
Saliva 0.43 qb 0.626 b 0.547 b 0.362 b, 
(n = 23) P=0.036 p=0.001 P=0.007 P=0.098 
P'= 0.22 P=0.008 P'= 0.049 
b 'Pearson's correlation coefficient (r). Spearman's correlation coefficient (r, ). 'n = 22. ND = Not 
determined. A= change in parameter (consultation 3- consultation 1). SI = stomatitis index. EU = 
ELISA units where the standard = 100 EU. P' =P value adjusted for multiple testing using the layered 
Bonferroni method. n= number of cats 
Table 8.11 Correlation coefficients for change in stomatitis index (ST) and the change in the 
concentration of secreted and transudated IgG, IgM and IgA between consultations I and 4 
versus A locally produced IgG A locally produced IgM A locally produced IgA 
(EU/ml) (EU/ml) (EU/ml) 
ASI (r) (br, ) 0.251b 0.504 b 0.428' 
(n = 22) P =0.26 P =0.017 P 0.047 
P, = 0.10 P, 0.19 
A transudated IgG A transudated IgM A transudated IgA 
(EU/ml) (EUlml) (EU/ml) 
ASI (r, ) -0.256 0.449 0.422 
(n = 22) P=0.25 P=0.036 p=0.051 
P'= 0.18 
'Pearson's correlation coefficient (r). Spearman's correlation coefficient (rJ. A= change in parameter 
(consultation 4- consultation 1). EU = ELISA units, where the standard = 100 EU. P' =P value 
adjusted for multiple testing using the layered Bonferroni method. n= number of cats. 
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8.4 DISCUSSION 
The comparative effects of four different treatments upon the serum and salivary IgG, IgM, IgA and 
albumin concentrations in cats with chronic gingivostomatitis were analysed. After 3 months of 
treatment only the change in serum IgG and serum albumin concentrations were found to differ 
significantly between treatment groups. Corticosteroids induced a significantly greater mean reduction 
in serum IgG levels by comparison to treatment with gold salts, or antibiotics, but not oral hygiene 
products - although inspection of the 95% confidence intervals (Table 8.4) suggests that treatment with 
corticosteroids would be much more likely to induce a reduction in the serum IgG concentration than 
would treatment with oral hygiene products. In addition, all of the cats receiving corticosteroids 
demonstrated an increase in their albumin concentration, and this change was significantly greater than 
the comparative response seen in the oral hygiene-treated group. After 6 months of treatment, 
however, no significant differences were found between the treatment groups in the changes in any of 
the serum or salivary parameters. 
It seems likely that the conflicting results in the change the serum IgG concentrations found after 3 and 
6 months of treatment were related to the reducing dose of methylprednisolone administered during 
the course of the study. Therefore, the results would suggest that daily dosing with methylprednisolone 
at 0.5 mg/kg is required in order to maintain a comparative reduction in serum IgG concentration in 
cats with chronic gingivostomatitis. 
Corticosteroids can exert multiple effects upon the immune system (Wilckens & De Rijk, 1997; 
Barnes, 1997). Changes in serum immunoglobulin concentrations following the administration of 
corticosteroids have previously been documented in man and other species, but not in the cat. Most of 
these studies have reported a reduction in serum IgG, and variable reductions in serum IgA and IgM, 
following the administration of various corticosteroids, including methylprednisolone (Levy & 
Waldmann, 1970; Butler & Rossen, 1973; McMillan, 1976; Settipane at al., 1978; Posey et al., 1978; 
Anderson et al., 1999; Rinkardt et al., 1999). By contrast, however, some studies found no significant 
change in serum immunoglobulin after administration of corticosteroids (Griggs et al., 1972; 
Wandinger et al., 1998) and others have demonstrated a dose dependant increase in serum IgA (Wira 
et al., 1990; Wira & Rossoll, 1991). The reasons for these conflicting results are not clear, but may 
result from differences between the study populations, the experimental methodology, or the agents 
administered, for example. 
The results from the present study are in agreement with the main body of evidence, which suggests 
that corticosteroids are capable of reducing the levels of serum IgG. The mechanisms thought to 
underlying this effect are complex and controversial. The immunoglobulin levels present in serum 
constitute a balance between synthesis and catabolism (Fahey & Robinson, 1963; Israel et al., 1996). 
While it has been shown that corticosteroids can increase the catabolism of immunoglobulins (Levy & 
Waldmann, 1970; Griggs et al., 1972; Butler & Rossen, 1973), decreased synthesis is considered to be 
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the major factor responsible for the corticosteroid-mediated reduction in serum immunoglobulin 
concentrations (Butler & Rossen, 1973). This may result from either decreased immunoglobulin 
secretion by plasma cells (McMillan et al., 1976), or by a reduction in the total number of plasma cells 
within the lymphoid tissues (Sabbele et al., 1983), or both. Corticosteroids can modulate the 
transcription of a spectrum of gene products, including many cytokines, in a wide range of cell types 
(Gillis et al., 1979; Waage et al., 1990; Almawi et al., 1991; Mukaida et al., 1994; Ray & Prefontaine, 
1994; Auphan et al., 1995; Batumann et al., 1995; Scheinman et al., 1995; Wilckens & De Rijk, 1997; 
Bames, 1997; DeKruyff et al., 1998). Suppression of B-cell-activating cytokines, such as IL-2 and IL- 
6, by corticosteroids could inhibit immunoglobulin synthesis, although direct evidence supporting this 
hypothesis is lacking. However by modulating cytokine production, and inhibiting antigen-receptor 
signalling, corticosteroids can profoundly affect T-cell function (Almawi et al., 1991; Elliot et al., 
1996; Baus et al., 1996; Wilckens & De Rijk, 1997). Thus, by downregulating the activation and 
proliferation of CD4+ T-helper cells, corticosteroids can indirectly suppress the activation and 
maturation of B-cells (Rosenberg et al., 1980; Parker & Purkerson, 1996; Wilckens & De Rijk, 1997; 
Swain, 1999). Furthermore, the immunosuppressive actions of corticosteroids upon antigen presenting 
cells, such a macrophages and dendritic cells, may further downregulate T-helper cell activity (Moser 
et al., 1995; Steer et al., 1997; Larsson & Linden, 1998). An additional mechanism by which 
corticosteroids might reduce irnmunoglobulin synthesis is by promoting apoptosis of B-cells or T- 
cells, or both, thereby reducing the lymphocyte population (Wyllie, 1980; Motyka et al., 1995; Lanza 
et al., 1996, Thompson, 1999; Milner et al., 1999). The mechanism by which the relative reduction in 
serum IgG was induced in cats receiving corticosteroids after 3 months of treatment cannot be 
established from the results of the present study. 
Methylprednisolone had no significant comparative effect upon the salivary immunoglobulin 
concentrations. The effect of corticosteroids upon salivary immunoglobulin levels has rarely been 
documented. Previous studies in rats have demonstrated a dose-dependent reduction in salivary IgG 
and IgA levels following treatment with dexamethasone, although the mechanism underlying this 
effect has not been clearly defined (Wira et at., 1990; Wira & Rossoll 199 1). It is disappointing that a 
decrease in salivary IgG was not seen in the present study following treatment with 
methylprednisolone. The reduction in the serum IgG concentrations of the cats given this treatment 
would be expected to result in a corresponding reduction in the IgG concentration of transudate 
entering the saliva. Furthermore, immunohistochernical studies performed on oral mucosa biopsies 
(described in Chapter 12) suggested that there was a relative reduction in the number of IgG' plasma 
cells within the oral lesions of the majority of cats receiving corticosteroids (see Chapter 12 for further 
discussion). While it is possible the potential effects of these factors could be counterbalanced by an 
increase in the volume or rate of transudating fluid, this would seem unlikely, as the cats receiving 
corticosteroids generally showed a reduction in the degree of oral inflammation after 3 months of 
treatment (see Chapter 3). Alternatively, changes in the salivary flow rate may have confounded the 
ability to detect changes in the salivary immunoglobulin concentrations between treatment groups. 
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Alternatively, the small number of cases within each treatment group may have been insufficient to 
permit the detection of relatively small changes in the salivary IgG concentrations. 
The potential effect of gold salts upon specific aspects of the feline immune system has not previously 
been documented. A number of studies have demonstrated inummosuppressive effects of 
aurothiornalate upon human and murine B-cell, T-cell, and macrophage functions. Nonetheless, the 
mechanisms of action thought to underlie these events are controversial and have not been clearly 
identified (Rosenberg & Lipsky, 1979; Riestra et al., 1988; Hirohata, 1996; Griem et al., 1995; Ishii et 
al., 1998). The results of the present study, however, show that long-term treatment with sodium 
aurothiomalate did not induce a comparatively significant change in the serum or the salivary 
immunoglobulin concentrations in cats with chronic gingivostomatitis. The effect of gold salts upon 
salivary immunoglobulin concentrations has not previously been reported. However, significant 
reductions in serum immunoglobulin concentrations have been documented in human patients 
receiving sodium aurothiomalate for the treatment of rheumatoid arthritis (RA) (Lorber at al., 1979). 
In this latter study the maximum response was not apparent until after I to 3 years of treatment. 
Nonetheless, significant reductions in serum immunoglobulin concentrations were detectable during 
the first 6 months of treatment (Lorber et al., 1979), thus it would seem likely that in the present study 
the duration of treatment would have been sufficient to detect potential changes in the immunoglobulin 
concentration. It is possible that the dose level used in the present study was suboptimal. In the study 
conducted by Lorber et al. (1979) the dose level for each person was adjusted to ensure that the serum 
concentration of gold was maintained between 300 to 700 gg/dI, which was considered to be the 
optimum therapeutic range. The pharmacokinetic properties of gold salts and the optimum therapeutic 
range for the serum concentration of gold have not been determined in the cat. Nevertheless, the dose 
level used in this study has previously proved effective in the treatment of autoimmune diseases in cats 
(Kristensen & Mehl, 1987). 
The results, instead, may suggest that the mechanisms underlying the increase in serum 
inummoglobulins seen feline chronic gingivostomatitis are insensitive to the mode(s) of action of 
sodium aurothiornalate. While this conclusion may at first appear to contrast with the findings in 
humans with RA, it should be noted that it has not yet been established whether changes in the serum 
immunoglobulin levels seen during the treatment of RA with gold salts arise directly from the effects 
of the drug, or are an indirect consequence of changes in the severity of the disease (Bloom et al., 
1988). It is interesting to note that during a7 year controlled trial no significant changes in the serum 
immunoglobulin concentrations, or in any of an additional panel of immunological parameters, were 
detected in non-nal dogs given gold salts (sodium aurothiomalate or auranofin) at a dose level similar 
to, or greater than, that used in humans and in cats (Bloom et al., 1988). Thus, collectively, these 
findings could indicate that species differences exist in the immunomodulatory potential of gold salts, 
or alternatively they may indicate that the ability of sodium aurothiornalate to suppress serum 
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immunoglobulin levels is disease-spccific and is dependent upon the underlying immunological 
aberrations. 
Studies analysing the potential immunomodulatory activity of metronidazole and spiramycin during 
their clinical use have not previously been documented. Metronidazole is a nitro-imidazole derivative 
that structurally resembles compounds such as histamine and cimetidine. Studies have demonstrated 
that metronidazole, and its hydroxy metabolite, possesses immunomodulatory activity (Saxen et al., 
1985; Kohli et al., 1987; Elizondo & Ostrosky-Wegman, 1996). However, both stimulatory and 
suppressive effects have been reported, and the mode of action of these effects has not been 
established (Saxen et al., 1985; Kohli et al., 1987; Elizondo & Ostrosky-Wegman, 1996). In addition, 
spiramycin was shown to induce a dose-dependant increase in IL-6 production when added to 
monocyte cultures (Bailly et al., 1993). Consequently, it is conceivable that these agents may be able 
to modulate immunoglobulin production when used therapeutically (Kohli et al., 1987). The present 
study, however, provides no evidence to support this hypothesis. 
Additional studies (data not shown) indicated that treatment with metronidazole and spiramycin 
dramatically suppressed the anaerobic bacteria present in the oral cavity. The absence of any 
corresponding reduction in the serum or salivary immunoglobulin concentrations suggests the lack of 
any relationship between the density of the oral anaerobic bacterial population and the serum and 
salivary immunoglobulin levels in cats with chronic gingivostomatitis. Studies demonstrating a 
polyclonal increase in specific serum antibodies against various anaerobic Gram-negative bacteria in 
cats with severe oral inflammation have led some authors to the hypothesis that Gram-negative 
anaerobes are key pathogens in the pathogenesis of feline chronic gingivostomatitis (Sims et al., 1990; 
Norris & Love 1995). While the findings in the current study do not disprove this latter hypothesis, 
they nonetheless challenge the notion that anaerobes play a dominant role in the perpetuation of the 
disease process. 
Immunoregulatory activity has not been reported for chlorhexidinc and glucose 
oxidase/lactoperoxidase, which are the active ingredients present within the oral hygiene products used 
in the present study. In this respect, therefore, the finding that oral hygiene treatment was 
comparatively ineffective in its ability to alter the serum or salivary immunoglobulin concentration is 
unremarkable. Furthermore, these findings generally support the above conclusions that the use of 
antibacterial agents to attempt to suppress the oral flora has no significant effect on local and systemic 
immunoglobulin production, although the effects of the oral hygiene products upon the oral flora were 
not assessed. 
Treatment with corticosteroids was associated with an increase in serum albumin concentration, 
although these changes were only significantly greater than the changes seen in cats treated with oral 
hygiene products. The reason for this different response is not clear. Scott et at. (1982) reported 
conflicting results from two normal cats given high-dose corticosteroids over a four week period 
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during which one cat demonstrated an increase, and the other a slight decrease, in serum albumin 
concentration. A short-term study in normal humans found that methylprednisolone did not alter the 
serum albumin concentration relative to controls (Butler & Rossen, 1973), however, other studies have 
demonstrated increased catabolism of albumin after steroid administration (Rothschild et al., 1958). 
Nevertheless, the effects upon diseased subjects has not been documented. The changes may reflect 
reduced transudation of albumin into the saliva from the mucogingival lesions. However, this 
hypothesis is not supported by the changes in the salivary albumin concentrations seen in each 
treatment group. Alternatively, therefore, the anti-inflammatory effects of methylprednisolone may 
effectively inhibit the down-regulatory influences upon albumin synthesis resulting from acute-phase 
inflammatory responses and the upregulation of globulin synthesis (Harvey & Gaskin, 1978; Stoddart 
et al., 1988; Baumann & Gauldie, 1994). 
Analyses were performed to investigate whether changes in the clinical severity of the oral lesions 
could be related to changes in the immunoglobulin composition of serum or saliva, irrespective of the 
treatment given. The results indicated that changes in the serum immunoglobulin concentrations did 
not correlate consistently with changes in the degree of oral inflammation. This implies that 
monitoring the change in serum immunoglobulin concentrations are unlikely to provide a reliable 
indication of the response to treatment in cases with chronic gingivostomatitis. By contrast, changes in 
the salivary immunoglobulin concentrations consistently demonstrated a positive correlation with 
changes in the oral inflammation. This relationship was most pronounced for IgM, and further analyses 
indicated these relationships were more dependent upon changes in the local production of 
immunoglobulins than changes in the transudated immunoglobulin component of saliva. These 
findings suggest that monitoring the changes in the salivary immunoglobulin concentrations, especially 
IgM, may be an appropriate method for assessing the response to treatment in cats with chronic 
gingivostomatitis. Further studies are required to corroborate this theory. 
As these latter findings were derived using results from cats receiving a range of treatments, the strong 
correlations found between the change in the salivary immunoglobulins and the change in the 
stomatitis index are likely to result from changes in the severity of the disease, rather than from the 
treatment having a specific effect upon immunoglobulin production. It is not clear, however, why it is 
the salivary IgM concentration that has the strongest relationship with the change in level of oral 
inflammation. It is possible that either a common factor, or a causal relationship, exists between the 
salivary IgM concentration and the level of mucogingival inflammation. The potent ability of IgM to 
activate complement via the classical pathway, and thereby initiate an inflammatory response, could be 
one such factor (Taylor et al., 1998; Prodinger et al., 1999). Alternatively it may simply be that, by 
comparison to IgG and IgA, IgM is less affected by undefined factors that increase the variability of 
the salivary immunoglobulin concentrations. 
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PART III: Histological and Immunohistochemical Studies 
Part III 
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CHAPTER 9: Matcrials and Mcthods for Part III 
9.1 CATS AND SAMPLE COLLECTION 
9.1.1 Clinical cases 
Excisional biopsies were collected from 30 cats with chronic gingivostomatitis (Chapter 2). 
9.1.2 Control samples 
Biopsies were collected from 19 cats with no history of chronic gingivostomatitis. These animals were 
housed within a research colony at the University of Bristol. Excisional biopsies were collected 
immediately after euthanasia from 19 clinically normal control cats (Table 5.1; CC-] 5 to CC-33). All 
of the cats were specified pathogen free (SPF) for feline leukaemia virus (FeLV) and feline 
immunodeficiency virus (FIV). None of the cats were found to be excreting feline calicivirus (FCV) or 
feline herpesvirus (FHV) based upon negative cultures from single oropharyngeal swabs collected 
immediately prior to euthanasia. The stornatitis index (SI) was recorded prior to euthanasia (Table 
5.1), and all of the cats had fauces scores of 0. 
9.1.3 Clinical grading and sample collection 
The fauces of each cat were scored using a four-point scale described in section 2.3.1. An excisonal 
biopsy was collected from the most severely inflamed faucal site, then immediately sectioned in to 3 
pieces of approximately equal size. Two pieces were embedded into separate strips of 2% (w/v) agar 
solution to maintain specimen orientation, prior to one piece being placed into 10% neutral buffered 
formalin (NBF), and the second piece being mounted in OCT compound (Bayer, Basingstoke, UK) on 
a cork disc then snap frozen in isopentane precooled over liquid nitrogen. The third piece was placed 
in a cryovial and snap frozen in liquid nitrogen for subsequent analysis by PCR. Frozen samples were 
stored at -700C. 
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9.2 TISSUE PROCESSING 
9.2.1 Formalin fixed tissues 
16-48 hours after collection, tissues in NBF were processed and embedded in paraffin wax. 5prn thick 
sections were cut and mounted onto slides coated with gelatine and bovine serum albumin for routine 
haematoxylin and eosin, and toluidine blue, staining; and 0.0 1% (w/v) poly-L-lysine (Sigma Chemical 
Co. Ltd, Poole, UK) for subsequent immunohistochemical procedures. Slides for 
immunohistochemical examination were air-dried at 371C for at least 72 hours before use. 
9.2.2 Frozen tissues 
8pm thick sections were cut at -20'C in a cryostat and mounted on 0.01% (w/v) poly-L-lysine coated 
slides. Sections were allowed to air dry for 12-24 hours at room temperature, and were then fixed in 
ice cold acetone for 10 minutes. Fixed slides were used immediately or were stored at -20*C in a 
sealed container until required. 
9.3 IMMUNOIJISTOCITENIISTRY 
Paired sections of biopsies harvested from cats with chronic gingivostomatitis pre- and post-treatment 
were run simultaneously to minimise any potential batch-to-batch variation in labelling. Wherever 
possible, sections from diseased and non-diseased animals were run simultaneously in each batch of 
slides. Immunohistochemistry was performed as described below. 
9.3.1 Fixed tissues 
Immunohistochemical labelling for IgG, IgM, IgA, leucocyte antigen Ll (LI), MHC class 11, CD3 and 
CD79a was performed on formalin-fixed tissues. Unless otherwise stated, all incubations were 
performed at room temperature and the slides were washed in PBS (3 x5 minutes) following each 
incubation period. Slides were deparaffinized in Histo-ClearTm (National Diagnostics, Hessle, UK) for 
a minimum of 6 minutes, then rehydrated through graded alcohols into purified water before being 
rinsed 3 times with purified water. For the demonstration of IgG, IgM, IgA, LI, or CD3 slides were 
incubated in 0.1% (w/v) calcium trypsin solution (pH 7.8) at 371C for 20 minutes. For the 
demonstration of MHC class II and CD79a slides were incubated in 0.0 1M citric acid (pH 6-0) (citrate 
buffer) held at 960C for 10 minutes and then left to cool at room temperature for 20 minutes. 
Endogenous peroxidase was then blocked in all tissues by incubating with 0.6% hydrogen peroxide in 
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50% methanol and 50% purified water for 30 minutes. From this point onwards, all incubations were 
performed in a humidified chamber. At this stage, sections used for the demonstration of IgG, IgA, and 
CD3 were incubated at 25'C for 2 hours with 100ptl of buffered heparinase-I solution (5U/mI) (Sigma, 
Poole, UK) per section to remove heparin contained within tissue mast cells. Non-specific binding was 
blocked by incubation with 20% rabbit serum in PBS QgG, IgM, IgA, LI, CD79a, MHC class 11) or 
20% goat serum and 2.5% cat serum in PBS (CD3) for 30 minutes, after which the blocking solution 
was removed and the appropriate, optimally-diluted primary antibody (Table 9.1) was applied to each 
section and incubated for 30 minutes (IgG, IgA, CD3) or overnight at 41C (IgM, LI, CD79a, MHC 
class II). Sections were then incubated with the appropriate, optimally-diluted biotinylated secondary 
antibody (Table 9.2) for 30 minutes. Each section was then incubated freshly prepared streptavidin- 
biotin-HRP complexes (Dako, Glostrup, Denmark) for 20 to 30 minutes. Subsequently, sections were 
incubated with 0.05% (w/v) diaminobenzidine (DAB) with 0.01% H202 in 0.05MTrisHCL (pH 7.6) 
for up to 20 minutes until optimal chromagen development had occurred. Slides were then washed in 
purified water (3 x5 minutes) then lightly counterstained with Mayer's haernatoxylin and washed in 
tap water for 2 minutes. Slides were then dehydrated through graded alcohols into Histo-ClearTM then 
mounted in DPX (Raymond Lamb, Eastbourne, UK). 
9.3.2 Frozen tissues 
Inununohistochemical labelling for C134 and CD8 was performed on frozen tissues. Unless otherwise 
stated, all incubations were performed at room temperature and the slides were washed in PBS (3 x5 
minutes) following each incubation period. Endogenous peroxidase was blocked by incubating with 
0.2% (w/v) periodic acid for 25-30 seconds. All subsequent incubations were performed in a 
humidified chamber. Non-specific binding was blocked by incubation with 20% rabbit serum in PBS 
for 30 minutes, after which the blocking solution was removed and 75pl of the appropriate, optimally- 
diluted primary antibody (Table 9.1) was applied to each section and incubated overnight at VC. 
Sections were then incubated with optimally-diluted biotinylated rabbit anti-mouse immunoglobulins; 
(Table 9.2) for 30 minutes. Each section was then incubated with freshly prepared streptavidin-biotin- 
HRP complexes (Dako) for 20-30 minutes. Subsequently, sections were developed, counterstained and 
mounted as described above (9.3.1). 
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Table 9.1 Primary antibody reagents used for immunohistochemistry 
Reactivity Reagent Isotype Protein 
cone" (g/L) 
Dilution Source 




Igm Mouse anti-cat IgM (F, ) IgG I 1.9b 1: 5000 Custom Monoclonals, 
Clone CM7 Sacramento, California, 
USA 
IgA Goat anti-cat IgA (Fj PC 38.7 b 1: 1500 Nordic Immunochemical 
antiserum Labs, Tilberg, The 
Netherlands 
CD3 Rabbit anti-human CD3' PC 0.5b 1: 200 DAKO, Glostrup, 
Denmark 
CD4 Mouse anti-cat CD4 IgG2a 3.3 b 1: 50 N. Gengozian, University 
Clone E248 of South Florida, USA 
CD4 Mouse anti-cat CD4 IgGI Unknown 1: 10 Serotec Ltd, Kidlington, 
Clone vpg 38 UK 
CD8 Mouse anti-cat CD8 IgGI 4 Ob 1: 250 N. Gengozian, University 
Clone CT87 d of South Florida, USA 
CD79a Mouse anti-human CD79a IgG 1 0.195C 1: 20 DAKO 
Clone HM57 
MHC Mouse anti-human HLA- IgGl 0.053' 1: 25 DAKO 
class 11 DR, cc-chain 
Clone TAL. I B5 
Ll Mouse anti-human IgG 1 0.275' 1: 1000 DAKO 
myeloid/histiocyte antigen 
Clone MAC387 
b Pc = Polyclonal. 'Affinity purified, Total protein concentration, 'Mouse immunoglobulin 
concentration ,d Marketed as monoclonal 25-2A anti-cat CD8 
by VMRD Inc., Pullman, USA 








CD3 Goat-anti rabbit Ig 3.3 b 1: 800 Sigma 
IgG Rabbit-anti goat Ig" 0.8' 1: 400 DAKO 
IgA 10 of to it 
CD79a Rabbit-anti mouse Ig' LOC 1: 100 it 
MHC class 11 if H it pf 
CD4 it 1: 400 of 
CD8 fF 
Igm 1: 800 
LI to 
'Affinity purified, b Total protein concentration, 'Specific immunoglobulin concentration 
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CD3 Rabbit Ig fraction Non-specific 15.03 1: 6000 DAKO 
LI Mouse IgGI Clone Aspergillus niger 0.10b 1: 400 
DAK-GOI glucose oxidase 
Igm Pr ff 1: 250 
MHC class Il it 
F1 1: 50 
CD79a if 1: 10 
CD8 it of 
CD4 (E248) it of 
IgG Goat IgG fraction Non-specific 24.0' 1: 20000 Sigma 
IgA Goat serum It 71.9" 1: 3000 to 
'Total protein concentration, bMouse immunoglobulin concentration 
9.3.3 Control sections 
Negative control sections were included for each tissue sample by replacing the primary antibody with 
an equivalent concentration of an isotype-matched antibody of an irrelevant specificity, or replacing an 
antiserum. with normal serum from the same species (Tables 9.1 & 9.3). Positive and negative control 
sections of feline lymph node were included in each batch of slides processed. 
9.4 SLIDE ANALYSIS METHODS 
9.4.1 Cell counts 
Sections were imaged using a Colour CoolView camera (Photonic Science, Robertsbridge, UK) 
connected to a Leitz DM RB microscope (Leica AG, St Gallen, Switzerland) and interfaced with a 
standard personal computer. Area and length measurements, and counts, were performed using Image 
Pro Plus version 3.0.01 (Media Cybernetics, Sliver Spring, Maryland, USA). Where present, 3 
morphological areas were identified in each section - the epithelium, the lamina propria/submucosa, 
and the salivary gIand tissue. Within each section, the density of positively labelled infiltrating cells 
within each of the 3 morphological areas, and the density of epithelial cell staining, were each scored 
from 0 to 4 (0 = none, I= sparse, 2= moderate, 3= dense, 4= very dense) and the distribution pattern 
of labelled cells was recorded as diffuse, focal or mixed. In sections labelled for CD3, CD4 and CD8 
the total number of positively labelled cells within the whole of the epithelial layer was counted. The 
total length of the epithelial basal cell layer was measured by tracing along the basement membrane 
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under the basal cells. The number of positive cells counted within the epithelium was then expressed 
per mm of epithelial basal cell layer. 
Within the lamina propria/submucosa present in each section, 3 to 6 representative x40 fields were 
digitally imaged. The number of positive cells was counted and the area of lamina propria/submucosal 
tissue within the image was measured, excluding any salivary gland tissue and large blood vessels. The 
number of positive cells was then expressed per O. IMM2 of tissue. 
Within the salivary gland tissue present within each section, I to 6 representative fields (x40 objective) 
were digitally imaged. The number of positive cells were counted, and the total area of salivary gland 
tissue within the image was measured. The number of positive cells were expressed per 0.1 mm 2 of 
glandular tissue. 
9.5 IgG SUBCLASS ELISA 
All incubations were performed within a sealed humidified container at room temperature unless 
otherwise stated. Plates were washed 3 times with 0.05%Tween in phosphate buffered saline (pH7.4) 
(PBSTw) between each incubation. Coating was performed using carbonate-bicarbonate buffer 
(15mM Na2CO3,35mM NaHC03, pH 9.6). Duplicate columns of wells within a 96-well plate (Greiner 
Labortechnik, Gloucester, UK) were coated over 5 rows (41 to #5) overnight at VC with 100gl per 
well of feline IgGl, or IgG2, or IgG3 (Custom Monoclonals, Sacramento, California, USA; all at 
I Ogg/ml), or cat serum (- I OýLg/ml IgG), or carbonate-bicarbonate buffer alone. Residual binding sites 
were blocked with 250gl blocking buffer, comprising 5% (w/v) milk powder (Marvel, Premier 
Beverages, Stafford, UK) in PBSTw, for I hour. 100[d of blocking buffer was then added to all rows 
#I to #3. Row #4 received I 00pl of monoclonal mouse anti cat IgG(Fc) [Clone K62 2D4] diluted I in 
50 with blocking buffer and incubated for I hour, Subsequently, lOOAl of blocking buffer was added 
to row #1,1 OOpLI of alkaline phosphatase (AP)-conjugated goat anti-cat IgG (H+L) (Jackson) diluted I 
in 15,000 in blocking buffer to row #2,100[d of AP-conjugated goat anti-cat IgG (Fc) (Jackson) 
diluted I in 10,000 in blocking buffer to row 43, and 100ýtl of AP-conjugated goat anti-mouse IgG 
(Sigma) diluted I in 1,000 with blocking buffer was added to row #4, and incubated for I hour. I mg 
per ml of 0.1% (w/v) p-nitrophenyl phosphate disodium hexahydrate (Sigma) was added, and the 
plates were read at 405nm (Multiskan Biochromatic plate reader, Labsystems, Finland) after 15 
minutes. 
9.6 STATISTICS 
The methods used for statistical analysis are described in Chapter 2. 
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CHAPTER 10: Development and Optimisation of Immunohistochernical Methods 
10.1 INTRODUCTION 
Immunohistochernical techniques facilitate the identification and enumeration of cell populations 
expressing specific antigens within tissue sections. However, before performing an 
immunohistochernical study it is first necessary to optimise the procedures used within the protocol, as 
such factors may vary between different laboratories and different tissues. This chapter summarises the 
findings obtained during the development and the optimisation of the immunohistochemical methods 
described within Chapters II and 12. 
10.2 MATERIALS& METHODS 
These are presented in Chapter 9. 
10.3 RESULTS 
10.3.1 Section processing 
During preliminary studies it was found that it was difficult to ensure the correct orientation of the very 
small tissue biopsies harvested from the oral cavity, especially with frozen sections in which the 
orientation could not be altered once the section was snap-frozen. Consequently, a method was devised 
whereby the biopsy was placed into a slit within a small section of 2% (w/v) agar solution to hold the 
tissue in a flat plane during formalin fixation or snap freezing, and subsequent processing. This 
procedure was very successful for tissues subjected to paraffin wax-embedding, however in some of 
the frozen sections it was found that the low density of the agar material created problems during the 
cutting process. 
An additional problem encountered was that the architecture of the frozen tissue was often poorly 
preserved. Consequently, wherever possible fixed tissue sections were chosen as the material of choice 
for the subsequent immunohistochemical studies. 
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10.3.2 Primary reagents 
A number of' cat-specific and cross-reactive antibodies were assessed I'Or flicir suitability for use in 
inunuriollistochernistry: 
Mouse anti-cat IgG(Fc) clone K62-2D4 (Serotec Ltd, Kidlin-ton, UK) and polyclonal ooat-anli cat 
IgG(Fc) (Jackson ImmunoResearch, Table 9.1) were shown to label plasnia cells in trvpsinised, 
formal in- fixed tissue. However usino an ELISA it was demonstrated that the monoclonal rea,, ent I 
detected feline IgG2 and IgG3, but not IgG 1.13ý contrast, the polyclonal rea-ent detected all 3 ol'the 
I gG isotypes tested (Fi- Lire 10.1). Con sequently, the po I ýc I on aI rea-ent was se I cc ted Ilor the detect ion 
of IgG' cells. 
Figure 10.1 ELISA-based determination of the reactivity of anti-cat IgG reagents with feline 
IgGI, IgG2, and IgG3 
100 
2 ý50 
* ý, 1 (X) 
'CD 
U 50 
1gG 1 Ig G2 lg G3 S er um 
0 (ioat anti-cat IýC(Fc) 
I El Mowse anti-cat lg(3(Fc) IK62 2D41 
El Posime control lGoai anti-cat IgQ1 I 
[3 Negatne control (PBS) 
Plates were coated with I ktg purified feline IgG 1, IgG2,1,, G3 oi- with cit seruni (- I po total 1(, (; ) oi- 
carbonate-b i carbonate buffer alone (background control) and these were prohed with various anti-cat 
IgG reagents or PBS (see Chapter 9.5 for inethodolo-y details). The optical density was measured at 
405nin after 15 111inUtCS. Columns represent the avera-e ot'duplicate wells. 
Polyclonal goat-anti cat IgM(Fc) (Nordic Laboratories, Tilberg, The Netherlands) was shown to be Z, 
applicable to trypsinised, fornialin-Ilixed tissue (Day et al., 1993). 1 lowever, ilic intensity of' specillic 
staining of' plasma cells was poorer, and the background staining greater, than that seen using mouse 
'anti-cat IgM(Fc) clone CM7 (Custom Monoclonals, 'Fable 9.1 ) (Grant 1995a). Consequently, Ilic 
monoclonal antibody was selected for use within the study 
Mouse anti-cat IgA(Fc) (clone I-A5-3B, Custom Monoclonals) (Grant 1995a), and polyclonal goat 
anti cat-IgA(I-c) (Nordic Laboratories) (Day ct al., 1993) were both found to bc suitable l'or the 
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detection of IgA+ positive cells in trypsinised, formalin-fixed tissues. The polyclonal reagent was 
selected for use within the study. 
A cross-reactive, rat anti-mouse CD45R, B220 (Ly 5) monoclonal antibody (Cedarlane Labs Ltd, 
Ontario, Canada), which had previously been validated for the detection of B-cells in the cat (Montieth 
et al., 1996), was found to give inconsistent labelling on trypsinised, formalin-fixed sections. However, 
a cross-reactive, mouse anti-human CD79a reagent (Clone HM57, DAKO) (Jones et al., 1993) 
previously validated for use in the cat (Day, 1995; Callanan et al., 1996) produced consistent staining 
of plasma cells and lymphocytes within B-cell dependent areas in citric acid-treated formalin-fixed 
lymph node sections. Thus, this latter reagent was selected for the identification and enumeration of 
the B-cell lineage. 
To detect T-cells, a cross-reactive rabbit anti-human CD3 (DAKO) reagent was selected based upon 
its previous validation for used in formalin-fixed tissues in the cat (Beebe et al., 1994; Day, 1995; 
Callanan et al., 1996; Jackson et al., 1996). This reagent is directed against a highly conserved 
intracytoplasmic peptide derived from the CD3 epsilon chain, and was shown to produce well 
demarcated labelling of paracortical lymphoid cells within trypsinised sections of lymph node. 
Four mouse anti-cat CD4 clones were assessed for use in frozen sections; 34174 (Southern 
Biotechnologies Assoc. Inc., Birmingham, Alabama, USA), E248 (N. Gengozian, University of South 
Florida, USA) (Sturgess, 1997), vpg38 and vpg39 (both Serotec Ltd) (Willet et al., 1994). E248 was 
found to provide the strongest staining of cells within T-dependent areas of lymphoid tissue sections, 
and therefore this reagent was selected for use within the study. E248 and vpg38 antibodies were 
shown to be unsuitable for the detection of CD4 in formalin-fixed lymph node sections. 
Mouse anti-cat CD8 (clone CT87, N. Gengozian) produced strong staining of T-cell dependent areas 
within frozen lymph node sections (Gengozian et al.,. 1988; Sturgess, 1997). This antibody was found 
to be unsuitable for use in formalin fixed sections. 
A cross-reactive mouse anti-human myeloid/histiocyte antigen reagent (clone MAC 387) which reacts 
with leucocyte antigen LI expressed by neutrophils, monocytes, certain reactive tissue macrophages, 
and squamous mucosal epithelium was used for the identification of cells from the 
granulocytic/monocytic lineage (Brandtzaeg et al., 1988; Callanan et al., 1996; Kipar et al. 1998). 
Specific staining of dendritic cells, lymphoid cells and macrophages was demonstrated in citric acid- 
treated formalin-fixed lymph node and faucal test sections using a cross-reactive mouse anti-human 
MHC class 11 (clone TAL. 1135, DAKO). The use of this antibody in the cat has been previously 
validated by Day (1998). 
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A cross-species-reactive mouse monoclonal antibody against human mast cell tryptase (clone DAKO 
Mast cell, AAI; DAKO, Glostrup, Denmark) was assessed in trypsinised, formalin-fixed tissue 
sections, but gave unacceptably high background staining. Consequently, toluidine blue staining was 
used to identify mast cells present within faucal tissue biopsies. 
10.3.3 Optimisation of antibody concentrations and antigen retrieval conditions 
The optimal antibody concentrations giving the best specific staining with the least background were 
determined for each antigen, and demonstrated using a checkerboard titration of the relevant primary 
and secondary antibodies (Tables 9.1 & 9.2). In addition, the optimal incubation times for antigen 
unmasking using trypsin were determined empirically, as were the optimal incubation temperature and 
times used in antigen unmasking with citric acid (see Chapter 9). It was found not to be necessary to 
heat the sections by microwaving during treatment with citrate buffer. 
Within the sections labelled for IgG, the level of background tissue staining was high. This effect was 
seen when either polyclonal or monoclonal anti-cat IgG antibodies were used as the primary reagent. 
Consequently, the number of IgG-positive cells within some sections, particularly within salivary 
gland tissues, was difficult to determine. 
Non-specific background staining, especially of the epithelium, was also relatively high in some 
sections labelled for CD3. However, attempts to reduce this effect using a commercial background 
reducing agent (DAKO antibody diluent, DAKO ) or by adding 1% or 10% dextran sulphate to the 
PBS used to dilute the stock antibody solution were not effective. Despite this, however, CD3' 
intraepthelial lymphocytes (IELs) could be easily identified. 
10.3.4 Non-specific mast cell staining 
During preliminary work it was noted that following some of the immunohistochernical procedures 
strong positive staining of a granulocytic cell population occurred within the negative control faucal 
tissue sections (Figure 10.2). The location of these cells corresponded to the position of mast cells 
demonstrated with toluidine blue (Figure 10.2). The immunolabelling of these cells was most 
prominent when goat, rabbit or mouse serum, or a mouse negative control IgG2b antibody was applied 
as the primary reagent. By contrast, when mouse negative control IgGl or lgG2a was utilised as the 
primary reagent the effect was absent or very minor (Figure 10.2). Furthermore, the labelling was not 
seen when the primary antibody or the secondary antibody were omitted, and was absent or slight 
when the endogenous peroxidase blocking step and the primary and secondary reagents were omitted 
(Figure 10.2). Hence, it was suspected that within the oral biopsy sections, non-specific non- 
immunological labelling of mast cells with the primary antibody was occurring (Schiltz et al., 1993). 
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A number of techniques were explored to try to abolish this effect. Reducing the pH of the PBS 
washing and dilution buffers to pH6.0 was found to diminish or eliminate the non-specific staining; 
however, increasing the NaCI content of the PBS (pH 6.0) to 0.5M was not found to provide any 
significant additional benefit. Preincubation of the primary antibody with IOOOU heparin per ml was 
also found to lessen or eliminate the non-specific labelling. Finally, preincubation of the sections with 
heparinase-I was found to remove the non-specific binding (Figure 10.3). Titration of the heparinase-I 
concentration and incubation period showed that 5U heparinase-I per in] applied for a2 hour 
incubation period at 250C was optimal for the elimination of non-specific mast cell binding within 
sections of fauces. Consequently, in all protocols in which a polyclonal primary reagent was used, each 
section was preincubated with heparinase-I prior to the application of the primary reagent. As the non- 
specific staining did not occur, or was negligible in sections using IgG I or IgG2a isotype primary 
reagents, heparinase-I pretreatment was considered to be unnecessary. 
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Figure 10.2 (a-f) Non-specific labelling of mast cells in feline oral mucosa 
(a) Intense labelling of mast cells with monoclonal mouse IgG2b negative control raised against 
Aspergillus niger glucose oxidase (DAKO) (14g/ml). (b) Weak labelling of mast cells (arrows) with 
monoclonal mouse IgGI negative control raised against Aspergillus niger glucose oxidase (DAKO) 
(10ýtg/ml). (c) Strong labelling of mast cells with normal goat serum (Sigma) (1: 40,000 dilution). (d) 
Metachromatic staining of mast cells with toluidinc blue. (e) Mast cell labelling is abolished when 
primary antibodies are not applied. (f) When blocking of endogenous pcroxidase activity is not 
performed, and primary and secondary antibodies are not applied, weak endogenous peroxidase 
activity is revealed in mast cells (large arrow) and strong endogenous peroxidase activity is seen in 
red blood cells (small arrows). (All images: x 320) 
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(Original magnification x128) 
Figure 10.3 (a & b) Pretreatment with heparinase-I abolishes non-specific labelling of mast 
cells 
(a) Non-specific labelling of mast cells with monoclonal mouse IgG2b negative control raised against 
Aspergillus niger glucose oxidase (DAKO) (Iýtg/ml) (b) Sections preincubated with heparinase-I 
(Sigma) (50U/ml) for 2 hours prior to application of mouse IgG2b negative control (I ýLg/ml). Non- 
specific labelling of mast cells is abolished. 
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10.4 DISCUSSION 
A number of studies have documented the results of immunohistochemical studies in the cat. 
Nevertheless, the range of reagents suitable for the detection of specific feline antigens remains 
comparatively limited. The antibody reagents selected for use in this study were chosen to enable the 
characterisation of the cellular infiltrate present in tissue samples collected from cats with chronic 
gingivostomatitis; typically lymphocytes, plasma cells, macrophages/monocytes and neutrophils. 
CD3 is part of the T-cell receptor complex and is first detectable in early thyrnocytes, hence detection 
of cells expressing CD3 permits the identification of all T-lymphocytes. In addition, the demonstration 
of CD4 or CD8 facilitates the identification of cells within the two major T-lymphocyte 
subpopulations. By contrast, CD79a (previously named mb-1) is part of the B-cell antigen receptor 
which is first expressed during the pre-B-cell stage and remains throughout subsequent maturation to 
the plasma cell stage (see Chapter 1). Consequently, the detection of CD79a facilitates the specific 
identification of B-lyrnphocytes and plasma cells. 
As discussed in Chapter 6, the existence of immunoglobulin subclasses means that care must be taken 
in selecting appropriate antibodies for the detection of immunoglobulin secreting cells. During the 
assessment of the suitability of anti-cat IgG reagents for the detection of IgG+ plasma cells, it was 
found that the monoclonal antibody K62-2134 detected feline IgG2 and IgG3, but not feline IgGI 
using an ELISA-based assay. Consequently, a polyclonal anti-cat IgG(Fc) reagent was selected which 
was demonstrated to have activity against all 3 recognised feline IgG subclasses. Furthermore, should 
a fourth class of feline IgG exist, as has been postulated (Grant, 1995a), it would seem more likely that 
a polyclonal reagent raised against purified IgG would detect this subclass than would a monoclonal 
reagent. A poIyclonal anti-cat IgA reagent was chosen for the detection of IgA' plasma cells rather 
than a monoclonal reagent. Although only one class of IgA is currently recognised in the cat, 
preliminary studies by Grant (1995a) suggests that two subclasses are likely to exist. Thus, it would 
seem prudent to use a polyclonal reagent raised against purified IgA rather than a monoclonal reagent, 
as it is more likely that a polyclonal reagent would detect both of these putative subclasses. By 
contrast, as only one class of IgM is recognised in the cat and other species, a monoclonal anti- 
19M(Fc) reagent may be reliably used for the detection of IgM+ plasma cells. 
Clone MAC387, which is specific for leucocyte antigen LI, has been shown to identify feline 
neutrophils, monocytes and a subpopulation of macrophages and histiocytes (Callanan et al., 1996). 
This marker therefore permits the identification of cells with a granulocytic/histiocytic lineage. 
MHC class II molecules comprise a and 0 chain heterodimers and are expressed by a large range of 
cell types including most B-cells, macrophages, dendritic cells, Langerhans' cells and, in contrast to 
humans and mice, the majority of feline resting T-cells (Rideout et al., 1990; Hunt & McConnell, 
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1995). Furthermore, it has been shown that under certain conditions local expression of MHC class 11 
molecules can be induced in other cell types, such as endothelial and epithelial cells (Wikstr6m et al., 
1996; Day, 1996). The immunohistochemical demonstration of MHC class 11 expression is 
complicated by the high degree of polymorphism displayed by these molecules, and by the fact that 
each individual can express a range of molecules. The antibody chosen for use in the present study for 
the detection of MHC class 11 molecules is specific for the invariant HLA-DR alpha-chain. 
Consequently, this reagent should detect all HLA-DR molecules expressed by each individual. Studies 
have shown that FLA-DRA genes homologous to human HLA-DRA genes exist in the cat, and that the 
deduced feline proteins also have monomorphic extracellular domains (Yuhki, 1995). This homology 
is likely to explain the cross-species-reactivity demonstrated by this reagent in the present study and 
previously (Day, 1998). 
During the assessment and optimisation of various primary reagents, non-specific labelling of mast 
cells was seen in sections from cats with and without chronic gingivostomatitis. Subsequent 
investigations showed that by enzymatically treating the tissue sections with heparinase-I this effect 
could be abrogated, thereby suggesting that the binding was being mediated by the presence of 
heparin. This phenomenon has not previously been reported in feline tissues, although similar findings 
have been documented in murine and human tissues (Ruck ct al., 1990; Schiltz et al., 1993). The 
phenomenon is thought to result from ionic interactions between antibody molecules and heparin 
contained within the mast cell granules (Ruck et al., 1990; Schlitz et al., 1993). As such, this 
interaction would be expected to be susceptible to disruption by changes in the environmental pH or 
by preincubing the antibodies with heparin (Schiltz et al., 1993). This was shown to be the case in the 
present study, which lends further support to the hypothesis that the interactions are non- 
immunological. 
Non-specific staining of mast cells can conceivably be mediated by other mechanisms. Binding of 
avidin to mast cell granules has been reported (Tharp et al., 1985), however this was shown not to be 
the cause of the non-specific labelling seen in the present study. Binding of antibodies to Fc receptors 
present on mast cells could also cause non-specific labelling. This possibility was not fully explored 
within the present study, however pre-treatment with heparinase would not be expected to eliminate 
this effect. 
The non-specific staining of mast cells was seen when normal sera from a range of species were 
applied as the primary antibodies. Furthermore, using commercially available negative control mouse 
monoclonal antibodies raised against a fungal enzyme (Aspergillus niger glucose oxidase), which is 
absent from mammalian tissues, the intensity of staining appeared to be subclass dependent, being 
most prominent when IgG2b was applied as the primary reagent, but absent or mild when IgGI or 
IgG2a isotypes were applied. It is possible that such an effect might be mediated by differences in the 
structure of the various subclasses of immunoglobulin molecules. Staining of mast cells was not seen 
when the primary reagent was omitted from the protocol. This is perhaps surprising as it might be 
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expected that the non-specific binding would also occur between the secondary antibodies and the 
heparin (Schlitz et al. 1993). The lack of binding may indicate that the biotin conjugate is able to 
disrupt the interaction between the antibody and heparin, perhaps in a steric manor or by altering the 
ionic charge. Further studies are required to confirm and investigate this finding. 
It is not clear whether the non-specific binding to mast cells seen in this study is a general effect within 
feline tissues or is a specific feature of mast cells present within the oral mucosa. Mast cells are 
considered to comprise a heterogenous cellular population within which various subpopulations have 
been classified based upon differences in histochernical fixation and staining characteristics and 
differences in the composition of the intracellular granules (Hill & Martin, 1998). In general, mast 
cells from cutaneous and peritonea] sites, which are often defined as connective tissue mast cells 
(CTMC), are resistant to formalin-fixation and contain heparin; whereas mast cells from the intestinal 
mucosa, often termed mucosal mast cells (MMC), are sensitive to formalin fixation and do not contain 
heparin (reviewed by Hill & Martin, 1998). Oral mast cells examined from various species have 
mainly been reported to have a CTMC phenotype (Fortier, 1990; Xu et al., 1993; Walsh et al., 1995), 
although both CTMC and MMC populations have been detected in oral mucosa from rats (Matsson, 
1992 & 1993). Studies examining mast cell heterogeneity have not yet been documented in the cat. 
The findings of present study show that a population of mast cells exists within the feline oral mucosa 
which are formalin resistant and are likely to contain heparin, which together implies that they have a 
CTMC-like phenotype. 
Based upon the results presented in this chapter it was decided that all sections in which a polyclonal 
antibody was utilised as the primary antibody would be pre-treated with heparinase in order to 
eliminate the possibility of non-specific binding to heparin. This procedure, although relatively 
expensive and time-consuming, was considered to be more reliable and effective in eliminating the 
potential problem of non-specific binding than was altering the pH of the buffers or preincubating the 
primary antibodies with heparin. In sections in which mouse IgG I or IgG2a monoclonal antibody was 
used as the primary reagent, pre-treatment with heparinase was considered to be unnecessary. 
The findings in this study have shown that non-specific binding of antibodies to mast cells can occur in 
formalin-fixed feline tissues. It is not clear, however, whether this is a general phenomenon or a 
feature peculiar to mast cells present within the oral mucosa. The results illustrate the importance of 
using isotype-matcbed control reagents in sections from feline tissues, as well as stressing the necessity 
to include adequate control sections in immunohistochernical studies. 
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CHAPTER 11: Immunohistochemical Analysis of Oral Mucosa Lesions in Cats 
with Chronic Gingivostomatitis 
11.1 INTRODUCTION 
The histological analysis of tissue samples enables the morphological characterisation of diseases at a 
cellular level. In addition, the demonstration of cellular antigens and products by 
immunohistochemistry facilitates the phenotypic characterisation and enumeration of specific cell 
populations present within tissue sections. Investigations utilising these techniques may prove 
invaluable in providing an insight into the processes underlying the pathogenesis of chronic 
gingivostomatitis. 
Previous studies documenting histopathological changes in oral biopsies from cats with chronic 
gingivostomatitis typically describe a chronic inflammatory infiltrate dominated by variable numbers 
of plasma cells, lymphocytes and sometimes macrophages and granulocytes (Reindel et al., 1987; 
Lyon, 1990; Gruffydd-Jones, 1991; Williams & Aller, 1992; White et al., 1992; Hennet, 1995; 
Harvey, 1995). In addition, Kyriazidou et al. (1989) reported a predominance of IgG plasma cells in 
gingival biopsies taken from 5 cats with gingivitis. However, detailed studies characterising and 
comparing the histopathological features and phenotype of the cellular infiltrate in oral biopsies from 
cats with chronic gingivostomatitis have not been reported. This chapter addresses this deficit, and 
reports upon the results of inimunohistochemical studies performed on oral mucosal biopsies from cats 
with and without chronic gingivostomatitis. 
11.2 MATERIALS AND METHODS 
These are presented in Chapters 9,5 & 2. 
11.3 CHARACTERISATION OF FAUCAL SECTIONS FRONITHE CONTROL POPULATION 
11.3.1 Histological findings 
Examination of haernatoxylin and eosin (H&E) stained sections from 19 healthy, control cats revealed 
an outer parakeratinised, stratified squamous epithelium with undulating shallow epithelial ridges 
(Figures 11.1 & 11.2). The epithelium contained occasional intraepithelial lymphocytes residing 
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predominantly within the basal layers and sparse melanocytes. Beneath the epithelium, the lamina 
propria contained loose connective tissue, numerous fibroblasts, and scattered small capillaries, 
lymphatics, and salivary ductules. Prominent clusters of lymphocytes were noted in subcpithelial 
locations in some sections (Figure 11.1). Very occasional plasma cells were seen within the lamina 
propria, In most sections, a submucosal. layer was present, which comprised loose connective tissue 
containing variable amounts of minor salivary glands, striated muscle bundles, blood vessels, 
lymphatics and salivary ductules. In some sections small numbers of lymphocytes and plasma cells 
were present around the blood vessels or muscle fibres. A few plasma cells were seen within the 
stroma surrounding the glandular salivary tissue. 
Toluidine blue-stained sections revealed the presence of a few metachromatic mast cells within the 
lamina propria and submucosal connective tissue in all sections. These cells often tended to be 
adjacent to capillaries. 
11.3.2 Immunohistochemical findings 
11.3.2.1 Morphological features 
Immunohistochemical labelling was performed for the demonstration of MHC class II, CD3, CD79a, 
IgG, IgM, IgA, and leucocyte antigen LI (LI) in sections from 19 control cats, and for the 
demonstration of CD4 and CD8 in sections from 17 of these cats (Figures 11.1 & 11.2). A frozen 
tissue sample from Control Cat 4 was not available, and the sections from Control Cat 17 were of 
inadequate size to provide any meaningU information. 
MHC class II labelling revealed the frequent presence of intraepithelial and subepithelial cells with a 
typical dendritic morphology (Figures 11.1 & 11.2). In some sections these cells formed foci within 
and below the epithelium, while in others they formed a diffuse layer extending between and beneath 
most of the basal epithelial cells, or were diffusely scattered throughout the epithelium. The 
microscopic appearance of these MHC class 11' cells suggested that were dendritic cells. These 
dendritic cells were closely associated with the subepithelial clusters of CD3+ cells that were also seen 
in some sections. Furthermore, cells within these clusters also stained positively for MHC class 11. 
Additional MHC class lI+ cells were seen scattered within the lamina propria and submucosal 
connective tissues, and in some sections they were closely associated with capillaries. Some MHC 
class lI+ cells were also seen adjacent to salivary glandular tissue. 
CD3+ T-lymphocytes were occasionally observed within the epithelium. In some sections, 
subepithelial clusters of CD3' cells were seen, which corresponded with the location of the 
subepithelial clusters of MHC class H staining cells and the subepithelial lymphocyte clusters seen in 
the H&E sections (Figure 11.1). Otherwise, CD3+ cells were rarely observed within the lamina propria 
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and the submucosa. CD4+ cells were not commonly seen within the epithelium. However in some 
sections they were present in a subepithelial position either as single cells or as clusters of cells. Single 
CD4+ cells were occasionally demonstrated elsewhere within the lamina propria. A small population of 
cells which labelled positively for CD8 was commonly seen within the epithelium. In many sections, 
occasional CD8' cells were present in a subepithelial position, while in others they formed clusters 
which corresponded with the location of CD4' clusters (Figure 11.2). CD8+ cells were otherwise rarely 
seen within the lamina propria or submucosa (Figure 11.2). 
Labelling for CD79a demonstrated a sparse population of postively labelled cells within the lamina 
propria, and occasional cells within the stroma adjacent to the salivary gland tissue. Very occasional 
CD79a' cells were seen within the epithelium. Labelling for IgG produced strong background staining 
in most of the sections. A few positively-labelled cells were occasionally seen in the lamina propria or 
submucosa, however these were not always identifiable as plasma cells based upon their morphology. 
IgM' plasma cells were rarely seen, except occasionally within salivary gland tissue. A few IgA+ 
plasma cells were seen within the lamina propria in some sections, and they were commonly seen 
within the stroma surrounding the glandular salivary tissues. Cells labelling positively for leucocyte 
antigen LI were rarely seen and were only detected within the lamina propria. and submucosa. Slight 
epithelial labelling for LI was seen in some sections. 
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Figure 11.1 (a-i) Subepithelial lymphOid clusters in healthy oral mucosa 
Sections of oral mucosal (Cat C-9) were stained with (a) H&E or labelled with antibodies or 
antiscra specific for (b) M1HC class 11 (c) CD3 (d) LI (e) CD79a (f & h) CD4 (g & i) CD8. (a) A 
cluster of cells is present in a subepithelial position (x 64) (b) Cells within the cluster label intensely 
MEC class If+ (x 32). MHC class II+ intraepithelial and subepithelial dendritic cells are evident 
(inset x 64). (c) Most of the cells within the cluster show membrane-labelling with CD3 (x 64). 
Intraepithelial CD3+ cells are evident (inset x 128). (d & e) Cells within the cluster are negative for 
LI (x 64) and CD79a (x 64). (M) Cells within the clusters show membrane labelling with CD4 (f x 
64; hx 128). and CD8 (g x 64; i: x 128). 
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Figure 11.2 (a-d) Immunohistochemical labelling of cells in normal feline oral mucosa 
Sections of oral mucosa were labelled with antibodies specific for (a & b) MI-lC class 11 (c) C134 (d) 
CD8. (a) Cat C-1 (x 32). Cells labelling with MIFIC class 11 often form discrete foci within the upper 
lamina propria or in a subepithelial and intraepithelial location (b) Cat C4 (x 128). Cells in the 
lamina propria and the epithelium labelling with MHC class 11 frequently show a dcndritic 
morphology (c & d) Cat C-14 (x 64). CD8' cells are more numerous than CD4' cells. 
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11.3.2.2 Quantification of the lymphoid, monocyte/granulocyte, and mast cell populations 
Figure 11.3 shows the number of cells within epithelium demonstrating specific labelling for CD3, 
CD4, or CD8. CD8+ cells were more prevalent than CD4+ in 15 of the 17 cases, and the median 
CD4: CD8 ratio was 0.16. The number of cells within the lamina propria and submucosal connective 
tissue demonstrating specific labelling for CD3, CD4, CD8, CD79a, IgG, IgM, IgA, LI, and showing 
metachromatic staining with toluidine blue (mast cells) are shown in Figure 11.4. Mast cells were 
identified most commonly. CD3+ T-lymphocytes were the next most frequently observed and were 
seen in all cases. Similar numbers of CD4+ and CD8+ cells detected, with a median CD4: CD8 ratio of 
1.0. LI+ and CD79+ cells were detected least frequently. The few plasma cells present were generally 
found to be either IgG+ or IgA+. In many sections, salivary gland tissue was absent. Cells labelling for 
CD4 or CD8 were not counted within the salivary gland-associated tissue due to poor tissue 
morphology. Furthermore, the number of cells labelled specifically for IgG could not be determined in 
most sections due to the high background staining within this tissue. Nevertheless, the results show 
that CD79a+ and IgA+ cells predominated in this area (Figure 11.5). 
Figure 11.3 Characterisation and enumeration of lymphocytes within the faucal epithelium 







CP CO (8 
0 0 
Antigen CD3 CD4 CD8 
N 19 17 17 
Median 0.6 0.2 1.8 
Minimum 0.1 00 
Maximum 5.2 2.2 7.2 
I st Quartile 0.4 0 0.7 
3rd Quartile 1.1 0.7 4.0 
Cells labelled with specific antisera to CD3, CD4, and CD8 within all of the epithelial tissue present in 
each section were counted. The length of the basal epithelial layer was measured and the cell counts 
expressed per I mm of basal epithelium. N= number cats from which sections were examined 
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11.4 CHARACTERISATION OF FAUCAL SECTIONS FROM CATS WITI I CHRON IC G ING IVOSTOMATITIS 
11.4.1 Histological rindings 
H&E stained sections from the faucal biopsies collected from 30 cats with chronic gingivostomatitis 
prior to entry onto the treatment trial were examined. A range of histopathological changes was seen 
within the sections (Figure 11.12). The least affected sections showed relatively normal tissue 
morphology. The epithelium in these sections consisted of either a relatively normal parakeratinised 
stratified squamous epithelium with shallow epithelial ridges and very little cellular infiltrate, or a 
slightly hyperplastic parakeratotic or hyperkeratotic stratified squamous epithelium with deeper 
epithelial ridges and an inflammatory infiltrate usually consisting of neutrophils and lymphocytes. 
Within the lamina propria, these sections generally had a sparse to moderate cellular infiltrate typically 
of plasma cells and lymphocytes with fewer macrophages. These tended to concentrate in a 
subepithelial location, and around capillaries and striated muscle bundles within the deep lamina 
propria or submucosa. 
The remaining sections showed a relatively dense, mixed inflammatory infiltrate which frequently 
effaced much of the normal mucosal tissue morphology. In these sections, the epithelium was regularly 
poorly demarcated, vacuolated and degenerate with areas of erosion or ulceration, and was variably 
infiltrated with large numbers of neutrophils, macrophages and lymphocytes. The underlying lamina 
propria and submucosal connective tissues typically contained a moderate to very dense cellular 
infiltrate. Although the composition of the infiltrate was variable, it was often dominated by plasma 
cells accompanied by variable numbers of lymphocytes, macrophages and neutrophils. Congestion and 
dilation of the capillaries was commonly seen and areas of haemorrhage were present in some of the 
most densely infiltrated sections. 
Toluidine blue-stained sections revealed the presence of a small or moderate number of metachromatic 
mast cells within the lamina propria and submucosal connective tissue in most sections. Many of the 
cells showed signs of degranulation. Mast cells were occasionally seen within the stroma surrounding 
the salivary glands. 
11.4.2 Immunohistochernical findings 
Immunohistochernical labelling was performed for the demonstration of MHC class 11, CD3, CD79a, 
IgG, IgM, IgA, and LI in 30 sections from cases with feline chronic gingivostomatitis (Figures 11 .6& 
11.7). Immuno-histochemical labelling for CD4 and CD8 (Figure 11.8) was performed in sections 
from 29 of these cases, owing to the loss of the frozen sample from Cat 3. 
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The overall level of MHC class 11 expression generally corresponded with the extent of inflammatory 
infiltration. In sections with only a few infiltrating cells, MHC class Ir cells were seen in the deeper 
lamina propria and submucosa. Intraepithelial and subepithelial MHC class lI+ dendritic cells were 
commonly seen, and in some sections these formed subepithelial clusters. As the level of infiltrate 
increased, MHC class 11 expression was generally associated with the infiltrating cells and was seen 
prominently in cells encircling capillaries and salivary ductuIes. In some sections, a prominent band of 
subepithelial cells expressing MHC class II was seen to correspond with CD79a"' and CD3+ infiltrates. 
In sections with degenerating epithelium, MHC class 11 expression was sometimes very intense within 
this tissue, Positive staining of salivary gland tissue was seen in some sections, as was positive staining 
of striated muscle bundles. 
The number of CD3' cells present generally corresponded with the density of the cellular infiltrate. In 
sections with little or mild levels of infiltration, CD3+ cells were occasionally seen in an intraepithelial 
and subepithelial position (Figure 11.7) and around capillaries and salivary ductules within the lamina 
propria and submucosa. As the severity of infiltration increased, CD3+ cells were commonly seen 
within the epithelium and lamina propria/submucosa. In many sections CDT" cells formed a prominent 
subepithelial band and dense clusters around the deeper capillaries, and infiltrated the stroma 
associated with salivary glands and muscle fibres. A heavy infiltrate of CD3+ cells was often present 
within degenerating epithelium (Figure 11.6) 
CD4+ and CD8' cells were present in most sections, however CD8+ cells usually predominated, 
especially within the subepithelial and intraepithelial infiltrates (Figure 11.8). 
CI)79aý cells were rare in tissues with slight or mild infiltrates. As the level of infiltration increased, 
CD79e cells also increased in number throughout the infiltrate. CD79a labelling was predominantly 
intracytoplasmic (Figures 11.6 & 11.7). In some sections, CD79a+ cells were distributed throughout 
the lamina propria and submucosa. In others they tended to concentrate in a subepithelial location, and 
also around blood vessels and salivary ducts and muscle fibres. CD79a+ cells were commonly 
associated with glandular salivary tissue. 
Within the infiltrates, IgG+ plasma cells always predominated and generally corresponded to the 
location of the CD79a' infiltrating cells (Figures 11.6 & 11.7). The level of background staining 
within the salivary tissue made it impossible to detect IgG+ cells. IgG labelling of the connective tissue 
and epithelium was generally strong. A few IgA+ plasma cells were occasionally seen in a subepithelial 
location close to the basement membrane, or in close apposition to salivary ductules. IgA+ plasma cells 
were often seen within the stroma adjacent to glandular salivary tissue. IgM+ plasma cells were 
generally sparse within the infiltrates. 
Ll+ cells were rare in sections with little infiltrate, although some epithelial staining was occasionally 
present (Figure 11.7). As the level of infiltrate increased, Ll' cells were seen within the congested 
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capillaries and within the infiltrate, and tended to be concentrated in the upper lamina propria and 
around the deeper blood vessels. Ll+ cells were prominent within areas of degenerating epithelium 
(Figure 11.6). In some sections with heavy infiltrates, Ll' cells were seen between the muscle fibres 
and within the connective tissue surrounding the salivary glands. Epithelial staining for LI was 
variable, but was often intense in sections containing moderate to heavy infiltrates (Figure 11.7). 
11.4.3 Quantification of the lymphoid, monocyte/granulocyte, and mast cell populations 
The numbers of cells within the epithelium demonstrating specific labelling for CD3, C134, and CD8 
are presented in Figure 11.9. Only a small number of samples had definable epithelial layers, within 
which there was a large variation in the number of CD3' cells and CD8+ cells (Figure 11.9). The 
numbers of cells within the lamina propria and submucosal connective tissue demonstrating specific 
labelling for CD3, CD4, CD8, CD79a, IgG, IgM, IgA, LI, and showing metachromatic staining with 
toluidine blue (mast cells) were enumerated. Figure 11.10 shows that CD79e, IgG+ and LI+ cells were 
most prevalent, while CD3' cells were the next most common cell type detected. CD8+ cells were 
detected more frequently than CD4+ cells in 27 of 29 cases, with a median CD4: CD8 ratio of 0.22. 
Relatively few IgM' or IgA+ plasma cells, or mast cells, were seen in the lamina propria and 
submucosal areas (Figure 11.10). Minor salivary gland tissue was absent in many sections, however 
the numbers of cells within the stroma surrounding the salivary tissue that was present demonstrating 
specific labelling for CD3, CD79a, IgG, IgM, IgA, LI, and showing metachromatic staining with 
toluidine blue (mast cells) are shown in Figure 11.11. Cells labelling for CD4 or CD8 were not 
counted within the salivary tissue due to poor tissue morphology, and IgG' cells within the stroma 
surrounding the salivary lobules could not be determined in most sections due to the high background 
staining within this tissue. The limited results demonstrate that a mixed population was present in this 
area, comprising predominantly C133, CD79', and IgA+ cells, with lesser number of Ll+, IgM+, and 
mast cells. 





Figure 11.6 (a-i) Oral mucosal biopsy from Cat 15 
Serial sections of oral mucosa have been stained with (a) H&E (d) Toluidine blue, or labelled with 
antibodies or antisera specific for (b) LI (c) CD3 (e) MHC class 11 (0 CD79a (g) IgG (h) IgM (i) 
IgA. The sections show a dense, n-fixed inflammatory infiltrate consisting of Ll' macrophage- 
monocyte/granulocytes cells, CD3' T-cells, and CD79' plasma cells. The vast majority of the plasma 
cells are IgG+. Cytoplasmic labelling of mononuclear cells with MHC class 11 is widespread. 
Metachromatic staining cells (mast cells) are rare J(d) arrows]. (All images x 128). 
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Figure 11.7 (a-h) Oral mucosal biopsy from Cat 26 
Serial sections of oral mucosa have been stained with (a) H&E or labelled with antibodies or 
antisera specific for (b) CD3 (c) LI (d) MHC class 11 (e) CD79a (f) IgG (g) IgM (h) IgA. The 
sections show hyperplastic epithelium and a moderate cellular infiltrate within the upper lamina 
propria consisting predominantly of CD79a' plasma cells, which are often in close apposition with 
the basal epithelial layer. MHC Class 11' dendritic cells are apparent mainly in the basal layer of the 
epithelium. Intraepithelial and CD3' T-cclls are also apparent. There is strong background labelling 
for IgG, but IgG+ plasma cells [(f) arrows] can be identified. Plasma cells are mostly IgG' with a few 
IgA+ cells, but no IgM' cells. Ll+ cells are sparse, and the epithelium (except the basal layer) is 
labelled with L I. (All images x 128; insets magnified x 6). 
















Figure 11.8 (a-d) Oral mucosal biopsies from Cats 6 and 12 
Oral mucosal biopsies were labelled with antisemm specific for (a & c) CD4 or (b & d) CD8. 
Sections from Cat 12 (a & b) and Cat 6 (c & d) show CI)4ý and CD8' labelling of the cellular 
infiltrate within the lamina propria. Sections from both cats demonstrate increased numbers of 
intraepithelial CD8' cells. Intraepithelial CD4' cells are less common. (All images x 128). 
Chapter 11 179 
Figure 11.9 Characterisation and enumeration of lymphocytes within the faucal epithelium 








T 20 -- 
0 Q9 
Antigen CD3 CD4 CD8 
n 7 4 4 
Median 17.4 0 18.7 
Minimum 1.7 0 2.4 
Maximum 127.3 2.3 73.8 
Cells labelling with specific antibodies or antisera to CD3, CD4, and CD8 
within all of the epithelial tissue present in each section were counted. The 
length of the basal epithelial layer was measured and the cell counts 
expressed per I mrn of basal epithelium. n= number cats in which counts 
were able to be performed. 
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Figure 11.11 Characterisation and enumeration of infiltrating cells associated with the faucal 














Antigen CD3 CD79a Igm IgA LI Mast cells 
n 2 4 4 3 3 5 
Median 35.2 12.7 1.2 36.1 6.8 2.4 
Minimum 8.4 1.3 0 6.5 0 1.8 
Maximum 62.1 29.8 4.1 54.3 20.3 7.8 
Cells labelling with antisera to CD3, CD79a, IgG, IgM, IgA, Leucocyte antigen LI (LI) or showing 
metachromatic staining with toluidine blue (mast cells) were counted in up to 6 representative high 
power fields (A00). The area of relevant tissue within each field was calculated and the cell counts 
expressed per 0.1 mm 2 of tissue. n= number cats from which counts were obtained. 
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11.5 COMPARISON OF THE INFILTRATING CELL POPULATIONS WITHIN SECTIONS FROM THE ORAL 
MUCOSA OF CONTROL AND DISEASED CASES 
Owing to the small number of cases in which the intraepithelial CD4+ and CD8+ cells could be 
enumerated, comparisons were not performed between these and the control group. Similarly, 
comparisons were not performed between the groups for the number of cells within the minor salivary 
gland tissue. 
Table 11.1 shows that in cats with chronic gingivostomatitis there was a significant increase in the 
number of intraepithelial CD3+ cells in comparison to the control cats. In addition, within the lamina 
propria/submucosa the number of cells per unit area expressing CD3, CD4, CD8, CD79a, IgG, IgM, 
IgA and LI, and the number of mast cells, were all significantly increased in cats with chronic 
gingivostomatitis, 
Table 11.1 Comparison of cell populations in faucal sections from control and diseased cases 
Mann-Whitney Test (Control cases v Diseased cases) 
Antigen/Site 95% Cl P value P 
Epithelium (Cells per nun basal layer) 
CD3 -57.4, -2.7 0.0003 <0.001 
Lamina propria/ (Cells per 0.1 MM2) 
submucosa 
CD3 -71.8, -44.9 <0.0001 <0.001 
CD4 -20.6, -1.6 0.0021 0.002 
CD8 -62.2, -30.5 <0.0001 <0.001 
CD79a -170.3, -80.2 <0.0001 <0.001 
IgG -136.4,40.3 <0.0001 <0.001 
Igm -1.4, -0.3 <0.0001 <0.001 
IgA 4.1, -1.3 <0.0001 <0.001 
Ll -132.8, -42.4 <0.0001 <0.001 
Mast cells -6.5, -2.0 0.0005 0.001 
95% Cl = 95.2% confidence interval for the difference in population medians (controls - diseased 
cases). P'= P value adjusted for multiple comparisons using the layered Bonferroni method. 
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11.6 HISTOPATHOLOGICAL GRADING OF FAUCAL 131OPSY SECTIONS AND CORRELATION WITH 
CLINICAL SCORE 
Based upon the features present in fixed sections ftom control cats, and cats with chronic 
gingivostomatitis, four histopathological grades were defined. These grades are illustrated 
schematically in Figure 11.12. In some sections there was insufficient deep lamina propria/submucosa 
tissue to distinguish between grade 4a and 4b, and these sections were assigned an unspecified grading 
of 4 (Table 11,2). In order to facilitate further analyses no differentiation was made between the 
sections classified as Grade 4a, 4b or 4 (unspecified). Figures 11.13 shows the cellular populations 
present in lamina propria/submucosal connective tissue in each of the 4 gradings in cats with chronic 
gingivostomatitis. As expected, the results reflect the histopathological descriptions for each grading. 
There was insufficient quantitative data available for the intraepithelial lymphocyte population, and for 
the salivary tissues, to permit meaningful comparisons to be made. 
Spearman's correlation coefficient between the histopatho logical grade of the biopsy and the local 
stomatitis index (SI) assigned to the site of biopsy showed that a significant positive relationship 
existed between these two parameters (Table 11.2). 
Table 11.2 Local stomatitis index score (ST) and the histopathological grade of the faucal biopsy 
in diseased cases and control cats 
Cat Local Sl Grade Cat Local SI Grade 
Case Case 
1 3 3 16 3 4 
2 3 3 17 3 3 
3 3 4 18 2 4 
4 2 4 19 3 4(b) 
5 0 2 20 3 4(b) 
6 3 4 21 3 4 
7 3 4(b) 22 3 4 
8 3 4(b) 23 3 4(a) 
9 1 4(a) 24 3 4 
10 3 4 25 2 4(b) 
I1 1 2 26' 1 3 
12 3 4(a) 27 1 2 
13 3 4(b) 28 1 4(a) 
14 3 4(b) 29 3 4 
15 3 4 30 0 1 
r, (local stornatitis index (SI) score v histopathological grade) 0.515 (P= 0.004) 
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illaries Capillaries Capillaries 
0-a/, --\ () 
Submucosa 
"-= infiltrating cclls 
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Cat 30 (x 64) 
(a) Grade I 
The parakeratotic stratified squamous epithelium contains a few intraepithelial CD3' cells. A few 
CD3' T-cclls are seen in a subepithelial position and may aggregate to form subepithelial clusters. 
Cells expressing MHC class 11 are present intraepithchally and subepithelially, and around 
capillaries. Salivary ductule epithelium is labelled by MIHC class 11. Very occasional IgG or IgA 
plasma cells may be present in the larnina propria/submucosa. Ll' monocytes and granulocytes arc 
absent. 
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(Figure 11.12 continued) 
(b) Gradc 2 
Cat II (x 32) 
The epithelium is intact and appears normal or slightly hyperplastic. There is increased numbers of 
intraepithelial and subepithelial CD3' T-cclls. There is an increase in the level of M14C class 11 
expression within the epithelium, and within the lamina propria/submucosa, especially in cells 
adjacent to capillaries. There may be a slight influx of CD79a+ (mainly plasma cells) into the upper 
lamina propria. The plasma cells generally express IgG. Ll' cells are usually sparse or absent. 
Occasionally, the cellular infiltrate may focus around salivary ductules in the lamina propria. 
pký 7r 
Z. 46 
Cat 26 (x 32) 
(c) Grade 3 
The epithelium is becoming less well defined with areas of degeneration and vacuolation, and it is 
often infiltrated with variable numbers of L I' macrophages and ncutrophils, and CD3' lymphocytes. 
There is a moderate cellular infiltrate within the upper lamina propria containing variable amounts 
of CD79a' plasma cells, CD3' T-lymphocyles, and Ll' macrophages and neutrophils. CD79a' 
plasma cells and CD3+ T-cells may be seen to form distinct subepithelial layers. IgG is the dominant 
plasma cell class. Increased MIFIC class 11 expression is generally seen throughout the infiltrate and 
around the capillaries. There is increased infiltration of CD79a+ plasma cells, CD3' T-lymphocy1cs, 
and Ll+ macrophages; and neutrophils around capillaries and striated muscle bundles present in the 
lower lamina propria/submucosa. 
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(F7gure 11.12 continued) 
(d) Grade 4a 
The epithelium is typically poorly demarcated, degenerate, and becoming increasingly infiltrated 
with L I* macrophages and neutrophils, and CD3' T-lymphocytes. There is a heavy cellular infiltrate 
of variable composition within the subepithelial/upper lamina propria and increased cuffing of 
deeper blood vessels and muscle. This gives a conspicuous demarcation between the upper lamina 
propria and the lower lamina propria/submucosa areas of infiltrate. In some sections distinct layers of 
CD79a' plasma cells and CD3' T-cells may be seen along the basal edge of the epithelium There 
may be a similar or lesser proportion of LV cells. Plasma cells almost exclusively express IgG. MEC 
class 11 expression is widespread. 
S-" 
. ": ". "': " . . 
,141,,.,.: :"v-. -! ý, 
(e) Grade 4b Cat 13 (x 32) 
The epithelium is extensively infiltrated and degenerate, and is mostly undefinable. There is a dense 
cellular infiltrate throughout most of the lamina propria extending into the submucosa, such that the 
demarcation between the upper lamina propri 
'a 
and the lower lamina propria/submucosa seen in 
Grade 4a is lost or less obvious. IgG' plasma cells predominate. MHC class 11 expression is 
widespread. The composition of cellular infiltrate varies, but some common patterns include (i) equal 
proportions of CD79a', CD3+ and Ll' cells (ii) CD79a+ cells predominating with some CD3' and 
Ll' cells which tend to lie along the underside of the degenerating epithelium (iii) Ll' cells 
predominating (iv) CD3' T-cells predominating. 
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Cat 23 (02) 
Figure 11.13 (a-c) Summary of the characteristics offile Cellular infiltrate present ill 111C I'lloill'i 
propria and subinucosal connective tissue ill scctiolls from faucal biopsics froill cals ý% ilh Chronic 










0 -. T- MAIN 
Grade 
Median (% 
Mast cells 80 68 5 2 
LI 20 8 37 4 
CD79a 0 8 51 44 
CD3 0 16 7 20 
22 




















Columns represent median values. Upper horizontal bars represent the 3rd quartile. Lower hori/. ontal 
bars represent the Ist quartile. Cells labelled with specific antibodies to CD3, CD4, CD8, UD79a, IoG, I 
IgM, IgA, Leucocyte antigen LI (1, I) or showing metachroinatic stainino with toluidine blue (Imust 
cells) were counted in 3 to 6 representative high power fields (x 400). The area of' lainina 
propria/submucosal connective tissue within each 1-icld was calculated and the cell counts expressed 
per 0.1 mrn2 of tissue. 
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11.7 DISCUSSION 
The results presented in this chapter provide the first detailed phenotypic characterisation of the cells 
infiltrating normal and diseased oral mucosa in the cat. Biopsies from the fauces were chosen for use 
in this study over other sites, such as the gingiva, for three main reasons. Firstly, this site is commonly 
affected in cats with chronic gingivostomatitis. Secondly, the changes occurring at the fauces are less 
likely to be influenced by concurrent periodontal disease or feline odontoclastic resorptive lesions, or 
any extractions performed. And finally, this site lends itself to the collection of biopsies of a 
reasonable size in clinical cases. 
Biopsies were collected from the fauces of a population of control cats with no clinical signs of oral 
disease except for mild and variable levels of gingivitis. Consequently, these samples were regarded as 
being representative of normal, healthy, oral mucosal tissue at the fauces. Histological and 
immunohistochemical analysis of sections from these biopsies demonstrated that only a sparse cellular 
infiltrate was present within the mucosal tissue. Within the epithelium, a small population of 
intraepithelial CD3" T-lymphocytes was noted. Intraepithelial lymphocytes (JELs) are found readily in 
mucosal tissues and have been previously documented in the feline intestinal tract (Sturgess, 1997; 
Roccabianca et al., 1997) and bile ducts (Day, 1998), but not the oral cavity. IELs are considered to 
comprise a heterogenous population consisting mainly of T-cells, which may express ap T-cell 
receptors (TCRs) or y8 TCRs (Abreu-Martin & Targan, 1996; Garcia et al., 1999; McGhee & Kiyono, 
1999), however T-cells expressing y5 TCRs have yet to be identified in the cat (Rezanka & Nei, 
1995). IELs are assumed to function as a primary source of effector cells within the mucosal 
epithelium and thereby provide an initial defence mechanism against pathogen invasion. Studies of 
normal human oral mucosal epithelium suggest that <1 to 35% of the CD3+ population are y8 T-cells, 
the remainder being ap T-cells (Colasante et al. 1992, Lundqvist & Hammarstr6m, 1993, Pepin et al., 
1993, Kawahara et al. 1995, Walton et al., 1996 & 1998; Boismenu & Havran, 1998 ). Furthermore, 
the majority of y5 T-cells were found to be double-negative for CD4 and CD8 expression, whereas ap 
T-cells expressed either CD4 or CD8 (Lundqvist & Hammarstr6m, 1993). It is not possible from the 
results of the present study to determine if double positive intraepithelial T-cells exist in feline oral 
mucosa. However the median ratio of intraepithelial CD4+ and CD8' cells was found to be 1: 6, which 
contrasts to human studies in which intraepithelial CD8+ cells are reported to be around twice as 
numerous as intraepithelial CD4+ cells within the oral mucosa (Walton et al., 1996 & 1998). The 
significance of this finding, if any, is not clear. 
An additional intraepithelial population was identified which labelled only with anti- MHC class 11 and 
had a dendritic morphology, thereby suggesting that these cells were dendritic cells (DCs). DCs 
comprise a heterogenous population found within lymphoid organs, mucosal sites, and skin (Rideout et 
al., 1990; Steinman, 1991 & 1999, Eriksson, 1996, Saint-Andrd Marchal et al., 1997). The presence of 
DCs within the oral mucosa of cats has not been previously documented, although they have been 
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reported in the tongue (Rideout et al., 1990). DCs function to capture antigen and, upon maturation, 
initiate T-cell responses (Steinmann, 1991 & 1999). In contrast to epidermal Langerhans' cells, which 
are considered to be functionally immature (Steinmann, 1991), recent studies in mice have suggest that 
mucosal DCs residing within the buccal epithelium may be capable of presenting antigen and 
activating specific T-cells at this site (Erikkson, et al. 1996). Studies analysing the phenotypic and 
functional properties of feline DCs within the oral mucosa are lacking, although feline Langerhans' 
cells firom the epidermis and lip were found to be phenotypically and ultrastructurally identical (Saint- 
Andrd Marchal et al., 1997). 
Relatively few cells were found within the lamina propria and submucosal connective tissues in 
sections from healthy oral mucosa. Mast cells were the most frequently identified cell type. As 
discussed in Chapter 10, additional studies indicated that these cells contained heparin, which in 
combination with their resistance to formalin fixation, suggests that they are phenotypically similar to 
connective tissue mast cells (CTMC) described in the rat and other species (Matsson, 1992; Hill & 
Martin, 1998; Welle et al., 1999; Lin & Befus, 1999). The density of the mast cell population found 
within healthy feline oral mucosa was similar to that described in the rat (Matsson, 1992), but slightly 
less than that reported by immunohistochemical methods in frozen sections of human oral mucosa 
(Natah et al., 1998). However, the use of formalin-fixed specimens in the present study precluded the 
detection of formalin-sensitive mast cells (Matsson, 1992, Hill & Martin, 1998), and therefore the 
results may have underestimated the total mast cell population within the feline oral mucosa. 
CD3' T-cells were the next most commonly detected cells in healthy feline oral mucosa. These were 
generally seen either as occasional isolated cells or, as clusters of cells in a subepithelial position in 
close apposition to sub-basal and intraepithelial MHC class 11-labefled dendritic cells. Labelling of 
frozen sections indicated that these clusters contained both CD4+ and CD8' cells. No other cell 
phenotypes were found to be associated with these sub-epithelial clusters, and the overlying epithelium 
appeared unremarkable in its morphology. While the presence of occasional CD4+ or CD8+ T-cells 
within the lamina propria/submucosal connective tissue can be regarded as a normal finding (Ahlfors 
et al., 1996), the subepithelial clusters of CD3+ cells seen in this study is an unusual observation. 
A number of studies have reported the existence of lymphoid tissue within the oral mucosa. Knapp 
(1970) described the presence of lymphoepithelial structures, termed the 'oral tonsils', within human 
oral mucosa, which were characterised by a central epithelial crypt surrounded by a circumscribed 
mass of lymphoid tissue with follicular and parafollicular areas. Similar structures have not been 
documented in the cat. Other investigators have described lymphoid tissue in close association with the 
ducts emanating from minor salivary glands, referred to as duct-associated lymphoid tissue (DALT) 
(Schroeder et al., 1983; Nair & Schroeder, 1986). DALT has primarily been characterised in monkeys, 
although Nair & Schroeder (1986) briefly reported the existence of DALT in cats, Histological studies 
have shown that DALT contains T-cells, B-cells, follicular dendritic cells, and monocytes, and has 
morphologically distinct follicular and parafollicular compartments (Schroeder et al., 1983). Based 
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upon these reported features, the subepithelial T-cell and dendritic cell clusters seen in the present 
study are not consistent with either 'oral tonsil' or DALT structures. More recently, small clusters of 
lymphocytes, termed cryptopatches, have been described within the murine intestinal lamina propria, 
(Kanamori et al., 1996). Cryptopatches predominantly contain T-lineage precursors and are considered 
to be extrathymic sites of T-cell development, which give rise to TCRaP and TCRys intestinal IELs 
(Kanamori et al., 1996; Saito et al., 1998; Poussier & Julius, 1999). However, as the majority of the T- 
cells present within cryptopatches are immature, few of the cells express CD3+ (0 to 2%), and CD4+ 
and CD8+ subsets comprise only 3 to 20% of the total population. This contrasts to the cell clusters 
seen in the present study in which CD3, CD4, and CD8 expression was apparent within a significant 
proportion of the population. 
Thus, the significance and possible function of the subepithelial T-cell and dendritic cell clusters seen 
in healthy feline oral mucosa is not clear. It is tempting to speculate that the intra/sub-epithelial MHC 
class II+ dendritic cells are presenting antigen to the adjacent T-cells, and therefore that these clusters 
may represent a specialised form of mucosal-associated lymphoid tissue (MALT) involved in the 
induction and regulation of T-cell responses (Brandtzaeg et al., 1999). Another possible hypothesis is 
that the T-cells are clustering around 'access-points' or holes in the basement membrane of the 
overlying epithelium which permit T-cell migration into the epithelium (Saito et al., 1998). 
Alternatively, the clusters may simply result from an ongoing response to, as yet, undetermined 
antigenic stimuli as part of the normal mechanisms affording immunological protection to the feline 
oral mucosa. Further studies are needed to confinn the presence of these clusters within the oral 
mucosa of other cats, and to characterise the inimunophenotypic and functional properties of the 
participating cells. 
Only occasional Ll+ cells were seen within the lamina propria/submucosa in samples from healthy 
cats. As discussed in Chapter 10, the Ll antigen is expressed on granulocytes and a subpopulation of 
monocytesýmacrophages corresponding to recent blood emigrants (Dale et al., 1983; Flavell et al., 
1987; Brandtzaeg et al., 1988 & 1992; Steinbakk et al., 1990; Callanan et al., 1996). These findings 
are consistent with previous murine studies (Ahlfors et al. 1996), and indicate that in healthy feline 
oral mucosa there is minimal emigration of Ll' cells from the circulation into the mucosal tissue. 
Similarly, only a very sparse population of CD79a+ B-cells and plasma cells were detected within the 
lamina propria/submucosal connective tissue. The few plasma cells found were generally IgG+ or 
IgA", and IgM' cells were rare. Thus, these findings show that in contrast to secretory effector sites, 
such as the intestine or salivary glands, plasma cells do not generally accumulate within healthy oral 
mucosal tissue (Brandtzaeg et al., 1999). 
In healthy tissues, the cellular infiltrate within the connective tissue stroma associated with the minor 
salivary glands was comprised predominately of CD79a' and IgA+ cells, although a small number of 
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IgM+ plasma cells were detected at this site. Unfortunately, the extent of the background staining 
associated with the salivary glandular tissue was such that the number of IgG+ plasma cells at this site 
could only be determined in three cases, and in each of these only a few IgG+ cells were found. A few 
mast cells were also found associated with the salivary gland tissues, as were occasional CD3+ T-cells 
and Ll' monocyte/macrophages. These findings are in accordance with previous studies demonstrating 
the predominance of IgA-producing plasma cells within the minor salivary glands (Crawford et al., 
1975), however no structures consistent with DALT-like morphology were seen in any of the sections 
(Nair& Schroeder, 1986). 
Histological and immunohistochemical analysis of sections of oral mucosa from cats with chronic 
gingivostomatitis generally demonstrated the presence of a florid, mixed inflammatory infiltrate within 
the oral mucosal lesions. In most cases the epithelium had degenerated to such an extent that it was not 
possible to define the margins of the epithelial layer. It is therefore difficult to draw widespread 
conclusions concerning changes in the intraepithelial cell population. However, the results indicate 
that there was a significant increase in the intraepithelial CD3+ T-cell population in cats with chronic 
gingivostomatitis, and that this was likely to have been caused by an increase in the CD8' rather than 
CD4+ population. Further studies are required to confirm these observations. 
Overall, faucal sections from cats with chronic gingivostomatitis demonstrated a significant increase in 
the number of T-cells (CD3), B-cells/plasma cells (CD79e), monocytes/gramilocytes (Ll+) and mast 
cells infiltrating the lamina propria and submucosal connective tissues. Furthermore. analysis of the 
number of CD4' and CD8' cells demonstrated a significant increase in both of these populations by 
comparison to that found in sections from healthy mucosa. Nonetheless, the relative population 
changes were disproportionate, and the number of CD8+ cells displayed a four fold median increase 
over CD4+ cells. This indicates that the infiltrating cells were not primarily CD4+CD8+ double 
positive. The number of IgG+, IgM+, and IgA' plasma cells within the mucosal lamina propria and 
submucosa all increased in cats with chronic gingivostomatitis, however IgG+ cells accounted for 93% 
of the plasma cell population compared to 5.5% for IgA+ cells, and 1.5% for lgM+ cells. These 
findings confirm and extend previous studies describing the histological appearance of oral lesions in 
feline chronic gingivostomatitis (Reindel et al., 1987; Lyon, 1990; Kyriazidou et al., 1990; Grufrydd- 
Jones, 1991; Williams & Aller, 1992; White et al., 1995; Hennet, 1995; Harvey, 1995). Moreover, 
they demonstrate that by comparison to healthy tissue, the oral mucosal lesions seen in chronic 
gingivostomatitis are dominated by an increase in IgG+ plasma cells, Ll+ monocytes/neutrophils and 
CD3+ T-cells (the majority of which are likely to be CD8+) within the lamina propria connective 
tissues. 
The morphological appearance and the phenotypic composition of the infiltrating cell population 
detected within the oral lesions was, however, variable between individuals. Based upon the density 
and distribution of the infiltrating cells within the tissue sections, five histopathological grades were 
defined (1,2,3,4a & 4b). Owing to the absence of an adequate amount of deep lamina 
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propria/submucosal tissue in a number of the sections it was not always possible to distinguish 
between grades 4a and 4b, consequently these grades were often combined and referred to as grade 4. 
The finding that the histological grade correlated significantly with the local stomatitis index, in 
addition to results presented in Chapter 12, which demonstrated that changes in the local stomatitis 
index of the lesions correlate with changes in the histological grading of the lesions, support the 
assumption that the tissue gradings represent sequential features seen during the progressive 
development of oral mucosal lesions in feline chronic gingivostomatitis. 
The number of mast cells within the infiltrating population increased progressively from grade I to 3 
then plateaued between grades 3 and 4. Mast cells were the predominant cell within the infiltrate of 
sections classified as grade I and 2, however they only accounted for a small proportion of the total 
cellular infiltrate in sections within grades 3 and 4. Nonetheless, through their ability to release a range 
of proinflammatory and immunomodulatory mediators, mast cells are potent effector cells, and it is 
conceivable that even a modest population of mast cells may have a profound effect upon the initiation 
and perpetuation of the local inflammatory and immunological responses in chronic gingivostomatitis 
(Walsh et at., 1995; Lin & Befus, 1999). Degranulating mast cells were commonly seen within the 
sections, consequently, investigations into the use of treatments which act to stabilise mast cells, or 
counteract the effect of their products, may be of merit in cats with chronic gingivostomatitis. 
A progressive increase in the number of CD79a+ cells was found in tissues graded I to 4, and CD79a+ 
cells were the primary cellular phenotype detected in lesions graded as 3 or 4. Moreover, the changes 
in the number of immunoglobulin-labelled cells corresponded with changes in the CD79+ population. 
Furthermore, it was shown that almost all of the plasma cells in lesions graded from 2 to 4 were 
producing IgG. This finding is in accordance with the results in Chapter 7 which demonstrated that 
cats with chronic gingivostornatitis have a significant increase in their salivary and serum IgG levels, 
and that in the saliva this can be attributed, in part, to an increase in local IgG production. 
Nonetheless, two fundamental questions concerning the mucosal plasma cell population remain 
unanswered. The first concerns the origin of the plasma cells, and the second relates to the specificity 
of the immunoglobulin they are producing. The dominance of IgG-producing cells indicates that the 
vast majority of the plasma cells have undergone class-switching (Lorenz & Radbruch, 1996, Snapper 
& Finkelman, 1999), which in turn suggests that they are derived from secondary reactions or late 
primary reactions. It is possible to envisage three principal circumstances leading to the generation of 
the IgG secreting plasma cells encountered within the oral mucosal lesions. First the plasma cells may 
be derived from circulating proplasmacytes activated in secondary lymphoid sites (lymph nodes and 
spleen), which are undergoing homing to peripheral effector sites, or the bone marrow, and express the 
appropriate surface receptors to facilitate their transmigration into the oral mucosa (Parker & 
Purkerson, 1996; Butcher & Picker, 1996; Picker & Seigelman, 1999). The milieu of cytokines 
produced by various cells present within the inflamed mucosa then promotes their terminal 
differentiation into plasma cells. Under such circumstances both non-specific and specific antibodies 
to possible local antigens would be present. The second scenario is one in which specific memory B- 
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cells migrating through the mucosa encounter antigen and present it to specific CD4' T-cells, which 
then promote the proliferation and differentiation of the B-cells into plasma cells within the local tissue 
(Sprent, 1997; Dutton et al., 1998; Silfka & Ahmed, 1998). The immunoglobulin produced under these 
conditions would be highly specific for local antigens. Finally, the presence of T-independent (TI) 
antigens within the oral mucosal tissue, such as, for instance, bacterial lipopolysaccharide (LPS), may 
non-specifically activate circulating memory B-cells within the oral mucosa (Laman & Classan, 1995). 
This would result in the production of antibody against a wide range of antigens, some of which may 
be historical in nature. From the results of the present study it is not possible to determine which of 
these mechanisms might underlie the accumulation of plasma cells seen in the oral lesions of cats with 
chronic gingivostomatitis. Further studies addressing these issues are needed. 
A progressive increase in Ll+ cells was also found over grades I to 4. Moreover, in lesions graded as 3 
or 4, Ll+ cells were the second most common cell phenotype recorded within the infiltrate. Most 
previous studies describing the histological features of oral lesions in cats with chronic 
gingivostornatitis have tended to focus upon the lymphocytic/plasmacytic component, and 
consequently the presence of monocytes and neutrophils within the infiltrate has often been 
overlooked. However, the results of the present study emphasise that a substantial proportion of the 
cells found within the lesions are of myeloid origin (Harvey 1995). 
The number of CD3 ' cells within the infiltrate also increased progressively over the four grades. In 
tissue sections classified as grade 2, the number of CD3+, CD79+, and Ll+ cells within the infiltrate 
was similar; but in lesions graded as 3 or 4 the CD3+ population was considerably smaller than the 
corresponding CD79'and Ll+ populations. Nevertheless, the number of T-cells infiltrating the lesions 
still represent a significant population with considerable potential to modulate the ongoing immune 
response. Analysis of CD4+ and CD8+ populations indicated that CD8+ cells predominated in each 
grade, and that CD4+ cells were mainly confined to the more-established lesions graded 3 or 4. It is 
also notable that the median density of CD8' cells decreased from grade 3 and 4. Although definite 
conclusions cannot be drawn from these limited results, if it is assumed that the T-cells present within 
the lamina propria are single positive for either CD4 or C138, this finding suggests that as the density 
of the infiltrate increases there is shift away from a CD8-dominated response towards a mixed CD8- 
and CD4-mediated response. Such changes would be consistent with the increase in the B-cell and 
plasma cell population, and are in accordance with the cytokine profiles found in these tissues 
described in Chapter 15. Nevertheless, the dominance of CD8+ cells within the lesions suggests that, in 
spite of the large plasma cell population, the underlying pathology is inducing a strong ccll-mediated 
(cytotoxic) effector response. Such a finding may indicate that intracellular pathogens, such as viruses, 
may be driving this response. It would be interesting to determine the response of these cells to feline 
viruses, especially feline calicivirus (FCV), which was isolated from all of the clinical cases (see 
Chapter 3). Alternatively, however, the preponderance of CD8+ cells may represent an aberrant and 
inappropriate response by the host tissues. 
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By contrast to the results for CD79a and inimunoglobulin labelling, it was found that the sum of the 
CD4+ and CD8+ cells did not always closely approximate the number of CD3' cells found in sections 
harvested from the same biopsy. It is most likely that this anomaly resulted from inherent variation 
within the methodology resulting from the unavoidable use of different pieces of the biopsy for 
formalin-fixed sections (CD3) and frozen sections (CD4 and C138). Consequently, the results will be 
affected by any variations in the infiltrate within the tissue. Furthermore, the efficiency of labelling of 
tissue antigens may vary depending upon the reagent and the degree of antigen degradation. Although 
frozen sections suffer from poor morphological preservation by comparison to formalin-fixed tissues, 
they are generally more sensitive and reliable for the demonstration of tissue antigens (Seymour et al., 
1995). Another possible factor which could contribute to this disparity is the presence within the 
infiltrate of CD3+CD4+CD8' double positive T-cells, or CD3+CD8-CD4' double negative T-cells, or 
natural killer (NK) cells which are CDY but can sometimes express CD8 (Guy-Brand et al., 1994; 
Yokoyama, 1999); although none of these populations has yet been positively identified in the cat 
(Willet & Callanan, 1995). Further studies are required to investigate these possibilities using either 
irnmunohistochemical multi-staining techniques on tissue sections or flow cytometry analysis with 
isolated cells. 
Owing to the lack of minor salivary gland tissue in the majority of the sections from cats with chronic 
gingivostomatitis the changes occurring in the cellular infiltrate at this site could not be thoroughly 
analysed. However, the results tended to suggest that there was a general increase in the number of 
cells infiltrating the stroma surrounding the salivary gland tissues, generally reflecting the changes 
within the lamina propria and submucosal connective tissues. 
To some extent, the features described in this study resemble the histopathological changes seen 
during the development of the lesions of plaque-induced periodontal disease (Page & Schroeder, 1976; 
Reichart et al., 1984; Lehner, 1992; Challacombe & Shirlaw, 1999). Periodontal disease is 
characterised by an initial acute inflammatory response to bacterial plaque, which is accompanied by a 
polymorphonuclear leucocyte infiltration within the gingival sulcus. Subsequently, there is 
replacement of the polymorphonuclear infiltrate with lymphocytes (predominantly T-cells) and some 
macrophages (Yamazaki et al., 1995). However, in contrast to the findings in the present study, CD4+ 
T-cells were found to predominate over CD8+cells (Yamazaki et al., 1995). As the lesion progresses 
there is an increase in the density of the infiltrate, and a shift in the population phenotype such that 
IgG-producing plasma cells dominate - although B-cells, T-cells and macrophages are also present 
(Okada et al., 1983, Takahashi et al., 1997). The similarities in the histopathological features of 
chronic periodontal disease and the mucosal lesions seen in FCGS may indicate that there are common 
underlying aetiological factors in both of these conditions. As such, this would support the hypothesis 
that bacteria play an important role in the pathogenesis of FCGS (Mallonee ct al., 1988; Gruffydd- 
Jones, 1991; Sims et al., 1990; Williams & Aller, 1992; Harvey, 1995; Norris & Love, 1995). 
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Alternatively, the resemblance in the histopathological features between these two diseases may simply 
reflect corm-non effector mechanisms arising from different initiating factors. 
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CHAPTER 12: Immunohisto chemical Changes in the Inflammatory Infiltrate 
Within Oral Mucosal Lesions After Treatment 
12.1 INTRODUCTION 
The effects of treatment upon the histological features of oral lesions in cats with chronic 
gingivostomatitis has not been studied. The analysis of tissue biopsies collected before and after a 
period of treatment provides a method by which the tissue response to treatment can be assessed and 
the most effective treatments identified. In addition, the changes seen during treatment may help to 
reveal aspects of the disease pathogenesis. This chapter reports the results of studies which utilised 
histological and immunohistochemical techniques to analyse changes in the cellular infiltrate within 
biopsies harvested from cats with chronic gingivostomatitis undergoing treatment with one of four 
different regimes. 
12.2 MATERIALS AND METHODS 
These are provided in Chapters 9&2 
12.3 REsuLTs 
12.3.1 Analysis of treatment groups at consultation I 
Following the first consultation, cats with chronic gingivostornatitis were randomly allocated to one of 
four long term treatment groups, as described in Chapter 2. Analysis of the results for the number of 
mast cells and LI, CD3, CD4, C8, CD79a, IgG, IgM or IgA positive cells from biopsies collected at 
consultation I indicated that there was a significant difference only in the number of CD3+ cells within 
the lamina propria/submucosal connective tissue in sections from cats within the corticosteroid-treated 
group and the oral hygiene-treated group (Figure 12.1, Table 12.1). Dunn's all pairs multiple 
comparisons test performed between groups for IgA+ cells within the lamina propria/submucosal 
connective tissue returned P>0.05 for all comparisons. 



























x 0. ) 


















222w 10 V r4 Q 
(iwwl*o md sjjo3)., W2j 
c) 
oc 
o 0 0 i 6 0, ý 
9 9 9 9 







Chapter 12 198 
Table 12.1 Tukey's pairwise comparison confidence intervals for the differences in the change 
in CD3+ cells between consultations 1 and 3 within the lamina propria/submucosa connective 
tissue 
Group OH GS cs 
GS -71.3,17.4 
cs -8.9, -100.7 -73.9,18.1 
AB -75.0,16.8 -48.1,43.8 -21.8,73.1, 
Family error rate = 0.050 Individual error rate = 0.0 11 
Critical value = 3.88 
ANOVA P=0.027 (Figure 12.1). Values are lower and upper 95% confidence intervals for column 
group mean - row group mean. OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB 
Antibiotics 
12.3.2 Changes in the infiltrating cell population after 3 months of treatment 
Replicate faucal biopsies were collected from 24 cats 3 months after treatment commenced (at 
Consultation 3). Biopsies were not collected from cats 2,13,26,29 as these cases had withdrawn from 
the treatment trial at this stage. In addition, samples were not collected from Cats 7 and 22, as in each 
case the cat was not able to be anaesthetised during this consultation. 
Based upon the histopathological appearance, each biopsy was graded I to 4 as described in Chapter 
11.5 (Table 12.2). The histopathology grade was found to correlate significantly with the local 
stornatitis index score (Table 12.2). In addition, the change in the histopathology grade and the change 
in the local stomatitis index between consultations I and 3 were shown to correlate significantly (Table 
12.2). 
The number of mast cells and L I, CD3, CD4, CS, CD79a, IgG, IgM, and IgA positive cells within the 
lamina propria/submucosal connective tissue was determined in sections from each biopsy, and the 
changes from consultation I were calculated (Figure 12.2). One way analysis of variance methods 
indicated that significant differences between treatment groups were present only in the number of IgG 
and IgM cells present within the biopsy sections after 3 months of treatment. Tukey's pairwise 
comparison confidence intervals for the differences in the change in IgG+ cells between groups 
indicated that the corticosteroid-treated group showed a significantly greater reduction in the number 
of IgG+ cells than did the oral hygiene-treated group (Table 12.3). However, Dunn's all pairs multiple 
comparisons test performed between groups for change in IgM' cells within the lamina 
propria/submucosal connective tissue returned non-significant values (P>0.05) for all comparisons. 
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The change in intraepithelial lymphocytes and the change in the salivary gland infiltrate after 3 months 
of treatment could only be evaluated in I case, consequently comparisons between treatment groups 
were not performed. 
Table 12.2 Local stomatitis index (SI) score and biopsy histopathology grades after 3 months of 
treatment 
Cat Treatment Local SI score ALocal Sl Histopathology AHistopathology 
score Grade Grade 
1 OH 3 0 4 1 
9 OH 1 0 4 0 
11 OH 1 0 3 1 
17 OH 2 -1 4 1 
is OH 2 0 3 -1 
25 OH 2 0 4 0 
27 OH 2 1 3 1 
3 GS 3 0 4 0 
16 GS 2 -1 4 0 
19 GS 2 -1 4 0 
30 GS 0 0 3 2 
4 cs 1 -1 3 -1 
6 cs 3 0 4 0 
10 cs 1 -2 2 -2 
14 cs 2 -1 4 0 
20 cs 3 0 4 0 
23 cs 3 0 4 0 
28 cs 0 -1 2 -2 
5 AB 0 0 2 0 
8 AB 2 -1 2 -2 
12 AB 1 -2 4 
15 AB 3 0 4 
21 AB 3 0 4 0 
24 AB 3 0 4 0 
r, p 
Local Sl score v Histopathology Grade 0.668 <0.001 
A Local SI score vA Histopathology Grade 0.481 0.017 
SI stomatitis index. A= change in parameter from consultation I to consultation 3. r, = Spearman's 
correlation coefficient 
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Table 12.3 Tukey's pairwise comparison confidence intervals for the differences in the change 
in IgG+ cells between consultations I and 3 within the lamina proprialsubmucosa connective 
tissue 
Group OH GS CS 
GS -13.9,335.0 
cs 21.5,319.1 -164.7,184.2 
AB -63.2,246.5 -248.6,110.7 -233.5,76.2 
Family error rate = 0.050 
Individual error rate = 0.0 11 
Critical value = 3.96 
ANOVA P=0.021 (Figure 12.3). Values are lower and upper 95% confidence intervals for column 
group mean - row group mean. OH = Oral hygiene, GS = Gold salts, CS = corticosteroids, AB 
Antibiotics 
12.4 DiscussioN 
The effects of treatment upon the cellular composition of oral lesions in cats with chronic 
gingivostomatitis have not previously been documented. In addition to providing an assessment of the 
effectiveness of therapeutic agents for the treatment of chronic gingivostomatitis, such investigations 
may help to expose aspects of the disease pathogenesis. This chapter reports the results of studies 
which aimed to investigate the comparative effects of four therapeutic regimes using hygiene products, 
gold salts, corticosteroids, or antibiotics, upon the cellular infiltrate present within oral mucosal lesions 
in cats with chronic gingivostomatitis. 
Histological and immunobistochemical analysis of mucosal biopsies taken from the fauces before and 
after 3 months of treatment generally revealed that each of the treatments had little effect upon the 
cellular composition of the inflammatory infiltrate within the mucosal lamina propria and submucosa. 
This finding is in accordance with the clinical findings described in Chapter 4, where the clinical 
response to all four treatments was generally regarded as being poor. Consequently, the results indicate 
that none of the treatments regimes analysed were especially effective in their ability to modify the 
pathological processes underlying the oral lesions encountered in feline chronic gingivostomatitis. 
In general, the change in the density of each cell phenotype between individuals was highly variable. 
While this finding may indicate that the cellular population infiltrating the oral mucosa in cats with 
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chronic gingivostornatitis is highly dynamic, much of this variability may have resulted from intrinsic 
variations in the cellular infiltrate present within the oral mucosa. It was not possible within the 
confines of the present study to determine how representative the biopsies were of changes occurring 
throughout the whole of the oral mucosa, or even within a defined site such as the fauces. Studies 
examining this aspect would be extremely valuable, but would require the collection of multiple 
biopsies from many oral sites, and therefore could only be performed using samples collected from 
post mortem cases. 
Another factor that must be considered is that a relatively small number of cases was present within 
each treatment group. As a result of this, it is likely that only moderate to large differences in the 
change in the cell populations between groups would be detected as being significant. However, it has 
to be questioned as to whether small changes would be of any significant clinical relevance. 
Despite these shortcomings, significant differences were found between treatment groups in the change 
in the number of IgG' cells within the lamina propria and submucosa of the faucal tissues. Cats 
receiving corticosteroids had a significantly greater reduction in the number of infiltrating IgG' cells 
than cats receiving oral hygiene treatment, but not those receiving gold salts or antibiotics. This 
Ending generally reflects the clinical results following three months of treatment, whereby oral 
hygiene treatment was identified as the being the least effective of the four regimes analysed, and 
corticosteroids provided the greatest clinical improvement (Chapter 4). Together, these findings 
provide limited evidence to suggest that the differences in the clinical response to treatment 
correspond with changes in the number of IgG+ plasma cells within the oral lesions. As discussed in 
Chapter 8, corticosteroids have pleotropic effects upon a wide range of cell types, including 
lymphocytes (Wilckens & De Rijk, 1997; Bames, 1997); whereas the active ingredients within the oral 
hygiene products, chlorhexidine and glucose oxidase/lactoperoxidase, are only considered to possess 
antibacterial activity. Nonetheless, it is not possible to deduce from the results of this study whether 
the differential response to corticosteroids and oral hygiene treatment resulted primarily from the 
direct or indirect effects of these treatments upon the development and maintenance of IgG' plasma 
cells within the oral lesions, This is especially relevant given the fact that changes in the density of the 
total cellular infiltrate (indicated by the histopathology grade) correlated significantly with changes in 
the severity of the local clinical signs of inflammation. 
Although significant differences were detected between treatment groups in the change in the IgG+ 
population present within the oral lesions after three months of treatment, no corresponding changes 
were detected in the total salivary IgG concentrations, or in the estimated levels of locally produced 
IgG within the saliva (see Chapter 8). IgG secreted from plasma cells residing within the oral mucosa 
will diffuse into the oral cavity via the gingival crevicular fluid or via compromised local epithelium 
(Gavin, 1968; Challacombe et al., 1978; Challacombe & Shirlaw, 1999). Thus, it would be logical to 
hypothesise that a reduction in the local mucosal IgG plasma cell population would lead to a reduction 
in the salivary IgG concentration. The fact that this was not found may indicate that the changes seen 
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within the tissues were not representative of the overall changes occurring within the oral mucosa, 
although other factors could be responsible (see Chapter 8 for further discussion). It is interesting to 
note, however, that cats receiving corticosteroid demonstrated a significant reduction in their serum 
IgG levels by comparison to each of the other treatment groups after 3 months of treatment (see 
Chapter 8) (Butler & Rossen, 1973). In addition to diffusing into the oral cavity, IgG secreted from 
plasma cells within the oral mucosa is likely to difftise into the circulation via the lymphatics and the 
blood vessels. Thus, the relative reduction in the IgG' plasma cell population within the oral mucosa 
may have contributed to the decrease in the serum IgG levels seen in cats treated with corticosteroids, 
Analysis of variance tests also indicated that there was a significant difference between the treatment 
groups in the change in the number of IgM" plasma cells within the oral mucosal tissue, however 
subsequent multiple comparison tests between treatment groups failed to identify any significant 
differences. Inspection of the results shows that any potential difference between the treatment groups 
is likely to lie in the fact that in some of the cats receiving oral hygiene treatment the number of IgM+ 
cells in the lamina propria/submucosa tended to remain stable or to increase, whereas in the other 
treatment groups there was a greater tendency for the number of IgM+ cells at this site to remain 
constant or to decrease. In order to detennine whether or not these treatments do lead to differential 
effects upon the mucosal IgM+ plasma cell population further studies using larger group sizes would 
be required. 
As was found with the pre-treatment biopsies, the histopathological grade of the lesions correlated 
significantly with the local stomatitis index score. Furthermore, the changes in the histopathological 
grade also correlated significantly with the change in the local stornatitis index. These findings imply 
that the histopathological grading system relates well with the clinical appearance of the lesions, and 
therefore validates the use of these scoring systems. Moreover, these findings provide evidence to 
support the view that the histological grading sequence (I to 4) correctly represents the sequential 
dynamic changes occurring in the cellular composition and histological features during the 
development of the oral mucosal lesions seen in feline chronic gingivostomatitis. 
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PARTIV: Cytokine Expression in Cats with Chronic 
Gingivostomatitis 
Part IV 205 
CHAPTER 13: Materials and Methods for Part IV 
13.1 ANINIALS 
13.1.1 Cases 
Faucal biopsy samples were collected from 30 cats (Chapter 3, Table 3.1) referred to the Feline 
Centre, University of Bristol, for clinical investigation of chronic gingivostomatitis (see Chapter 2). 
Excisional biopsies were collected at consultation I (Chapter 2), immediately prior to entry onto a 
treatment trial, and again at consultation 3, three months after treatment had commenced (Chapter 2). 
13.1.2 Control cats 
Faucal biopsies were collected immediately following euthanasia from 17 cats with no history of 
chronic gingivostomatitis (Chapter 5 and Table 5.1 Cats CC-15, -17, -18, -19, and CC-21 to CC-33). 
The stornatitis index (SI) (Chapter 2) was scored within 24 hours prior to sample collection. 
Additional oral mucosal tissues were collected from various cats immediately following euthanasia. 
13.1.3 Stomatitis index, sample collection methods and disease treatment 
See Chapter 2. 
13.2 FELINE T-CELL LINE 
FL4 T-cells were kindly provided by Dr Janet Yarnamoto (University of California). 
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13.3 TISSUE HONIOGENISATION 
13.3.1 Hybaid Recovcry RiboLyser kits 
Tissues were processed using the Hybaid Recovery RiboLyser kits (Hybaid, Ashford, UK) as per the 
manufacturer's instructions. 
13.3.2 Glass-tissue grinders 
Homogenisation of case and control samples was performed using a motor driven (maximum 400 rpm) 
I ml capacity Duall glass tissue grinder and pestle (Kimble Kontes, Vineland, New Jersey). All 
glassware was baked at 160-180"C for a minimum of 3 hours prior to use. 
13.4 RNA ISOLATION 
13.4.1 RNA isolation following tissue homogenisation in Tri Reagent 
The method used for isolation of RNA from tissues or cells homogenised in Tri Reagent (Sigma 
Chemical Co. Ltd, Poole, UK) has been previously described by Gunn-Moore et al. (1998). Briefly, 
samples homogenised in Iml of Tri Reagent were placed into 1.5ml microcentrifuge tubes, vortexed 
for 15 seconds then left to stand at room temperature for 5 minutes. 200ýtL of molecular grade 
chloroform (Sigma) was added, the tube vortexed for 30 seconds then centrifuged at 13,000g at VC 
for 15 minutes. The aqueous upper layer was removed and placed into 500[d of ice-cold isopropanol, 
vortexed and then left to precipitate overnight at 40"C. The precipitate was pelleted by centrifugation 
at 13,000g at 4*C for 15 minutes, then the supernatant was discarded. I ml of cold 75% ethanol 
(Merck, Poole, UK) was added, vortexed, and then the tube was centrifuged at 8,000g at 4*C for 10 
minutes. The supernatant was then discarded and the remaining RNA pellet briefly dried at 50'C. 
Finally 20jil of 0.0 1% diethylpyrocarbonate (Sigma) (DEPC)-treated purified water was added and the 
pellet resuspended. Eluted RNA was stored at -70'C. 
13.4.2 SV Total RNA Isolation system 
RNA was isolated using the SV Total RNA Isolation System (Promega UK, Southampton, UK) 
according to the manufacturer's instructions, except that tissue sample RNA was eluted into 35pl of 
RNase-free water passed through the column 3 times. Eluted RNA was stored at -70*C. Due to the 
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small amount of biopsy tissue available, the sample RNA eluent concentrations were too low to be 
measured by spectrophotometry. 
13.5 REVERSE TRANSCRIPTION AND CDNA PREPARATION 
Prior to cDNA synthesis, I pl of RNA from each sample was subjected to PCR analysis (see below) 
with primers for glyceraldehyde-3-phosphate dehydrogenase (G3PDH) in order to check for genomic 
DNA contamination. RNA extracts from samples demonstrating a PCR product for G3PDH were 
considered to have genomic contamination and were re-extracted and re-checked as above. First strand 
cDNA synthesis was performed using Superscript Preamplification System (Life Technologies, 
Paisley, UK) according to the manufacturer's instructions using II [d of the eluted RNA per reaction. 
13.6 DNA EXTRACHON 
Genomic DNA was extracted from FL-4 T-cells using the QlAamp Tissue Kit (Qiagen Ltd, Dorking, 
UK) according to the manufacturer's instructions. 
13.7 POLYNI ERASE CHAIN REAMON (PCR) 
13.7.1 Primer design 
MacVector version 6 (Oxford Molecular, Oxford, UK) was utilised to design primers using feline- 
specific or consensus gene sequences. 
13-7.2 PCR protocol 
Gene-specific cDNA amplification was performed using Taq PCR Master Mix (Qiagen) with 2pl 
cDNA sample solution or 10.5ýd standard cDNA solution or IgI RNA sample solution, 0.33gM (final 
concentration) of each primer (Tables 14.1 & 14.3), in a final volume of 25ýd or 50ýd. The PCR was 
performed in a Hybaid Touchdown thermal cycler (Hybaid). Following an initial incubation at 94"C 
for 90 seconds, 35 or 40 cycles were performed of denaturation at 94"C for 45 seconds, annealing at 
55T (all probe primers), 57C (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 p35, IL-12 p40) or 60"C (IFN-y, 
G3PDH) for 45 seconds, then extension at 72'C for 45 seconds; a final 7211C extension was provided 
for 3 minutes. 10-15pi of reaction product was separated by electrophoresis (70mV constant voltage 
-1 hour) in a 1% agarose gel in TAE buffer (0.04M Tris acetate, 0.001M EDTA, 1.14% glacial acetic 
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acid) containing ethidiurn bromide (-Ijig/ml) and visualised using a GDS8500 Gel Documentation 
and Analysis System (UVP, Cambridge, UK). Non-diseased and diseased samples were generally 
analysed concurrently. Due to the small amount of tissue available most determinations were only 
performed once. 
13.7.3 Monitoring for cross-contamination 
Negative control samples consisting of RNase- and DNase-free purified water (Sigma) were 
periodically run through the RNA isolation and cDNA synthesis procedures, and then subjected to 
PCR analysis for each target sequence. In addition, each PCR contained a negative control reaction 
containing purified water (Sigma) in place of cDNA. 
13.8 CDNA PURIFICATION AND SEQUENCING 
PCR reaction products obtained using cDNA derived from FL4-cells as a template were run on a gel 
as described above, and single band products were purified using the Hybaid Recovery DNA 
Purification Kit (Hybaid) according to the manufacturer's instructions, with a final elution volume of 
25gl. The elutant DNA concentration was measured by spectrophotometry at 260nm and used for 
automated fluorescence DNA sequencing (ABI prism, model version 2.1.1). 
13.9 QUANTIFICATION OF SINGLE BAND PCR PRODUCTS 
Quantification of single band PCR products was performed by three dimensional volume calculations 
of the digitised gel image using GelWorks ID Advanced software (UVP) and expressed as the 
integrated optical density (10D). The relative concentration of gene-specific cDNA template in 
samples was estimated from co-amplified standard curves generated using two- or four-fold serial 
dilutions of appropriate purified reaction product as PCR starting template. Each undiluted cytokine 
standard solution was allocated an arbitrary concentration Of IX106 Units (U) per 10.5pl. Curve fitting 
was performed using Axum version 5.0 (MathSoft, Bagshot, UK). Relative sample concentrations 
were calculated from the standard curve equation using Excel version 5.0 (Microsoft Corporation, 
USA). The final results for each cytokine were then expressed relative to the sample G3PDH 
concentration (U). 
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13.10 SOUTHERN BLOTTING 
Southern blotting was performed using a downward capillary transfer method (Chomczynski, 1992) 
with an alkaline buffer. 15pI of reaction product was separated on 1% agarose gels (4 to 5mm deep), 
as described above. The gel was then rinsed in purified water then soaked in an excess of OAM NaOl I 
for 20 minutes on a rocking platform. A piece of Whatman 3MM filter paper soaked in 20x SSC 
(0.3M Na3 citrate, 3M NaCI) was placed on top of 4 additional pieces of dry Whatman 3MM filter, 
which in turn were on top of a 2-3cm stack of paper towels. A piece of nylon membrane (Hybond-N"; 
Amersham Parmacia Biotech. Ltd., Buckinghamshire, UK) slightly larger than the gel was pre-soaked 
in purified water for 2 minutes, then rolled on to the uppermost filter paper. Strips of clingfilm (Saran 
Wrap; Appleton Woods, Birmingham, UK) were placed so they would overlap the edges of the gel, 
prior to the gel then being placed on top of the nylon membrane. Three layers of Whatman 3MM filter 
paper soaked in 20x SSC and cut to the same size of the gel, were placed on top of the gel. Two larger 
pieces of Whatman 3MM paper soaked in 20x SSC were then placed to form a bridge between the top 
of the stack and a reservoir of 20x SSC. A get plate was placed over the top of the stack. 90 minutes 
later the stack was dismantled and the gel rinsed in 2x SSC for 2 to 5 minutes prior to undergoing 
DNA hybridisation. 
13.11 DOT BLOTS 
Purified PCR products were diluted as required in DEPC-treated water. Samples were heated in a 
boiling water bath for 5 minutes, chilled rapidly on ice, then centrifuged at 13,000g for 2 minutes at 
4"C. 2pl of sample was pipetted onto nylon membrane (Hybond N"; Amersham), allowed to air dry, 
then UV fixed for 60 seconds using a calibrated transilluminator (Model TM-40; UVP). The 
membrane was soaked in 5x SSC prior to hybridisation with labelled probes. 
13.12 PROBE LABELLING AND HYBRIDISATION 
13.12.1 Probe labelling 
Approximately I OOng of purified probe DNA was labelled using the ECL direct nucleic acid labelling 
and detection system (Amersham) as per the manufacturer's instructions. Probes were stored in 50% 
glycerol (Sigma) at -200C. 
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13.12.2 Hybridisation 
Southern blots and dot blots were hybridised with ECL-labelled probe DNA using the ECL direct 
nucleic acid labelling and detection system (Amcrsham) as describe in the manufacturer's protocol 
using hybridisation and stringency washing tubes in a hybridisation oven (flybaid). llybridisation was 
performed overnight at 42'C using 5ng probe per ml of hybridisation buffer. 
13.12.3 Signal generation and detection 
Following hybridisation, signal was generated using enhanced chemoluminescence (ECL direct 
nucleic acid labelling and detection system; Amersham) as per the manufacturer's instructions, and 
detected on autoradiography film (Hyperfilm-ECL, Amersham). 
13.13 STATISTICS 
The methods used for statistical analysis are provided in Chapter 2. 
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Chapter 14: Development of Semi-quantitative PCR Methodology for tile 
Analysis of Cytokines in FeIine Oral Mucosal Biopsies 
14.1 INTRODUCTION 
Cytokines comprise a diverse range of highly potent regulatory polypeptides with pleotropic effects. 
They can be produced by a wide range of nucleated cells, and act as intercellular messengers in an 
autocrine, paracrine or endocrine manner to orchestrate the host's immune and inflammatory 
responses. Over the past two decades, it has become increasingly clear that the pathological changes 
seen in a number of disorders may be correlated with altered expression of one or more cytokines 
(Reiner & Locksley, 1995; Abbas et al., 1996; Romagnani, 1996; Feldmann et al., 1996). 
Consequently, the analysis of cytokine expression by cells or tissues has become an important element 
in the study of the pathogenesis and treatment of many diseases. 
Currently, the cytokine response generated during an immune response is often characterised by a T- 
helper I (Thl) / T-helper 2 (M) paradigm based upon initial studies performed using murine CD4' 
T-cell clones (Mosmann et al., 1986; Mosmann & Coffman, 1989; Romagnani, 1997) (see Chapter 1). 
Within this model (reviewed by Seder & Mosmann, 1999) a Thl (type 1) response is associated with 
the promotion of cell mediated responses, such as the activation of macrophages and cytotoxic CD8* 
T-cells, and is characterised by a preponderance in the production of interferon-gamma (IFN-y), 
interleukin (IL)-2, IL-12, IL-18 and lymphotoxin. By contrast, a Th2 (type 2) response is associated 
with the induction of humoral responses, and is characterised by a preponderance in the production of 
IL-4, IL-5, IL-6, IL-9, IL-13 and, less-specifically, IL-10. In vivo studies have demonstrated that 
susceptibility and resistance to certain diseases correlate with a polarised Thl or Th2 response (Reiner 
& Locksley, 1995; Liblau et al., 1995; Balasa & Sarvetnick, 2000). However, additional investigations 
have shown that in many diseases the immune response displays a degree of heterogeneity in cytokine 
production (London et al., 1998). Furthermore, it is not clear if the typical cytokine profiles seen in the 
murine model can be transposed directly into other species, such as the cat (Pedersen et al., 1998). 
Nonetheless, the Thl/Th2 model provides a simplified framework in which the proffle of cytokine 
expression can be classified prior to performing more detailed and specific scrutinisation of the 
response. 
The analysis of the cytokine expression within cell populations is commonly accomplished through the 
use of the reverse-transcription - polymerase chain reaction (RT-PCR), which enables the 
demonstration of cytokine-specific mRNA sequences within cellular or tissue homogenatcs (Saiki et 
al. 1985; Wadhwa & Thorpe, 1998). The sensitivity of this methodology makes it particularly suitable 
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for the detection of cytokines in small tissue samples, such as biopsies (Sam Babu et al., 1993). This 
chapter summarises the work performed during the development of semi-quantitative RT-PCR assays 
used subsequently for the analysis of cytokine mRNA expression in feline oral mucosal biopsies. 
14.2 MATERIALS& METHODS 
These are detailed in Chapter 13. 
14.3 RESULTS 
14.3.1 Homogenisation of tissues and RNA extraction 
Prior to the extraction of RNA from tissues it was first necessary to homogcnise the tissue and lyse the 
cells. During preliminary studies, four methods were evaluated for the homogenisation of faucal tissue 
biopsies and subsequent extraction of RNA: 
1. Disruption of the tissue in Tri Reagent (Sigma Chemical Co. Ltd, Poole, UK) by shearing forces 
created by repeated suction through progressively smaller hypodermic needles. 
2. Grinding of frozen tissue using a mortar and pestle cooled with liquid nitrogen before adding Tri 
Reagent. 
3. Use of an automated tissue disrupting system - Hybaid Recovery RiboLyser kits (Hybaid, Ashford, 
UK). This system relies on the use of a lysing matrix containing ceramic particles in a small tube to 
lyse tissue cells during high speed shaking and twisting motion applied to the sample tube. 
4. Grinding of tissue with Tri Reagent in a glass tissue-grinder. 
Initial studies performed using the first method for RNA extraction found the procedure to be slow and 
inefficient, consequently this method was rejected. Although RNA was extracted successfully by 
grinding samples in a liquid nitrogen-cooled mortar and pestle, this method was judged to be 
unsuitable for the small size of the biopsy samples, and bad the potential for significant sample loss on 
the apparatus. Comparisons performed on RNA extracted from comparative samples using the 
RiboLyser system or manual homogenisation using glass tissue-grinders with Tri-reagent indicated that 
the manually processed tissues gave stronger G3PDH product bands on agarose gels following RT and 
amplification by PCR (not shown). In addition, technical problems were encountered with the 
RiboLyser-based method that prevented the effective homogenisation of some samples. Hence, the 
glass-tissue grinders were selected as the optimal method for the homogenisation of oral tissue 
biopsies. 
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14.3.2 RNA EXTRACTION 
Following the preliminary studies into the homogenisation methods a commercial kit (SV Total RNA 
Isolation System; Promega UK, Southampton, UK) was subsequently used for the isolation and 
purification of RNA. The kit provided a rapid and relatively simple method for the isolation of RNA, 
thereby minimising the amount of handling of the samples, which in turn reduced the risk of 
contamination with RNases or cDNA/DNA. The rapidity of the process also facilitated the concurrent 
processing of multiple samples. The methodology also included a DNase treatment step which used 
manganese as a cofactor, rather than magnesium. In the presence of manganese DNase I cleaves DNA 
strands in such a manner that blunt-ended fragments are produced, whereas in the presence of 
magnesium each DNA strand is cleaved in a random position resulting in the production of many 
overlapping ("sticky") ends. While it is difficult for the blunt ended fragments to re-anneal, this may 
occur spontaneously with the "sticky" ends - potentially resulting in the generation of false-positive 
PCR products (Bauer et al., 1997). 
14.3.3 REVERSE TRANSCRIPTION 
A combined RT-PCR system (Access RT-PCR System, Promega, Southampton, UK) was assessed for 
use within the study. However, this product was not used as it was found to be less sensitive than the 
initial method using separate RT and PCR steps (data not shown). 
14.3.4 PRIMERS 
14.3.4.1 Primer sequences 
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) primer sequences were as previously published 
(Gunn-Moore et al., 1998) (Table 14.1). Interleukin (IL)-2, IL-4, IL-6, IL-10 and interferon (IFN)-y 
primers (Table 14.1) were designed using feline-specific sequences which had been published 
(Bradley et al., 1993; Ohashi et al. 1993; Cozzi et al., 1993; Schijns et al., 1995; Argyle et al., 1995) 
or deposited in Genbank. At the time that this work was conducted sequences for feline IL-5 and IL-12 
were not available. Primers for IL-5 (Table 14.1) were derived ftorn consensus IL-5 sequences 
available in Genbank for a range of species. Based upon a subsequently published feline IL-5 
sequence (Padrid et al., 1998), 3 base-mismatches were present in the reverse primer (Table 14.2). IL- 
12 p35 and IL-12 p40 primer sequences were kindly provided by Karen Brown (University of South 
Florida College of Medicine) and were based upon consensus sequences. In comparison to sequences 
subsequently published, the forward IL-12 p35 primer has I mismatched base, and the forward IL-12 
p40 primer has 2 mismatched bases (Table 14.2). 
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Table 14.1 Feline cytokine-specific primer pair sequences 
Target gene Primer sequence 5'-* 3' Predicted product 
size (bp) 
03PDH CACGGCAAATTCCACGGCAC 400 
TTTTGGGTGGCGGTGATGGC 
IL-2 GCAATTACTGCTGGATTTACGGTTGC 358 
AGTCAGCGTTGAGAAGATGCTTTG 
IL4 CATTTACCAGCACCTTCGTCCACG 334 
TGCATGATCGCTTTTAGCCTTTCC 
IL-5 GCTTCTGCATTTGAGTTTGC 384 
ATCCACTCGGTGTTCATTACAC 
IL-6 GACCTGCCTGACAAGAATCACTACTGG 352 
CGTGAACTACAGCAATCTTAGATGCCC 
IL-10 ACAACTGCACCCACTTCTCAGTCAGC 335 
CACCACCTTGCTCTTGTTTTCACAGG 
IL-12 p35 CCTCCTGGACCACCTCAGTTTG 372 
GAACTCCACCTGGTACATCTTCAAGTC 
IL-12 p40 TCAAAGAGTTTGGAGATGCTGGCC 464 
TGATGATGTCCCTGATGAAGAAGC 
IFNýy TAGCAGATGGTGGGTCGCTTTTCG 346 
AACAGATTCTGGCTCCTTTTCCGC 
Table 14.2 Alignment of primer sequences for IL-5, IL-12 p35 and IL-12-p4O with subsequently 
published sequences 
Sequence (5' -). 3') Position 
IL-5 forward primer 
Feline IL-V 
IL-5 reverse primer 
Feline IL-V 
IL- 12 p3 5 forward primer 
Feline IL-12 p35 b 
IL-12 p35 reverse primer 
Feline IL-12 p35b 
IL- 12 p40 forward primer 











IL-12 p40 reverse primer TGATOATGTCCCTGATGAAGAAGC 
Feline IL-12 p4ob TGATGATGTCCCTGATGAAGAAGC 679-703 
' Padrid et al., 1998 b Schijns et al., 1997 Bold underlined bases indicate a mismatch 
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14.3.4.2 Optimisation of primer annealing temperatures 
Optimisation of the annealing temperature for each primer pair was performed empirically over a 
temperature range of 50 to 65C using cDNA derived from FL-4 cells. Annealing temperatures 
providing single product bands of maximum intensity when stained with ethidium bromide on an 
agarose gel after 35 or 40 cycles were selected for subsequent use. 
14.3.5 PCR PRODUCTS 
14.3.5.1 Confirmation of product speciricity 
The product produced by each primer pair was purified and sequenced [GenBank accession numbers 
AF054608 (G3PDH), AF054601 (IL-2), AF054602 (IL-4), AF051372 (IL-5), AF054603 (IL-6), 
AF054604 (IL-10), AF054605 (IL-12 p35), AF054607 (IL-12 p40), AF054606 (IFN-y)]. Sequence 
comparisons with the Genbank database confirmed the specificity of the appropriate products for 
feline G3PDH, IL-2, IL-4, IL-6, IL-10 and IFN-y. The sequences from the products produced by the 
IL-5, IL-12 p35 and IL-12 p40 primers closely matched sequences from equivalent cytokines 
originating from various other species. Subsequently, these sequences have been demonstrated to 
match the relevant published feline sequences. 
14.3.5.2 Products generated from RNA and genomic DNA 
A comparison was performed between the PCR products produced when cDNA or DNA extracted 
from FL4 cells was used as the template. Only the G3PDH primers produced an equivalently sized 
product to that produced by cDNA (Figure 14.1). 
14.3-5.3 Quantification of PCR products 
When this work was started, the gel-analysis equipment that was finally used for the quantification of 
PCR product bands from agarose gels was not available. Consequently, preliminary investigations 
were conducted into alternative methods for quantification of the PCR products. 
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14.3.5.3.1 Imaging photographs 
Initial experiments were conducted to assess the feasibility of quantillying Kit product binds rMill 
photographs of gels. Titration curves of PCR products were produced using 2 or 3 fold dilutions or tile 
positive control RNA provided in the Access RT-PCR System kit (Promcgl) or tile Supcrscript kit 
(Lire Technologies, Paisley, UK) as template. After separation on an agarose gel tile product bands 
were photographed, scanned, then quantified using an Image analysis program (NIII-linage) by 
calculating the product or the number or pixels within the image of each band and the mean pixel 
intensity. The results (not shown) indicated that predictable standard curves could be produced by this 
method. However difficulties were encountered in quantifying some of tile fainter bands present within 
the gels. Consequently, alternative methods were investigated. 
14.3.5.3.2 Dot blotting 
The use of a blotting methodology was investigated to provide increased sensitivity over photographic 
analysis. Based upon the previously derived sequences (Chapter 14.3.5.1). internal primers (Tablc 
14.3) were designed for each of the PCR products generated above. Using the purified G3PDll or 
cytokine PCR products as template these primers were used to generate probe DNA by PCR. 17he 
probes were labelled and their efficacy confirmed on Southern blots of PCR products produced from 
cDNA derived from tonsils from two cats or from FLA cells (Figure 14.2). 
Experiments were performed to determine if dot blotting could be used to quantify PCR product 
concentrations. Dot blots were constructed using serial dilutions ofpurificd PCR products forG3PDII 
or one or other of the cytokines under investigation, and quantified dens itorrictrical ly. The results 
revealed a potential problem, in that for many of the blots the titration curves were sinusoidal In nature 
and, paradoxically, at the highest PCR product concentrations the area and maximum density (OD) 
were seen to decrease with increasing product concentration (examples shown in Figure 14.3), This 
implied that the quantification of PCR product concentrations from single dots was unreliable and that 
titration curves would be necessary for each sample, 
Concurrent studies were also performed using serial dilutions of purified PCR product as template to 
generate standard curves. These investigations demonstrated that titration curves could W produced, 
however, they also indicated that below a certain concentration or template (equivalent to 
approximately 50 to 100 molecules of dsDNA template) the generation of product by PCR became 
unpredictable (Figure 14.4). Furthermore, for template concentrations above this critical limit, G 
product band was generally visible on ethidium bromide-stained agarose gels after 35 IICR cylles. 
Tliese findings indicated, dicrerbre, that the superior sensitivity of the blotting method was 
unnecessary for the detection of all but very low levels or cDNA template, %% hereupon the generation 
of detectable products by PCR became an unreliable process (Figure 14.4). 
Chapter 14 218 
Table 14.3 Internal primersequences for the genera I ion of probes agalnit C#3111)11 11 lid c)loklnc 
PCII products 
Probe target Primer sequence 5'-* 3' Predicted pn)Jucl 
size (bp) 
G3 PDI I (probe) ACTTTCCAGGAGCGAGATCC 282 
TGCCGAAGTGGTCATOGAATG 
I L-2 (probe) CCAAACTCTCCAGGATGCTC 249 
CAATGGTTGCTGTCTCATCATC 
IL-4 (probe) TTGAACATCCTCACAGCGAG 219 
TTCATTCACAGAACAGGTCCTG 
IL-5 (probe) AAGTCCCATGAATAGGCTGG 238 
TTTTGGCGGTCTATGTGTTC 
I L-6 (probe) TCTCCAGGACAAGTATGAGGO 233 
GGCTGAACTGAAGGAAGTCC 
I L-10 (probe) GACMCTTTCAAACCAAGGACG 201 
AGGGTCTTCAGCl II ICTCC 
I L- 12 p3 5 (probe) TCAGCAACACGCTTCACAAGG 241 
ATACTGATAAGGCACAGGGTCG 
I L-12 p40 (probe) GGAAGATGGAATTTGGTCCAC 340 
TGAGCTTGTGAATAGCGTCC 
I FN-y (probe) CAAAGCCAAATTGTCTCCTTC 237 
CTTGGTGAGAGATCATTCATCAC 
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14.3.5.3.3 Gel analysis 
Analysis of sample cDNA concentrations IrOM PCR PrOCILICt I-MMIS USing iuhl"C JIMIN'SiS CqUipluClIt 
was investi-ated. Ima(yes of sin-le-band PCR products were di-itised directIN 1rom c1hidium broinide- 
stained agarose gels and quantified by three-diInCnSiOMIl V0111111e CACLI1,16011S biISCd UpOn OIC ý11-Ca and 
intensity of staining (GDS8500 Gel Documentation and Analysis Systcm and Gel Works ID Advanced 
software, UVP, Carnbrid-e, UK). Experiments demonstrated that standard curves could be pencrated 
over a3 to 4 log-fold dilution range of reaction usin- this methodology I'm G-111DI I (Fipire 14.5) and 
each of the cytokines under investigation. Consequently, this method XVaS SCICCtCd 101' SLIbSCqIICI1I 
analysis of relative cytokine expression in feline tissue. 















95% confidence intcrval 
G3PDH (400 bp). 25 lil reaction rnixes containin- 10.5pl of' G311I)II standard cDNA solution were 
amplified simultaneously for 35 cycles as described in Chapter 13 l5p] of'cach reaction product was 
separated by electrophoresis in a 1% agarose gel containino -I polnil ethidiLlIn bt-011liLIC. LaneS I& 
12: 250 base pair (bp) ladder mo I ecular we ig lit marker (MW). Lanes 2-9: G3111A I PCR products 1roin 
sequential I in 4 dilutions of the G3PDlI standard solution (Ix 10" Units per 10.5pl). Lanc 11: 
Negative control (Neg) containing purified water in place of' cDNA template solution. Lane 10: 
Empty, Bands were imaged and quantified (IOD) using GelWorks 11) Advanced sofiware (UVP). 
Curve fitting was performed with Axurn v. 5.0 (MatliSolt, Ba-shot, U K). I 
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14.3.6 Assay reliability and precision 
In order to estimate the reliability and precision of the methodology, a homogenate of feline tonsil was 
divided into four unequal aliquots and the G3PDH and IFN-y concentrations of each aliquot were 
determined in triplicate (Figure 14.6, Table 14.4). The IFN-y concentration in aliquot I was below the 
minimum level of detection (Figure 14.6b), however this was consistent with the comparatively low 
G3PDH concentration recorded in this aliquot. Overall, the results showed relatively good 
repeatability with mean coefficients of variation less than 20% (Table 14.4). The use of ratios suffers 
from the inherent problem of the multiplication of standard errors which can create a substantial 
increase in spread in individual data values. The maximum and minimum values of each triplicate 
were used to provide an estimate of the potential range of IFN-y: G3PDH for each aliquot (Table 14.4). 
These results suggested that there may be up to a 2.5 fold spread (mid-value ± 43%) in the value of a 
single data point. 
Table 14.4 Summary results of IFN-y and G3PDH cDNA concentrations derived from amplified 
PCR products shown in Figure 14.6 
Aliquot 
cDNA concentration (UX 103 /sample)' 
IFN-y cv(%) G3PDH cv(%) 
Ratio IFN-y/ 
G3PDH 
Range b (x i o-3) 
I ND 2.9 ± 1.4 47.4 
2 2.0 0.4 21.4 217.2 ± 6.1 2.8 6.9-11.2 
3 2.0 0.3 17.3 291.0 ± 64.3 22.1 4.8-10.7 
4 0.6 ± 0.1 13.0 113.7 ± 3.6 3.2 4.5-6.0 
Mean 17.2 18.9 
' Values are means ± standard deviations (from triplicate determinations) from four unequal aliquots 
of a single feline tonsil homogenate (see 14.3.6); b Values derived using maximum and minimum 
values from each triplicate; cv = coefficient of variation; ND = not detectable 
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14.4 DiscussiON 
Cytokines are pleotropic regulatory proteins which, through their capacity to modulate many of the 
functions of the cells of the immune system, play a central role in orchestrating inflammatory and 
immune responses. Evaluation of cytokine expression during health and disease has led to an increased 
understanding of the pathogenesis of many conditions, and has facilitated the identification of potential 
therapeutic targets for the treatment of some diseases (Haworth et al., 1998; Feldmann et al., 1996; 
Dunham, 1999). However, by comparison to humans and rodents, relatively few studies have analysed 
aspects of feline cytokine biology (Rottman et al., 1995; Dean et al., 1998; Dean & Pedersen, 1998; 
Pedersen et al., 1998; Levy et al., 1998; Leutenegger et al., 1999; Linenberger & Deng 1999). 
The aim of the work outlined in this chapter was to develop suitable methods for the detection and 
quantification of various cytokines in oral mucosal tissue from cats with and without signs of chronic 
gingivostomatitis. Cytokine expression in tissues may be detected using a number of approaches, 
which have recently been reviewed by Wadhwa & Thorpe (1998). Cytokine protein can be detected 
using techniques which utilise specific-anti cytokine antibodies, such as ELISPOT or immuno- 
cytochemistry (Wadhaw & Thorpe, 1998). However, specific monoclonal antibodies generated against 
feline cytokines are not yet available. An alternative, and commonly used, method is to detect the 
expression of cytokine mRNA transcripts within individual cells or whole tissues (Rottman et al., 
1995). The major drawback to this methodology is that the expression of mRNA may not always 
correlate with the production and secretion of the relevant protein (Feldmann et al., 1996; Rottman et 
al., 1995; Pioli et al., 1998). Nonetheless, a number of studies have demonstrated that the patterns of 
cytokine expression within cell populations or whole tissues can correlate with the nature of the 
underlying immune response (Yamamura et al., 199 1; Romagnani, 1996). 
Two general approaches can be utilised for the detection of cytokine mRNA within tissues (Dallman et 
al., 1991). In situ hybridisation performed on tissue sections permits the detection of specific mRNA 
transcripts within individual cells, and has the additional advantage that it may be possible to 
simultaneously determine the phenotype of the cell of origin (Matsuki et al., 1992). Nevertheless, the 
technique is non-quantitative and has the disadvantage of being technically demanding. Alternatively, 
specific mRNA transcripts can be detected within homogenates prepared from sorted cells or from 
whole tissues using hybridisation methods, such as northern blotting, or, more commonly, reverse 
transcription-polymerase chain reaction (RT-PCR) (Dallman et al., 1991; Rottman et al., 1995). While 
these techniques do not permit the detection of the cellular origin of the transcripts in whole tissue or 
mixed cell isolates, they can facilitate quantification of specific mRNA transcripts (Wang et al., 1989; 
Dean et al., 1998). In many situations the superior sensitivity and rapidity of PCR-based methods over 
hybridisation methods makes RT-PCR the method of choice for the detection of cytokine transcripts - 
especially when the tissue source is limited and/or the transcripts are rare, as was the case in the 
present study. Consequently, as several feline cytokine sequences had been determined at the time at 
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which this work commenced, RT-PCR was selected as the most suitable method for the detection and 
semi-quantification of cytokine transcripts in feline oral mucosa. 
RT-PCR provides a sensitive technique for the detection and quantification of specific mRNA 
transcripts. A number of methodologies have been used for the quantification of specific products by 
PCR, all of which have inherent advantages and disadvantages (reviewed by Zimmermann & 
Mannhalter, 1996). Two general approaches can be taken. The first is the measurement of the amount 
of product in unknown samples by reference to the dilution series of an external standard (Coutled et 
al., 1995). This method has the advantage of being relatively simple and does not necessitate the use of 
multiple reactions for the determination of each unknown sample. However, the main disadvantage of 
this method is that variables occurring during sample preparation and the reaction processes are 
amplified and result in loss of precision of the results. These variabilities can be partly overcome by 
normalising the amount of specific gene products to an internal reference template (a 'housekeeping' 
gene - see below), such as G3PDH or O-actin. The alternative approach is to use a competitive RT- 
PCR assay (Zimmermann & Mannhalter, 1996). This methodology is based upon the co-amplification 
of specific target sequence with known amounts of an internal standard within the same tube. Both 
targets must share the same primer sequences and be amplified with the same efficiency, and it must be 
possible to analyse the products from each target independently. The ratio of the products within each 
reaction are determined, from which the amount of template in the unknown sample is derived. This 
methodology controls for variations in the PCR reaction between tubes, and by using an RNA internal 
standard the efficiency of the RT step is also controlled. Competitive RT-PCR assays provide the most 
precise quantification of RNA transcripts and have the additional advantage that they do not require 
analysis to be performed during the exponential phase of the reaction (Souazd et al., 1996). However, 
they are more complex in their design, and often necessitate the use of multiple reactions for each 
sample. Furthermore, the method does not control for differences in the efficiency of the RNA 
extraction process between samples, Consequently, normalization of the results against a housekeeping 
gene may still be necessary. Competitive RT-PCR assays for the measurement of feline cytokine gene 
expression have been described by Rottman et al. (1996) and Dean et al. (1998). 
Within the present study, the primary factor that influenced the choice of methodology used for the 
detection and semi-quantification of specific gene products was the relatively small amount of tissue 
available from each case. Consequently, the limited amount of RNA effectively precluded the use of 
multi-reaction competitive RT-PCR assays for the detection of multiple cytokines. Furthermore, in 
view of the dense inflammatory infiltrate that is commonly seen in oral mucosal lesions in cats with 
chronic gingivostomatitis, it was anticipated that large differences in the levels of cytokine expression 
between healthy tissue from control cats and inflamed tissue from cats with chronic gingivostomatitis 
would be present. Consequently, the absolute precision of the assay was not an overriding factor. 
Hence, an approach was adopted whereby the amount of product in unknown samples was determined 
by reference to a co-amplified dilution series of a purified native standard. Based upon previous 
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studies in the cat, G3PDH expression was selected for use as an internal control (Gunn-Moore et al., 
1998). G3PDH is one of a number of genes which are commonly referred to as housekeeping genes. 
Housekeeping genes are constitutively expressed at a relatively constant level within tissues. 
Consequently, they can be used as a positive control to confirm the combined success of the 
extraction, RT, and amplification processes within RT-PCR assays. In addition, during quantitative 
analysis, it is common practice to normalise the level of expression of the target gene to that of a 
housekeeping gene. This procedure aims to control for inter-sample variations in sample size, RNA 
extraction efficiency, and RT efficiency, but relies upon the assumption that the housekeeping gene is 
expressed at a constant rate within the tissue cells being analysed, and that the extraction efficiency 
and efficiency of RT of all of the target genes are the same. These assumptions, however, will not 
always be met. 
Initial experiments were performed to determine the optimal method for the extraction of RNA from 
representative samples of feline oral mucosal tissue. Owing to the small amount of RNA present within 
the eluates, it was not possible to assess the quantity or the quality of the RNA by spectrophotometry, 
as is commonly performed. However, RNA from tissues processed using glass-tissue grinders 
consistently produced the strongest product for G3PDH following amplification by RT-PCR. If it is 
assumed that the efficiency of the RT-PCR process was similar in all of the samples processed, the 
amount of PCR product generated will depend upon the quality and the quantity of specific RNA 
present within the eluates. Thus, the results suggested that homogenisation of the tissue using the 
glass-tissue grinders was the method of choice for the extraction of RNA from oral mucosal biopsies. 
Although it is not yet clear if the murine Thl: Th2 paradigm can be reliably transposed into the feline 
immune system (see Chapter 1), the principles provide a useful framework around which hypotheses 
can be generated. Within the present study, it was therefore decided to analyse a range of cytokines 
that would be representative of type I and type 2 responses. Consequently, IFN-y, IL-2 and IL-12 were 
chosen as type I cytokines, and IL4, IL-5 and IL-6 as type 2 cytokines. In addition IL-10 was selected 
as being representative of a type 2 cytokine, based upon its ability to inhibit IL-12 synthesis (D'Andrea 
et al., 1992), although in humans IL-10 can be produced by both Th-type I and Th-type 2 cells (Del 
Prete et al., 1993). Primers for feline IL-2, IL4, IL-6, IL-10 and IFN-y were designed using feline. 
specific sequences that had been published or deposited in Genbank (Bradley et al., 1993; Ohashi et 
al., 1993; Cozzi et al., 1993; Schijns et al., 1995; Argyle et al., 1995) (see Table 1.2). The specificity 
of each of these primer pairs was confirmed following sequence analysis of the PCR product generated 
by each primer pair. Feline IL-5 and IL-12 nucleotide sequences were unavailable at the time when 
this work was conducted, consequently consensus primer sequences were used for the detection of 
each of these cytokines. In the case of the IL-5 primer pair, the reverse primer was subsequently shown 
to have three base mismatches by comparison to the published nucleotide sequence of cloned feline 
IL-5 (Padrid et al., 1998). These mismatches were in the middle or at the 5' end of the primer. As 
DNA polymerases carry out synthesis in the S' to 3' direction, this fact will have limited the potential 
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effects the mismatches may have had on the functional ability of the primer. Nonetheless, it is possible 
that these mismatches reduced the efficiency of the reverse primer, although the specificity of the 
product generated by the IL-5 primer pair was confirmed by sequence analysis. Base mismatches were 
also shown to be present in the forward primers for IL-12 p35 (one mismatch) and the IL-12 p40 (two 
mismatches), by comparison to subsequently published feline IL-12 sequences (Scbjjns et aL, 1997; 
Fehr et al., 1997). However, these too were in the middle, or near the 5' end, of the primer, so the 
effect of the mismatches upon primer function may have been limited. The specificity of the IL-12 p35 
and p40 products were also confmned by sequence analysis. 
Experiments using each of the primer pairs showed that genomic DNA and cDNA produced PCR 
products of identical sizes only for G3PDH. This observation was most likely caused by the existence 
of processed G3PDH pseudogenes within the feline genome, as have been described in a number of 
other species(Benharn et al., 1984; Galland et al., 1990; Lum & Linial, 1997), but not previously in the 
cat. Thus, in order to prevent the generation of false-positive G3PDH results, it was vital to ensure that 
the eluate derived from the RNA extraction procedure was free from detectable genomic 
contamination prior to RT. This was achieved by subjecting an appropriate volume of eluate to PCR 
analysis for G3PDH, whereby a positive result was indicative of genomic contamination. In the small 
number of cases in which this occurred, the eluate was shown to be free from detectable genomic 
contamination after RNA re-extraction was performed. 
Three methods were investigated for the identification and quantification of specific products 
generated by RT-PCR. Separation of product bands by electrophoresis in ethidium bromide stained 
agarose gels permitted identification of appropriately sized products bands. However attempts to 
quantify these products by digital analysis of photographs of the gels was hindered by a loss of 
sensitivity. Furthermore, it was often necessary to take multiple exposures to avoid saturation of the 
image for the most intense product bands. The use of dot-blots was then explored to increase the 
sensitivity of the detection procedure. However, preliminary investigations into the production of 
titration curves using purified PCR products revealed a phenomenon whereby at high product 
concentrations, the product signal began to decrease. This effect was seen in a number of the blots. It 
is possible that the anomaly was caused by technical errors during the construction of the blot. 
However, the effect occurred in blots in which samples were applied in different orders, thus ruling out 
a methodical pipetting error. It would therefore seem peculiar that the apparent loss of signal only 
appeared to affect the dot containing the highest concentration of product. An alternative explanation 
may be that above a critical point, the density of the product attached to the membrane inhibits the 
binding of the probe, possibly as a result of steric hindrance. Further studies would be required to 
reveal the cause of this phenomenon. Studies using dot blots to analyse standard curves generated by 
PCR using serial dilutions of template, indicated that below a critical number of starting template 
molecules (calculated to be approximately 50-100 dsDNA molecules) the PCR reaction became 
unreliable and unpredictable. Furthermore, it was found that this point closely corresponded with the 
point below which the amount of product generated by a single round of 35 cycles of PCR could not 
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be visually detected in ethidiurn bromide-stained gels. Thus, these findings indicated that the detection 
of all but very low levels of starting cDNA template could be achieved using ethidium bromide-stained 
gels. Furthermore, any product bands that were undetectable were not quantitatively reliable. Based 
upon these findings and the subsequent acquisition of digital gel-analysis equipment, the use of dot- 
blots for the quantification of PCR products was not pursued. Digital gel-analysis equipment permitted 
the detection of all of the visible product bands present within ethidiurn bromide-stained gels, and this 
equipment was subsequently used to image the gels and to perform volumetric (area x intensity) 
analysis of product bands, from which standard curves were generated and the unknown concentration 
of template in co-amplified samples derived. 
As discussed above, the method applied for the quantification of mRNA transcripts in this study is 
prone to the accumulation and amplification of variations that may arise during the RT and PCR steps 
of the analysis. In addition, errors can occur during the production and analysis of gels owing to 
factors such as minor discrepancies in the volumes of reaction mix loaded onto the gel, and variations 
in the intensity of ethidium bromide staining across the gel. Furthermore, using a ratio to normalise the 
results against the level of expression of G3PDH will result in multiplication of the standard errors. 
Nevertheless, the analysis of multiple aliquots from a mucosal tissue sample homogenate indicated that 
although the assay would not be suitable for the detection of small or moderate changes in the relative 
level of cytokine expression, it would be sufficiently reliable to demonstrate substantial (6 to 10 fold) 
differences in the relative expression of cytokines. 
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CHAPTER 15: Cytokine mRNA Expression in Oral Mucosal Lesions in Cats with 
Chronic Gingivostomatitis 
15.1 INTRODUCTION 
In recent years it has become apparent that the immune system is regulated by a complex cytokine 
network (Mosmann et al., 1986; Mosmann & Coffman, 1989; Abbas et al., 1996; Romagnani, 1997; 
Thomson, 1998). Furthermore, various diseases, including oral diseases, have been correlated with 
functional changes involving one or more cytokines (Fujihashi et al., 1996; Prabhu et al., 1996; 
Romagnani, 1996; Tokoro et al., 1997). In addition to providing a greater understanding of the 
pathogenesis underlying various diseases, these findings have also raised the potential for the 
development of new therapeutic strategies aimed at manipulating the expression or activity of specific 
cytokines (Weiss, 1995; Dunham, 1999; Argyle, 1999). 
A number of studies have analysed cytokine gene expression in cats (Rottman et al., 1995; Dean et al., 
1998a & 1998b; Pedersen et al., 1998; Gunn-Moore et al., 1998; Sukura et al., 1998; Leutenegger et 
al., 1999). Nonetheless, the cytokine profile expressed by the feline oral mucosa has not been 
documented. This chapter reports the application of semi-quantitative RT-PCR to examine cytokine 
gene expression within oral mucosal tissue from cats with or without clinical signs of chronic 
gingivostomatitis. 
15.2 MATERIALS AND METHODS 
These are provided in Chapters 13,5 and 2. 
15.3 RESULTS 
15.3.1 Cytokine gene expression in control (non-diseased) cats 
Biopsies collected from 17 control cats were processed for cytokine mRNA analysis, During the RNA 
extraction procedure, problems were encountered in 6 samples owing to clogging of the extraction 
column. Subsequent analysis of 4 of these samples demonstrated a significant reduction in the RNA 
yield and/or quality from the affected samples, resulting in up to a 2000-fold reduction in the 
detectable G3PDH mRNA per milligram of tissue compared to the non-clogged control samples 
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(Table 15.1). Consequently, to prevent any bias resulting from processing differences the clogged 
samples were excluded from any further analysis. 
Variable levels of cytokine mRNA expression were detected in the II remaining faucal tissue biopsies 
from the healthy (non-diseased) control cats. IFN-y, IL-2, IL-12 (p35 and p40), and IL-10 were 
detected in the majority of these samples (Figure 15,1). By contrast IL-6 was detected in only a small 
proportion of the samples, and neither IL-4 nor IL-5 was detected in any of the samples from non- 
diseased control cats (Fig 15.1). 
Table 15.1 G3PDH concentrations in clogged and non-clogged control tissue samples 
Samples Median' Range' 
(X 105 U G3PDH/mg tissue) (x 105 U G3PDfUmg tissue) 
Non-clogged (n =1 1) 18.92 15.52 - 65.84 
Clogged (n = 4) 0.11 0.03-0.23 
Mann-Whitney test P=0.004 
aResults represent the concentration of G3PDH cDNA in 2pL] cDNA solution for each sample 
expressed per mg of tissue from which RNA was extracted (Chapter 13). 
15.3.2 Cytokine expression in cats with chronic gingivostomatitis 
Faucal tissue biopsies from 30 cats with chronic gingivostomatitis were processed for analysis of 
cytokine mRNA expression. Table 15.2 shows that there was no significant difference in the levels of 
G3PDH present within the extracts from the diseased and the non-diseased groups, 
IL-2, IL-6, IL-10, IL-12 (p35 & p40) and IFN-y were detected in virtually all of the samples from cats 
with chronic gingivostomatitis, while IL-4 was identified in 18 of 30 of these samples, and IL-5 was 
only detected in I sample (Figure 15.1). Comparison of the diseased and non-diseased populations 
revealed no difference in the relative IL-5 mRNA expression between the two populations (P = 0.55; 
Kruskal-Wallis test). In contrast, the relative levels of IL-2, IL-4, IL-6, IL-10, IL-12 (p35 & p40) and 
IFN-y mRNA expression were all significantly higher in the diseased population (all P<0.01; 
Kruskat-Wallis/Mann-Whitney tests adjusted for multiple tests with the layered Bonferroni method). 
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Table 15.2 G3PDH concentrations (Units) in samples from non-diseased and diseased cats 
loglo G3PDIl (Units)' 
Group n Mean SD 
Non-diseased (controls) 11 7.335 0.445 
Diseased (cases) 30 7.351 0.162 
t-test (controls v cases) T= -0.16 P=0.87 
95% confidence interval for mean diseased - mean non-diseased = -0.207,0.177 
n= number of samples. SD = standard deviation. 'Units per 2pl cDNA sample. 
Figure 15.1 Clinical scores and cytokine: G3PDH mRNA expression ratios in faucal biopsies 
from healthy control cats and cats with chronic gingivostomatitis 
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Biopsies from cats with chronic gingivostomatitis were taken following the withdrawal of previous 
treatment for a minimum time-period of 2-6 weeks and immediately prior to their entry onto the 
treatment trial (see Chapters 2&3 for details). None of the healthy control cats were receiving 
medication prior to biopsy collection. Median value of each clinically graded group is represented by 
an adjacent bar (-). The median value of the entire diseased population is represented by a triangle 
(A). nd = not detected. 
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15.4 DISCUSSION 
The first part of the present study investigated the cytokine gene expression profile of non-inflamed 
oral mucosal tissue from healthy cats without clinical signs of chronic gingivostomatitis. IL-2, IL-10, 
IL- 12 (p3 5& p40), and IFN-y were shown to be expressed within the oral mucosa from the maj ority of 
these cats. By contrast IL-6 was only found in a minority of samples, and IL-4 and IL-5 were both 
undetectable. Cytokine expression profiles from the feline oral mucosa have not previously been 
documented, however the results are similar to those reported from healthy gingival tissue in humans 
(Prabhu et al., 1996). 
The division of immune responses into T-helper (Th) type I and type 2 responses has been based upon 
the demonstration in murine and, to a lesser extent, human studies of functionally distinct subsets of 
helper T-cells which display distinct patterns of cytokine production (Mosmann & Coffman, 1989; 
Abbas et al., 1997; Romagnani, 1997). However, additional investigations have indicated that 
substantial species differences may occur (Davis & Hamilton, 1998). In recent studies in the cat, 
Pedersen and colleagues (1998) were unable to demonstrate cytokine profiles that conformed to the 
type I and type 2 responses seen in mice. This raises questions as to the validity of trying to fit the 
responses seen in the present study into the classical murine model (see Chapter 1). Nevertheless, the 
findings indicate that the non-inflamed feline oral mucosa is an active immunological site, and show 
that the cell population is predominantly, but not exclusively, biased towards a type I profile of gene 
expression. Studies of early responses to both bacterial and viral pathogens have shown cytokine 
patterns that are dominated by IL-12, IFN-y, IL-6 and IL-10 expression (Biron & Gazzinelli, 1995; 
Gause & Lu, 1996). Since the feline oral cavity barbours a large number and array of commensal 
bacteria (Mallonee et al., 1988), and the oral mucosa is subjected to a daily barrage of minor insults 
during the normal course of eating, the pattern of cytokine exposure seen in the non-diseased mucosa 
may simply reflect an ongoing immune response to recurrent minor bacterial invasions. 
The source of the cytokine mRNA detected within the healthy mucosal tissues cannot be determined 
from the present study. IFN-y is produced by T-cells and natural killer (NK) cells, whereas the 
production of IL-2 is limited solely to T-cells (Snapper, 1996; Mcllraith & Lipsky, 1996; Gaffen et al., 
1998; De Maeyer & De Maeyer-Guingnard, 1998). Thus, the resident T-cells within the oral mucosal 
tissue are likely to be the source of these transcripts. By contrast, IL-6, IL-10 and IL-12 can be 
produced by a wide range of cell types, including Langerhans' cells, keratinocytes, monocytes- 
macrophages, T-cells (IL-6, IL-10), B-cells (IL-6, IL-10), and fibroblasts (IL-6) (Gause & Lu, 1996; 
Trinchieri, 1995; Yamamoto & Osaki, 1995; Hirano, 1998; de Waal Malefyt & Moore, 1998; Storkus 
et al., 1998). Further studies are required to determine the precise cellular sources of these cytokine 
transcripts within the oral mucosal tissue using methods such as in situ hybridisation or 
immunohistochemistry. 
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The second part of this study investigated cytokine gene expression within the mucosal lesions of cats 
with chronic gingivostomatitis. Biopsies from most cases were found to express IL-2, IL-6, IL-10, IL- 
12 (p35 & p40) and IFN-y, whereas IL-4 was expressed in biopsies from two thirds of affected cats. 
By contrast, IL-5 was only detected in one case. Subsequent comparisons with the results from the 
healthy cats showed a significant increase in the relative expression of IL-2, IL-4, IL-6, IL-10, IL-12 
(p35 & p40), and IFN-y within the oral mucosa from cats with chronic gingivostomatitis. Since the 
G3PDH levels within the extracts from healthy or diseased tissue biopsies were similar, there are no 
grounds to suspect that these latter findings may have resulted ftom differences in the amount of RNA 
extracted between the two groups. 
The heterogeneous and complex cytokine response seen in this study makes interpretation of the 
results difficult. Moreover, the levels of gene expression measured may not necessarily correlate with 
the levels of cytokine transcription and secretion (Feldmann et al., 1996; Pioli et al., 1998; Rottman et 
al., 1995), and additional factors interacting upon levels of cytokine receptor expression and receptor 
signalling pathways may influence the response to various cytokines and confound the ability to 
interpret the data (Vilcek, 1998; Gately et al., 1998). Furthermore, the factors controlling the 
development of type I and type 2 responses at the oral mucosa are poorly understood. Much of the 
current understanding of the mechanisms underlying the development of type I and type 2 responses is 
derived from studies using naive T-cells - however these cells will migrate preferentially to lymph 
nodes rather than peripheral sites (Butcher & Picker, 1996). Finally, the effects of cytokines upon the 
feline immune system have not been extensively investigated. Hence, any attempt to interpret the 
results necessarily relies upon the extrapolation of responses seen in other species and from in vitro 
studies, with the caveat that such assumptions may subsequently prove to be invalid. 
With the exception of IL-5, there was a generalised and progressive increase in the expression levels 
of all of the cytokines analysed as the clinical severity of the lesions increased. However, IL4 
expression was mainly detected in well-established lesions. These findings suggest that as the clinical 
severity of the lesions increases, there is a shift in the cytokine expression profile away from a 
(predominantly) type I response towards that of a mixed type I and type 2 response within the oral 
mucosa. As demonstrated in Chapter 11, a heterogenous infiltrate was present within the oral lesions 
present in cats with chronic gingivostornatitis comprising plasma cells, macrophages-monocytes, 
lymphocytes, and mast cells. These, and additional cell populations resident within the oral mucosa, 
such as fibroblasts, epidermal cells, and dendritic cells, are likely to contribute to the cytokine milieu. 
Thus, the finding of a mixed type I and type 2 response is perhaps not unexpected. 
Two of the samples from cats with chronic gingivostomatitis were harvested from oral mucosal sites 
that appeared clinically normal (grade 0). The cytokine profiles and levels of mRNA expression 
measured in these latter samples were generally similar to those found in healthy mucosal samples 
from control cats, with the exception of IL-6, for which the levels of expression were 10 and 100 fold 
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greater than that seen in any of the control cats. The small number of samples analysed prevents firm 
conclusions from being drawn, however the findings suggest that increased IL-6 transcription occurs 
very early in the pathogenesis of the oral mucosal lesions seen in cats with chronic gingivostomatitis. 
Additional studies are required to corroborate these findings. Furthermore, studies analysing the 
source of the IL-6 within these early lesions would be of considerable interest. IL-6 is a 
multifunctional cytokine which, as mentioned previously, is produced by a wide range of cell types 
(Tanaka et al., 1996, Tilg et al., 1997; Hirano, 1998). One of the main biological functions of IL-6 is 
its ability to stimulate B-cell differentiation and immunoglobulin synthesis. Consequently, 
hypergammaglobulinaernia is commonly associated with diseases in which abnormal production of IL- 
6 occurs (Jourdan et al., 1990; Hagiwara & Klinman, 1996). Thus, it is possible that increased 
expression and secretion of IL-6 by cells within the oral mucosa may underlie the systemic 
hypergammaglobulinaernia that occurs in cats with chronic gingivostornatitis (Chapter 7) (Zetner et al., 
1989; White et al., 1992). Measurement of systemic IL-6 levels would be required to investigate this 
hypothesis (Ma et al., 1995). 
Samples from lesions with evidence of inflammation (grades I to 3) exhibited a generalised increase in 
the relative expression of cytokines associated with type I responses (IL-12, IFN-y and IL-2) and type 
2 responses (IL-4, IL-6 and IL-10). However, it was noticeable that IL-4 was only detected in one of 
the five lesions with mild inflammation, but was found in 15 of 20 biopsies collected from sites with 
severe inflammation. In murine and human immunity, IL-12 and IL4 are considered to be pivotal in 
influencing the development of type I or type 2 responses respectively (Seder & Paul, 1994; Abbas et 
al., 1996; Romagnani, 1997; Szabo et al., 1997; Gately et al., 1998; Murphy, 1998). IL-12 promotes a 
type I response by up-regulating IFN-y production by T-cells and NK cells, and together these 
cytokines promote the differentiation of Th I -like cells and suppress the growth of IL4 producing Th2- 
like cells (Trinchieri, 1995; Lederer et al., 1996; Szabo et al., 1997; Ahn et al., 1997; Okamura et al., 
1998; Gately et al., 1998). Conversely, IL-4 antagonises the biological effects of IL-12 upon Th-cell 
differentiation, and IL4 and IL-10 both act to down-regulate IL-12 production (Trinchieri, 1995; 
Koch et al., 1996; Szabo et al., 1997; de Waal Malefyt & Moore, 1998; Ria et al., 1998). Thus, in the 
early oral mucosal lesions in cats with chronic gingivostornatitis the cytokine expression profiles 
would suggest that the balance of IL- 12: IL-4 is in the favour of the former, and therefore that a type I- 
dominated environment is likely to be generated. A type I envirorunent would facilitate the functional 
development of CD8+ cytotoxic cells and macrophages-monocytes, and immunohistochemical analysis 
(Chapter 11) indicated the presence of significant numbers of these cells within the oral lesions. 
Nevertheless, the expression of IL-10 in conjunction with IL-2 and IL-6 would also be expected to 
facilitate the differentiation of pro-plasmacytes and reactivated memory B-cells entering the mucosal 
tissues, in addition to promoting immunoglobulin secretion (Kono et al., 1991; Briere et al., 1996; 
McIlraith & Lipsky, 1996; Hirano, 1998; Nagumo & Agematsu, 1998; de Waal Malefyt & Moore, 
1998). This may provide the mechanism which affords the development of the prominent plasma cell 
population that is seen within the oral lesions (Chapter 11). Furthermore, as the lesions develop, the 
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progressive increase in IL-4 expression would be expected to ftirther promote the development of 13- 
cells and plasma cells, and would promote the stable development of Th2-type effector cells 
trafficking into the lesion (Koch et al., 1996; Murphy, 1998). In this respect, it is perhaps surprising 
that IL-5 expression was not detected in oral mucosa from the diseased or non-diseased cats. IL-5 has 
been associated with type 2 responses, and is produced by T-cells, mast cells, cosinophils and, 
possibly, B-cells (Sanderson, 1998, Padrid et al., 1998). However, IL-5 acts to stimulate B-cell 
development, and although the response of feline B-cells to IL-5 is unknown, in some species it can 
enhance the production of IgA at mucosal sites (Takatsu et al., 1994; Takatsu, 1996; Sanderson, 
1998). Relatively few IgA producing cells were found to be present within the oral mucosal tissue 
lesions (Chapter 11), hence the absence of IL-5 mRNA expression within the oral mucosal tissues is 
consistent with this finding. Moreover, these results are in accordance with a number of recent human 
studies investigating chronic gingivitis and periodontal disease in which IL-5 expression was not 
detected or was negligible (Tokoro et al., 1996; Fujihashi et al., 1996; Yamamoto et al., 1997). 
These results of this study raise a number of questions with regard to the aetiopathogenesis of feline 
chronic gingivostomatitis. One question relates to the factors involved in the induction and promotion 
of the initial lesions and the generation of a type Wominated response. Type I responses promote 
various aspects of cell-mediated immunity and are normally induced in response to particulate and 
intracellular microbes (Biron & Gazzinelli, 1995; Reiner & Locksley, 1995; Kerksiek & Pamer, 1999). 
Thus, the early induction of a type I cytokine profile in cats with chronic gingivostornatitis may 
suggest that the response is being driven by intracellular infection. As previously discussed (Chapters 
I& 3), the role of viruses in the pathogenesis of feline chronic gingivostomatitis is controversial. 
Persistent feline calicivirus (FCV) infection is strongly associated with feline chronic 
gingivostomatitis, and FCV was isolated from all of the clinical cases within the present study 
(Chapter 3). Hence, it could be hypothesised that the type I profile of cytokine expression seen within 
the early lesions results from the host's local response to chronic FCV infection. However, studies that 
clearly demonstrate the presence of FCV within the oral lesions seen in FCGS have not been 
documented. Future investigations are required to address this issue, and to analyse the local 
immunological response generated within the oral mucosa during acute and chronic FCV infection. 
Furthermore, investigations analysing the potential role of other intracellular organisms may be of 
value. 
A further question relates to the significance of the increase in expression of IL4 mRNA within the 
developing lesions. As the detection of IL-4 mRNA was generally shown to concur with the 
development of the most severe lesions, it could be hypothesised this cytokine plays a critical role in 
the progression of the disease. A scenario could be envisaged whereby the induction of this cytokine 
results in a fundamental change in the underlying local immune response, which is consequently 
detrimental to the host. IL-4 can be produced by T-cells (M), some NK cell populations 
(NKI. I+CD4+ T-cells), mast cells and basophils (Bradding et al., 1992; Chomarat et al., 1998). 
However, the source of the IL-4 transcripts within the lesions cannot be determined from the results of 
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the present study. Further investigations are required to identify the cells producing these transcripts to 
determine whether the appearance of IL4 heralds the arrival of a novel population of cells within the 
infiltrate; or whether the change results from the induction of IL-4 expression by cells already residing 
within, or trafficking into, the oral lesions. Immunohistochemical analysis of the biopsy tissues 
(Chapter 11) indicated that as the clinical severity of the lesions increased there was a progressive 
increase in the density of the inflammatory infiltrate within the lesions. Comparison of the number of 
CD4+ and CD8+ cells within the lesions demonstrated that CD8+ cells were predominant in all grades 
of lesion. This finding is consistent with the induction of a prominent type I response within the 
lesions, which would favour the activation and differentiation of CD8+ cytotoxic cells. However, it was 
also noted that as the density of the infiltrate reached its maximum, the number, and relative 
proportion, of CD4+ cells increased, whereas and the number of CD8+ cells decreased. Together with 
the cytokine expression results, these findings would support the hypothesis that as the severity of the 
lesion increases, the CD4+ T-helper population entering the tissue shifts from a predominantly Thl- 
biased population to a mixed Th I /Th2 population. 
The mechanisms which may underlie the changes seen in the tissue cytokine profiles are not apparent. 
Histological examination revealed that as the severity of the lesion increased there was progressive 
disruption and degeneration of the mucosal epithelium. As the epithelium becomes compromised this 
will predispose the oral mucosa to bacterial invasion and infection, which will provoke an 
inflammatory response. Extracellular bacteria typically generate a mixed type I and type 2 host 
response, and this has recently been confirmed in the cat (Pedersen et al., 1998). Thus, the change in 
the cytokine profile occurring within the lesions in feline chronic gingivostornatitis may reflect 
increased invasion and colonisation of the lesions by bacteria. As discussed previously (Chapters 1,4, 
& 7), the role of bacteria within the aetiopathogenesis of feline chronic gingivostomatitis is 
controversial. Studies of bacterial-induced chronic gingivitis and periodontal disease in humans have 
reported the presence of a mixed type I and type 2 cytokine response within the mucogingival tissues, 
with a bias towards a type 2 response as the disease becomes more advanced (Kono et al., 1991, 
Fujihashi et al., 1993 & 1996; Prabhu et al., 1996; Yamamoto et al., 1997; Tokoro et al., 1997). This 
may suggest that there are some common factors in the pathogenesis of feline chronic 
gingivostornatitis and human periodontal disease. Alternatively, it may simply be that a conserved 
array of cytokines are expressed during chronic inflammation of the oral mucosa arising from various 
aetiologies in different species (Yamamoto & Osaki et al., 1995; Lilic et al., 1996). It is also 
recognised that additional factors such as the dose or concentration of antigen can influence the 
generation of type I and type 2 responses. Low doses of antigen tend to promote Th I responses, 
whereas high doses or repeated doses of antigen tend to induce Th2 responses (Abbas et al., 1996). 
Consequently, it is possible that in early lesions, where the epithelium remains largely intact, there is a 
low level of antigenic stimulus which promotes a type I response. However as the severity of the 
epithelial disruption increases, there is increased entry of antigenic components, such as bacteria and 
food particles, and consequently this promotes the development of a type 2 response. 
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Moreover, it is becoming increasingly apparent that adhesion molecules and chemokines play a central 
role in determining the nature of the immune response within peripheral sites (Lichtman & Abbas, 
1997; Sallusto et al., 1998; Butcher, 1999). The recruitment of s from the vasculature into the tissues is 
mediated by the expression of various surface molecules on the leucocyte, and the presence of 
appropriate ligands and receptors on endothelial and tissue cells (Butcher & Picker, 1996; Humphries 
& Newham, 1998). Recent studies have demonstrated the differential expression of various chemokine 
receptors and selectin-binding ligands in Thl and Th2 cells (Austrup et al., 1997; Siveke & Hamann, 
1998; Sallusto et al., 1998). Consequently, it is possible that the shift in the cytokine expression 
profiles seen in the lesions from cats with chronic gingivostomatitis results from altered recruitment of 
T-cells, mediated by changes in the expression of adhesion molecules and/or chemokines on the 
endothelium. and various cells present within the oral mucosal lesions. Numerous human studies have 
reported altered expression of adhesion molecules within the gingival and oral mucosa during chronic 
oral diseases (Steffensen et al., 1992; Jones et al., 1993; Gemmel et al., 1994 & 1995; Haapasalmi et 
al., 1995; Tonetti et al., 1995; Pietrzak et al., 1996; Castillo et al., 1996), however similar studies have 
not been reported in the cat. Investigations addressing this issue may provide a valuable insight into 
the pathogenesis of the chronic inflammatory response occurring in the oral tissues in feline chronic 
gingivostomatitis. 
Finally, during the course of this study the levels of gene expression of both IL-12 subunits (p35 and 
p40) were analysed. It was found the relative expression of both p35 and p40 mRNA transcripts 
increased similarly during the development of oral mucosal tissue lesions. However, the complicated 
biology of IL-12 (see Chapter 1) makes interpretation of these findings difficult and speculative. The 
concurrent increase in expression of mRNA for both p35 and p40 could result in elevated secretion of 
the biologically active heterodimer and a proportionate increase in the level of secreted free p40. 
Nonetheless, as many cell-types can express the p35 chain, whereas expression of the p40 chain is 
primarily restricted to antigen presenting cells (D'Andrea et al., 1992), an alternative interpretation 
would be that in cells producing both subunits, the average increase in p40 expression is likely to be 
greater than the average increase in p35 expression, which would therefore lead to an increase in the 
amount of free p40 relative to the increase in the p70 heterodimer. Controversially and paradoxically, 
such changes might lead to a relative inhibition of the IL-12 p70-mediated response, due to a greater 
concentration of antagonistic (p40)2 homodimers; (Yoshimoto et al., 1998). In order to investigate 
these possibilities, additional studies assaying the production of p70 and p40 would be required 
(D'Andrea et al., 1992). 
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CHAPTER 16: Changes in Cytokine mRNA Expression Within Oral Mucosal 
Lesions in Cats with Chronic Gingivostomatitis Following Treatment 
16.1 INTRODUCTION 
The development of successful treatments for feline chronic gingivostomatitis has been confounded by 
a poor understanding of the disease aetiopathogenesis, and by a lack of studies providing an objective 
analysis of the response to treatment (White et al., 1992; Hennet, 1995). The presence of a 
hypergammaglobulinaernia (Johnessee & Hurvitz, 1983; White et al., 1992; Zetner et al., 1989) (see 
Chapter 7), and a high proportion of plasma cells and lymphocytes within the oral lesions (Johnessee 
& Hurvitz 1983; Lyon 1990; Gruffydd-Jones, 1991; Williams & Aller, 1992; White et al., 1992; 
Hennet, 1995; Harvey, 1995) (see Chapter 11) has prompted a number of authors to suggest that there 
may be an immunological basis to the condition. Nevertheless, the effect of treatment upon the 
ongoing immune responses occurring in oral lesions arising in feline chronic gingivostomatitis has not 
previously been studied. By comparison to healthy oral mucosa, there is a significant increase in the 
relative expression of a range of cytokines within the oral mucosal lesions occurring in cats with 
chronic gingivostomatitis (see Chapter 15). In order to be able to treat this condition successfully, it 
would be expected that an effective therapeutic regime would be able to directly, or indirectly, induce 
significant alterations in cytokine expression within the oral lesions. Thus, monitoring such changes 
may provide a useful method for assessing the effectiveness of the response to treatment at a molecular 
level. Moreover, by correlating the changes in tissue cytokine expression with changes in the clinical 
severity of the lesion, this may reveal further aspects of the underlying disease pathogenesis, and 
facilitate the future development of more effective therapeutic strategies. 
The present chapter details the results from studies which examined the comparative effects of four 
different therapeutic agents upon the relative expression levels of various cytokines within the oral 
mucosal lesions from cats with chronic gingivostomatitis. 
16.2 MATERIALS& METHODS 
These are presented in Chapters 13 and 2. 
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16.3 RESULTS 
16.3.1 Analysis between treatment groups of the cytokine expression In oral biopsies collected at 
consultation I 
Cats with chronic gingivostomatitis from which pretreatment biopsies were collected and examined for 
cytokine expression (reported in Chapter 15) at consultation I were randomly allocated to one of four 
treatment groups (see Chapters 2 and 4). Figure 16.1 shows that there was no significant difference 
between treatment groups in the relative expression of each of the cytokines: analysed at this baseline 
time-point. 
16.3.2 Cytokine expression in oral mucosal biopsies collected at consultation 3 
After 3 months of treatment (consultation 3), repeat biopsies were collected from the same faucal site 
as the pretreatment biopsy in 23 of the cats within the treatment trial. Biopsies were not collected from 
cats 2,13,26,29 as these cases had withdrawn from the treatment trial at this stage. In addition, 
samples were not collected from Cats 7 and 22 as in each case they were not able to be anacsthetised 
at this consultation. The sample from case 27 was lost during processing. 
Tables 16.1 & 16.2 show that mass of the biopsy tissue processed and the concentration of G3PDH 
present within the extracts from the biopsies collected at consultation 3 were both significantly smaller 
than the corresponding biopsies collected at consultation I- 
The relative expression of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p35 & p40), and IFN-y were 
determined for each biopsy. Figure 16.2 shows that IL-2, IL-6, IL-10, IL-12 (p35 and p40) and IFN-y 
were detected in the majority of the samples, whereas IL-4 was only detected in 6 samples and IL-5 
was not detected in any of the samples. 
16.3.3 Changes in cytokine expression in oral lesions after 3 months of treatment 
The change in relative cytokine expression was calculated for each pair of biopsies (Figure 16.3). A 
significant difference between treatment groups was only indicated for IL-2 (Figure 16.3). Dunn's 
multiple comparison test indicated that a significant difference existed between the change in relative 
expression of IL-2 in the antibiotic and gold salt treated groups (Table 16.3). The data were then re- 
analysed after the removal of inconclusive data, in other words, results derived from pairs in which the 
expression of an individual cytokine was not detected within both samples, or in which cytokine 
expression was not detected in the sample with the lower G3PDH concentration. Table 16.4 shows that 
the results were similar to those from the original analysis using all of the data points. 
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Figure 16.1 (a-h) Relative expression of cytokines in biopsies collected at consultation I within 
each treatment group 
(a) IFN-y (b) IL-2 
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Figure 16.2 (a-h) Clinical scores and cytokine: G3PDH mRNA expression ratios in faucal 
biopsies from cats with chronic gingivostomatitis at consultation 3 
(a) IFN-T (b) IL-2 
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The change in relative cytokine expression was calculated from paired biopsies collected from cats 
with chronic gingivostomatitis taken immediately prior and 3 months after entry onto the treatment 
trial (see Chapters 2&3 for details). Median value of each clinically graded group is represented by 
an adjacent bar (-). nd = not detected. 
Table 16.1 Mass of paired tissue biopsies collected at consultations 1&3 
Biopsy mass (mg) 
n Mean SD 
Consultation 1 23 5.42 3.00 
Consultation 2 23 3.51 3.15 
Difference 23 -1.91 3.46 
Paired t-test T=2.65 P=0.015 
Table 16.2 G3PDH concentration of paired biopsy extracts at consultations I&3 
G3PDH concentration (loglo Units)_ 
n Mean SD 
Consultation 1 23 7.367 0.370 
Consultation 2 23 6.200 0.950 
Difference 23 -1.166 0,973 
Wilcoxon matched pairs signed WS = 3.0 P<0.001 
rank sum test 
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Figure 16.3 (a-g) Change in relative cytokine expression in paired oral tissue biopsies collected 
at consultations 1 and 3 
(a) IFN-y (b) IL-2 
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Table 16.3 Dunn's multiple comparisons tests for change in the relative expression of IL-2 using 
all available data points 
Comparison Difference in rank sum P value 
OHvGS -3.83 p>0.05 
oHvcs 2.02 p>0.05 
OHvAB 8.50 p>0.05 
GSvCS 5.86 p>0.05 
GSvAB 12.33 p<0.05 
CSvAB 6.48 p>0.05 
OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB = Antibiotics 
Table 16.4 Results of Kruskal-Wallis and Dunn's multiple comparison tests on the change In the 
relative expression of cytokines between consultations 1 and 3 after the removal of inconclusive 
data points 
(a) Kruskal-Wallis test results 
Cytokine P value Cytokine P value 
IL-2 P=0.025 IL-10 P=0.61 
IL-4 N/A IL-12 p35 P=0.94 
IL-5 N/A IL-12 p40 P=0.45 
IL-6 P=0.79 IFN-y P=0.16 
N/A = not applied owing to small group sample sizes 
(b) Dunn's multiple comparisons tests for change in the relative expression of IL-2 
Comparison Difference in rank sum P value 
OH v GS -2.17 P>0.05 
OH v CS 3.00 P>0.05 
OH v AB 8.50 P>0.05 
GSvCS 5.17 P>0.05 
GSvAB 10.67 P<0.05 
CS v AB 5.50 P>0.05 
OH = Oral hygiene, GS = Gold salts, CS = Corticosteroids, AB = Antibiotics 
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16.3.4 Examination of the relationship between the change in relative cytokine exprcssion and 
the change in local stomatitis index 
The changes in the levels of relative cytokine expression were compared with the changes in the local 
stornatitis index of the site from which the biopsies were harvested. In order to facilitate this analysis, 
based upon their change in the local stomatitis index (Chapter 12, Table 12.2), cats were classified as 
showing either no improvement (no change or an increase in the local Sl score) or improvement (a 
reduction in the SI score). As above, the results were analysed twice; first using all of the available 
data (Table 16.5), and then following the removal of results derived from pairs in which the expression 
of an individual cytokine was not detected within both samples, or in which cytokine expression was 
not detected in the sample with the lower G3PDH concentration (Table 16.6). However, no 
statistically significant differences in the change in relative cytokine expression were found between 
cats showing an improvement, or no improvement in their local SI scores, using either of the data sets. 
Table 16.5 Mann-Whitney test results comparing the change in relative cytokine expression In 
cats showing no change or an increase in their local faucal stomatitis index (SI) score (no 
improvement) against cats showing a reduction in the local faucal SI score (improvement) using 
all available data values 
Cytokine pP Lower 
95% Cl 
Upper 
11-2 0.59 -10883 13432 
11-4 0.82 -3.4 7.6 
IL-6 0.045 0.32 -33094 -170 
IL-10 0.15 -2957 649 
IL-12 p35 0.92 -232 217 
IL- 12 p40 0.55 -253 259 
IFNy 0.15 -22126 2999 
Cl = confidence interval for median (improvement) - median (no improvement). P' = adjusted P value 
using the layered Bonferroni method. 
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Table 16.6 Mann-Whitney test results comparing the change In relative cytokine expression In 
cats showing no change or an increase in their local faucal stomatitis Index (SI) score (no 
improvement) against cats showing a reduction in the local faucal SI score (improvement) after 
the removal of inconclusive data values 
95% Cl 
Cytokine p Lower Upper 
IL-2 0.75 -18160 15202 
IL-4 0.25 -12.9 51.6 
IL-6 0.064 -38680 1026 
IL-10 0.057 -3992 340 
IL- 12 p3 5 1.0 -301 339 
IL-12 p40 0.44 -657 774 
IFNy 0.14 -25040 3000 
CI = confidence interval for median (improvement) - median (no improvement). 
16.4 DISCUSSION 
The relative expression levels of a range of cytokines associated with (T-helper[Th] 1) type I responses 
(IFN-y, IL-2, IL-12 p35 & p40) and (Th2) type 2 responses (IL4, IL-5, IL-6, and IL-10) were 
determined in oral mucosal biopsies collected from cats with chronic gingivostomatitis three months 
after commencing therapy with one of four treatment regimens. The cytokine profiles obtained from 
these samples were similar to those found in the pre-treatment biopsies (Chapter 15), and showed a 
mixed type I and type 2 profile, with a tendency for type I cytokines to predominate. Hence, taken 
together with the results in Chapter 15, these findings indicate that the profile of cytokine mRNA 
expression obtained from oral mucosal tissues from cats with chronic gingivostomatitis observed 
within this study was a repeatable phenomenon. 
The mass of the post-treatment biopsies, and the concentration of G3PDII present within the RNA 
extracts from these biopsies, were both significantly smaller than those for the corresponding pre- 
treatment biopsies. This factor posed a potential problem for the analysis of the change in relative 
mRNA expression levels between the paired samples. For if a particular cytokine product was not 
detected in the sample with the lower G3PDH concentration, but was detected in the other sample, the 
apparent change in cytokine expression (from positive to negative, or vice versa) may have been an 
artificial finding resulting from the difference in sample template concentrations, rather than 
differences in the relative level of gene expression. In addition, in situations where both samples were 
negative it could not be implied that there was no change in the relative cytokine expression levels; 
only that in both samples the level of expression was below the minimum detection limit of the assay. 
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In order to address this issue the results were analysed twice; first using all of the available data, and 
subsequently after the removal of results in which the change in the level of expression of cytokines 
were inconclusive. 
Overall, there was little consistency in the change in the relative level of cytokine expression within 
any of the treatment groups after three months of treatment. Only the changes in the level of 
expression of IL-2 in the gold salt-treated and the antibiotic-treated group were found to be 
significantly different - both with and without the inclusion of inconclusive data points. Sodium 
aurothiomalate treatment was generally associated with an increase the level of IL-2 mRNA 
expression, whereas the converse was found in cats treated with metronidazole and spiramycin. The 
significance of this finding is not clear. if it is assumed that a reduction in the level of cytokine mRNA 
expression within the oral lesions is inclined to be beneficial, then these findings suggest that treatment 
with metronidazole and spiramycin is likely to be more advantageous than treatment with sodium 
aurothiomalate. Nonetheless, no significant difference in the clinical effectiveness of these treatments 
was seen after three months of therapy (Chapter 4). 
As discussed previously in Chapter 8, a number of studies have indicated that sodium aurothiornalate, 
and to a lesser extent, both metronidazole and spiramycin, all possess immunomodulatory activity - 
although the mechanisms underlying these effects are poorly defined (Jennings et al., 1979; Saxen et 
al., 1985; Kohli et al., 1987; Hashimoto et al., 1992; Bailly et al., 1993; Elizondo & Ostrosky- 
Wegman, 1996; Hirohata, 1996; Qasim et al., 1997). The effects of metronidazole or spiramycin upon 
IL-2 expression have not previously been documented. However, the results of the present study 
conflict with those of Hashimoto et al. (1992) who reported that sodium aurothiornalate suppressed the 
production of IL-2 by Jurkatt cells in vitro. Nonetheless, the significant differences between the latter 
and the present study make direct comparison of the results difficult, For instance, the level of gene 
expression, as reported in the present study, may not correlate with the levels of cytokine secretion 
(Pioli et al., 1998); and the results from a simplified in vitro model may not rightly represent the 
changes occurring within the complex in vivo environment examined in the present study. 
It is disappointing that additional significant differences were not seen in the cytokine expression 
levels between treatment groups. As discussed previously (Chapter 8), corticosteroids can modulate 
the expression of a diverse range of cytokines (Daynes & Araneo, 1989; Waage et al., 1990; Mukaida 
et al., 1994; Ray & Prefontaine, 1994; Auphan et al., 1995; Batuman et al., 1995; Scheinman et al., 
1995; Merchant et al., 1996; Wilckens & De Rijk, 1997; Bames, 1997; DeKruyff et al., 1998). By 
contrast, immunoregulatory activity has not been described for the active ingredients of the oral 
hygiene products, chlorhexidine and glucose oxidase/lactoperoxidase. Hence, it was hypothesised that 
cats treated with corticosteroids (or gold salts or antibiotics) would be most likely to demonstrate 
differences in their levels of cytokine expression relative to the group receiving oral hygiene treatment, 
especially as oral hygiene products were shown to be the least cffective treatment after three months of 
treatment (Chapter 4). However, studies have shown that the immunosuppressive effects of 
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corticosteroids can be inhibited by various cytokines, such as IL-I, IL-6 and IFN-y (Almawi et al., 
1991; Wilckens, 1995). Thus, it may be the case that the tissues were rendered refractory to the 
immunomodulatory effects of methyl prednisolone by the high levels of cytokine expression present 
within the mucosal lesions. Alternatively, it is possible that the methods applied within the present 
study may not have been sufficiently sensitive to discriminate subtle but consistent changes in the level 
of cytokine expression. Furthermore, immunomodulatory effects can be mediated via non- 
transcriptional pathways such as the regulation of translation or secretion, which would not be detected 
in this study (Wu et al., 1998). Nonetheless, the fact that few differences were found between any of 
the treatment groups is in accordance with the poor clinical, serological, and immunohistological 
responses to treatment, previously documented in Chapters 4,8 & 12. 
In order to investigate whether changes in the expression of specific cytokines could be associated 
with changes in the clinical severity of disease, comparisons were performed between mucosal sites 
which had, or had not, shown signs of clinical improvement, irrespective of the treatment received. No 
significant differences were found between these two groupings, although the 95% confidence 
intervals showed that signs of clinical improvement tended to be associated with a reduction in the 
level of expression of IL-6, IL- 10 and IFN-y. However, further studies would be required to determine 
if these trends are of any importance. Such studies would require the use of more effective therapeutic 
regimens than those used in the present study. 
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CHAPTER 17: Summary & General Discussion 
17.1 SUMMARY AND GENERAL DISCUSSION 
The objectives of the present study were to investigate and characterise aspects of the 
aetiopathogenesis of feline chronic gingivostomatitis (FCGS), and to prospectively assess the 
comparative effectiveness of four different treatments for the management of this condition. Prior to 
the commencement of this study, knowledge of the immunopathological features of FCGS was sparse, 
and the long term effectiveness of treatments had not been evaluated using controlled clinical trials. In 
order to perform these studies, it was necessary to develop and validate a number of methods, 
including ELISAs, immunohistochernistry techniques, and serniquantitative RT-PCR, for their use in 
feline tissues. 
17.1.1 The aetiopathogenesis of feline chronic gingivostomatitis 
Factors influencing the development of FCGS are poorly understood, however it is likely that the 
disease has a multifactorial aetiology. Much attention has been paid previously to the association of 
this disease with viruses, especially feline calicivirus (FCV) (Table 1.1). In the present study FCV was 
isolated from all of the cats with FCGS. Furthermore, FCV was detected in 80% of the cats at two 
time-points six months apart, which strongly sug ests that they were persistently infected with FCV. C19 
These findings support the hypothesis that chronic FCV carriage is associated with FCGS (Thompson 
et al., 1984), however the fundamental question as to the role of FCV in the disease aetiopathogenesis 
remains unanswered. It is possible that the association between FCV and FCGS is due to a common 
factor, such as an immunological predilection, which on the one hand prevents the host from 
eliminating the virus, while on the other predisposes the cat to the development of FCGS. Under these 
circumstances, the persistence of FCV infection could be considered as a risk indicator for FCGS. 
Alternatively, FCV may be a genuine aetiological factor that promotes the development of FCGS 
through currently unknown mechanisms. One major attraction of this latter hypothesis is the fact that 
the lesions in FCGS are generally confined to distinct sites within the oral cavity. A model for the 
aetiopathogenesis of FCGS (Figure 17.1) needs to account for this predilection, and the persistence of 
FCV within the oral mucosa could provide such an explanation (Wardley & Povey 1977; Dick Ct al., 
1989). In order to advance this hypothesis, future studies should aim to examine the mechanisms of 
persistence of FCV, and to examine whether this results from an aberrant host response. In addition, 
the effects of FCV upon host factors such as the maintenance of the integrity of the oral mucosa, and 
the regulation of immune responses within the oral mucosa, should be investigated. 
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Only four of the thirty cats with FCGS within this study were seropositive for feline immunodeficiency 
virus (FIV). Furthermore, feline leukaemia virus (FeLV) and feline herpes virus (FIIV) were not 
detected in any of the cases. The low prevalence of these viruses in cats with FCGS suggests that they 
are not primary aetiological factors in the disease pathogenesis. Nonetheless, it is conceivable that 
when present, the immunosuppressive effects of FIV and FeLV contribute to the disease pathogenesis, 
either by increasing the host susceptibility to infection, or by promoting an aberrant immune response 
(Yamamoto et al., 1989; Williams & Aller, 1992; Bishop, 1995; English & Tompkins, 1995) (Figure 
17.1). 
Case-specific details were also analysed for evidence of possible predisposing factors for FCGS. 
Previous studies have suggested that certain breeds are predisposed to the development of FCGS (Von 
Schlup, 1982; Frost & Williams, 1986). While this hypothesis could not be tested in the present study, 
it was demonstrated that pure-bred cats developed signs of FCGS at a younger age than did domestic 
short-haired and domestic long-haired cats (DSH/DLH). This strongly suggests that genetic factors 
influence host susceptibility to the disease (Figure 17.1). Studies in humans have demonstrated that 
susceptibility to various oral inflammatory diseases is associated with the major histocompatibility 
complex (MHC) (Challacombe & Shirlaw, 1999). The nature of the genetic predisposition in cats with 
FCGS is not apparent, but it would be of interest to investigate any MHC-disease association in these 
cats. It was also found that cats from multi-cat households develop signs of FCGS at a younger age, 
which suggests environmental factors influence the age at which the disease develops in susceptible 
cats (Figure 17.1). The critical factors associated with this observation could not be determined, but 
they might include increased social stress or increased likelihood of exposure to common pathogens, 
such as FCV (Pedersen, 199 1). 
Studies examining the role of bacteria as potential aetiological agents were not undertaken during this 
study. Nevertheless, it seems highly probable that bacteria contribute to the aetiopathogenesis of the 
disease (Sims et al., 1990; Norris & Love, 1995) particularly as a source of antigenic stimulation 
within the oral mucosa during the initiation and/or progression of the mucosal lesions. Further studies 
are needed to address this issue. 
Thus, a number of factors are likely to contribute to the initiation of FCGS and these may vary 
between individuals. Nonetheless, these factors all focus upon the central issue of the underlying 
inflammatory and immune responses, which give rise to the pathological features of the disease. 
The main clinical features of FCGS are severe inflammatory mucogingival lesions. A major problem 
associated with the classification of this disease, is the overlap in the appearance of the lesions with 
those seen in bacterially-induccd chronic inflammatory periodontal disease (PD), A characteristic that 
distinguishes the two conditions is the fact that in FCGS the inflammatory lesions extend beyond the 
mucogingival junction, and they frequently affect the fauces (Williams & Aller, 1992). Within the 
present study it was demonstrated that underlying PD can account for a considerable portion, but by no 
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means all, of the inflammation seen in FCGS. Thus the oral lesions present in cats with FCGS should 
be thought of as being caused by PD and FCGS. Although this may seem an obvious detail, it is one 
that is often overlooked, and is important in the management of these cases -a point further 
highlighted by the finding that a considerable proportion of the improvement seen in the cats following 
treatment could be associated with the extraction of teeth with severe PD. The hypothesis was not 
tested in the present study, but it would be interesting to determine if cats with chronic 
gingivostomatitis are predisposed to the development of PD. 
It has been recognised that cats with FCGS commonly have a polyclonal hypergammaglobulinaernia 
(Johnessee & Hurvitz, 1983; Zetner et al., 1989; White et al., 1992). This fact was confirmed in the 
present study using class-specific ELISAs, and was shown to result predominantly from an increase in 
IgG, although both IgM and IgA levels were also elevated (Zetner et al., 1989). The mechanism 
underlying this process has not been elaborated, but it is possible that it is caused by overproduction of 
IL-6 (Jourdan et al., 1990; Hagiwara & Klinman, 1996) (Figure 17.1). Analysis of the oral mucosal 
tissue biopsies demonstrated a dramatic increase in the relative level of expression of IL-6 mRNA 
within the oral mucosa in cats with FCGS. However, further studies are needed to test this hypothesis 
by analysing serum IL-6 levels - and, if the hypothesis is correct, to determine whether the abnormality 
is an intrinsic factor, or is induced by the disease. Excessive production of IL-6 may also be 
responsible for promoting the maturation of the dominant plasma cell population seen within the oral 
lesions (Kono et al., 1991). 
Saliva is an important defence factor for the mouth, and abnormalities in saliva production or 
composition can predispose to the development of oral lesions (Challacombe & Shirlaw, 1999). 
Consequently it was hypothesised that alterations in salivary immunoglobulin concentrations may 
predispose cats with FCGS to the development of oral disease. Cats with chronic gingivostornatitis had 
increased levels of total salivary IgG, IgM, and albumin, which were attributable to an increased 
transudation of serum components into the saliva, and an increase in the amount of locally secreted 
19G. While increased IgG within the oral cavity can be beneficial in some oral diseases (Challacombe 
& Shirlaw, 1999), there is a danger that excessive transudation and activation of other factors, such as 
complement, may result in local tissue destruction and further disruption of the integrity of the 
mucosal barrier. This may provide a mechanism that perpetuates the local inflammatory process in 
FCGS (Figure 17.1). Increased transudation of IgA into the saliva also occurred, but the amount of 
locally secreted IgA was significantly lower than that of the healthy control population. Thus, cats with 
chronic gingivostomatitis were found to have a relative deficiency in their salivary IgA concentrations, 
caused by a lack of secreted IgA. it is not clear, however, if this deficiency results from a primary 
inability to secrete IgA, or from other factors, such as altered salivary flow rate, occurring secondary 
to the disease process. Nevertheless, a deficiency in salivary IgA may compromise the ability of 
affected cats to effectively control intra-oral pathogens, and provide a mechanism by which chronic 
gingivostomatitis may arise, or be perpetuated (Figure 17.1). Further studies are needed to expand 
these observations. 
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The lack of an experimental model for FCGS has hindered the study of the progression and 
development of the disease and the oral lesions. During the present study, biopsy samples collected 
from mucosal lesions of varying severity provided the opportunity to characterise the 
immunopathogenesis of the lesions at different stages of development using immunohistochemistry, 
and RT-PCR methods. As the clinical severity of the mucosal lesion increased there was a 
corresponding increase in the density of the cellular infiltrate. Early lesions tended to have a mixed 
infiltrate consisting of plasma cells (>90% JgGý, LI + macrophage-monocytes/granulocytes, and fewer 
CD3+ T-cells, which were predominantly CD8 +. These histological features were associated with 
increased expression of the type I-biased profile of cytokine mRNA (IL-12, IFN-y, IL-2, IL-10, IL-6) 
seen in healthy feline oral mucosa (Figure 17.1). As the density of the infiltrate increased, JgG' plasma 
cells, and Ll+ macrophage-monocytes/granulocytes remained the predominant phenotype within the 
infiltrate, however the relative proportion of CD3+ T-cells increased, as did the CD4: CD8 ratio - 
although CD8' cells were always in excess. These changes were also associated with a marked 
upregulation of cytokine mRNA - however IL-4 was also detectable in the majority of these biopsies, 
suggesting that the immune response had switched towards a mixed type I and type 2 profile (Figure 
17.1). 
It is tempting to speculate that the type I environment seen in the early lesions is largely promoted in 
response to persistent FCV infection. However, as the lesions develop, the integrity of the mucosa 
becomes progressively compromised, which results in increased exposure to bacteria and bacterial 
products. This then promotes an intense, but mixed, type I and type 2 response. 
Such a hypothesis would account for the similarities and differences seen in the FCGS and PD. The 
early stages of PD are initiated by exposure to bacterial plaque antigens and toxins, and (unlike the 
mucosal lesions in FCGS) the lesions are dominated by T-cells, and B-cells/plasma cells are rare (Page 
& Schroeder, 1976; Lehner, 1992). However as PD progresses and there is increased exposure to 
bacterial antigens, the lesion becomes dominated by IgG' plasma cells, and upregulation of type 2 
cytokines (Page & Schroeder, 1976; Lehner, 1992; Tokoro et al., 1997; Yamamoto et al., 1997). Thus, 
it is proposed that the factors initiating the early lesions in FCGS and PD are different, but that the 
end-stage lesions of both conditions are similar, and result from chronic exposure to bacterial antigens. 
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17.1.2 Treatment of feline chronic gingivostomatitis 
The effects of four different treatment regimes using oral hygiene products, corticosteroids, gold salts, 
or antibiotics were analysed over a six month treatment period in cats with chronic gingivostomatitis in 
a controlled clinical trial. In general, the response to treatment at clinical, cellular, and molecular 
levels was disappointing, although a few individuals demonstrated considerable clinical improvement. 
After six weeks of therapy, it was concluded that methylpredn iso lone was the most effective of the 
agents analysed for the short term treatment of FCGS. However, none of the therapeutic regimes 
demonstrated superiority for the long term treatment of FCGS. Analysis of the immunological effects 
after three and six months of therapy found that treatment with corticosteroids tended to be associated 
with greater reductions in both the number of IgG+ plasma cells within the oral lesions, and serum IgG 
levels. However, there was no significant difference between the treatment groups in the change in the 
salivary immunoglobulin levels or local cytokine mRNA expression. It was concluded from these 
results that corticosteroids are able to exert a greater immunosuppressive effect upon local and 
systemic immunoglobulin production by comparison to other treatments (Butler & Rossen, 1993; 
Settipane et al., 1978) - although this was not pronounced at the dose level selected. 
Thus, conventional therapies have little ability to combat the pathological changes occurring in FCGS. 
Future studies should explore the possibility of using novel treatments which are more potent in their 
capacity to downregulate the immune response. In addition, the effect of agents that are able to 
counteract the hypothesised initiating factors, discussed above, would be of considerable interest. In 
particular, the development of an effective antiviral agent against FCV would be of great value in 
helping to dissect the role of this agent in the pathogenesis of the disease. 
Of note, however, was the fact that the change in the level of PD could predict over 40% of the change 
in the level of oral inflammation. It was concluded, therefore, that a large proportion of the clinical 
improvement seen in the cats with chronic gingivostomatitis could be attributed to the extraction of 
teeth. This finding supports the observations made by several authors that the extraction of teeth is 
often, but not always, beneficial in FCGS (Williams & Aller, 1992; Harvey, 1995; Hennet, 1995). The 
extraction of teeth may reduce (i) the PD-related component of the overall oral inflammation, (ii) the 
bacterial burden within the oral cavity, (iii) the degree of bacterial antigenic stimulation within the 
(muco)gingival tissues. Thus, within the model proposed above (Figure 17.1), the extraction of teeth 
may help to reduce the bacterial antigen-driven progression and maintenance of the lesions, but will 
not address the underlying factors that initiate the disease process. These conclusions highlight the 
need for a multifaceted approach to the management of FCGS, which in turn reflects the multifactorial 
and complex aetiopathogenesis of the disease. 
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17.2 SyNopsis 
This study has advanced the understanding of the immunopathogenesis of FCGS, and has Wntified 
possible predisposing and aetiological factors. In addition, it has demonstrated a lack of superiority in 
the effectiveness of conventional therapeutic agents for the long term management of this condition. 
Based upon these findings, it will be possible to further explore and test hypotheses relating to the 
aetiopathogenesis and treatment of FCGS. 
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